# (19), World Intellectual Property Organization International Bureau



# 

## (43) International Publication Date 1 August 2002 (01.08.2002)

## **PCT**

C12N

# (10) International Publication Number WO 02/059271 A2

(51) International Patent Classification7:

(21) International Application Number: PCT/US02/02176

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language: Profile

English

(26) Publication Language: English

(30) Priority Data:

60/263.757 25 January 2001 (25.01.2001) US 60/286.090 25 April 2001 (25.04.2001) US 60/292.517 23 May 2001 (23.05.2001) US

(71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ORR, Michael, S. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). NATION, Michele


[US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). DIGGANS, James, C. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). ZENG, Wen [CN/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

- (74) Agent: MORGAN, LEWIS & BOCKIUS LLP; TUS-CAN, Michael S., WEIMAR, Elizabeth C. et al., 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,

[Continued on next page]

(54) Title: GENE EXPRESSION PROFILES IN BREAST TISSUE





(57) Abstract: The present invention results from the examination of tissue from breast carcinomas to identify genes differentially expressed between tumor biopsies and normal tissue. The invention includes diagnostic and screening methods using these genes as well as solid supports comprising oligonucleotide arrays that are complementary to or hybridize to the differentially expressed genes.

## WO 02/059271 A2



GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

 with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

#### Published:

 without international search report and to be republished upon receipt of that report For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

# GENE EXPRESSION PROFILES IN BREAST TISSUE

INVENTORS: Michael S. Orr, Michele Nation, J.C. Diggans and Wen Zeng

## 5 RELATED APPLICATIONS

This application claims the priority of U.S. Provisional Application Nos. 60/263,757, filed January 25, 2001, 60/286,090, filed April 25, 2001, and 60/292,517, filed May 23, 2001, all of which are herein incorporated by reference in their entirety.

## 10 BACKGROUND OF THE INVENTION

One of the most pressing health issues today is breast cancer. In the industrial world, about one woman in every nine can expect to develop breast cancer in her lifetime. In the United States, it is the most common cancer amongst women, with an annual incidence of about 175,000 new cases and nearly 50,000 deaths. Despite an ongoing improvement in our understanding of the disease, breast cancer has remained resistant to medical intervention. Most clinical initiatives are focused on early diagnosis, followed by conventional forms of intervention, particularly surgery and chemotherapy. Such . interventions are of limited success, particularly in patients where the tumor has undergone metastasis. There is a pressing need to improve the arsenal of therapies available to provide more precise and more effective treatment in a less invasive way. A promising area for the development of new modalities has emerged from recent understanding of the genetics of cancer.

One model used to characterize breast carcinogenesis asserts that normal cells undergo a multi-step process that broadly includes the steps of hyperplasia, pre-malignant change and in situ carcinoma. Multiple factors lead to atypical cell proliferation followed by carcinoma in situ. Carcinoma in situ is characterized as either ductal or lobular in form with the majority of invasive carcinomas being classified as ductal (85-95%). Among the ductal carcinomas, 15-20% encompass tubular, medullary, mucinous, papillary, adenoid, cystic, metaplastic, apocrine, squamous, secretory, lipid-rich, and cystic hypersecretory while the remaining ductal carcinomas are not specified.

To date, researchers have been able to identify a few genetic alterations believed to underlie tumor development. These genetic alterations include amplification of oncogenes and mutations that result in the loss of tumor suppressor genes. Tumor suppressor genes are genes that, in their wild-type alleles, express proteins that suppress abnormal cellular

15

20

)

25

30

15

20

25

30

proliferation. When the gene coding for a tumor suppressor protein is mutated or deleted, the resulting mutant protein or the complete lack of tumor suppressor protein expression may fail to correctly regulate cellular proliferation, and abnormal proliferation may take place, particularly if there is already existing damage to the cellular regulatory mechanism. A number of well-studied human tumors and tumor cell lines have missing or non-functional tumor suppressor genes. Examples of tumor suppressor genes include, but are not limited to, the retinoblastoma susceptibility gene or RB gene, the p53 gene, the deletion in colon carcinoma (DCC) gene and the neurofibromatosis type 1 (NF-1) tumor suppressor gene (Weinberg, *Science* 254,1138-1146 (1991)). Loss of function or inactivation of tumor suppressor genes may play a central role in the initiation and/or progression of a significant number of human cancers.

Classification of heterogeneous populations of tumor types is a daunting task; yet, studies utilizing gene expression patterns to identify subtypes of cancer have produced initial results (see Perou, C. M. et al., Proc Natl Acad Sci USA 96, 9212-9217 (1999), Golub, T. R. et al., Science 286, 531-7 (1999), Alizadeh, A. A. et al., Nature 403, 503-11 (2000), Alon, U. et al. Proc Natl Acad Sci U S A 96, 6745-50 (1999) and Bittner, M. et al., Nature 406, 536-40 (2000)). For example, molecular classification of B-cell lymphoma by gene expression profiling elucidated clinically distinct diffuse large-B-cell lymphoma subgroups (see Alizadeh supra). Stratification of patients based on their distinctive gene expression profiles may allow researchers to precisely group similar patient populations for evaluating chemotherapeutic agents. The more homogenous population of patients decreases the variability of patient-to-patient responses leading to the development of ageroapable of eradicating specific subtypes of cancers previously unknown using standard classification techniques.

A study by Martin et al. (Cancer Res 60, 2232-8 (2000)) used a custom microarray composed of 124 genes discovered by differential display associated with either normal breast epithelial cells or from the MDA-MB-435 malignant breast tumor cell line. Using the custom microarray, researchers examined the relationship between expression patterns discovered by clustering a number of genes with clinical stages of breast cancer, indicating that gene expression patterns were capable of grouping breast tumors into distinct categories (Martin et al., supra).

The utilization of gene expression profiles to classify tumors, to identify drug targets, to identify diagnostic markers and/or to gain further insights into the consequences of chemotherapeutic treatments could facilitate the design of more efficacious patient—

10

15

20

25

30

specific stratagems for treating a variety of cancers. In breast cancer, studies utilizing limited numbers of genes have classified tumors into subtypes based on gene expression profiles, and this study indicated a diversity of molecular phenotypes associated with breast tumors (Perou, C. M. et al., Nature 406, 747-52 (2000).

Although these studies have demonstrated that expression profiling may be used to produce improvements in diagnosis of breast cancer as well as the development of improved therapeutic strategies, further studies are needed as only a small portion of the genome was studied and analyses containing greater numbers of genes will advance our understanding of breast tumors even further. Accordingly, there remains a need in the art for materials and methods that permit a more accurate diagnosis of breast cancer and, in particular, ductal carcinoma. In addition, there remains a need in the art for methods to treat and methods to identify agents that can effectively treat breast cancer. The present invention meets these and other needs.

## SUMMARY OF THE INVENTION

The present invention is based on the discovery of the genes and their expression profiles associated with various types and stages of breast cancer.

The invention includes methods of diagnosing breast cancer in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer.

The invention also includes methods of detecting the progression of breast cancer. For instance, methods of the invention include detecting the progression of breast cancer in a patient comprising the step of detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer progression. In some preferred embodiments, PCA (Principal Component Analysis) based on all or a portion of the group of 50 genes identified in Table 1 may be used to differentiate between the different stages of breast cancer such as normal versus DCIS (ductal carcinoma *in-situ*) or DCIS versus microinvasive tissue samples. In some preferred embodiments, one or more genes may be selected from Tables 1, 3, 4 and/or 5.

In some aspects, the present invention provides a method of monitoring the treatment of a patient with breast cancer, comprising administering a pharmaceutical composition to the patient and preparing a gene expression profile from a cell or tissue

4

sample from the patient and comparing the patient gene expression profile to a gene expression from a cell population comprising normal breast cells or to a gene expression profile from a cell population comprising breast cancer cells or to both. In some preferred embodiments, the gene profile will include the expression level of one or more genes in Tables 1-5.

5

10

15

20

25

30

Another aspect of the present invention includes a method of treating a patient with breast cancer, comprising administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5, preparing a gene expression profile from a cell or tissue sample from the patient comprising tumor cells and comparing the patient expression profile to a gene expression profile from an untreated cell population comprising breast cancer cells.

In another aspect, the present invention provides a method of identifying ductal carcinoma in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 1-5, wherein differential expression of the genes in Tables 1-5 is indicative of ductal carcinoma. In addition, by determining the expression level of two or more genes in the group of genes listed in Tables 1-5, one skilled in the art can differentiate between DCIS and a cribiform type of DCIS that is more prone to microinvasion.

In another aspect, the present invention provides a method of detecting the progression of carcinogenesis in a patient, comprising detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast carcinogenesis. Figures 6 and 7 are a graphical representation of how the genes listed in Table 5 cluster with disease stages in breast cancer.

The invention further includes methods of screening for an agent capable of modulating the onset or progression of breast cancer, comprising the steps of exposing a cell to the agent; and detecting the expression level of two or more genes from Tables 1-5. In some embodiments, the breast cancer may be a ductal carcinoma. In some preferred embodiments, one or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5. In some preferred methods, it may be desirable to detect all or nearly all of the genes in the tables.

The invention further includes compositions comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 1-5 as well as solid supports comprising at least two probes, wherein each of the probes comprises a sequence that specifically hybridizes to

10

15

20

25

30

a gene in Tables 1-5. In some preferred embodiments, one or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5.

The invention further includes computer systems comprising a database containing information identifying the expression level in breast tissue of a set of genes comprising at least two genes in Tables 1-5 and a user interface to view the information. In some preferred embodiments, one or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5. The database may further include sequence information for the genes, information identifying the expression level for the set of genes in normal breast tissue and cancerous tissue and may contain links to external databases such as GenBank.

Lastly, the invention includes methods of using the databases, such as methods of using the disclosed computer systems to present information identifying the expression level in a tissue or cell of at least one gene in Tables 1-5, comprising the step of comparing the expression level of at least one gene in Tables 1-5 in the tissue or cell to the level of expression of the gene in the database. In some preferred embodiments, two or more genes may be selected from a group consisting of those listed in Tables 1, 3, 4 and/or 5.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an E- northern showing the expression of topoisomerase II alpha in various tissue types.

Figure 2 is an E-northern showing the expression of ICBP90 in various tissue types.

Figure 3 is an E-northern showing the expression of MCT4 gene.

Figure 4 is an E-northern showing the expression of the frizzled related protein.

Figure 5 is an E-northern showing the expression of an EST Affy ID AI668620.

Figure 6 is a PCA of the set of 28 samples using the top 50 genes identified by p-values.

Figure 7 is a PCA of the set of 33 samples using the top 50 genes and ESTs identified by p-values.

Figure 8 is a PCA of the set of 91 samples using the top 31 myo-lamina genes and ESTs.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Many biological functions are accomplished by altering the expression of various genes through transcriptional (e.g., through control of initiation, provision of RNA precursors, RNA processing, etc.) and/or translational control. For example, fundamental

6

biological processes such as cell cycle, cell differentiation and cell death, are often characterized by the variations in the expression levels of groups of genes.

5

10

15

20

25

30

Changes in gene expression also are associated with pathogenesis. For example, the lack of sufficient expression of functional tumor suppressor genes and/or the over expression of oncogene/protooncogenes could lead to tumorgenesis or hyperplastic growth of cells (Marshall, *Cell* 64, 313-326 (1991); Weinberg, *Science*, 254, 1138-1146 (1991)). Thus, changes in the expression levels of particular genes (e.g., oncogenes or tumor suppressors) serve as signposts for the presence and progression of various diseases.

Monitoring changes in gene expression may also provide certain advantages during drug screening and development. Often drugs are pre-screened for the ability to interact with a major target without regard to other effects the drugs have on cells. Often such other effects cause toxicity in the whole animal, which prevent the development and use of the potential drug.

Applicants have examined samples from normal breast tissue and from cancerous breast tissue to identify global changes in gene expression between tumor biopsies and normal tissue. These global changes in gene expression, also referred to as expression profiles, provide useful markers for diagnostic uses as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

The gene expression profiles described herein were derived from normal and tumor samples from female patients between the ages of 39 and 52 years old, and were from three different ethnic origins (Caucasian, African-American and Asian). Infiltrating Ductal Carcinoma (IDC) patient samples were studied for cancer-related expression, as 85% of the breast cancer patients were afflicted with this form of the disease.

Histological analysis of each tissue sample was performed and samples were segregated into either normal or malignant categories. The normal tissue samples were acquired from neighboring tissue of patients suffering from one of the following disorders: macromastia, mild fibrosis, infiltrating lobular carcinoma, or infiltrating ducal carcinoma, however; each tissue was diagnosed as normal by histological analysis. Samples were also characterized by the type and grade of IDC for each patient sample utilized in the study.

The present invention provides compositions and methods to detect the level of expression of genes that may be differentially expressed dependent upon the state of the cell, *i.e.*, normal versus cancerous. These expression profiles of genes provide molecular tools for evaluating toxicity, drug efficacy, drug metabolism, development, and disease

PCT/US02/02176

monitoring. Changes in the expression profile from a baseline profile can be used as an indication of such effects. Those skilled in the art can use any of a variety of known techniques to evaluate the expression of one or more of the genes and/or gene fragments identified in the instant application in order to observe changes in the expression profile in a tissue or sample of interest.

## **Definitions**

5

10

15

20

25

30

In the description that follows, numerous terms and phrases known to those skilled in the art are used. In the interest of clarity and consistency of interpretation, the definitions of certain terms and phrases are provided.

As used herein, the phrase "detecting the level of expression" includes methods that quantify expression levels as well as methods that determine whether a gene of interest is expressed at all. Thus, an assay which provides a yes or no result without necessarily providing quantification of an amount of expression is an assay that requires "detecting the level of expression" as that phrase is used herein.

As used herein, oligonucleotide sequences that are complementary to one or more of the genes described herein, refers to oligonucleotides that are capable of hybridizing under stringent conditions to at least part of the nucleotide sequence of said genes. Such hybridizable oligonucleotides will typically exhibit at least about 75% sequence identity at the nucleotide level to said genes, preferably about 80% or 85% sequence identity or more preferably about 90% or 95% or more nucleotide sequence identity to said genes.

"Bind(s) substantially" refers to complementary hybridization between a probe nucleic acid and a target nucleic acid and embraces minor mismatches that can be accommodated by reducing the stringency of the hybridization media to achieve the desired detection of the target polynucleotide sequence.

The terms "background" or "background signal intensity" refer to hybridization signals resulting from non-specific binding, or other interactions, between the labeled target nucleic acids and components of the oligonucleotide array (e.g., the oligonucleotide probes, control probes, the array substrate, etc.). Background signals may also be produced by intrinsic fluorescence of the array components themselves. A single background signal can be calculated for the entire array, or a different background signal may be calculated for each target nucleic acid. In a preferred embodiment, background is calculated as the average hybridization signal intensity for the lowest 5% to 10% of the probes in the array, or, where a different background signal is calculated for each target gene, for the lowest 5%

to 10% of the probes for each gene. Of course, one of skill in the art will appreciate that where the probes to a particular gene hybridize well and thus appear to be specifically binding to a target sequence, they should not be used in a background signal calculation. Alternatively, background may be calculated as the average hybridization signal intensity produced by hybridization to probes that are not complementary to any sequence found in the sample (e.g., probes directed to nucleic acids of the opposite sense or to genes not found in the sample such as bacterial genes where the sample is mammalian nucleic acids). Background can also be calculated as the average signal intensity produced by regions of the array that lack any probes at all.

5

10

15

20

25

30

The phrase "hybridizing specifically to" refers to the binding, duplexing or hybridizing of a molecule substantially to or only to a particular nucleotide sequence or sequences under stringent conditions when that sequence is present in a complex mixture (e.g., total cellular) DNA or RNA.

Assays and methods of the invention may utilize available formats to simultaneously screen at least about 100, preferably about 1000, more preferably about 10,000 and most preferably about 1,000,000 or more different nucleic acid hybridizations.

The terms "mismatch control" or "mismatch probe" refer to a probe whose sequence is deliberately selected not to be perfectly complementary to a particular target sequence. For each mismatch (MM) control in a high-density array there typically exists a corresponding perfect match (PM) probe that is perfectly complementary to the same particular target sequence. The mismatch may comprise one or more bases that are not complementary to the corresponding bases of the target sequence.

While the mismatch(s) may be located anywhere in the mismatch probe, terminal mismatches are less desirable as a terminal mismatch is less likely to prevent hybridization of the target sequence. In a particularly preferred embodiment, the mismatch is located at or near the center of the probe such that the mismatch is most likely to destabilize the duplex with the target sequence under the test hybridization conditions.

The term "perfect match probe" refers to a probe that has a sequence that is perfectly complementary to a particular target sequence. The test probe is typically perfectly complementary to a portion (subsequence) of the target sequence. The perfect match (PM) probe can be a "test probe", a "normalization control" probe, an expression level control probe and the like. A perfect match control or perfect match probe is, however, distinguished from a "mismatch control" or "mismatch probe."

10

15

20

25

30

As used herein a "probe" is defined as a nucleic acid, preferably an oligonucleotide, capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (i.e., A, G, U, C or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in probes may be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages.

The term "stringent conditions" refers to conditions under which a probe will hybridize to its target subsequence, but with only insubstantial hybridization to other sequences or to other sequences such that the difference may be identified. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH.

Typically, stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

The "percentage of sequence identity" or "sequence identity" is determined by comparing two optimally aligned sequences or subsequences over a comparison window or span, wherein the portion of the polynucleotide sequence in the comparison window may optionally comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical subunit (e.g., nucleic acid base or amino acid residue) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Percentage sequence identity when calculated using the programs GAP or BESTFIT (see below) is calculated using default gap weights.

Homology or identity may be determined by BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx,

10

15

20

25

30

tblastn and tblastx (Karlin et al., Proc Natl Acad Sci USA 87, 2264-2268 (1990) and Altschul, J Mol Evol 36, 290-300 (1993), fully incorporated by reference) which are tailored for sequence similarity searching. The approach used by the BLAST program is to first consider similar segments between a query sequence and a database sequence, then to evaluate the statistical significance of all matches that are identified and finally to summarize only those matches which satisfy a preselected threshold of significance. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al., (Nature Genet 6, 119-129 (1994)) which is fully incorporated by reference. The search parameters for histogram, descriptions, alignments, expect (i.e., the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff et al., Proc Natl Acad Sci USA 89, 10915-10919, (1992) fully incorporated by reference). Four blastn parameters were adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink<sup>th</sup> position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings were Q=9; R=2; wink=1; and gapw=32. A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

## Uses of Differentially Expressed Genes

The present invention identifies those genes differentially expressed between normal breast tissue and cancerous breast tissue. One of skill in the art can select one or more of the genes identified as being differentially expressed in Tables 1-5 and use the information and methods provided herein to interrogate or test a particular sample. For a particular interrogation of two conditions or sources, it may be desirable to select those genes which display a great deal of difference in the expression pattern between the two conditions or sources. At least a two-fold difference may be desirable, but a three-fold, five-fold or ten-fold difference may be preferred in some instances. Interrogations of the genes or proteins can be performed to yield different information.

Diagnostic Uses for the Breast Cancer Markers

10

15

20

25

30

As described herein, the genes and gene expression information provided in Tables 1-5 may be used as diagnostic markers for the prediction or identification of the malignant state of breast tissue. For instance, a breast tissue sample or other sample from a patient may be assayed by any of the methods known to those skilled in the art, and the expression levels from one or more genes from Tables 1-5, may be compared to the expression levels found in normal breast tissue, tissue from breast carcinoma or both. Expression profiles generated from the tissue or other samples that substantially resemble an expression profile from normal or diseased breast tissue may be used, for instance, to aid in disease diagnosis. Comparison of the expression data, as well as available sequence or other information may be done by researcher or diagnostician or may be done with the aid of a computer and databases as described herein.

For example, genes over-expressed by 3-fold or greater, as well as having the smallest p-values from a t-test, were discovered by comparing 13 normal tissue samples and 15 infiltrating ductal carcinoma tissue samples composed of mostly stage II and III tissue samples. This analysis provided a set of genes (listed in Table 1) capable of distinguishing between the 13 normal and 15 tumor samples by PCA (Principal Component Analysis). In order to evaluate the ability of the genes to distinguish between normal and tumor tissue samples, a group of 33 tissues was selected from an existing gene expression database composed of normal, benign, DCIS (ductal carcinoma *in-situ*), microinvasive, stage I, stage II, and stage III breast cancer samples. PCA of the 33 tissue samples indicated that the genes selected based on the smallest p-values classified 32 out of 33 tissue samples correctly, while one stage I tissue sample was misclassified as a normal sample. Accordingly, these genes can be used diagnostically to differentiate normal/benign samples from tissue samples containing intraductal or infiltrating ductal carcinoma of the breast.

In another study, the PCA based on this group of genes indicates that these genes may be used to differentiate between the different stages of breast cancer such as normal versus DCIS or DCIS versus microinvasive tissue samples as graphically shown in Figures 6 and 7. The DCIS sample that contained focal microinvasions was grouped with the Stage I and II tumor samples. This group of genes may be used to determine if a DCIS sample contains microinvasions.

Use of the Breast Cancer Markers for Monitoring Disease Progression

Molecular expression markers for breast cancer can be used to confirm the type and progression of cancer made on the basis of morphological criteria. For example, normal

12

breast tissue could be distinguished from invasive carcinoma based on the level and type of genes expressed in a tissue sample. In some situations, identifications of cell type or source is ambiguous based on classical criteria. In these situations, the molecular expression markers of the present invention are useful.

In addition, progression of ductal carcinoma in situ to microinvasive carcinoma can be monitored by following the expression patterns of the involved genes using the molecular expression markers of the present invention. Monitoring of the efficacy of certain drug regimens can also be accomplished by following the expression patterns of the molecular expression markers.

5

10

15

20

25

30

\*

In addition to the different disease progression stages which have been shown in Figures 6-7, as shown in the examples below, other developmental stages can be identified using these same molecular expression markers. While the importance of these markers in development has been shown here, variations in their expression may occur at other times. For example, variation in the expression level of one or more of the marker genes identified herein may be use to distinguish benign stages of breast cancer from malignant states.

As described above, the genes and gene expression information provided in Tables 1-5 may also be used as markers for the direct monitoring of disease progression, for instance, the development of breast cancer. For instance, a breast tissue sample or other sample from a patient may be assayed by any of the methods known to those of skill in the art, and the expression levels in the sample from a gene or genes from Tables 1-5 may be compared to the expression levels found in normal breast tissue, tissue from breast cancer or both. Comparison of the expression data, as well as available sequence or other informationary be done by researcher or diagnostician or may be done with the aid of a computer and databases as described herein.

For instance, methods of this invention may use the 35 gene group (profile) composed of genes expressed in myoepithelial cells and basal lamina components in Table 3. The absence of both myoepithelial cells or basement membrane components usually indicates that the intraductal carcinoma is invasive. This group of 35 genes listed in Table 3 may be used to determine if myoepithelial and/or basal lamina components are present in a tissue sample. It includes 23 genes exhibiting a fold change of 3 fold or higher and 12 genes displaying a change of less than 3 fold. This group of 23 genes was used to distinguish between normal and tumor samples for a group of 33 tissue samples. In this study, the 23 genes were able to classify 32 out of 33 samples correctly and 26 out of 28 samples used to isolate this subgroup of genes. This group of genes can be used to identify

WO 02/059271

the various stages of ductal carcinoma tissues more discretely than the 50-gene set. The study also demonstrates that this group of genes can differentiate between DCIS and a cribiform type of DCIS that is more prone to microinvasion. Clinically, the ability to discern DCIS with microinvasions or phenotypes prone to microinvasions such as the cribiform type would allow subgrouping of the samples containing microinvasions as a type of patient that should be treated more aggressively than DCIS patients lacking this gene expression fingerprint. A subclass of DCIS (cribiform type) based on the gene expression fingerprint may be subgrouped as a micro invasive sample based on the gene expression pattern associated with this sample.

10

15

5

## Use of the Breast Cancer Markers for Drug Screening

According to the present invention, potential drugs can be screened to determine if application of the drug alters the expression of one or more of the genes identified herein. This may be useful, for example, in determining whether a particular drug is effective in treating a particular patient with breast cancer. In the case where a gene's expression is affected by the potential drug such that its level of expression returns to normal, the drug is indicated in the treatment of breast cancer. Similarly, a drug which causes expression of a gene which is not normally expressed by epithelial cells in the breast, may be contraindicated in the treatment of breast cancer.

20

25

According to the present invention, the genes identified in Tables 1-5 may also be used as markers to evaluate the effects of a candidate drug or agent on a cell, particularly a cell undergoing malignant transformation, for instance, a breast cancer cell or tissue sample. A candidate drug or agent can be screened for the ability to stimulate the transcription or expression of a given marker or markers (drug targets) or to down-regulate or inhibit the transcription or expression of a marker or markers. According to the present invention, one can also compare the specificity of a drug's effects by looking at the number of markers affected by the drug and comparing them to the number of markers affected by a different drug. A more specific drug will affect fewer transcriptional targets. Similar sets of markers identified for two drugs indicates a similarity of effects.

30

Assays to monitor the expression of a marker or markers as defined in Tables 1-5 may utilize any available means of monitoring for changes in the expression level of the nucleic acids of the invention. As used herein, an agent is said to modulate the expression of a nucleic acid of the invention if it is capable of up- or down-regulating expression of the nucleic acid in a cell.

Agents that are assayed in the above methods can be randomly selected or rationally selected or designed. As used herein, an agent is said to be randomly selected when the agent is chosen randomly without considering the specific sequences involved in the association of the a protein of the invention alone or with its associated substrates, binding partners, etc. An example of randomly selected agents is the use a chemical library or a peptide combinatorial library, or a growth broth of an organism.

As used herein, an agent is said to be rationally selected or designed when the agent is chosen on a nonrandom basis which takes into account the sequence of the target site and/or its conformation in connection with the agents action. Agents can be selected or designed by utilizing the peptide sequences that make up these sites. For example, a rationally selected peptide agent can be a peptide whose amino acid sequence is identical to or a derivative of any functional consensus site.

The agents of the present invention can be, as examples, peptides, small chemical molecules, vitamin derivatives, as well as carbohydrates, lipids, oligonucleotides and covalent and non-covalent combinations thereof. Dominant negative proteins, DNA encoding these proteins, antibodies to these proteins, peptide fragments of these proteins or mimics of these proteins may be introduced into cells to affect function. "Mimic" as used herein refers to the modification of a region or several regions of a peptide molecule to provide a structure chemically different from the parent peptide but topographically and functionally similar to the parent peptide (see Grant in Molecular Biology and Biotechnology, Meyers, ed., VCH Publishers (1995)). A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of the present invention.

#### 25 Assay Formats

5

10

15

20

30

The genes identified as being differentially expressed in breast cancer may be used in a variety of nucleic acid detection assays to detect or quantify the expression level of a gene or multiple genes in a given sample. For example, traditional Northern blotting, nuclease protection, RT-PCR and differential display methods may be used for detecting gene expression levels.

The protein products of the genes identified herein can also be assayed to determine the amount of expression. Methods for assaying for a protein include Western blot, immunoprecipitation, radioimmunoassay. It is preferred, however, that the mRNA be assayed as an indication of expression. Methods for assaying for mRNA include Northern

10

15

20

25

30

blots, slot blots, dot blots, and hybridization to an ordered array of oligonucleotides. Any method for specifically and quantitatively measuring a specific protein or mRNA or DNA product can be used. However, methods and assays of the invention are most efficiently designed with PCR or array or chip hybridization-based methods for detecting the expression of a large number of genes.

Any hybridization assay format may be used, including solution-based and solid support-based assay formats. A preferred solid support is a high density array also known as a DNA chip or a gene chip. One variation of the DNA chip contains hundreds of thousands of discrete microscopic channels that pass completely through it. Probe molecules are attached to the inner surface of these channels, and molecules from the samples to be tested flow through the channels, coming into close proximity with the probes for hybridization. In one assay format, gene chips containing probes to at least two genes from Tables 1-5 may be used to directly monitor or detect changes in gene expression in the treated or exposed cell as described herein. Assays of the invention may measure the expression levels of about one, two, three, five, seven, ten, 15, 20, 25, 50, 100 or more genes in the Tables.

The genes and ESTs of the present invention may be assayed in any convenient sample form. For example, samples may be assayed in the form mRNA or reverse transcribed mRNA. Samples may be cloned or not and the samples or individual genes may be amplified or not. The cloning itself does not appear to bias the representation of genes within a population. However, it may be preferable to use polyA+RNA as a source, as it can be used with less processing steps. In some embodiments, it may be preferable to assay the protein or peptide expressed by the gene.

The sequences of the expression marker genes of Tables 1-5 are available in the public databases. Tables 1-5 provide the Accession numbers and name for each of the sequences. The sequences of the genes in GenBank are herein expressly incorporated by reference in their entirety as of the filing date of this application. (see <a href="https://www.ncbi.nim.nih.gov">www.ncbi.nim.nih.gov</a>).

Additional assay formats may be used to monitor the ability of the agent to modulate the expression of a gene identified in Tables 1-5. For instance, as described above, mRNA expression may be monitored directly by hybridization of probes to the nucleic acids of the invention. Cell lines are exposed to an agent to be tested under appropriate conditions and time and total RNA or mRNA is isolated by standard procedures such those disclosed in Sambrook et al., Molecular Cloning - A Laboratory Manual, Cold Spring Harbor

10

15

20

25

30

SICHTOOID JUIC MARCOTTA !

16

Laboratory Press, Cold Spring Harbor, NY (1989)). In some embodiments, it may be desirable to amplify one or more of the RNA molecules isolated prior to application of the RNA to the gene chip. Using techniques well known in the art, the RNA may be reverse transcribed and amplified in the form of DNA or may be reverse transcribed into DNA and the DNA used as a template for transcription to generate recombinant RNA. Any method that results in the production of a sufficient quantity of nucleic acid to be hybridized effectively to the gene chip may be used.

In another format, cell lines that contain reporter gene fusions between the open reading frame and or the 3' or 5' regulatory regions of a gene in Tables 1-5 and any assayable fusion partner may be prepared. Numerous assayable fusion partners are known and readily available including the firefly luciferase gene and the gene encoding chloramphenical acetyltransferase (Alam et al., Anal Biochem 188, 245-254 (1990)). Cell lines containing the reporter gene fusions are then exposed to the agent to be tested under appropriate conditions and time. Differential expression of the reporter gene between samples exposed to the agent and control samples identifies agents which modulate the expression of the nucleic acid.

In another assay format, cells or cell lines are first identified which express one or more of the gene products of the invention physiologically. Cells and/or cell lines so identified would preferably comprise the necessary cellular machinery to ensure that the transcriptional and/or translational apparatus of the cells would faithfully mimic the response of normal or cancerous breast tissue to an exogenous agent. Such machinery would likely include appropriate surface transduction mechanisms and/or cytosolic factors. Such cell lines may be, but are not required to be, derived from breast tissue. The cells and/or cell lines may then be contacted with an agent and the expression of one or more of the genes of interest may then be assayed. The genes may be assayed at the mRNA level and/or at the protein level.

In some embodiments, such cells or cell lines may be transduced or transfected with an expression vehicle (e.g., a plasmid or viral vector) containing an expression construct comprising an operable 5'-promoter containing end of a gene of interest identified in Tables 1-5 fused to one or more nucleic acid sequences encoding one or more antigenic fragments. The construct may comprise all or a portion of the coding sequence of the gene of interest which may be positioned 5'- or 3'- to a sequence encoding an antigenic fragment. The coding sequence of the gene of interest may be translated or un-translated after transcription of the gene fusion. At least one antigenic fragment may be translated. The antigenic

fragments are selected so that the fragments are under the transcriptional control of the promoter of the gene of interest and are expressed in a fashion substantially similar to the expression pattern of the gene of interest. The antigenic fragments may be expressed as polypeptides whose molecular weight can be distinguished from the naturally occurring polypeptides. In some embodiments, gene products of the invention may further comprise an immunologically distinct tag. Such a process is well known in the art (see Sambrook et al., supra).

Cells or cell lines transduced or transfected as outlined above are then contacted with agents under appropriate conditions; for example, the agent comprises a pharmaceutically acceptable excipient and is contacted with cells comprised in an aqueous physiological buffer such as phosphate buffered saline (PBS) at physiological pH, Eagles balanced salt solution (BSS) at physiological pH, PBS or BSS comprising serum or conditioned media comprising PBS or BSS and serum incubated at 37°C. Said conditions may be modulated as deemed necessary by one of skill in the art. Subsequent to contacting the cells with the agent, said cells will be disrupted and the polypeptides of the lysate are fractionated such that a polypeptide fraction is pooled and contacted with an antibody to be further processed by immunological assay (e.g., ELISA, immunoprecipitation or Western blot). The pool of proteins isolated from the "agent-contacted" sample will be compared with a control sample where only the excipient is contacted with the cells and an increase or decrease in the immunologically generated signal from the "agent-contacted" sample compared to the control will be used to distinguish the effectiveness of the agent.

Another embodiment of the present invention provides methods for identifying agents that modulate the levels, concentration or at least one activity of a protein(s) encoded by the genes in Tables 1-5. Such methods or assays may utilize any means of monitoring or detecting the desired activity.

In one format, the relative amounts of a protein of the invention produced in a cell population that has been exposed to the agent to be tested may be compared to the amount produced in an un-exposed control cell population. In this format, probes such as specific antibodies are used to monitor the differential expression of the protein in the different cell populations. Cell lines or populations are exposed to the agent to be tested under appropriate conditions and time. Cellular lysates may be prepared from the exposed cell line or population and a control, unexposed cell line or population. The cellular lysates are then analyzed with the probe, such as a specific antibody.

5

10

15

20

25

30

Probe Design

5

10

15

20

25

30

DESCRIPTION OF THE PROPERTY AND LA

Probes based on the sequences of the genes described herein may be prepared by any commonly available method. Oligonucleotide probes for assaying the tissue or cell sample are preferably of sufficient length to specifically hybridize only to appropriate, complementary genes or transcripts. Typically the oligonucleotide probes will be at least 10, 12, 14, 16, 18, 20 or 25 nucleotides in length. In some cases longer probes of at least 30, 40, or 50 nucleotides will be desirable.

One of skill in the art will appreciate that an enormous number of array designs are suitable for the practice of this invention. The high density array will typically include a number of probes that specifically hybridize to the sequences of interest. See WO 99/32660 for methods of producing probes for a given gene or genes. In addition, in a preferred embodiment, the array will include one or more control probes.

High density array chips of the invention include "test probes." Test probes may be oligonucleotides that range from about 5 to about 500 or about 5 to about 50 nucleotides, more preferably from about 10 to about 40 nucleotides and most preferably from about 15 to about 40 nucleotides in length. In other particularly preferred embodiments, the probes are about 20 or 25 nucleotides in length. In another preferred embodiment, test probes are double or single strand DNA sequences. DNA sequences may be isolated or cloned from natural sources or amplified from natural sources using natural nucleic acid as templates. These probes have sequences complementary to particular subsequences of the genes whose expression they are designed to detect. Thus, the test probes are capable of specifically hybridizing to the target nucleic acid they are to detect.

In addition to test probes that bind the target nucleic acid(s) of interest, the high density array can contain a number of control probes. The control probes fall into three categories referred to herein as (1) normalization controls; (2) expression level controls; and (3) mismatch controls.

Normalization controls are oligonucleotide or other nucleic acid probes that are complementary to labeled reference oligonucleotides or other nucleic acid sequences that are added to the nucleic acid sample. The signals obtained from the normalization controls after hybridization provide a control for variations in hybridization conditions, label intensity, "reading" efficiency and other factors that may cause the signal of a perfect hybridization to vary between arrays. In a preferred embodiment, signals (e.g., fluorescence

19

intensity) read from all other probes in the array are divided by the signal (e.g., fluorescence intensity) from the control probes thereby normalizing the measurements.

Virtually any probe may serve as a normalization control. However, it is recognized that hybridization efficiency varies with base composition and probe length. Preferred normalization probes are selected to reflect the average length of the other probes present in the array, however, they can be selected to cover a range of lengths. The normalization control(s) can also be selected to reflect the (average) base composition of the other probes in the array, however in a preferred embodiment, only one or a few probes are used and they are selected such that they hybridize well (i.e., no secondary structure) and do not match any target-specific probes.

Expression level controls are probes that hybridize specifically with constitutively expressed genes in the biological sample. Virtually any constitutively expressed gene provides a suitable target for expression level controls. Typical expression level control probes have sequences complementary to subsequences of constitutively expressed "housekeeping genes" including, but not limited to the  $\beta$ -actin gene, the transferrin receptor gene, the GAPDH gene, and the like.

Mismatch controls may also be provided for the probes to the target genes, for expression level controls or for normalization controls. Mismatch controls are oligonucleotide probes or other nucleic acid probes identical to their corresponding test or control probes except for the presence of one or more mismatched bases. A mismatched base is a base selected so that it is not complementary to the corresponding base in the target sequence to which the probe would otherwise specifically hybridize. One or more mismatches are selected such that under appropriate hybridization conditions (e.g., stringent conditions) the test or control probe would be expected to hybridize with its target sequence, but the mismatch probe would not hybridize (or would hybridize to a significantly lesser extent). Preferred mismatch probes contain a central mismatch. Thus, for example, where a probe is a twenty-mer, a corresponding mismatch probe may have the identical sequence except for a single base mismatch (e.g., substituting a G, a C or a T for an A) at any of positions 6 through 14 (the central mismatch).

Mismatch probes thus provide a control for non-specific binding or cross hybridization to a nucleic acid in the sample other than the target to which the probe is directed. Mismatch probes also indicate whether a hybridization is specific or not. For example, if the target is present the perfect match probes should be consistently brighter

5

10

15

20

25

30

20

than the mismatch probes. In addition, if all central mismatches are present, the mismatch probes can be used to detect a mutation. The difference in intensity between the perfect match and the mismatch probe (I(PM) - I(MM)) provides a good measure of the concentration of the hybridized material.

5

10

15

20

25

30

#### Nucleic Acid Samples

As is apparent to one of ordinary skill in the art, nucleic acid samples used in the methods and assays of the invention may be prepared by any available method or process. Methods of isolating total mRNA are also well known to those of skill in the art. For example, methods of isolation and purification of nucleic acids are described in detail in Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology, Vol. 24, Hybridization With Nucleic Acid Probes: Theory and Nucleic Acid Probes, P. Tijssen, ed., Elsevier Press, New York (1993). Such samples include RNA samples, but also include cDNA synthesized from a mRNA sample isolated from a cell or tissue of interest. Such samples also include DNA amplified from the cDNA, and an RNA transcribed from the amplified DNA. One of skill in the art would appreciate that it may be desirable to inhibit or destroy RNase present in homogenates before homogenates can be used.

Biological samples may be of any biological tissue or fluid or cells from any organism as well as cells raised *in vitro*, such as cell lines and tissue culture cells. Frequently the sample will be a "clinical sample" which is a sample derived from a patient. Typical clinical samples include, but are not limited to, breast tissue biopsy, sputum, blood, blood-cells (*e.g.*, white cells), tissue or fine needle biopsy samples, urine, peritoneal fluid, and pleural fluid, or cells therefrom.

Biological samples may also include sections of tissues, such as frozen sections or formalin fixed sections taken for histological purposes.

### Solid Supports

Solid supports containing oligonucleotide probes for differentially expressed genes can be any solid or semisolid support material known to those skilled in the art. Suitable examples include, but are not limited to, membranes, filters, tissue culture dishes, polyvinyl chloride dishes, beads, test strips, silicon or glass based chips and the like. Suitable glass wafers and hybridization methods are widely available, for example, those disclosed by Beattie (WO 95/11755). Any solid surface to which oligonucleotides can be bound, either directly or indirectly, either covalently or non-covalently, can be used. In some

21

embodiments, it may be desirable to attach some oligonucleotides covalently and others non-covalently to the same solid support.

A preferred solid support is a high density array or DNA chip. These contain a particular oligonucleotide probe in a predetermined location on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the predetermined location has an identical sequence. Such predetermined locations are termed features. There may be, for example, from 2, 10, 100, 1000 to 10,000, 100,000 or 400,000 of such features on a single solid support. The solid support, or the area within which the probes are attached may be on the order of a square centimeter.

Oligonucleotide probe arrays for expression monitoring can be made and used according to any techniques known in the art (see for example, Lockhart et al., Nat Biotechnol 14, 1675-1680 (1996); McGall et al., Proc Nat Acad Sci USA 93, 13555-13460 (1996)). Such probe arrays may contain at least two or more oligonucleotides that are complementary to or hybridize to two or more of the genes described herein. Such arrays my also contain oligonucleotides that are complementary or hybridize to at least 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50, 70 or more the genes described herein.

Methods of forming high density arrays of oligonucleotides with a minimal number of synthetic steps are known. The oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling (see Pirrung et al., (1992) U.S. Patent No. 5,143, 854; Fodor et al., (1998) U.S. Patent No. 5,800,992; Chee et al., (1998) U.S. Patent No. 5,837,832).

In brief, the light-directed combinatorial synthesis of oligonucleotide arrays on a glass surface proceeds using automated phosphoramidite chemistry and chip masking techniques. In one specific implementation, a glass surface is derivatized with a silane reagent containing a functional group, e.g., a hydroxyl or amine group blocked by a photolabile protecting group. Photolysis through a photolithogaphic mask is used selectively to expose functional groups which are then ready to react with incoming 5' photoprotected nucleoside phosphoramidites. The phosphoramidites react only with those sites which are illuminated (and thus exposed by removal of the photolabile blocking group). Thus, the phosphoramidites only add to those areas selectively exposed from the preceding step. These steps are repeated until the desired array of sequences have been synthesized on the solid surface. Combinatorial synthesis of different oligonucleotide

5

10

15

20

25

30

٠.

22

analogues at different locations on the array is determined by the pattern of illumination during synthesis and the order of addition of coupling reagents.

In addition to the foregoing, additional methods which can be used to generate an array of oligonucleotides on a single substrate are described in Fodor *et al.*, WO 93/09668. High density nucleic acid arrays can also be fabricated by depositing pre-made or natural nucleic acids in predetermined positions. Synthesized or natural nucleic acids are deposited on specific locations of a substrate by light directed targeting and oligonucleotide directed targeting. Another embodiment uses a dispenser that moves from region to region to deposit nucleic acids in specific spots.

10

15

20

25

30

5

#### Hybridization

Nucleic acid hybridization simply involves contacting a probe and target nucleic acid under conditions where the probe and its complementary target can form stable hybrid duplexes through complementary base pairing (see Lockhart et al., WO 99/32660). The nucleic acids that do not form hybrid duplexes are then washed away leaving the hybridized nucleic acids to be detected, typically through detection of an attached detectable label. It is generally recognized that nucleic acids are denatured by increasing the temperature or decreasing the salt concentration of the buffer containing the nucleic acids. Under low stringency conditions (e.g., low temperature and/or high salt) hybrid duplexes (e.g., DNA-DNA, RNA-RNA or RNA-DNA) will form even where the annealed sequences are not perfectly complementary. Thus, specificity of hybridization is reduced at lower stringency. Conversely, at higher stringency (e.g., higher temperature or lower salt) successful hybridization requires fewer mismatches. One of skill in the art will appreciate that hybridization conditions may be selected to provide any degree of stringency. In a preferred embodiment, hybridization is performed at low stringency, in this case in 6x SSPE-T at 37°C (0.005% Triton x-100) to ensure hybridization and then subsequent washes are performed at higher stringency (e.g., 1× SSPE-T at 37°C) to eliminate mismatched hybrid duplexes. Successive washes may be performed at increasingly higher stringency (e.g., down to as low as 0.25× SSPET at 37°C to 50°C) until a desired level of hybridization specificity is obtained. Stringency can also be increased by addition of agents such as formamide. Hybridization specificity may be evaluated by comparison of hybridization to the test probes with hybridization to the various controls that can be present (e.g., expression level control, normalization control, mismatch controls, etc.).

In general, there is a tradeoff between hybridization specificity (stringency) and signal intensity. Thus, in a preferred embodiment, the wash is performed at the highest stringency that produces consistent results and that provides a signal intensity greater than approximately 10% of the background intensity. Thus, in a preferred embodiment, the hybridized array may be washed at successively higher stringency solutions and read between each wash. Analysis of the data sets thus produced will reveal a wash stringency above which the hybridization pattern is not appreciably altered and which provides adequate signal for the particular oligonucleotide probes of interest.

### Signal Detection

The hybridized nucleic acids are typically detected by detecting one or more labels attached to the sample nucleic acids. The labels may be incorporated by any of a number of means well known to those of skill in the art (see Lockhart *et al.*, WO 99/32660).

#### 15 Databases

10

20

25

30

The present invention includes relational databases containing sequence information, for instance for one or more of the genes of Tables 1-5, as well as gene expression information in various breast tissue samples. Databases may also contain information associated with a given sequence or tissue sample such as descriptive information about the gene associated with the sequence information, descriptive information concerning the clinical status of the tissue sample, or information concerning the patient from which the sample was derived. The database may be designed to include different parts, for instance a sequence database and a gene expression database. Methods for the configuration and construction of such databases are widely available, for instance, see Akerblom *et al.*, (1999) U.S. Patent No. 5,953,727, which is specifically incorporated herein by reference in its entirety.

The databases of the invention may be linked to an outside or external database. In a preferred embodiment, as described in Tables 1-5, the external database is GenBank and the associated databases maintained by the National Center for Biotechnology Information (NCBI).

Any appropriate computer platform may be used to perform the necessary comparisons between sequence information, gene expression information and any other information in the database or provided as an input. For example, a large number of computer workstations are available from a variety of manufacturers, such has those

available from Silicon Graphics. Client-server environments, database servers and networks are also widely available and appropriate platforms for the databases of the invention.

The databases of the invention may be used to produce, among other things, electronic Northern blots (E-Northerns) to allow the user to determine the cell type or tissue in which a given gene is expressed and to allow determination of the abundance or expression level of a given gene in a particular tissue or cell. The E-northern analysis can be used as a tool to discover tissue specific candidate therapeutic targets that are not over-expressed in tissues such as the liver, kidney, or heart. These tissue types often lead to detrimental side effects once drugs are developed and a first-pass screen to eliminate these targets early in the target discovery and validation process would be beneficial.

The databases of the invention may also be used to present information identifying the expression level in a tissue or cell of a set of genes comprising at least one gene in Tables 1-5 comprising the step of comparing the expression level of at least one gene in Tables 1-5 in the tissue to the level of expression of the gene in the database. Such methods may be used to predict the physiological state of a given tissue by comparing the level of expression of a gene or genes in Tables 1-5 from a sample to the expression levels found in tissue from normal breast tissue, tissue from breast carcinoma or both. Such methods may also be used in the drug or agent screening assays as described herein.

20

25

30

innonin aun magnatus I

5

10

15

Kits

The invention further includes kits combining, in different combinations, high-density oligonucleotide arrays, reagents for use with the arrays, signal detection and array-processing instruments, gene expression databases and analysis and database management software described above. The kits may be used, for example, to monitor the progression of breast cancer, to identify genes that show promise as new drug targets and to screen known and newly designed drugs as discussed above.

The databases packaged with the kits are a typically a compilation of expression patterns from human breast cancer tissue or cell lines and for gene and gene fragments as described herein (corresponding to the genes of Tables 1-5). In particular, the database software and packaged information include the expression results of Tables 1-5 that can be used to predict the cancerous state of a tissue sample by comparing the expression levels of the genes in the tissue or cell sample to the expression levels presented in Tables 1-5.

The kits may used in the pharmaceutical industry, where the need for early drug testing is strong due to the high costs associated with drug development, but where bioinformatics, in particular gene expression informatics, is still lacking. These kits will reduce the costs, time and risks associated with traditional new drug screening using cell cultures and laboratory animals. The results of large-scale drug screening of pre-grouped patient populations, pharmacogenomics testing, can also be applied to select drugs with greater efficacy and fewer side-effects. The kits may also be used by smaller biotechnology companies and research institutes who do not have the facilities for performing such large-scale testing themselves.

Databases and software designed for use with use with microarrays is discussed in Balaban et al., (2001) U.S. Patent Nos. 6,229,911, a computer-implemented method for managing information, stored as indexed tables, collected from small or large numbers of microarrays, and 6,185,561, a computer-based method with data mining capability for collecting gene expression level data, adding additional attributes and reformatting the data to produce answers to various queries. Chee et al., (1999) U.S. Patent No. 5,974,164, disclose a software-based method for identifying mutations in a nucleic acid sequence based on differences in probe fluorescence intensities between wild type and mutant sequences that hybridize to reference sequences. The object of the method is to predict regions or positions of mutation.

20

25

5

10

15

Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The preceding working examples therefore, are illustrative only and should not be construed as limiting in any way the scope of the invention.

#### Examples

## Example 1: Preparation of Breast Cancer Profiles

Tissue Sample Acquisition and Preparation

30

The patient tissue samples were derived from female patients; the average age for the normal and tumor samples was 39 and 52 years respectively. They stem from three different ethnic origins (Caucasian, African-American, and Asian). Furthermore, all tissue samples from Infiltrating Ductal Carcinoa (IDC) patient samples were studied for cancer-related expression, as 85% of the breast cancer patients were afflicted with this form of the

15

20

25

30

NICOTON AND DODGOTTAD I

disease. The samples are composed of normal, benign, DCIS (ductal carcinoma *in-situ*), microinvasive, stage II, and stage III breast cancer samples.

Histological analysis of each of the tissue samples was performed and samples were segregated into either normal or malignant categories. The normal tissue samples were acquired from neighboring tissue of patients suffering from one of the following disorders: macromastia, mild fibrosis, infiltrating lobular carcinoma, or infiltrating ducal carcinoma, however; each tissue was diagnosed as normal by histological analysis.

With minor modifications, the sample preparation protocol followed the Affymetrix GeneChip Expression Analysis Manual. Frozen tissue was first ground to powder using the Spex Certiprep 6800 Freezer Mill. Total RNA was then extracted using Trizol (Life Technologies). The total RNA yield for each sample (average tissue weight of 300 mg) was 200-500  $\mu$ g. Next, mRNA was isolated using the Oligotex mRNA Midi kit (Qiagen). Since the mRNA was eluted in a final volume of 400  $\mu$ l, an ethanol precipitation step was required to bring the concentration to 1  $\mu$ g/ $\mu$ l. Using 1-5  $\mu$ g of mRNA, double stranded cDNA was created using the SuperScript Choice system (Gibco-BRL). First strand cDNA synthesis was primed with a T7-(dT<sub>24</sub>) oligonucleotide. The cDNA was then phenol-chloroform extracted and ethanol precipitated to a final concentration of 1  $\mu$ g/ $\mu$ l.

From 2 µg of cDNA, cRNA was synthesized according to standard procedures. To biotin label the cRNA, nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics) were added to the reaction. After a 37°C incubation for six hours, the labeled cRNA was cleaned up according to the Rneasy Mini kit protocol (Qiagen). The cRNA was then fragmented (5× fragmentation buffer: 200 mM Tris-Acetate (pH 8.1), 500 mM KOAc, 150 mM MgOAc) for thirty-five minutes at 94°C.

55 μg of fragmented cRNA was hybridized on the human and the Human Genome U95 set of arrays for twenty-four hours at 60 rpm in a 45°C hybridization oven. The chips were washed and stained with Streptavidin Phycoerythrin (SAPE) (Molecular Probes) in Affymetrix fluidics stations. To amplify staining, SAPE solution was added twice with an anti-streptavidin biotinylated antibody (Vector Laboratories) staining step in between. Hybridization to the probe arrays was detected by fluorometric scanning (Hewlett Packard Gene Array Scanner). Following hybridization and scanning, the microarray images were analyzed for quality control, looking for major chip defects or abnormalities in hybridization signal. After all chips passed QC, the data was analyzed using Affymetrix GeneChip software (v3.0), and Experimental Data Mining Tool (EDMT) software (v1.0).

15

20

25

30

Gene Expression Analysis

All samples were prepared as described and hybridized onto the Affymetrix Human Genome U95 array. Each chip contains 16-20 oligonucleotide probe pairs per gene or cDNA clone. These probe pairs include perfectly matched sets and mismatched sets, both of which are necessary for the calculation of the average difference. The average difference is a measure of the intensity difference for each probe pair, calculated by subtracting the intensity of the mismatch from the intensity of the perfect match. This takes into consideration variability in hybridization among probe pairs and other hybridization artifacts that could affect the fluorescence intensities. Using the average difference value that has been calculated, an absolute call for each gene or EST is made.

The absolute call of present, absent or marginal is used to generate a Gene Signature, a tool used to identify those genes that are commonly present or commonly absent in a given sample set, according to the absolute call. For each set of samples, a median average difference was calculated using the average differences of each individual sample within the set. The median average difference typically must be greater than 20 to assure that the expression level is at least two standard deviations above the background noise of the hybridization. For the purposes of this study, only the genes and gene fragments with a median average difference greater than 20 were further studied in detail.

The Gene Signature for one set of samples is compared to the Gene Signature of another set of samples to determine the Gene Signature Differential. This comparison identifies the genes that are consistently present in one set of samples and consistently absent in the second set of samples.

The Gene Signature Curve is a graphic view of the number of genes consistently present in a given set of samples as the sample size increases, taking into account the genes commonly expressed among a particular set of samples, and discounting those genes whose expression is variable among those samples. The curve is also indicative of the number of samples necessary to generate an accurate Gene Signature. As the sample number increases, the number of genes common to the sample set decreases. The curve is generated using the positive Gene Signatures of the samples in question, determined by adding one sample at a time to the Gene Signature, beginning with the sample with the smallest number of present genes and adding samples in ascending order. The curve displays the sample size required for the most consistency and the least amount of expression variability from sample to sample. The point where this curve begins to level off represents the minimum

number of samples required for the Gene Signature. Graphed on the x-axis is the number of samples in the set, and on the y-axis is the number of genes in the positive Gene Signature. As a general rule, the acceptable percent of variability in the number of positive genes between two sample sets should be less than 5%.

5

10

20

25

30

THEODORIO JAIO CONTOCTIAN I

#### Fold Change analysis

The data was first filtered to exclude all genes that showed no expression in any of the samples. The ratio (tumor/normal) was calculated by comparing the mean expression value for each gene in the breast cancer sample set against the mean expression value of that gene in the normal breast sample set. For Table 2, genes were included in the analysis if they had a fold change  $\geq 3$  in either direction, and a p-value < 0.05 as determined by a two-tail unequal variance t-test. Out of the  $\sim 60,000$  genes surveyed by the Human Genome U95 set, 802 genes were present in the overall fold change analysis

15 Expression Profiles of Genes Differentially Expressed in Breast Cancer

Using the above described methods, genes that were predominantly over-expressed in breast cancer, or predominantly under-expressed in breast cancer were identified. Genes with consistent differential expression patterns provide potential targets for broad range diagnostics and therapeutics. For simplicity, applicants examined known genes by hierarchical cluster analysis developed by Eisen and colleagues to determine if functionally related genes would cluster together (see Eisen, et al. Proc Natl Acad Sci USA 95, 14863-14868 (1998)).

Table 2 lists the genes determined to be differentially expressed in cancerous breast tissues compared to normal breast tissue, with the fold change value for each gene. These genes or subsets of these genes comprise an overall breast cancer gene expression profile.

The well-characterized proliferation marker for breast cancer KI-67 had an average-fold change value of 2.8, which was calculated from 15 IDC tissue samples analyzed (see Gerdes, Semin Cancer Biol 1, 199-206 (1990)). As the fold change was below the present 3 fold criteria, the fold change value was not presented in Table 2. Some genes previously shown to be over or under expressed in breast cancer as indicated from the literature such as cytokeratins 5, 14, 15, 17, maspin, MMP 9 and 11, fibronectin, and pituitary tumor transforming 1, etc. are displayed in Table 2 as well as some genes such as p57(kip2), p63/p51/KET, mitosin, and pCDC55 whose expression levels were not previously known to vary in breast cancer.

29

The pituitary-tumor transforming 1 gene has been shown to produce *in vitro* and *in vivo* tumor-inducing activity (see Zhang *et al. Mol Endocrinol* 13, 156-66 (1999). In a recent publication, pituitary-tumor transforming 1 has been shown to be over-expressed in mammary adenocarcinomas (see Saez *et al. Oncogene* 18, 5473-6 (1999)). Also, another study discovered that all 48 colon carcinomas examined over-expressed PTTG1 as compared to normal colorectal tissue, and invasion of the surrounding tissue was associated with higher PTTG1 expression levels (see Heaney *et al.* Expression of pituitary-tumour transforming gene in colorectal tumours [see comments] *Lancet* 355, 716-9 (2000)).

Genes listed in Table 2, not reported in the literature to be over-expressed in human breast cancer tissues, include RAD2, FLS353, CKS2, cyclin-selective ubiquitin carrier protein E2-C, ZWINT, Lamin B1 and H2A.X. Although FLS353 has been recently found to be over-expressed in colorectal cancer (see Hufton *et al. FEBS Lett* 463, 77-82 (1999)), differential expression of FLS353 in breast tumor cells had not been previously demonstrated.

Cyclin-ubiquitin carrier protein E2-C is another gene over-expressed in breast cancer, which was discovered in this study. Previous studies have shown that when a dominant-negative form of the protein is over-expressed, the mammalian cells arrested in M phase and evidence was provided indicating that this mutant form of cyclin-ubiquitin carrier protein E2-C blocked the destruction of both cyclin A and B (see Townsley et al., Proc Natl Acad Sci USA 94, 2362-7 (1997)).

The expression levels of the genes in Tables 4 and 5 are associated with various stages of infiltrating ductal carcinoma (Table 4) or infiltrating lobular carcinoma (Table 5). The Tables present the fold change value of expression in the particular disease state compared to normal breast tissue. The genes in these tables may be used alone, or in combination with those listed in Tables 1-3 in the methods, compositions, databases and computer systems of the invention.

## Example 2: Diagnostic Subset of Breast Cancer Associated Genes

Table 1 lists the members of a diagnostic subset of genes selected by p-value. This group of genes can be used to differentiate between normal/benign and breast tumor tissue samples including two DCIS samples. Assays using these genes are capable of distinguishing between normal and tumor samples with near 100% efficiency (see Figure 6). Only 1 of the 33 samples shown was misclassified as a normal sample based on the gene

5

10

15

20

25

30

expression profile when this set of genes was used to analyze the 33 sample set (see Figure 7).

Figures 6 and 7 are three-dimensional plots displaying the relationship of variance derived from gene expression data obtained from patient samples. In Figure 6, normal tissue samples are displayed as darker spheres and the infiltrating ductal carcinoma tissue samples are the lighter spheres. The x-axis represents the first principal component that contains the greatest variance in data of 80%. The y-axis represents the second principal component of 4%. The z-axis represents the third principal component of 3%. Figure 7 displays the results obtained from a separate 33 sample set which is composed of new samples that have no relation to the 28 sample set utilized to discover the gene set of Table 1. Again, the x, y, and z-axes represent the first (63%), second (10%), and third principal components (6%), respectively.

The gene set of Table 1 can thus be used to distinguish normal from cancerous breast tissue.

15

20

25

30

5

10

## Example 3: Myoepithelial and Luminal Cell Marker Genes Examined on a Global Scale

Previous studies have indicated that myoepithelial cells express both epithelial and smooth muscle gene expression markers while luminal epithelial cells fail to express these genes (see Lazard et al., Proc Natl Acad Sci USA 90, 999-1003 (1993)). Cluster analysis identified a group 35 fragments representing 31 genes into one highly correlative cluster and the combination of genes and ESTs are listed in Table 3.

Previous studies have indicated that calponin and myosin heavy chain are expressed in smooth muscle cells and myoepithelial cells while luminal epithelium lack the expression of these genes. Furthermore, the proteins are usually not expressed in invasive ductal carcinoma of the breast (Lazard, et al., supra). Both calponin (fold change -11) and myosin heavy chain (fold change -10.8) were under-expressed in IDC. As indicated in Table 3, other genes associated with smooth muscle that were under-expressed such as smooth muscle gamma-actin, myosin light chain kinase, myosin, heavy polypeptide 11, and Leiomodin 1 and both mysoin polypeptide 11 and leiomodin 1 have not been previously reported to be under-expressed in breast cancer as compared to normal tissue samples.

The expression pattern represented in this particular cluster indicates that a preponderance of tissue samples diagnosed as infiltrating ductal carcinoma exhibit a luminal phenotype while myoepithelial cells were absent. More evidence to support this finding includes the under-expression of cytokeratins 5, 14, 15, and 17 in the tumor samples as

10

15

20

25

30

-7. 40

٠٠. يې پ

shown in Table 3. Normal myoepithelial cells express cytokeratins 5, 14, 15, and 17 and breast carcinoma cells do not (Trask et al. Proc Natl Acad Sci USA 87, 2319-2323 (1990)). A previous study has indicated that myoepithelial cells are present in normal, benign lesions, grade I infiltrating ductal carcinoma but are absent in carcinomas of grades II and III (Gusterson et al. Cancer Res 42, 4763-4770 (1982)).

In addition, components of the basal lamina such as laminin were under-expressed in the infiltrating ductal carcinoma relative to normal tissue samples (Table 3). Both laminin S B3 and laminin-related protein were under-expressed as indicated in Table 3. It has been reported that myoepithelial and basal lamina markers are useful in differentiating microinvasive from ductal carcinomas of the breast (Damiani *et al. Virchows Arch* 434, 227-234 (1999)).

The set of 35 fragments representing 31 genes as shown in Table 3 could distinguish between intraductal carcinoma and microinvasive DCIS tissue samples based on the disappearance of genes expressed in either basal lamina or myoepithelial cells. There is evidence in the literature that the collapse of the basement membrane as well as the disappearance of an intact myoepithelial cell layer occurs during the invasion process. A multi-gene screen utilizing either of these sets of genes can be used to differentiate between benign and invasive breast neoplasm based on the gene expression fingerprint elucidated in this study.

Figure 8 shows the results of PCA of the 91 sample set with all 35 fragments (representing 31 genes and ESTs) in Table 3. These results demonstrate that PCA using the genes in Table 3 is able to distinguish between non-invasive and invasive breast tissue samples. Figure 8 provides evidence that this group of genes is diagnostically useful for differentiating DCIS samples that are intraductal (non-invasive) from those containing microinvasion. As shown in Figure 8, this group of genes and ESTs is capable of differentiating between two subtypes of DCIS and may constitute a set that is a more sensitive predictor of a microinvasion phenotype.

### Example 4: Discovery of Breast Tissue Specific Genes in IDC

Electronic northern (E-northern) analysis determines if a gene of interest is present in a tissue from a database of gene expression information, and if it is present, then at what levels. Expression levels were determined using a GeneChip set that evaluated the expression levels of 60,000 genes in each type of tissue from 28 different normal human tissues. Similar to multi-tissue northern blot analysis, E-northern analysis quickly

10

15

20

25

30

determines if a gene of interest is expressed in a particular tissue type and also at what level. E-northern analysis of multiple tissue samples can be evaluated and the determination of exactly how many samples of a particular group that express the gene of interest is tabulated and statistical analysis can be implemented. Multiple samples from the same tissue are not available at this time using conventional multi-tissue northern blot analysis.

The E-northern analysis can be used as a tool to discover tissue specific candidate therapeutic targets that are not over-expressed in tissues such as the liver, kidney, or heart. These tissue types often lead to detrimental side effects once drugs are developed and a first-pass screen to eliminate these targets early in the target discovery and validation process would be beneficial. Furthermore, different tissues have very unique gene expression profiles related to parameters such as proliferation, differentiation, or cell types contained in the tissue that can provide interesting clues into the biological roles of the ESTs.

E-northern analysis was performed for many of the genes clustered in Table 2. Analysis of the E-northerns revealed that most of the genes were expressed at elevated levels in the thymus. There is high rate of mitosis present in the thymus during T-lymphocyte maturation and many proliferation-associated genes are expressed at elevated levels such as CDC2, cyclin B1, and topoisomerase II alpha. Figure 1 displays the E-northern analysis for topoisomerase II alpha indicating elevated levels of expression in the thymus as compare to the other tissue types detected. Figure 2 shows the results of an E-Northern analysis of transcription factor ICBP90, implicated to be involved with topoisomearse II alpha expression. ICBP90 was also expressed at high levels relative to ti other tissue types in the thymus (Figure 2). A study by Hopfner et al. indicated that adult thymus and fetal thymus contained the highest levels of ICBP90 using a 50-tissue RNA dot blot protocol (Hopfner et al. Cancer Res 60, 121-128 (2000)). Most of the genes contained in this cluster contained the highest levels of expression in the thymus.

Figure 3 shows the results of an E-Northern analysis of the monocarboxylate transporter 4 (MCT4; formerly known as MCT3) which was grouped with genes associated with proliferation. MCT4 is most evident in cells with a high glycolytic rate such as muscle, white blood cells, and tumor cells (Halestrap et al., Biochem J 343 (Pt 2), 281-299 (1999)). A group of multi-tissue northern blots from a recent publication indicate that MCT4 is expressed at high levels in leukocytes but also other tissue types as well (Price et al., Biochem J 329, 321-328 (1998)). Furthermore, electronic-northern analysis indicated high levels of MCT4 were expressed in blood and white blood cells (Figure 3).

A previously uncharacterized gene only expressed in breast tissue was identified from this study and an E-Northern analysis of the expression pattern of this gene is shown in Figure 4. The distribution pattern of the expression of the gene shows it be used as a marker for breast cancer. The E-northern analysis only displays tissues where the gene of interest is present at detectable levels and breast tissue was the only tissue that this particular gene was under-expressed by -4.2 fold in IDC making it particularly useful as a diagnostic marker.

Another gene that may be used as a diagnostic marker that was not present in a particular cluster is the secreted frizzled-related protein 1. This gene was under-expressed in IDC by -17.7 fold, and the E-northern analysis shown in Figure 5 indicates that it was expressed at greatest levels in breast tissue as well as in the cervix. Using the combination of clustering, fold-change analysis, and E-northern analysis on microarray data one skilled in the art can readily select additional therapeutic and diagnostic markers.

15

20

10

5

Although the present invention has been described in detail with reference to examples above, it is understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims. All cited patents and publications referred to in this application are herein incorporated by reference in their entirety.

Table '	1: Top 50	Table 1: Top 50 by p-value		i			
##	SedID	Affy	Genbank	Description	Fold Change	p-values	
<del></del>	1006	37892_at	J04177	Cluster Incl J04177:Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds /cds=(161,5581) /gb=J04177 /gi=179729 /ug=Hs.82772 /len=6158	10.18941323	1.24E-12	
74	278	35832_at	AB029000	Cluster Incl AB029000:Homo sapiens mRNA for KIAA1077 protein, partial cds /cds=(0,2456) /gb=AB029000 /gi=5689490 /ug=Hs.70823 /len=4834	4.243716901	2.469E-12	
ო	1227	38566_at	X60382	Cluster Incl X60382:H.sapiens COL.10A1 gene for collagen (alpha-1 type X) /cds=(0,2042) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198	9.164231149	4.719E-12	
4	1226	38181_at	X57766	Cluster Incl X57766:Human stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gi=456256 /ug=Hs.155324 /len=2247	13.96572736	5.309E-12	
5	1159	1651_at	U73379	U73379 /FEATURE= /DEFINITION=HSU73379 Human cyclin-selective ubiquitin carrier protein mRNA, complete cds	4.802394237	5.8315E-11	
ဖ	1161	33143_s_at U81800	U81800	Cluster Incl U81800:Homo sapiens monocarboxylate transporter (MCT3) mRNA, complete cds /cds=(62,1459) /gb=U81800 /gi=2463633 /ug=Hs.85838 /len=1982	0.07793742	6.2406E-11	
~	296	34342_s_at AF052124	AF052124	Cluster Incl AF052124:Homo sapiens clone 23810 osteopontin mRNA, complete cds /cds=(87,989) /gb=AF052124 /gi=3360431 /ug=Hs.313 /len=1504	8.862541971	1.1789E-10	
ω	1008	31859_at	J05070	Cluster Incl J05070:Human type IV collagenase. mRNA, complete cds /cds=(19,2142) /gb=J05070 /gi=177204 /ug=Hs.151738 /len=2334	4.66285568	1.68E-10	
<b>o</b>	961	38116_at	D14657	Cluster Incl D14657:Human mRNA for KIAA0101 gene, complete cds /cds=(61,396) /gb=D14657 /gi=285938 /ug=Hs.81892 /len=836	0.17	2.1736E-10	
6	1007	2092_s_at	J04765	J04765 /FEATURE= /DEFINITION=HUMOSTRO Human osteopontin mRNA, complete cds	4.119810176	3.9853E-10	
<del>-</del>	277	39109_at	AB024704	Cluster Incl AB024704:Homo sapiens mRNA for fls353, completeds /cds=(471,2714) /gb=AB024704 /gi=4589928 /cg=Hs.9329 /len=3403	0.228960682	6.59E-10	

•	<b>p-values</b> 7.4333E-10	7.7763E-10	9.3518E-10	1.10E-09	1.5685E-09	1.5906E-09	1.7499E-09	2.013E-09	2.0933E-09	2.11E-09
	Fold Change 9.431588747	10.43	5.975488989	6.152409861	0.068952382	0.139391318	0.047728145	7.363245733	8.54	0.233878866
	Lescription Cluster Incl M10905:Human cellular fibronectin mRNA /cds=(0,2383) /gb=M10905 /gi=182696 /ug=Hs.118162 /len≈2384	Cluster Incl Y15915:Homo sapiens mRNA for chimaeric transcript of collagen type 1 alpha 1 and platelet derived growth factor beta, 1068 bp /cds=(0,1067) /gb=Y15915 /gi=3288486 /ug=Hs.172928 /len=1068	Cluster Incl AA203213:zx57e04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446622 /clone_end=5" /gb=AA203213 /gi=1798923 /ug=Hs.833 /len=879"	Cluster Incl M97936:Human transcription factor ISGF 6.152409861 3 mRNA sequence /cds=UNKNOWN /gb=M97936 /gi=475254 /ug=Hs.21486 /len=2607	Cluster Incl L32137:Human germline oligomeric matrix protein (COMP) mRNA, complete cds /cds=(25,2298) /gb=L32137 /gi=602449 /ug=Hs.1584 /len=2439	Cluster Incl AL050118:Homo sapiens mRNA; cDNA DKFZp586C201 (from clone DKFZp586C201) /cds=(0,936) /gb=AL050118 /gi=4884143 /ug=Hs.184641 /len=2621	Cluster Incl AA418080:zv97h07.s1 Homo sapiens CDNA, 3 end /clone=IMAGE-767773 /clone_end=3" /gb=AA418080 /gi=2079881 /ug=Hs.3972 /len=543"	Cluster Incl M91670:Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds /cds=(59,736) /db=M91670 /gi=181915 /uq=Hs.174070 /len=890	Cluster Incl AA203476:zx55e01.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446424 /clone_end≐5" /gb=AA203476 /gi=1799203 /ug=Hs.159626 /len=828"	Cluster Incl L37747:Homo sapiens lamin B1 gene /cds=(340,2100) /gb=L37747 /gi=576839 /ug=Hs.89497 /len=2849
	Genbank M10905	Y15915	AA203213	M97936	L32137	AL050118	AA418080	M91670	AA203476	L37747
A 66.	AUX 31720_s_at	35474_s_at Y15915	38432_at	33338_at	40161_at	32190_at	34778_at	40619_at	40412_at	37985_at
	1030 1030	1240	83	1059	1021	892	105	1057	83	1025
4	# 2	5	4	12	9	17	18	19	20	21

<u>p-values</u> 2.35E-09	2.42E-09	2.6578E-09	2.8399E-09	3.1699E-09	3.56E-09	4.0319E-09	4.2586E-09	5.41E-09
<u>Fold Change</u> 7.935291557	4.329038319	0.233804467	0.16	0.284181885	6.816530863	10.36	0.103783146	4.690939862
<u>Description</u> M13755 /FEATURE=mRNA /DEFINITION=HUMIFN15K Human interferon- induced 17-kDa/15-kDa protein mRNA, complete cds	Cluster Incl X14850:Human H2A.X mRNA encoding histone H2A.X /cds=(73,504) /gb=X14850 /gi=31972 /ina=Hs 147097 /len=1585	Cluster Incl X54942:H.sapiens ckshs2 mRNA for Cks1 protein homologue /cds=(95,334) /gb=X54942	M91670 /FEATURE= /DEFINITION=HUME2EPI Human ubiquitin carrier protein (E2-EPF) mRNA,	Cluster Incl K02581:Human thymidine kinase mRNA, complete cds /cds=(57,761) /gb=K02581 /gi=339708	Cluster Incl Al375913:tc14c08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2063822 /clone_end=3" /gb=Al375913 /gi=4175903 /ug=Hs.156346 /len=916"	Cluster Incl AF067656:Homo sapiens ZW10 interactor Zwint mRNA, complete cds /cds=(24,857) /gb=AF067656 /gi=3901271 /ug=Hs.42650 /len=1639	Cluster Incl AA704137:ag47g01.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-1119984 /clone_end=3" /gb=AA704137 /gi=2714055 /ug=Hs.125359 /len=923"	L47276 /FEATURE=UTR#1 /DEFINITION=HUMTOPATR Homo sapiens (cell line HL-60) alpha topoisomerase truncated-form mRNA, 3"UTR
Genbank M13755	X14850	X54942	M91670	K02581	Al375913	AF067656	AA704137	L47276
Affy 1107_s_at	40195_at	40690_at	893_at	41400_at	40145_at	35995_at	39395_at	904_s_at
<b>SeqID</b> 1034	1221	1224	1057	1010	4 <del>4</del>	303	205	1027
## 22	23	24	25	26	27	28	29	30

BNBDOOLD: -WO MOSCOCZIAO I -

<b>%</b> 0	6	80	80	80	80	86
<b>p-values</b> 8.99E-09	9.64E-09	1.0442E-08	1.1081E-08	1.1279E-08	1.2153E-08	1.4629E-08
<b>Fold Change</b> 4.165483399	0.216723881	0.292506358	3.425226104	8.270850261	0.054106026	0.17504844
Description Cluster Incl U59877:Human low-Mr GTP-binding protein (RAB31) mRNA, complete cds /cds=(60,644) /gb=U59877 /gi=1388194 /ug=Hs.223025 /len=907	Cluster Incl AF095448:Homo sapiens putative G protein-coupled receptor (RAIG1) mRNA, complete cds /cds=(99,1172) /gb=AF095448 /gi=4063889 /ug=Hs.194691 /len=2288	Cluster Incl Al885852:wl62d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2429487 /clone_end=3" /gb=Al885852 /gi=5591016 /ug=Hs.795 /len=580"	M29874 /FEATURE= /DEFINITION=HUMCYP2BB Human cytochrome P450-IIB (hIIB1) mRNA, complete	M15205 /FEATURE=cds /DEFINITION=HUMTKRA Human thymidine kinase gene, complete cds, with clustered Alu repeats in the introns	Cluster Incl AC004770:Homo sapiens chromosome 11, BAC CIT-HSP-311e8 (BC269730) containing the hFEN1 gene /cds=(2644,3786) /gb=AC004770 /ai=3212836 /ua=Hs.4756 /len=4522	Cluster Incl X70940:H.sapiens mRNA for elongation factor 1 alpha-2 /cds=(83,1474) /gb=X70940 /gi=38455 /ug=Hs.2642 /len=1755
<b>Genbank</b> U59877	AF095448	AI885852	M29874	M15205	AC004770	X70940
Affy Genbs 33371_s_at U59877	33730_at	32609_at	1371_s_at	910_at	41583_at	35174 <u>i</u> at X70940
<u>SeqID</u> 1155	307	756	1044	1036	281	1233
## 4	45	43	 44	45	46	47

DEICHOOLD - NEO MONEGOTEAN I

Eold Change p-values	l type XI 12.80130327 9.03E-07 ete cds 79729	-10A1 gene 7.973012437 6.70E-09	0,2042) 729	(0,2042) 729 ilysin-3 7.957396249 2.35E-08 'gi=456256	7.957396249 256 3379 7.935291557 oteln	0,2042) 729 Iysin-3 7.957396249 gi=456256 =HSU73379 7.935291557 rrier protein 7.624017858 3) mRNA, 181800	0,2042) 729 ilysin-3 7.957396249 gi=456256 =HSU73379 7.624017858 3) mRNA, J81800 82 ns clone 7.205250917 e cds 360431
Cluster Description	Cluster Incl J04177:Human alpha-1 type XI collagen (COL11A1) mRNA, complete cds /cds=(161,5581)/gb=J04177/gi=179729 /ug=Hs.82772/len=6158	Cluster Incl X60382:H.sapiens COL10A1 gene	ror collagen (alpha-1 type X) /cds=(U,ZU4Z) /gb=X60382 /gl=30094 /ug=Hs.179729 /len=3198	ror collagen (alpha-1 type X) /cds=(U,zU4z) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198 Clüster Incl X57766:Human stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gi=456256 /ug=Hs.155324 /len=2247	ror collagen (alpha-1 type X) /cds=(0,2042) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198 Clüster Incl X57766:Human stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gi=456256 /ug=Hs.155324 /len=2247 U73379 /FEATURE= /DEFINITION=HSU73379 Human cyclin-selective ubiquitin carrier protein mRNA, complete cds	ror collagen (alpha-1 type X) /cds=(0,2042) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198 Clüster Incl X57766:Human stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gl=45625(ug=Hs.155324 /len=2247 U73379 /FEATURE= /DEFINITION=HSU733 Human cyclin-selective ubiquitin carrier protemRNA, complete cds Cluster Incl U81800:Homo sapiens monocarboxylate transporter (MCT3) mRNA, complete cds /cds=(62,1459) /gb=U81800 /gi=2463633 /ug=Hs.85838 /len=1982	ror collagen (alpha-1 type X) /cds=(0,2042) /gb=X60382 /gi=30094 /ug=Hs.179729 /len=3198 Cluster Incl X57766:Hurnan stromelysin-3 mRNA /cds=(9,1475) /gb=X57766 /gi=4562! /ug=Hs.155324 /len=2247 U73379 /FEATURE= /DEFINITION=HSU73 Hurnan cyclin-selective ubiquitin carrier prot mRNA, complete cds Cluster Incl U81800:Homo sapiens monocarboxylate transporter (MCT3) mRNA complete cds /cds=(62,1459) /gb=U81800 /gi=2463633 /ug=Hs.85838 /len=1982 Cluster Incl AF052124:Homo sapiens clone 23810 osteopontin mRNA, complete cds /cds=(87,989) /gb=AF052124 /gi=3360431 /ug=Hs.313 /len=1504
ter#			/gb=X60382 /len=3198		•	•	•
Cluster#	Hs.82772	Hs.179729		Hs.155324	Hs.155324 Hs.93002	Hs.155324 Hs.93002 Hs.85838	
Gene Name	collagen, fype XI, alpha 1	collagen, type X, alpha 1 (Schmid	metaphyseal chondrodysplasia)	metaphyseal chondrodysplasia) matrix metalloproteinase 11 (stromelysin 3)	metaphyseal chondrodysplasia) matrix metalloproteinase 11 (stromelysin 3) ubiquitin carrier protein E2-C	metaphyseal chondrodysplasia) matrix metalloproteinase 11 (stromelysin 3) ubiquitin carrier protein E2-C solute carrier family 16 (monocarboxylic acid transporters), member 3	metaphyseal chondrodysplasia) matrix metalloproteinase 11 (stromelysin 3) ubiquitin carrier protein E2-C solute carrier family 16 (monocarboxylic acid transporters), member 3 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
S-C-D-E Genbank	J04177	X60382		X57766	X57766 U73379	X57766 U73379 U81800	X57766 U73379 U81800
Table 2: Final Chip A-B-C-D-E SeqID Affy Gen	37892_at	38566_at		38181_at	38181_at 1651_at	38181_at 1651_at 33143_s_at	# # # # # # # # # # # # # # # # # # #
Table 2: Fi SeqID	1006	1227		1226			
##	~	8		ო	ω 4	ω 4 ν	ω 4 το Φ

					40			
p-values	1.20E-04		1.10E-09	1.72E-04	1.76E-02	1.69E-07	6.09E-06	2.18E-06
Fold Change	6.188665921		6.152409861	6.01925663	5.903615342	5.34214829	5.267240726	4.694613277
Cluster Description	J04765 /FEATURE=	/DEFINITION≂HUMOSTRO Human osteopontin mRNA, complete cds	Cluster Incl AB024704:Homo sapiens mRNA for fls353, complete cds /cds=(471,2714) /gb=AB024704 /gl=4589928 /ug=Hs.9329 /len=3403	Cluster Incl M10905:Human cellular fibronectin mRNA /cds=(0,2383) /gb=M10905 /gi=182696 /ug=Hs.118162 /len=2384	Cluster Incl Y15915:Homo sapiens mRNA for chimaeric transcript of collagen type 1 alpha 1 and platelet derived growth factor beta, 1068 bp /cds=(0,1067) /gb=Y15915 /gi=3288486 /ug=Hs.172928 /len=1068	Cluster Incl M97936:Human transcription factor ISGF-3 mRNA sequence /cds=UNKNOWN /gb=M97936 /gi=475254 /ug=Hs.21486 /len=2607	Cluster Incl L32137:Human germline oligomeric matrix protein (COMP) mRNA, complete cds /cds=(25,2298) /gb=L32137 /gi=602449 /ug=Hs.1584 /len=2439	Hs.174070 Cluster Incl M91670:Human ubiquitin carrier protein (E2-EPF) mRNA, complete cds /cds=(59,736) /gb=M91670 /gi=181915 /ug=Hs.174070 /len=890
Cluster#	Hs.313		Hs.9329	Hs.118162	Hs.172928	Hs.21486	Hs.1584	Hs.174070
Gene Name	secreted	phosphoprotein 1 (osteopontin, bone sialoprotein I, early T- lymphocyte activation 1)	chromosome 20 open reading frame 1	fibronectin 1	collagen, type I, alpha 1	signal transducer and activator of transcription 1, 91kD	cartilage oligomeric matrix protein (pseudoachondroplasi a, epiphyseal dysplasia 1, multiple)	ubiquitin carrier protein
Genbank	J04765		AB024704	M10905	Y15915	M97936	L32137	M91670
	2092_s_at			31720_s_at	35474_s_at	33338_at	40161_at	40619_at
SedID	1007		277	1030	1240	1059	1021	1057
##	œ		တ	9	<del></del>	12	<del>.</del>	4

BNGCCCIC- -WC 02050271421

<b>p-values</b> 5.41E-09	1.68E-10	1.97 <b>E-</b> 06	3.67E-07	1.59E-08	9.67E-08	8.99E-09	0.00077416	1.88E-07
<b>Fold Change</b> 4.690939862	4.66285568	4.621425831	4.485125913	4.465375169	4.357390421	4.165483399	4.09	4.002408289
Cluster Incl AA203476:zx55e01.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446424 /clone_end=5" /gb=AA203476 /gi=1799203 /ug=Hs.159626 /len=828"	Cluster Incl L37747:Homo sapiens lamin B1 gene /cds=(340,2100) /gb=L37747 /gi=576839 /ug=Hs,89497 /len=2849	M13755 /FEATURE=mRNA /DEFINITION=HUMIFN15K Human interferon- induced 17-kDa/15-kDa protein mRNA,	Cluster Incl X14850:Human H2A.X mRNA encoding histone H2A.X /cds=(73,504) /gb=X14850 /gi=31972 /ug=Hs.147097 /len=1585	Cluster Incl X54942:H.saplens ckshs2 mRNA for Cks1 protein homologue /cds=(95,334) /gb=X54942 /gi=29978 /ug=Hs.83758 /len=612	Hs.105097 Cluster Incl K02581:Human thymidine kinase mRNA, complete cds /cds=(57,761) /gb=K02581 /gi=339708 /ug=Hs.105097 /len=1421	Cluster Incl AF067656:Homo sapiens ZW10 interactor Zwint mRNA, complete cds /cds=(24,857) /gb=AF067656 /gl=3901271 /ua=Hs,42650 /len=1639	M97935 Homo sapiens transcription factor ISGF-3 mRNA, complete cds (_5, _MA, MB, _3 represent transcript regions 5 prime, MiddleA, MiddleB, and 3 prime respectively)	L47276 /FEATURE=UTR#1 /DEFINITION=HUMTOPATR Homo sapiens (cell line HL-60) alpha topoisomerase truncated form mRNA, 3"UTR
Cluster# Hs.252587	Hs.89497	Hs.833	Hs.147097	Hs.83758	Hs.105097	Hs.42650	Hs.21486	
Gene Name pituitary tumor- transforming 1	lamin B1	interferon-stimulated protein, 15 kDa	H2A histone family, member X	CDC28 protein kinase 2	thymidine kinase 1, soluble	ZW10 interactor	signal transducer and activator of transcription 1, 91kD	
<u>Genbank</u> AA203476	L37747	M13755	X14850	X54942	K02581	AF067656	M97935	L47276
<b>Affy</b> 40412_at	37985_at	1107_s_at	40195_at	40690_at	41400_at	35995_at	AFFX- HUMISGF3A/ M97935_MA_ _at	904_s_at
SeqID 83	1025	1034	1221	1224	1010	303	1058	1027
## 15	16	17	18		20	21	8	23

(Int	ထ	ဖ	_	m	42 ~	10	
p-values	1.06E-06	2.48E-06	2.95E-07	2.60E-08	4.11E-03	1.28E-05	3.71E-04
Fold Change	3.870563686	3.855167487	3.813256493	3.80895841	3.800908625	3.796503387	3.781923678
Cluster Description	Cluster Incl U05340:Human p55CDC mRNA, complete cds /cds=(110,1609) /gb=U05340 /gi=468031 /ug=Hs.82906 /len=1686	Cluster Incl X02761:Human mRNA for fibronectin (FN precursor) /cds=(0,6987) /gb=X02761 /gi=31396 /ug=Hs.118162 /len=7680	Cluster Incl U74612:Human hepatocyte nuclear 3.813256493 factor-3/fork head homolog 11A (HFH-11A) mRNA complete cds /cds=(114,2519) /gb=U74612 /gi=1842252 /ug=Hs.239 /len=3474	Cluster Incl M25753:Human cyclin B mRNA, 3 end /cds=UNKNOWN /gb=M25753 /gi=181243 /ug=Hs.23960 /len=1452"	Cluster Incl J03464:Human collagen alpha-2 type I mRNA, complete cds, clone pHCOL2A1 /cds=(469,4569) /gb=J03464 /gi=179595 /ug=Hs.179573 /len=5416	Cluster Incl X15998:H.sapiens mRNA for the chondroitin sulphate proteoglycan versican, V1 splice-variant; precursor peptide /cds=(266,7495) /gb=X15998 /gi=37662 /ug=Hs.81800 /len=8224	Cluster Incl AC003107:Human DNA from chromosome 19-specific cosmid R30064 containing the COMP gene, genomic sequence (cds=(0,2453) /gb=AC003107 /gi=2623749 /ug=Hs.1584 /len=2454
Cluster#	Hs.82906	Hs.118162	Hs.239	Hs.23960	Hs.179573	Hs.81800	Hs.1584
Gene Name	CDC20 (cell division cycle 20, S. cerevisiae, homolog)	fibronectin 1	forkhead box M1	cyclin B1	collagen, type I, alpha 2	chondroitin sulfate proteoglycan 2 (versican)	cartilage oligomeric matrix protein (pseudoachondroplasi a, epiphyseal dysplasia 1, multiple)
Genbank	U05340	X02761	U74612	M25753		X15998	AC003107
Affy		31719_at	1160 34715_at		32305_at	38112 <u>g</u> at	40162_s_at
SeqID	1136	1216	1160	1043	1002	1222	279
##	24	25	56	27		53	30

DEICHOOSIN - 1870 10005007180 1

Fold Change p-values	3.74871763 9.37E-05	3.620640004 1.57E-07	3.607432569 1.35E-04	3.556183255 5.17E-03	3.539960818 1.67E-05	3.437302377 9.47E-08	3.435786237 3.03E-03	3.427509519 1.22E-03
Cluster Description Fol	3263 /FEATURE= /DEFINITION=HUMARB nan androgen receptor mRNA, complete	RAB31, member RAS Hs.223025 Cluster Incl U59877:Human low-Mr GTP- 3.63 oncogene family binding protein (RAB31) mRNA, complete cds /cds=(60,644) /gb=U59877 /gi=1388194 /uq=Hs.223025 /len=907	omo sapiens putative or (RAIG1) mRNA, 172) /gb=AF095448 691 /len=2288	874 /FEATURE= FINITION=HUMCYP2BB Human chrome P450-IIB (hIIB1) mRNA, complete	M15205 /FEATURE=cds /DEFINITION=HUMTKRA Human thymidine kinase gene, complete cds, with clustered Alu repeats in the introns	0:Homo saplens 2: CIT-HSP-311e8 ig the hFEN1 gene =AC004770 /gi=3212836	apiens mRNA for a-2 /cds=(83,1474) 'ug=Hs.2642 /len=1755	X67325 /FEATURE=cds /DEFINITION=HSP27 3.4; H.sapiens p27 mRNA
Cluster #	Hs.99915 M2: Hur cds	Hs.223025 Cl bir /cc	Hs.194691 CI G co /gi	Hs.1360 M29 /DEI cyto cds	Hs.105097 M·/D//D//D//D//D//D//D//D//D//D//D//D//D/	្ត្រ ម <u>ុ</u> ធ ស្គ	Hs.2642 Cli	Hs.278613 X6 H.
Gene Name	androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)	RAB31, member RAS oncogene family	retinoic acid induced 3	cytochrome P450, subfamily IIB (phenobarbital- inducible)	thymidine kinase 1, soluble		eukaryotic translation elongation factor 1 alpha 2	interferon, alpha- inducible protein 27
Genbank	M23263	U59877	AF095448	M29874	M15205	AC004770	X70940	X67325
Affy	1577_at	33371_s_at	33730_at	1371_s_at	910_at	41583_at	35174 <u>i</u> at	425_at
SeqID	1041	1155	307	1044		281	1233	1231
##	£	32	33	8	35	36	37	38

 $\bigcirc$ 

<b>p-values</b> 2.25E-05	4.06E-07	6.11E-04	5.33E-04	1.78E-04	7.75E-07	0.000054	0.00000608
<b>Fold Change</b> 3.247818871	3.190855222	3.147501909	3.044487778	3.044067136	3.036676875	0.327422466	0.326731583
Cluster Description Cluster Incl M77836:Human pyrroline 5- carboxylate reductase mRNA, complete cds /cds=(11,970) /gb=M77836 /gi=189497 /ua=Hs,79217 /len=1792	Cluster Incl M63193:Human platelet-derived endothelial cell growth factor mRNA, complete cds /cds=(123,1571) /gb=M63193 /gi=189700 /ug=Hs, 73946 /len=1587	Cluster Incl U70370: Human hindlimb expressed homeobox protein backfoot (Bft) mRNA, complete cds /cds=(111,1055) /gb=U70370 /gi=1870670 /ug=Hs.84136	Cluster Incl U39840:Human hepatocyte nuclear factor-3 alpha (HNF-3 alpha) mRNA, complete cds /cds=(87,1508) /gb=U39840 /gi=1066121	Cluster Incl L29254:Human (clone P1-5) L-iditol-2 dehydrogenase gene /cds=(137,1210) /gb=L29254 /gi=808013 /ug=Hs.878 /len=2519	X05360 /FEATURE=cds /DEFINITION=HSCDC2 Human CDC2 gene	Cluster Incl AF002282:Homo sapiens alpha- actinin-2 associated LIM protein mRNA, alternatively spliced product, complete cds /cds=(46,996) /gb=AF002282 /gi=3138923	U50527 /FEATURE= /DEFINITION=HSU50527 Human BRCA2 region, mRNA sequence
Cluster# Hs.79217	Hs.73946	Hs.84136	Hs.105440	Hs.878	Hs.184572	Hs.135281	Hs.22174
Gene Name pyrroline-5- carboxylate reductase 1	endothelial cell growth factor 1 (platelet-derived)	paired-like homeodomain transcription factor 1	hepatocyte nuclear factor 3, alpha	sorbitol dehydrogenase	cell division cycle 2, G1 to S and G2 to M	alpha-actinin-2- associated LIM protein	
Genbank M77836	M63193	U70370	U39840	L29254	X05360	AF002282	U50527
<b>Affy</b> 37741_at	36879_at	37920_at	37141_at	38763_at	1803_at	39690_at	1527_s_at
<b>SeqID</b> 1053	1049	1158	1149	1020	1219	285	1153
## <del>\$</del>	64	20	51	52	53	2	55

				46				
p-values	0.0000229	0.000191	0.0001	2.84E-08	0.000642	0.00000552	0.0000133	0.000834
Fold Change	0.326719388	0.326431324	0.323566748	0.323306977	0.323187581	0.323178779	0.321819387	0.3197207
Cluster Description	Cluster Incl AF001691:Homo sapiens 195 kDa cornfied envelope precursor mRNA, complete cds /cds=(90,5360) /gb=AF001691 /gj=3168845 /ug=Hs.74304 /len=6227	U84487 /FEATURE= /DEFINITION=HSU84487 Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds	Cluster Incl D84110:Homo sapiens mRNA for RBP-MS/type 4, complete cds /cds=(566,1156) /gb=D84110 /gi=1669552 /ug=Hs.80248 /len=1594	Cluster Incl D14686:Human gene for glycine cleavage system T-protein /cds=(145,1356) /gb=D14686 /gi=994760 /ug=Hs.102 /len=2119	Cluster Incl J02876:Human placental folate binding protein mRNA, complete cds /cds=(262,1029) /gb=J02876 /gi=182413 /ug=Hs.24194 /len=1211	S62539 /FEATURE= /DEFINITION=S62539 insulin receptor substrate-1 [human, skeletal muscle, mRNA, 5828 nt]		Cluster Incl U58516:Human breast epithelial antigen BA46 mRNA, complete cds /cds=(60,1223)/gb=U58516/gi=1381161 /ug=Hs.3745/len=1934
Cluster#	Hs.74304	Hs.80420	Hs.80248	Hs.102	Hs.24194	Hs.96063	Hs.180433	Hs.3745
Gene Name	periplakin	small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine,	neurotactin) RNA-binding protein gene with multiple splicing	aminomethyltransfera se (glycine cleavage system protein T)	folate receptor 2 (fetal)	insulin receptor substrate 1	rTS beta protein	milk fat globule-EGF factor 8 protein
Genbank	AF001691	U84487	D84110	D14686	J02876	S62539	X67098	U58516
Affy	36890_at	823_at	38049_g_at	41120_at	33871_s_at	851_s_at	33263_at	34403_at
SedID	284	1164	973		1001	1120	1230	1154
#1	20	22	89	28	09	61	62	83

DEIGNOCIN- JAMO MONEGOTTAN I .

<b>ge p-values</b> 36 0.000387	55 0.00529	44 0.00523	19 0.000012	47 0.0224	15 0.0000881	3 0.000764
<b>Fold Change</b> 0.319370936	0.317801655	0.314829644	0.313476219	0.313295747	0.312357015	0.31152273
Cluster Description Cluster Incl V00568:Human mRNA encoding the c-myc oncogene /cds=(558,1877) /gb=V00568 /gi=34815 /ug=Hs.79070	Cluster Incl M22324:Human aminopeptidase N/CD13 mRNA encoding aminopeptidase N, complete cds /cds=(120,3023) /gb=M22324 /gi=178535 /ug=Hs.1239 /len=3477	Hs.112360 Cluster Incl AF027208:Homo sapiens AC133 antigen mRNA, complete cds /cds=(37,2634) /gb=AF027208 /gi=2688948 /ug=Hs.112360 /len=3794	D00632 /FEATURE= /DEFINITION=HUMGSHPXA Homo sapiens mRNA for glutathione peroxidase, complete cds	L22524 /FEATURE=expanded_cds /DEFINITION=HUMMATRY06 Human matrilysin gene, exon 6 and complete cds	Cluster Incl Z26653:H.sapiens mRNA for laminin M chain (merosin) /cds=(49,9381) /gb=Z26653 /gi=438055 /ug=Hs.75279 /len=9534	L13740 /FEATURE= /DEFINITION=HUMTR3A Human TR3 orphan receptor mRNA, complete cds
Cluster# <sup></sup> Hs.79070 C	Hs.1239	Hs.112360	Hs.172153	Hs.2256	Hs.75279	Hs.1119
Gene Name v-myc avian myelocytomatosis viral oncogene homolog	alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150)	prominin (mouse)-like 1	glutathione peroxidase 3 (plasma)	matrix metalloproteinase 7 (matrilysin, uterine)	laminin, alpha 2 (merosin, congenital muscular dystrophy)	nuclear receptor subfamily 4, group A, member 1
Genbank V00568	M22324	AF027208	D00632	L22524	<b>Z</b> 26653	L13740
<b>Affy</b> 37724_at	39385_at	41470_at	770_at		36917_at	279_at
<b>SeqID</b> 1169	1040	292	958	1018	1244	1016
## 42	65	99	29	89	69	20

				48				
a-values	0.0000193	0.00000415	0.000274	0.000239	0.0000802	1.85E-07	7.42E-08	0.00149
Fold Change	0.310894189	0.308897008	0.306961223	0.303827048	0.303503697	0.300299695	0.297519832	0.296769339
- Cluster Description	Cluster Incl AF082868:Homo sapiens gamma butyrobetaine hydroxylase (BBH) mRNA, complete cds /cds=(66,1229) /gb=AF082868 /gi=3746804 /ug=Hs,9667 /len=1584	Cluster Incl AF016004:Homo sapiens m6b1 mRNA, complete cds /cds=(254,1051) /gb=AF016004 /gi=3387766 /ug=Hs.78361 /len=1616	Cluster Incl Y11306:Homo sapiens mRNA for hTCF-4 /cds=(307,2097) /gb=Y11306 /gi=4469251 /ug=Hs.154485 /len=2444	U04313 /FEATURE= /DEFINITION=HSU04313 0.303827048 Human maspin mRNA, complete cds	Cluster Incl Z19574:H.sapiens gene for ⊜554 eratin 17 /cds=(64,1362) /gb=Z19574 /gi≕30378 /ug=Hs.2785 /len=1518	Cluster Incl U22398:Human Cdk-inhibitor p57KIP2 (KIP2) mRNA, complete cds /cds=(260,1210) /gb=U22398 /gi=790247 /ug=Hs.106070 /len=1511	Cluster Incl M15036:Human vitamin K-dependent plasma protein S mRNA, complete cds /cds=(146,2176) /gb=M15036 /gi=190288 /ug=Hs.64016 /len=3309	Cluster Incl L48215:Homo sapiens beta-globin (HBB) gene, with a to c allele 28 bp 5 to exon 1, (J00179 bases 61971-63802) /cds=(50,493) /gb=L48215 /gi=1066772 /ug=Hs.155376 /len=626"
Cluster#	Hs.9667	Hs.5422	Hs.285857	Hs.55279	Hs.2785	Hs.106070	Hs.64016	Hs.155376
Gene Name	butyrobetaine (gamma), 2- oxoglutarate dioxygenase (gamma- butyrobetaine hydroxylase)	glycoprotein M6B	transcription factor 7- like 2 (T-cell specific, HMG-box)	profease inhibitor 5 (maspin)	keratin 17	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	protein S (alpha)	hemoglobin, beta
Genbank	AF082868	AF016004	Y11306	U04313	Z19574	U22398	M15036	L48215
Affy	38339_at	37251_s_at	32025_at	863_g_at	34301_r_at	39545_at	35752_s_at	32052_at
SeqID	305	290	1239	1135	1242	1143	1035	1028
##	7	22	23	45	75	92	F	48

DAISDOCID - JUN MONEGOTIAN I -

		•	, ,0			
<b>p-values</b> 0.0000556	0.00000184	0.00999	0.00000996	0.00688	8.07E-07	0.000483
<b>Fold Change</b> 0.295641772	0.29509428	0.29444252	0.292877726	0.29048531	0.2896161	0.288749983
Cluster Incl AF052389:Homo sapiens LIM domain binding protein (LDB1) mRNA, complete cds /cds=(254,1297) /gb=AF052389 /gi=3044065 /ug=Hs.4980 /len=2398	Cluster Incl AJ000388:Homo sapiens mRNA for calpain-like protease CANPX /cds=(182,2107) /gb=AJ000388 /gi=2274961 /ua=Hs.169172 /len=3615	Cluster Incl M12272:Homo sapiens alcohol dehydrogenase class I gamma subunit (ADH3) mRNA, complete cds /cds=(80,1207) /gb=M12272 /gi=178147 /ug=Hs.2523 /len=1466	Cluster Incl U85267:Homo sapiens down syndrome candidate region 1 (DSCR1) gene, alternative exon 1, complete cds /cds=(84,677) /gb=U85267 /gi=2612867 /ug=Hs.184222 /len=2272	Cluster Incl AF098462:Homo sapiens stanniocalcin-related protein mRNA, complete cds /cds=(134,1042) /gb=AF098462 /gi=4050037 /ug=Hs.155223 /len=2380	Cluster Incl AL021977:bK447C4.1 (novel MAFF (v-maf musculoaponeurotic fibrosarcoma (avian) oncogene family, protein F) LIKE protein) /cds=(0,494) /gb=AL021977 /gi=4914526 /ug=Hs.51305 /len=2128	Cluster Incl Z22865:H.sapiens dermatopontin mRNA, complete CDS /cds=(12,617) /gb=Z22865 /gi=311613 /ug=Hs.80552 /len=729
Cluster#	Hs.169172	Hs.2523	Hs.184222	Hs.155223	Hs.51305	Hs.80552
	<u>_</u>		_			
Gene Name LIM domain binding 2,polymyositis/sclerod erma autoantigen 2 (100kD)	calpain-like protease H	alcohol dehydrogenase 1 (class I), alpha polypeptide,alcohol dehydrogenase 3 (class I), gamma polypeptide	ome n gene 1	stanniocalcin 2	v-maf musculoaponeurotic fibrosarcoma (avian) oncogene family, protein F	dermatopontín
te Name ain binding ositis/sclerod oantigen 2	ike protease	M12272	ome n gene 1		AL021977 v-maf musculoaponeurotic fibrosarcoma (avian) oncogene family, protein F	Z22865 dermatopontin
Affy Genbank Gene Name 36065_at AF052389 LIM domain binding 2,polymyositis/sclerod erma autoantigen 2 (100kD)	calpain-like protease		32168_s_at U85267 Down syndrome critical region gene 1	stanniocalcin 2		_
Gene Name AF052389 LIM domain binding 2,polymyositis/sclerod erma autoantigen 2 (100kD)	AJ000388 calpain-like protease	M12272	U85267 Down syndrome critical region gene 1	AF098462 stanniocalcin 2	AL021977	Z22865

					30				
p-values	0.00000058	0.000216	0.0000355	0.00679	0.000174	0.0000231	0.000495	0.00000039	0.000161
Fold Change	0.288106064	0.287855932	0.287831724	0.287696584	0.285399252	0.283121329	0.282677481	0.281207961	0.279338963
Cluster Description	Cluster Incl J04111:Human c-jun proto oncogene (JUN), complete cds, clone hCJ-1 /cds=(974,1969) /gb=J04111 /gi=186624 /ug=Hs.78465 /len=3336	L24203 /FEATURE= /DEFINITION=HUMDK Homo sapiens ataxia-telanglectasia group D- associated protein mRNA, complete cds			L19871 /FEATURE= /DEFINITION=HUMATF3X Human activating transcription factor 3 (ATF3) mRNA, complete cds	Cluster Incl U31384:Human G protein gamma- 11 subunit mRNA, complete cds /cds=(107,328) /gb=U31384 /gi=995920 /ug=Hs.83381 /len=622	Cluster Incl AB002409:Homo sapiens mRNA for SLC, complete cds /cds=(58,462) /gb=AB002409 /gi=2335034 /ug=Hs.57907 /len=852	L08488 /FEATURE= /DEFINITION=HUMINOS Human inositol polyphosphate 1-phosphatase mRNA, complete cds	Cluster Incl U48959:Homo sapiens myosin light chain kinase (MLCK) mRNA, complete cds /cds=(119,5863) /gb=U48959 /gi=1377819 /ug=Hs.211582 /len=5926
Cluster#	Hs.78465	Hs.82237	Hs.173859	Hs.171695	Hs.460	Hs.83381	Hs.57907	Hs.32309	Hs.211582
Gene Name	v-jun avian sarcoma virus 17 oncogene homolog	ataxia-telangiectasia group D-associated protein	frizzled (Drosophila) homolog 7	dual specificity phosphatase 1	activating transcription factor 3	guanine nucleotide binding protein 11	small inducible cytokine subfamily A (Cys-Cys), member 21	inositol polyphosphate-1- phosphatase	myosin, light polypeptide kinase
Genbank	J04111	L24203	AB017365	X68277	L19871	U31384	AB002409	L08488	U48959
Affy	32583_at	1898_at	3322_at	1005_at	287_at	37908_at	36503_at	656_at	32847_at
SeqiD	1004	1019	274	1232	1017	1145	270	1013	1151
##	98	87	88	68	06		95	93	94

					31	l.			
	p-values	0.00000917	0.00000688	0.000014	6.7E-09	0.0000349	4.33E-07	0.00000159	0.000228
	Fold Change	0.278228021	0.276610822	0.273963608	0.273622601	0.26818697	0.267616256	0.263585259	0.260058306
	Cluster Description	Cluster Incl S62539:insulin receptor substrate-1 [human, skeletal muscle, mRNA, 5828 nt] /cds=(1020,4748) /gb=S62539 /gi=386256 /ug=Hs.96063 /len=5799	U22398 /FEATURE= /DEFINITION=HSU22398 Human Cdk-inhibitor p57KIP2 (KIP2) mRNA, complete cds	Ciuster Incl U07919:Human aldehyde dehydrogenase 6 mRNA, complete cds /cds=(52,1590)_/gb=U07919 /gi=995897 /ug=Hs.75746 /len=3442	Cluster Incl U35139:Human NECDIN related protein mRNA, complete cds /cds=(58,1023) /gb=U35139 /gi=1754970 /ug=Hs.50130 /len=1592	Cluster Incl M68840:Human monoamine oxidase A (MAOA) mRNA, complete cds /cds=(73,1656) /gb=M68840 /gi=187352 /ug=Hs.183109 /len=1949	Cluster Incl AF093118:Homo sapiens UP50 mRNA, complete cds /cds=(168,1514) /gb=AF093118 /gi=3676821 /ug=Hs.11494 /len=2019	Cluster Incl U10492:Human Mox1 protein (MOX1) mRNA, complete cds /cds=(29,793) /gb=U10492 /gi=505653 /ug=Hs.438 /len=2315	Cluster Incl AF022797:Homo sapiens intermediate conductance calcium-activated potassium channel (hKCa4) mRNA, complete cds /cds=(396,1679) /gb=AF022797 /gi=2674355 /ug=Hs.10082 /len=2238
İ	Cluster#	Hs.96063	Hs.106070	Hs.75746	Hs.50130	Hs.183109	Hs.11494	Hs.438	Hs.10082
	Gene Name	insulin receptor substrate 1	cyclin-dependent kinase inhibitor 1C (p57, Kip2)	aldehyde dehydrogenase 6	necdin (mouse) homolog	monoamine oxidase A	fibulin 5	mesenchyme homeo box 1	potassium intermediate/small conductance calcium- activated channel, subfamily N, member
	Genbank	S62539	U22398	U07919	U35139	M68840	AF093118	U10492	AF022797
	Affy	41049_at	1787_at	36686_at	36073_at	41772_at	39038_at	36010_at	41106_at
	SeqID	1120	1143	1138	1147	1050	306	1139	291
	#1	92	96	97	86	66	100	101	102

				•	52			
p-values	4.12E-07	0.0000904	0.0000232	0.0025	0.00000113	0.000041	0.00041	0.00105
Fold Change	0.260055335	0.259339901	0.259264106	0.258780062	0.258230155	0.257792937	0.256900234	0.256815942
Cluster Description	Cluster Incl U17760:Human laminin S B3 chain (LAMB3) gene /cds=(399,3917) /gb=U17760 /gi=2182192 /ug=Hs.75517 /len=4213	M98539 /FEATURE=exon /DEFINITION=HUMPDS03 Human prostaglandin D2 synthase gene, exon 7	Cluster Incl W61005:zd29a11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-342044 /clone_end=3" /gb=W61005 /gi=1367764 /ug=Hs.14896 /len=786"		Cluster Incl U61374:Human novel protein with short consensus repeats of six cysteines mRNA, complete cds /cds=(41,1426) /gb=U61374 /gi=1778409 /ug=Hs.15154 /len=1800	Cluster Incl X57025:Human IGF-I mRNA for insulin-like growth factor I /cds=(166,627) /gb=X57025 /gi=33007 /ug=Hs.85112 /len=7236	Cluster Incl M15856:Human lipoprotein lipase mRNA, complete cds /cds=UNKNOWN /gb=M15856 /gi=187209 /ug=Hs.180878 /len=3549	Cluster Incl X00129:Human mRNA for retinol binding protein (RBP) /cds=(51,650) /qb=X00129 /qi=35896 /uq=Hs.76461 /len=882
Cluster#	Hs.75517	Hs.8272	Hs.14896	Hs.251577	Hs.15154	Hs.85112	Hs.180878	Hs.76461
Gene Name	laminin, beta 3 (nicein (125kD), kalinin (140kD), BM600 (125kD))	prostaglandin D2 synthase (21kD, brain)	DHHC1 protein	hemoglobin, alpha 1	sushi-repeat- containing protein, X chromosome	insulin-like growth factor 1 (somatomedia C)	lipoprotein lipase	retinol-binding protein 4, interstitial
Genbank	U17760	M98539	W61005	J00153	U61374	X57025	M15856	X00129
Affy	36929 <u>_</u> at	216_at	39750_at	31525_s_at J00153	31855_at	38737_at	41209_at	32552_at
SegID	1141	1060	1191	666	1156	1225	1037	1214
#1	103	104	105	106	107	108	109	110

<b>p-values</b> 0.000837	0.0321	0.000106	0.000998	0.000037	0.0000523	0.0000179	0.000763
<b>Fold Change</b> 0.256739005	0.251627664	0.251471671	0.251434843	0.250173978	0.249382262	0.248516754	0.242494771
Cluster Description Cluster Incl U41518:Human channel-like integral membrane protein (AQP-1) mRNA, clone AQP-1-2344, partial cds /cds=(0,460) /gb=U41518 /gi=1314305 /ug=Hs.74602 /len=2344	Cluster Incl Y10179:H.sapiens mRNA for prolactin-inducible protein /cds=(36,476) /gb=Y10179 /gi=2292895 /ug=Hs.99949 /len=576	Cluster Incl *K03000:Human aldehyde dehydrogenase 1 mRNA /cds=(0,1022) /gb=K03000 /gi=178399 /ug=Hs.76392 /len=1560	Cluster Incl M25079:Human sickle cell betaglobin mRNA, complete cds /cds=(0,443) /gb=M25079 /gi=179408 /ug=Hs.234764 /len=468	Cluster Incl U39447:Human placenta copper monamine oxidase mRNA, complete cds /cds=(160,2451) /gb=U39447 /gi=1399031 /ug=Hs.198241 /len=4023	X57025 /FEATURE=mRNA /DEFINITION=HSIGFACI Human IGF-I mRNA for insulin-like growth factor I	L07594 /FEATURE= /DEFINITION=HUMTGFB3C Human transforming growth factor-beta type III receptor (TGF-beta) mRNA, complete cds	Cluster Incl U05861:Human hepatic dihydrodiol dehydrogenase gene /cds=(26,997) /gb=U05861 /gj=487134 /ug=Hs.201967 /len=1222
Cluster# Hs.74602	Hs.99949	Hs.76392	Hs.155376	Hs.198241	Hs.85112	Hs.79059	Hs.275374
Gene Name aquaporin 1 (channel- forming integral protein, 28kD)	prolactin-induced protein	aldehyde dehydrogenase 1, soluble	hemoglobin, beta	amine oxidase, copper containing 3 (vascular adhesion protein 1)	insulin-like growth factor 1 (somatomedia C)	transforming growth factor, beta receptor III (betaglycan, 300kD)	aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20- alpha (3-alpha)- hydroxysteroid dehydrogenase)
Genbank U41518	Y10179	K03000	M25079	U39447	X57025	L07594	U05861
Affy 36156_at	41094_at	37015_at	31687_f_at	33756_at	1501_at	1897_at	32805_at
<b>SeqID</b> 1150	1238	1011	1042	1148	1225	1012	1137
# 5	112	113	114	115	116	117	118

					54				
p-values	2.11E-09	0.0000034	3.37E-08	6.59E-10	0.000415	0.031	3.52E-07	0.00000788	0.0000975
Fold Change	0.233878866	0.233549169	0.231782987	0.228960682	0.228917694	0.226749627	0.225166891	0.222238905	0.220336613
Cluster Description	Cluster Incl U81992:Homo sapiens C2H2 zinc finger protein PLAGL1 (PLAGL1) mRNA, complete cds /cds=(176,1411) /gb=U81992 /gi=3513452 /ug=Hs.75825 /len=2561	Cluster Incl X93510:H.saplens mRNA for 37 kDa LIM domain protein /cds=(41,1027) /gb=X93510 /gl=1085021 /ug=Hs.79691 /len=1130	Cluster Incl AF039843:Homo sapiens Sprouty 2 (SPRY2) mRNA, complete cds //cds=(390,1337) /gb=AF039843 /gi=2809399 /ug=Hs.18676 /len=2117	Cluster Incl L10373:Human (clone CCG-B7) mRNA sequence /cds=UNKNOWN /gb=L10373 /gi=307287 /ug=Hs.82749 /len=1792	D10667 /FEATURE= /DEFINITION=HUMMHCAAA Homo saplens mRNA for smooth muscle myosin heavy chain, partial cds	Cluster Incl U33147:Human mammaglobin mRNA, complete cds /cds=(60,341) /gb=U33147 /gi=1199595 /ug=Hs.46452 /len=503	Cluster Incl J04076:Human early growth response 2 protein (EGR2) mRNA, complete cds /cds=(203,1423) /gb=J04076 /gi=181986 /ug=Hs.1395 /len=2700	Cluster Incl Y16961:Homo sapiens mRNA for KET protein /cds=(27,2069) /gb=Y16961 /gi=3970716 /ug=Hs.137569 /len=4849	Cluster Incl U50410:Human heparan sulphate proteoglycan (OCI5) mRNA, complete cds /cds=(144,1886) /gb=U50410 /gi=1245416 /ug=Hs.119651 /len=226
Cluster#	Hs.75825	Hs.79691	Hs.18676	Hs.82749		Hs.46452	Hs.1395	Hs.137569	Hs.119651
Gene Name	pleiomorphic adenoma gene-like 1	LIM domain protein	sprouty (Drosophila) homolog 2	transmembrane 4 superfamily member 2		mammaglobin 1	early growth response 2 (Krox-20 (Drosophila) homolog)	tumor protein 63 kDa with strong homology to p53	glypican 3
Genbank	U81992	X93510	AF039843	L10373	D10667	U33147	J04076	Y16961	U50410
Affy	36943_r_at	32610_at	33700_at	38408_at	774_g_at	36329_at	37863_at	31791_at	39350_at
SedID	1162	1237	294	1014	096	1146	1003	1241	1152
-	ν-	•		•		•	-		•

DEIODOCID: 3850 - 000E007440

<b>p-values</b> 0.00000138	9.64E-09	0.0000527	0.0000209	0.00000443	0.000166	0.0000371	4.51E-07
<b>Fold Change</b> 0.218509986	0.216723881	0.216083178	0.207358276	0.206077576	0.202234909	0.19705452	0.196869236
Cluster Incl X54162:Human mRNA for a 64 Kd autoantigen expressed in thyroid and extraocular muscle /cds=(212,1930) /gb=X54162 /gi=28968 /ug=Hs.79386 /len=3849	Cluster Incl U69263:Human matrilin-2 precursor mRNA, partial cds /cds=(0,941) /gb=U69263 /gi=2072789 /ug=Hs.19368 /len=1033	Cluster Incl L38486:Human microfibril- associated glycoprotein 4 (MFAP4) mRNA, 3 end of cds /cds=(0,771) /gb=L38486 /oi=790816 /ug=Hs 118223 /len=1757"	Cluster Incl M36820:Human cytokine (GRO-beta) mRNA, complete cds /cds=(74,397) /gb=M36820 /gi=183628 /ug=Hs.75765 /len=1110	Cluster Incl U19495:Human intercrine-alpha (hIRH) mRNA, complete cds /cds=(473,742) /gb=U19495 /gi≈1754834 /ug=Hs.169672 /len=2244	Cluster Incl X04470:Human mRNA for antileukoprotease (ALP) from cervix uterus /cds=(18,416) /gb=X04470 /gi=28638	Cluster Incl AF000959:Homo sapiens transmembrane protein mRNA, complete cds /cds=(120,776) /gb=AF000959 /gi=2150012 /ug=Hs.110903 /len=1348	Cluster Incl L13463:Human helix-loop-helix basic phosphoprotein (G0S8) mRNA, complete cds /cds=(32,667) /gb=L13463 /gi=292054 /ug=Hs.78944 /len=1345
Cluster# Hs.79386	Hs.19368	Hs.118223	Hs.75765	Hs.237356	Hs.251754	Hs.110903	Hs.78944
Gene Name leiomodin 1 (smooth muscle)	matrilin 2	microfibrillar- associated protein 4	GRO2 oncogene	stromal cell-derived factor 1	secretory leukocyte protease inhibitor (antileukoproteinase)	claudin 5 (transmembrane protein deleted in velocardiofacial syndrome)	regulator of G-protein signalling 2, 24kD
<u>Genbank</u> X54162	U69263	L38486	M36820	U19495	X04470	AF000959	L13463
<b>Affy</b> 37765_at	32239_at	39066_at	37187_at	32666_at	32275_at	38995_at	37701_at
SeqID 1223	1157	1026	1045	1142	1218	282	1015
128	129	130	131	132	133	134	135

12 -

			J <b>u</b>			
p-values	0.0108	2.64E-10	0.000818	4.71E-08	0.00058	9.21E-08
Fold Change	0.195015273	0.191432122	0.19139473	0.187743879	0.187570884	0.186647173
Cluster Description	Cluster Incl U95626:Homo sapiens ccr2b (ccr2), ccr2a (ccr2), ccr5 (ccr5) and ccr6 (ccr6) genes, complete cds, and lactoferrin (lactoferrin) gene, partial cds /cds=(2,1429) /gb=U95626 /gi=2104517 /ug=Hs.105938 /len=1607	Cluster incl M18533:Homo sapiens dystrophin (DMD) mRNA, complete cds /cds=UNKNOWN /gb=M18533 /gi=181856 /ug=Hs.169470 /len=13957	Cluster Incl AF044311:Homo sapiens gamma- synuclein gene, complete cds /cds=(52,435) /gb=AF044311 /gi=3347841 /ug=Hs.63236 /len=708	Cluster Incl L34155:Homo sapiens laminin- related protein (LamA3) mRNA, complete cds /cds=(0,5141) /gb=L34155 /gi=551596 /ug=Hs.83450 /len=5433	Cluster Incl M69199:Human G0S2 protein gene, complete cds /cds=(160,471) /gb=M69199 /gi=609453 /ug=Hs.95910 /len=863	Cluster Incl L35594:Human autotaxin mRNA, complete cds /cds=(49,2796) /gb=L35594 /gi=537905 /ug=Hs.174185 /len=3231
Cluster#	Hs.347	Hs.169470	Hs.63236	Hs.83450	Hs.95910	Hs.174185
Gene Name	lactotransferrin	dystrophin (muscular dystrophy, Duchenne and Becker types), includes DXS142, DXS164, DXS230, DXS239, DXS268, DXS269, DXS270, DXS272	synuclein, gamma (breast cancer- specific protein 1)	laminin, alpha 3 (niceln (150kD), kalinin (165kD), BM600 (150kD), epilegrin)	putative lymphocyte G0/G1 switch gene	ectonucleotide pyrophosphatase/pho sphodiesterase 2 (autotaxin)
Genbank	U95626	M18533	AF044311	L34155	M69199	L35594
Affy	37149_s_at	40488_at	36555_at	37909_at	38326_at	41124 <u>r</u> at
SeqID	1168	1038	295	1023	1051	1024
#1	136	137	138	139	140	141

<b>Se</b>	<b>SeqID</b> 1000	<b>Affy</b> 36681_at	Genbank J02611	Gene Name apolipoprotein D	Cluster# Hs.75736	Cluster Description Cluster Incl J02611:Human apolipoprotein D mRNA, complete cds /cds=(61,630) /gb=J02611 /gi=178840 /ug=Hs.75736	<b>Fold Change</b> 0.186645351	<b>p-values</b> 0.00041
	1056	41618_at	M91669	collagen, type XVII, alpha 1	Hs.117938	Cluster Incl M91669:Human Bullous pemphigoid autoantigen BP180 gene, 3 end /cds=(0,4598) /gb=M91669 /gi=179516	0.185170181	1.65E-07
133	1235	36042_at	X75958	neurotrophic tyrosine kinase, receptor, type 2	Hs.47860	Cluster Incl X75958:H.saplens trkB mRNA for protein-tyrosine kinase /cds=(97,1530) /gb=X75958 /gi=473007 /ug=Hs.47860	0.185137314	9.59E-07
	1024	41123_s_at	L35594	ectonucleotide pyrophosphatase/pho sphodiesterase 2	Hs.174185	Cluster Incl L35594:Human autotaxin mRNA, complete cds /cds=(49,2796) /gb=L35594 /gi=537905 /ug=Hs.174185 /len=3231	0.176679484	6.44 <b>E-</b> 07
J	1022	33902_at	L34041	ohosphate nase 1	Hs.286116	Cluster Incl L34041:Homo sapiens L-glycerol-3 phosphate-NAD oxidoreductase mRNA, complete cds /cds=(29,1078) /gb=L34041	0.173326424	0.00000343
J	1016	280 <u>_g_</u> at	L13740	nuclear receptor subfamily 4, group A,	Hs.1119	L13740 /FEATURE= /DEFINITION=HUMTR3A Human TR3 orphan receptor mRNA, complete	0.173040601	0.0000486
ā	996	40658_r_at	D45371	adipose most abundant gene transcript 1	Hs.80485	Cluster Incl D45371:Human apM1 mRNA for Cluster Incl D45371:Human apM1 mRNA for GS3109 (novel adipose specific collagen-like factor), complete cds /cds=(26,760) /gb=D45371 /gi=871886 /ug=Hs.80485	0.172026427	0.000161
m .	301	32542_at	AF063002	four and a half LIM domains 1	Hs.239069	Cluster Inci AF063002:Homo sapiens LIM protein SLIMMER mRNA, complete cds /cds=(84,1055)/gb=AF063002 /gi=3859848 /lig=Hs 75329 /len=2042	0.168054499	0.00000205
CA .	1228	40375_at	X63741	early growth response 3	Hs.74088	Cluster Incl X63741:H.sapiens pilot mRNA /cds=(353,1516) /gb=X63741 /gi=35472 /ug=Hs.74088 /len=4272	0.163077134	0.00000359

				58				
<b>p-values</b> 0.00506	0.00282	0.0000162	5.79E-09	0.00000648	0.0000201	0.00000235	0.000768	0.0000385
<b>Fold Change</b> 0.161923599	0.161859881	0.155156674	0.145966282	0.143559713	0.138540058	0.137509192	0.137096706	0.136296847
Cluster Description Cluster Incl U15979:Human (dlk) mRNA, complete cds /cds=(173,1321) /gb=U15979	K00650 /FEATURE=cds //DEFINITION=HUMFOS Human fos proto-	Cluster Incl X03350:Human mRNA for alcohol dehydrogenase beta-1-subunit (ADH1-2 allele) //cds=(72,1199) /gb=X03350 /gi=28415	Cluster Incl X64559:H.sapiens mRNA for tetranectin /cds=(93,701) /gb=X64559 /di=37408 /uq=Hs.65424 /len=848	Cluster Incl AF032108:Homo sapiens integrin alpha-7 mRNA, complete cds /cds=(161,3574) /gb=AF032108 /gi=2897115 /ug=Hs.74369 /len=4061	M57399 /FEATURE= /DEFINITION=HUMHBNF1 Human nerve growth factor (HBNF-1) mRNA, complete cds	M62402 /FEATURE= /DEFINITION=HUMIGFBP4 Human insulin-like growth factor binding protein 6 (IGFBP6) mRNA, complete cds	Cluster Incl M12963:Human class I alcohol dehydrogenase (ADH1) alpha subunit mRNA, complete cds /cds=(72,1199) /gb=M12963 /ci=178089 /uc=Hs.73843 /len=1450	
Cluster # Hs.169228	Hs.25647	Hs.4	Hs.65424	Hs.74369	Hs.44	Hs.274313	Hs.73843	Hs.103253
Gene Name delta-like homolog (Drosophila)	v-fos FBJ murine osteosarcoma viral oncodene homolog	alcohol dehydrogenase 2 (class 1), beta	tetranectin (plasminogen-binding profein)	integrin, alpha 7	pleiotrophin (heparin binding growth factor 8, neurite growth-	insulin-like growth factor binding protein 6	alcohol dehydrogenase 1 (class I), alpha	perilipin
<b>Genbank</b> U15979	K00650	X03350	X64559	AF032108	M57399	M62402	M12963	AB005293
<b>Affy</b> 32648_at	2094_s_at	35730_at	36569_at	36892_at	234_s_at	1736_at	34637_f_at	37122_at
<b>SeqID</b> 1140	1009	1217	1229	. 293	1047	1048	1032	271
## 15	152	153	154	155	156	157	158	159

			3	19		
<u>p-values</u> 1.19E-07	0.000082	0.0000134	.9.26E-08	9.15E-08	0.000222	0.000439
<b>Fold Change</b> 0.13521119	0.124249102	0.121953593	0.118530255	0.118243196	0.116969229	0.108941232
Cluster Incl AJ001183:Homo sapiens mRNA for Sox10 protein /cds=(120,1520) /gb=AJ001183 /gi=2909359 /ug=Hs.44317	/len=254/ Cluster Incl L49169:Human G0S3 mRNA, complete cds /cds=(593,1609) /gb=L49169 /gi=1082037 /ug=Hs.75678 /len=3775	AF001548 /FEATURE=mRNA /DEFINITION=HUAF001548 Human Chromosome 16 BAC clone CIT987SK-A- 815A9, complete sequence				Cluster Incl AA128249:zl29d09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-503345 /clone_end=5"/gb=AA128249 /gi=1688343 /ug=Hs.83213 /len=648"
Cluster# Hs.44317 C	Hs.75678	Hs.78344	Hs.155597	Hs.283750	Hs.195850	Hs.83213
Gene Name SRY (sex determíning region Y)-box 10	FBJ murine osteosarcoma viral oncogene homolog B	myosin, heavy polypeptide 11, smooth muscle	D component of complement (adipsin)	tenascin XA	keratin 5 (epidermolysis bullosa simplex, Dowling- Meara/Kobner/Weber-	Cockayne types) fatty acid binding protein 4, adipocyte
<b>Genbank</b> AJ001183	L49169	AF001548	M84526	U89337	M21389	AA128249
<b>Affy</b> 36018_at	36669_at	767_at	40282_s_at	38508_s_at	613_at	38430_at
SeqID 849	1029	283	1055	1166	1039	45
## 160	161	162	163	<del>2</del>	165	166

iv:

					60			
p-values	9.35E-07	5.83E-07	0.000249	0.00000084	0.0000236	2.66E-08	3.51E-07	0.00000596
Fold Change	0.108244989	0.10121597	0.097312672	0.096634153	0.092826583	0.091111614	0.090848213	0.070781449
Cluster Description	Cluster Incl U95367:Human GABA-A receptor pi subunit mRNA, complete cds /cds=(156,1478)/gb=U95367/gi=2197000 /ug=Hs.70725/len=3264	Cluster Incl M57399:Human nerve growth factor (HBNF-1) mRNA, complete cds /cds=(395,901) /gb=M57399 /gi=292072 /ug=Hs.44 /len=1029	Cluster Incl X07696:Human mRNA for cytokeratin 15 /cds=(61,1431) /gb=X07696 /gi=34070 /ug=Hs.80342 /len=1709	Cluster Incl M69225:Human bullous pemphigold antigen (BPAG1) mRNA, complete cds /cds=UNKNOWN /gb=M69225 /gi=179522 /ug=Hs.620 /len=8930	Cluster Incl AF013570:Homo sapiens smooth muscle myosin heavy chain SM2 mRNA, alternatively spliced, partial cds /cds=(0,1767) /gb=AF013570 /gi=2352944 /ug=Hs.78344 /len=2580	Cluster Incl D17408:Homo sapiens mRNA for calponin, complete cds /cds=(92,985) /gb=D17408 /gi=1783204 /ug=Hs.21223 /len=1517	D00654 /FEATURE=cds /DEFINITION=HUMACTSG7 Homo sapiens gene for enteric smooth muscle gamma-actin, exon9, complete cds	Cluster Incl J00124:Homo sapiens 50 kDa type I epidermal keratin gene, complete cds /cds=(61,1479) /gb=J00124 /gi=186704 /ug=Hs.117729 /len=1634
Cluster #	Hs.70725	Hs.44	Hs.80342	Hs.620	Hs.78344	Hs.21223	Hs.77443	Hs.117729
Gene Name	gamma-aminobutyric acid (GABA) A receptor, pi	pleiotrophin (heparin binding growth factor 8, neurite growth- promoting factor 1)	Keratin 15	bullous pemphigoid antigen 1 (230/240kD)	myosin, heavy polypeptide 11, smooth muscle	calponin 1, basic, smooth muscle	actin, gamma 2, smooth muscle, enteric	keratin 14 (epidermolysis bullosa simplex, Dowling-Meara,
Genbank	U95367	M57399	X07696	M69225	AF013570	D17408	D00654	J00124
Affy	40339_at	34820_at	37582_at	40304_at	37407_s_at	34203_at	1197_at	39052_at
SedID	1167	1047	1220	1052	288	964	959	866
#4	167	168	169	170	171	172	173	174

מופרותיות אוות מתבחידות ו

<b>p-values</b> 5.77E-09	0.00055334	0.00136502	4.5016E-06	0.00129495	0.00039175	2.7406E-06
<b>Fold Change</b> 0.0564074	7.73694268	4.18	0.282343722	3.871753195	0.308362018	0.227899817
Cluster Incl AF056087:Homo sapiens secreted frizzled related protein mRNA, complete cds /cds=(302,1243) /gb=AF056087 /gi=3033550 /ug=Hs.7306 /len=4458	Cluster Incl. AW007442:wt55g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2511418 /clone_end=3' /gb=AW007442 /gl=5856220 /in=Hs 235961 /len=424'				Cluster Incl. AI283888:qk51f12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1872527 /clone_end=3'/gb=AI283888 /gi=3922121	Cluster Incl. AI589804:tm74e11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2163884 /clone_end=3'/gb=AI589804 /gi=4598852 /ug=Hs.12828 /len=508'
Cluster#	Hs.821	Hs.179718	Hs.49765	Hs.151678	Hs.186961	Hs.12828
Gene Name secreted frizzled- related protein 1	zinc finger protein homologous to Zfp92 in mouse	v-myb avian myeloblastosis viral oncogene homolog-	VLCS-H1 protein	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6)	ubiquitin specific protease 25	tweety (Drosophila) homolog 1
Genbank AF056087	AW007442	A1990026	AA614135	AL118633	AI283888	Al589804
<b>Affy</b> 32521_at	74989_at	80675_at	64695_at	59253_at	91419_at	48513_at
<b>SeqID</b> 299	923	843	183	901	111	525
# 175	176	177	178	179	180	181

				6	52			
p-values	0.00017707	1.0421E-05	3.9817E-06	1.5585E-05	7.4333E-10	0.00109754	0.00022486	6.75E-04
Fold Change	6.818460543	4.363660627	4.2443289	4.256819836	9.431588747	5.50	0.149624624	4.122293677
Cluster Description	Cluster Incl. AW003626:wx34e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2545562 /clone_end=3' /gb=AW003626 /gi=5850542 /ug=Hs.234018 /len=707'	Cluster Incl. Al973225:wr53c11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2491412 /clone_end=3' /gb=Al973225 /gi=5770051 /ug=Hs.233704 /len=399'	-		Cluster Incl. AW003286:wq65a02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2476106 /clone_end=3' /gb=AW003286 /gi=5850202 /ug=Hs.232126 /len=773'	Cluster Incl. AA707213:zj32h06.s1 Homo sapiens cDNA, 3 end /clone=452027 /clone_end=3' /gb=AA707213 /gi=2717131 /ug=Hs.14319 /len=527'	Cluster Incl. AI480357:tm51d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2161647 /clone_end=3' /gb=AI480357 /gi=4373525 /ug=Hs.91877 /len=830'	Cluster Incl AA704137:ag47g01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1119984 /clone_end=3"/gb=AA704137 /gi=2714055 /ug=Hs.125359 /len=923"
Cluster#	Hs.159154	Hs.169840	Hs.104019	Hs.108106	Hs.270810	Hs.317	Hs.91877	Hs.125359
Gene Name	tubulin, beta, 4	TTK protein kinase	transforming, acidic colled-coll containing protein 3	transcription factor	topoisomerase (DNA) II alpha (170kD)	topolsomerase (DNA) I	thyroid hormone responsive SPOT14 (rat) homolog	Thy-1 cell surface antigen
Genbank	AW003626	AI973225	A1990642	AA026429	AW003286	AA707213	Al480357	AA704137
	57034_at	74593_at	52238_s_at	63346_at	74096_at	.90442_at	57778_at	39395_at
SedID	913	833	847	9	911	208	488	205
##	182	183	184	185	186	187	188	189

 $\bigcirc$ 

			03				
<u>p-values</u> 0.00065669	3.1699E-09	0.00058351	3.4432E-06	2.6069E-05	0.00051209	0.00133643	0.0000138
<b>Eold Change</b> 3.418467862	0.284181885	99.9	0.31	4.206790316	3.273076721	0.325281828	0.277326129
Cluster Incl. AA527151:ni07b08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-967287 /clone_end=3' /gb=AA527151 /gi=2269220 /ucl=Hs 108977 /len=559'		Cluster Incl. AL036753:DKFZp564I0663_r1 Homo sapiens cDNA, 5 end /clone=DKFZp564I0663 /clone_end=5' /gb=AL036753 /gi=5927893 /ug=Hs.133482 /len=617'			Cluster Incl. H10816;ym04e12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-46664 /clone_end=5 /gb=H10816 /gi=875636 /ua=Hs.22065 /len=660'	Cluster Incl. N45415;yw97h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-260219 /clone_end=5 /gb=N45415 /gi=1186581 /ug=Hs.24395 /len=647'	Cluster Incl AI720438:as81g04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2335158 /clone_end=3"/gb=AI720438/gi=5037694 /ug=Hs.20144 /len=550"
Cluster # Hs.184242	Hs.243678	Hs.32964	Hs.129872	Hs.106260	Hs.22065	Hs.24395	Hs.20144
Gene Name sterol-C5-desaturase (fungal ERG3, delta-5 desaturase)-like	SRY (sex determining region Y)-box 8	SRY (sex determining region Y)-box 11	sperm surface protein Hs.129872	sorting nexin 10	small protein effector 1 of Cdc42	small inducible cytokine subfamily B (Cys-X-Cys), member 14 (BRAK)	small inducible cytokine subfamily A (Cys-Cys), member 14
Genbank AA527151	AI675177	AL036753	Al949433	AI285531	H10816	N45415	AI720438
<i>⋽</i> <b>હ</b>			<u></u>	ä	**	`ਜ਼	æ'
<b>Affy</b> 48101_at	43039_at	91880_at	78444_at	63335_at	49498_at	65823_at	33790_at
SeqID Af	585 43039_at	854 91880_at	800 78444_a	412 63335 <u>.</u>	980 49498_	1077 65823_	616 33790_

p-values	1.7128E-08	0.000166	5.5177E-07	2.1786E-06	0.02422274	0.00029667	3.31E-03	30 37760 0
Fold Change	0.13254339	0.147972137	0.279118305	0.113932898	3.52	5.371729632	3.31996447	5 815056061
Cluster Description	Cluster Incl. AA102575:zn42c03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-550084 /clone_end=3' /gb=AA102575 /gi=1647767 /ug=Hs.26530 /len=589'		-	Cluster Incl. AI829385:wk64e08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2420198 /clone_end=3 /gb=AI829385 /gi=5450056 /ug=Hs.59729 /len=480'		Cluster Incl. Al864016:wj53h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2406595 /clone_end=3' /gb=Al864016 /gi=5528123 /ug=Hs.234375 /len=511'	Cluster Incl AA131149:zo16d05.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-587049 /clone_end=5" /gb=AA131149 /gi=1692640 /ug=Hs.2962 /len=464"	Chretor Incl. A1000A05 we20h10 v1 Homo
Cluster #	Hs.26530	Hs.181062	Hs.132792	Hs.59729	Hs.279623	Hs.313	Hs.2962	112 404004
Gene Name	serum deprivation response (phosphatidylserine- binding protein)	serum amyloid A1	serologically defined colon cancer antigen 43	semaphorin sem2	selenoprotein X	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T- lymphocyte activation 1)	S100 calclum-binding protein P	
Genbank	AA102575	AA829286	AI832477	AI829385	W92110	Al864016	AA131149	201000
Affx	50094_at	33272_at	63580_at	62486_at	78757_at	74815_at	34319_at	4- 70073
SegID	36	233	732	729	1213	746	46	;
##	198	199	200	201	202	203	204	6

/clone\_end=3' /gb=Al990405 /gi=5837286 /ug=Hs.233881 /len=481

p- <u>values</u> 4.5657E-06	0.02812425	0.00031747	4.4105E-06	2.9782E-08	1.3574E-05	2.9836E-06	9.3518E-10
Fold Change 0.18	0.30	3.28	4.031107597	6.276196882	0.26701338	0.183592799	5.975488989
Cluster Incl. AL110368:DKFZp564P1078_s1 Homo sapiens cDNA, 3 end /clone=DKFZp564P1078 /clone_end=3' /gb=AL110368 /gi=5865976 /ug=Hs.198353 /len=720'		Cluster Incl. AI799107:we98h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2349171 /clone_end=3 /gb=AI799107 /gi=5364579 /un=Hs 128501 /len=713	Cluster Incl. AL079372:DKFZp564H1178_s1 Homo sapiens cDNA, 3 end /clone=DKFZp564H1178 /clone_end=3' /gb=AL079372 /gi=5423266 /ug=Hs.23044 /len=655'	Cluster Incl. AI739117:w/18c04.x1 Homo saplens cDNA, 3 end /clone=IMAGE-2390598 /clone_end=3 /gb=AI739117 /gi=5101098 /ua=Hs.73625 /len=762'	Cluster Incl. Al858626:wl40g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2427416 /clone_end=3 /gb=Al858626 /gi=5512242 /ug=Hs.30807 /len=617	Cluster Incl. Al304339:qo58g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1912770 /clone_end=3'/gb=Al304339 /gi=3988028 /ua=Hs.8364 /len=614'	Cluster Incl. AA195614:zr37b09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-665561 /clone_end=5' /gb=AA195614 /gi=1783791 /ug=Hs.5101 /len=635'
Cluster # Hs. 12246	Hs.106185	Hs.128501	Hs.23044	Hs.73625	Hs.198281	Hs.8364	Hs.5101
<u>Gene Name</u> reelin	ral guanine nucleotide Hs.106185 dissociation stimulator	RAD54, S. cerevisiae, homolog of, B	RAD51 (S. cerevislae) homolog (E coli RecA homolog)	RAB6 interacting, kinesin-like (rabkinesin6)	pyruvate kinase, muscle	pyruvate dehydrogenase kinase, isoenzyme 4	protein regulator of cytokinesis 1
Genbank AL110368	AA147088	AI799107	AL079372	AI739117	AI858626	Al304339	AA195614
<b>Affy</b> 69473_r_at	91384_at	74300_at	44037_at	46683_at	57173_at	48647_at	45799_at
SeqiD 900	19	229	80	620	737	420	<u>~</u>
## 206	207	208	209	210	211	212	213

3	22	<b>m</b>					
	5.5208E-05	0.03570463	0.00261362	7.8961E-05	0.00044405	9.7327E-07	6.0939E-06
· ·	0.181794989	3.638706185	0.158415546	0.062026919	0.19	0.14	5.25
sapiens cDNA, 3 end /clone=IMAGE-2422116 /clone_end=3' /gb=Al828396 /gi=5449067 /ug=Hs.201574 /len=465'	Cluster Incl. AI741776:wg22g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2365890 /clone_end=3'/gb=AI741776 /gi=5110064 /ug=Hs.8944 /len=641'	Cluster Incl. AA593830:nn17b11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1084125 /clone_end=3' /gb=AA593830 /gi=2408508 /ug=Hs.163833 /len=405'	Cluster Incl. Al863965:wj54b08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2406615 ./clone_end=3' /gb=Al863965 /gi=5527996 /ug=Hs.15285 /len=601'	Cluster Incl. Al697470:tq08h01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2208241 /clone_end=3' /gb=Al697470 /gi=4985370 /ug=Hs.205126 /len=494'	Cluster Incl. AL044906:DKFZp434K183_r1 Homo sapiens cDNA, 5 end /clone=DKFZp434K183 /clone_end=5' /gb=AL044906 /gi=5433103 /ug=Hs.211647 /len=485'	Cluster Incl. Al492388:ti27d10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2131699 /clone_end=3' /gb=Al492388 /gi=4393391 /ug=Hs.145011 /len=477'	Cluster Incl. AA535819:nj79e01.s1 Homo sapiens cDNA /clone=IMAGE-998712 /gb=AA535819 /gi=2280072 /ug=Hs.238355 /len=522
	Hs.8944	Hs.163833	Hs.279898	Hs.205126	Hs.75813	Hs.117176	Hs.83883
	procollagen C- endopeptidase enhancer 2	PRO0611 protein	PRO0529 protein	polymeric immunoglobulin receptor	polycystic kidney disease 1 (autosomal dominant)	poly(A)-binding protein, nuclear 1	PMEPA1 protein
	Al741776	AA593830	AI863965	Al697470	AL044906	Al492388	AA535819
<b>1</b>	55569_at	84574_r_at	65700_at	45294_at	71106_i_at	90494_at	91095_s_at
3	625	173	745	209	874	492	161
<u>+</u>	215	216	217	218	219	220	22.1
	5	625 55569_at Al741776 process profited the sapiens cDNA, 3 end /clone=iMAGE-2422116 /clone_and=3'/gb=Al828396 /gi=5449067 /ug=Hs.201574 /len=465' endopeptidase /clone_and=3'/gb=Al741776:wg22g10.x1 Homo 0.181794989 enhancer 2 /clone_and=3'/gb=Al741776 /gi=5110064 /ug=Hs.8944 /len=641'	sapiens cDNA, 3 end /clone=IMAGE-2422116 /clone_end=3 /gb=Al828396 /gi=5449067 /ug=Hs.201574 /len=465' endopeptidase endopeptidase enhancer 2 /ug=Hs.8944 /len=641'  173 84574_r_at AA593830 PRO0611 protein Hs.163833 Cluster Incl. AA593830 /gi=2408508 /clone_end=3 /gb=Al741776 /gi=5110064 /ug=Hs.8944 /len=641'  173 84574_r_at AA593830 PRO0611 protein Hs.163833 Cluster Incl. AA593830 /gi=2408508 /clone_end=3 /gb=AA593830 /gi=2408508 /clone_end=3 /gb=AA593830 /gi=2408508 /ug=Hs.163833 /len=405'	625 5569_at Al741776 procollagen C- Hs.8944 Cluster Incl. Al741776 /gl=5449067 /lone_and=3' (gb=Al828396 /gl=5449067 /lone_and=3' (gb=Al828396 /gl=5449067 /lone_and=3' (gb=Al741776 /gl=5449067 /lone_and=a' (gb=Al741776 /gl=5110064 /lone_and=a' (gb=Al74176 /gl=5110064 /lone_and=a' (gb=Al74176 /gl=5110064 /lone_and=a' (gb=Al74176 /gl=5110064 /lone_and=a' (gb=Al863830 in17b11.s1 Homo and and a' (gb=Al863830 in17b11.s1 Homo and a' (gb=Al86385 in18b125 in18b118546 and a' (gb=Al863965 /gl=5527996 /lone_and=a' (gb=Al863965 /gl=5527996 /lone_and=a' (gb=Al863965 /gl=5527996 /lone_and=a' (gb=Al863965 /gl=5627996	625 55569_at Al741776 procollagen C- Hs.8944 Cluster Incl. Al741776:wg22g10.x1 Homo endegatidase endegations conversion protein the company of the company o	625 55569_at Al741776 procollagen C- Hs.8944 Cluster Inc. Ab2030.0074.16n=6465  173 84574_r_at AA593830 PRO0611 protein Hs.163833 Cluster Incl. Ab593830.0177176 (jai=240867)  1745 65700_at Al863965 PRO0529 protein Hs.279898 Cluster Incl. Al863965 (jai=54706115 Clone_and=3' (jai=A4087)  175 84574_r_at AA593830 PRO0611 protein Hs.163833 Cluster Incl. Ab693830 (jai=240808)  176 65700_at Al863965 PRO0529 protein Hs.279898 Cluster Incl. Al863965 (jai=527996 / loine_and=3' (jai=A4087)  177 845 65700_at Al863965 PRO0529 protein Hs.279898 Cluster Incl. Al863965 (jai=527996 / loine_and=3' (jai=A408163965) (jai=527996 / loine_and=3' (jai=A408163965) (jai=527996 / loine_and=3' (jai=A408163965) (jai=527996 / loine_and=3' (jai=A408163965) (jai=4985370 / loine_and=3' (jai=A408163965) (jai=4985370 / loine_and=3' (jai=A408163965) (jai=4985370 / loine_and=3' (jai=A408163965) (jai=4986370 / loine_and=3' (jai=A408163965) (jai=4986370 / loine_and=3' (jai=A408163965) (jai=4986370 / loine_and=3' (jai=A408163965) (jai=4986370 / loine_and=3' (jai	625 55569_at Al741776 procollegen C- Hs.8944 Cluster incl. Al74176**vg22g10:x1 Homo endopeptidase endo-signate incl. Al741776**vg22g10:x1 Homo endopeptidase endo-signate incl. Al74176**vg22g10:x1 Homo endopeptidase endopeptidase endo-signate incl. Al74176**vg22g10:x1 Homo endopeptidase e

. :

				6	8			
p-values	0.00020188	0.00307749	6.6167E-05	0.000479	1.4629E-08	6.7348E-06	4.93E-06	5.3066E-07
Fold Change	0.199980315	3.316200333	4.64	0.117240353	0.17504844	0.262530591	4.698983711	3.809930405
Cluster Description	Cluster Incl. Al355848:qu02d09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1963601 /clone_end=3' /gb=Al355848 /gi=4096001 /ug=Hs.239464 /len=715'	Cluster Incl. Al935353:wo82d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2461847 /clone_end=3' /gb=Al935353 /gi=5674223 /ug=Hs.234669 /len=532'	Cluster Incl. AI479933:tm73b08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2163735 /clone_end=3' /gb=AI479933 /gi=4373101 /ug=Hs.223933 /len=465'	Cluster Incl. W48800;zc44f03.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-325181 /clone_end=5' /gb=W48800 /gi=1336949 /ug=Hs.167297 /len=451'	Cluster Incl. AA427578:zw54b07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-773845 /clone_end=3' /gb=AA427578 /gi=2112006 /ug=Hs.220975 /len=525'	Cluster Incl. AI052524:oz27f07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1676581 /clone_end=3' /gb=AI052524 /gi=3308515 /ug=Hs.4799 /len=537'	Cluster Incl AA418080:zv97h07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-767773 /clone_end=3" /gb=AA418080 /gi=2079881 /ug=Hs.3972 /len=543"	Cluster Incl. AI742260:wg39g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367522 /clone_end=3' /gb=AI742260 /gi=5110548 /ug=Hs.93847 /len=789'
Cluster#	Hs.35841	Hs.243886	Hs.159623	Hs.44054	Hs.266902	Hs.3821	Hs.3972	Hs.93847
Gene Name	nuclear factor I/X (CCAAT-binding transcription factor)	nuclear autoantigenic sperm protein (histone-binding)	NK-2 (Drosophila) homolog B	ninein	neurotrophin 5 (neurotrophin 4/5)	neurobeachin	NeuAc-alpha-2,3-Gal- beta-1,3-GalNAc- alpha-2, 6- sialyltransferase alpha2,6- sialyltransferase	NÁDPH oxidase 4
Genbank	Al355848	AI935353	Al479933	W48800	AA427578	A1052524	AA418080	AI742260
Affy	63877_r_at	49666_s_at	72236_at	82657_f_at	72026_g_at	56809_at	34778_at	55457_at
SeqID	435	790	486	1188	114	328	105	630
##	230	231	232	233	234	235	236	237

<b>p-values</b> 4.4362E-07	0.0000139	0.00225117	0.00151003	1.1301E-05	0.0000045	0.00267462	0.0000502
<b>Fold Change</b> 0.32670528	0.168769332	0.288946314	4.848524211	3.068295724	0.23811529	0.23	0.246437105
# Cluster Description  22 Cluster Incl. AA526844:ni92d10.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-984307 /clone_end=3' /gb=AA526844 /gi=2268913 /ua=Hs. 77310 /len=669'	•	-	6 Cluster Incl. N78139:yv73d07.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-248365 /clone_end=5'/gb=N78139 /gi=1240840 /ug=Hs.239825 /len=656'			Hs.177536 Cluster Incl. AA776393:ah16g09.s1 Homo sapiens cDNA, 3 end /clone=1156864 /clone_end=3'/gb=AA776393 /gi=2835727 /ug=Hs.177536 /len=602'	
Cluster # Hs.211582	Hs.78344	Hs.239663	Hs.42346	Hs.240	Hs.183109	Hs.17753	Hs.279771
Gene Name myosin, light polypeptide kinase	myosin, heavy polypeptide 11, smooth muscle	myeloid/lymphoid or mixed-lineage leukemia (trithorax (Drosophila) homolog); translocated to, 7	muscle-specific protein	M-phase phosphoprotein 1	monoamine oxidase A	metallocarboxypeptid ase CPX-1	melanoma inhibitory activity,ras-related GTP-binding protein 4b
Genbank AA526844	AF001548	AI814178	N78139	N27428	AA420624	AA776393	AA461365
<b>Affy</b> 46276_at	32582_at	46743_s_at	58494_r_at	59624_g_at	41771_g_at	84934_at	39271_at
<b>SeqID</b> 150	283	269	. 1093	1069	<del></del>	222	127
738 ##	239	240	241	242	243	244	245

	WO 02/059271			70			PC1/US02/02176		
p-values	6.1415E-06	1.9615E-06	0.00253759		0.0005914	0.00014885	8.7304E-05	6.1228E-07	
Fold Change	0.196704294	0.12	0.307354772	4.366999247	0.247555921	0.214230439	0.322163154	3.542386026	
Cluster Description	Cluster Incl. Al972357:wr37c09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2489872 /clone_end=3'/db=Al972357 /gi=5769183	/ug=Hs.237874 /len=524' Cluster Incl. Al459139:tj65e05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2146400 /clone_end=3'/gb=Al459139 /gi=4311718	/ug=Hs.235590 /len=519' Cluster Incl. Al969879:wq76f05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2477217 /clone_end=3'/gb=Al969879 /gi=5766697 /ug=Hs.233610 /len=329'	Cluster Incl. W22091:61F10 Homo sapiens cDNA /clone=(not-directional) /gb=W22091 /qi=1298924 /ug=Hs.234460 /len=637					
Cluster #	Hs.19368	Hs.56729	Hs.89137	Hs.1770	Hs.97044	Hs.84728	Hs.182965	Hs.279766	
Gene Name		lymphocyte-specific protein 1	low density lipoprotein related protein 1 (alpha-2- macroglobulin	receptor) ligase I, DNA, ATP- dependent	Kv channel- interacting protein 2	Kruppel-like factor 5 (intestinal)	Kruppel-like factor 4 (gut)	kinesin family member 4A	
Genhank	Al972357	Al459139	Al969879	W22091	F36908	AI815057	Al290876	AA004208	
ν ψ	75254_at	78644_at	74541_at	74835_r_at	48950_at	47113_at	48587_at	51160_at	
	829	480	819	1176	976	669	416	7	
4	# 246	247	248	249	250	251	252	253	

			7	1			
<b>p-values</b> 3.2252E-06	0.00090706	0.00048007	0.00894957	9.936E-05	4.1926E-05	1.24E-12	1.69E-06
<b>Fold Change</b> 0.189411148	0.317853152	0.28929478	3.778012983	0.231260722	0.20	10.18941323	3.635450964
Cluster Incl. W68504:zd36b01.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-342697 /clone_end=5' /gb=W68504 /gi=1377374 /ug=Hs.21288 /len=613'			Cluster Incl. AI073544:ov45e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1640282 /clone_end=3' /gb=AI073544 /gi=3400188 /ua=Hs 120703 /len=481'	Cluster Incl. Al097463:qb90a04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1707342 /clone_end=3 /gb=Al097463 /gi=3447045 /ug=Hs. 21035 /len=464	Cluster Incl. H19400:ym46g07.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-51511 /clone_end=5 /gb=H19400 /gi=888095 /ug=Hs.21035 /len=488'	Cluster Incl AB029000:Homo sapiens mRNA for KIAA1077 protein, partial cds /cds=(0,2456) /gb=AB029000 /gi=5689490 /ug=Hs.70823 /len=4834	Cluster Incl AB020713:Homo sapiens mRNA for KIAA0906 protein, partial cds /cds=(0,2772) /gb=AB020713 /gi=4240300 /ug=Hs.56966 /len=4217
Cluster# Hs.191098	Hs.230188	Hs.263395	Hs.62576	Hs.21035	Hs.21035	Hs.70823	Hs.56966
Gene Name KIAA1479 protein	KIAA1396 protein	KIAA1368 protein	KIAA1240 protein	KIÀA1130 protein	KIAA1130 protein	KIAA1077 protein	KIAA0906 protein
<b>Genbank</b> W68504	AA912409	AF063500	AI073544	Al097463	H19400	AB029000	AB020713
<b>Affy</b> 49599_at	88138_at	63393_at	76253_at	52793_at	90920_at	35832_at	41812_s_at
<b>SeqID</b> 1194	250	302	334	350	986	278	276
## 254	255	256	257	258	259	260	261

	WO 02/059	271		7	72		PC	T/US02/02176
p-values	9.6801E-06	0.04190137	2.62E-08	5.93E-09	5.5307E-05	3.56E-09	0.0000146	0.01054263
Fold Change	0.247630859	0.33	0.226047115	0.075355998	0.22	6.816530863	0.325833287	0.3274967
Cluster Description	Cluster Incl. AA142956:zl43g02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-504722 /clone_end=3'/gb=AA142956 /gi=1712334 /ug=Hs.239142 /len=640	Cluster Incl. AA701619:zi41f11.s1 Homo sapiens cDNA, 3 end /clone=433389 /clone_end=3'/gb=AA701619/gi=2704784 /ug=Hs.190382 /len=398'	.Cluster Incl AB011089:Homo sapiens mRNA for KIAA0517 protein, partial cds /cds=(0,2380) /gb=AB011089 /gi=3043557 /ug=Hs.12372 /len=6740	Cluster Incl AB002351:Human mRNA for KIAA0353 gene, partial cds /cds=(0,4125) /gb=AB002351 /gi=2224646 /ug=Hs.10587 /len=6651	Cluster Incl. AA706612:ah26c02.s1 Homo sapiens cDNA, 3 end /clone=1239938 /clone_end=3' /gb=AA706612 /gi=2716530 /ug=Hs.115740 /len=949'	Cluster Incl D14657:Human mRNA for KIAA0101 gene, complete cds /cds=(61,396) /gb=D14657 /gi=285938 /ug=Hs.81892 /len=836	Cluster Incl D14664:Human mRNA for KIAA0022 gene, complete cds /cds=(184,696) /gb=D14664 /gi=285952 /ug=Hs.2441 /len=3694	
Cluster#	Hs.42676	Hs.7314	Hs.12372	Hs.10587	Hs.115740	Hs.81892	Hs.2441	Hs.111758
Gene Name	KIAA0781 protein	KIAA0614 protein	KIAA0517 protein	KIAA0353 protein	KIAA0210 gene product	KIAA0101 gene product	KIAA0022 gene product	keratin 6B
Genbank	AA142956	AA701619	AB011089	AB002351	AA706612	D14657	D14664	Al831452
Affy	65593_at	68283_r_at	39382_at	39544_at	91405_at	38116_at	34760_at	62998_at
SeqID	28	203	273	569	207	961	962	731
#11	262	263	264	265	266	267		269

<u>p-values</u> 0.00012792	0.0007796	7.6279E-07	1.23E-05	0.01689309	1.29E-07	0.0007917	6.2389E-06
Fold Change 0.18	3.175184161	0.146596341	5.51416519	0.25	0.171820134	0.310324615	0.223459008
Cluster Incl. Al566193:tq69f02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2214075 /clone_end=3' /gb=Al566193 /gi=4524645 /lun=Hs. 196927 /len=393'		Cluster Incl. AW008322:wv53d07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990848 /clone_end=3 /gb=AW008322 /gi=5857100 /ua=Hs.234145 /len=556*	Cluster Incl AA203213:zx57e04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-446622 /clone_end=5" /gb=AA203213 /gi=1798923 /lin=Hs 833 /len=879"	Cluster Incl. Al971748:wr07f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2480871 /clone_end=3'/gb=Al971748 /gi=5768574 /len=841'	Cluster Incl AL021786:Human DNA sequence from PAC 696H22 on chromosome Xq21.1-21.2. Contains a mouse E25 like gene, a Kinesin like pseudogene and ESTs /cds=(0,680) /gb=AL021786 /gi=2853186	Cluster Incl. AW022660:df42a02.y1 Homo sapiens cDNA, 5 end /clone=IMAGE-2485899 /clone_end=5'/gb=AW022660 /gi=5876190 /ua=Hs.236002 /len=505'	Cluster Incl. AA031286:zk13b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-470383 /clone_end=3' /gb=AA031286 /gi=1501241 /ug=Hs.10494 /len=512'
Cluster# Hs.196927	Hs.237868	Hs.64310	Hs.833	Hs.85266	Hs.17109	Hs.85112	Hs.143648
Gene Name Iroquois homeobox protein 4	interleukin 7 receptor	interleukin 11 receptor, alpha	interferon-stimulated protein, 15 kDa	integrin, beta 4	integral membrane protein 2A	insulin-like growth factor 1 (somatomedia C)	insulin receptor substrate 2
Genbank Al566193	Al655781	AW008322	AA203213	Al971748	AL021786	AW022660	AA031286
<b>Affy</b> 79663_at	63628_at	89921_at	38432_at	73285_!_at	40775_at	64305_s_at	56338_at
SeqID 518	557	928	83	826	850	942	4
# 270	271	272	273	274	275	276	277

		/-			
p-values 0.0000161	0.0016656	0.000411	0.00034019	1.7517E-05	3.744E-08
<b>Fold Change</b> 0.309888618	0.316720069	0.23941203	0.302724058	10.30345974	0.1264716
Cluster Incl AL022726:Human DNA sequence from clone 625H18 on chromosome 6p22.2-23. Contains the gene for ID4 Helix-loop-helix DNA binding protein and part of an alternatively spliced novel gene. Contains ESTs, STSs, GSSs and putative CpG islands //ds=(368,853) /gb=AL022726 /gi=3676217	Cluster Incl. AA152276:zl06e06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-491554 /clone_end=5' /gb=AA152276 /gi=1721679 /ug=Hs.204038 /len=618'	Cluster Incl Al660656:wf23c07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2351436 /clone_end=3" /gb=Al660656 /gi=4764239 /ug=Hs.76325 /len=522"	Cluster Incl. Al813866:wk61b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2419853 /clone_end=3' /gb=Al813866 /gi=5425081	Cluster Incl. Al828404:wk84f07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2422117 /clone_end=3' /gb=Al828404 /gi=5449075 /ive=He_2-26037 /lan=601'	
Cluster# Hs.34853	Hs.204038	Hs.76325	Hs.283305	Hs.140	Hs.112844
Gene Name inhibitor of DNA binding 4, dominant negative helix-loop- helix protein	indolethylamine N- methyltransferase	immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides	immunoglobulin heavy contant alpha 1	immunoglobulin heavy constant gamma 3 (Gm	marker) hypothetical protein PRO2160
<u>Genbank</u> AL022726	AA152276	AI660656	Al813866	Al828404	AW016235
<b>Affy</b> 41536_at	63798_at	37006_at	75127_f_at	58869 <u>i_a</u> t	64258_f_at
<b>SeqID</b> 852	29	570	969	727	935
. 278	279	280	281	282	283

b-values	2.1399E-07	4.8443E-05	1.7499E-09	5.2039E-08	0.00014333	0.00241384	1.8721E-05	0.00187809
Fold Change	0.297383187	3.983397486	0.047728145	0.289179561	3.336721416	0.32	3.188106939	4.36
Cluster Description	Cluster Incl. AA651733:ns67b07.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-1188661 /clone_end=5' /gb=AA651733 /gi=2583385 /ug=Hs.21861 /len=515'	Cluster Incl. N21131;yx52g04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-265398 /clone_end=3 /gb=N21131 /gi=1126301 /ua=Hs.233612 /len=571	·					Cluster Incl. Al149537:qc70g02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1714994 /clone_end=3'/gb=Al149537 /gi=3678006 /ug=Hs.203401 /len=527'
Cluster #	Hs.21861	Hs.42949	Hs.271277	Hs.169764	Hs.118552	Hs.267368	Hs.133260	Hs.263081
Gene Name	hypothetical protein MPMGp800C04260Q 003	hypothetical protein HES6	hypothetical protein from EUROIMAGE 363668	hypothetical protein FLJ20701	hypothetical protein FLJ20539	hypothetical protein FLJ20489	hypothetical protein FLJ20354	hypothetical protein FLJ20320
Genbank	AA651733	N21131	AA020743	AA521440	AI276023	AA563601	AA813827	AI149537
Affy		49633_at	50223_at	54742_at	47427_at	91394_at	56634_at	70129 <u>r_at</u>
SedID	195	1063	თ	144	406	167	231	371
##	284	285	286	287	288	289	290	291

	-			76			FC 170302/	021/0
<b>p-<u>values</u></b> 0.00010396	0.00090349	6.097E-08	3.4283E-07	1.2408E-05	0.00013093	9.6896E-05	1.4039E-06	0.00250076
<b>Fold Change</b> 3.437531315	4.739571659	3.646875259	0.299454892	0.263536613	0.223334551	0.142325635	3.915587607	0.33
Cluster Description Cluster Incl. AA181060.zp66h06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-625211 /clone_end=3' /gb=AA181060 /gi=1764543 /ug=Hs.239302 /len=607'	Cluster Incl. AI766666:wi02e05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2389088 /clone_end=3 /gb=AI766666 /gi=5233175 /ug=Hs.233608 /len=518'	Cluster Incl. AA741298:oc86a07.s1 Homo sapiens cDNA /clone=IMAGE-1356564 /gb=AA741298 /gi=2779890 /ug=Hs.23495 /len=530	Cluster Incl. Al376944:tc34b06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2066483 /clone_end=3'/gb=Al376944 /gi=4186797 /ug=Hs.6166 /len=492'	Cluster Incl. W27376:28b7 Homo sapiens cDNA /gb=W27376 /gi=1307036 /ug=Hs.8395 /len=596	Cluster Incl. Al971695:wq88e01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2479128 /clone_end=3' /gb=Al971695 /gi=5768521 /ug=Hs.237607 /len=573'	Cluster Incl. AA708740:zl57g12.s1 Homo sapiens cDNA, 3 end /clone=506086 /clone_end=3' /gb=AA708740 /gi=2718658 /ug=Hs.23467 /len=475'	Cluster Incl. AA195220:zr34g09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-665344 /clone_end=5' /gb=AA195220 /gi=1784932 /ug=Hs.26516 /len=637'	Cluster Incl. Al811688:tw44g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2262594 /clone_end=3' /gb=Al8116R8 /gi=5398254 /ug=Hs.128766 /len=455
Cluster# Hs.92254	Hs.161554	Hs.23495	Hs.6166	Hs.8395	Hs.107882	Hs.23467	Hs.26516	Hs.128766
Gene Name hypothetical protein FLJ20163	hypothetical protein FLJ20159	hypothetical protein FLJ11252	hypothetical protein FLJ11196	hypothetical protein FLJ10781	hypothetical protein FLJ10659	hypothetical protein FLJ10633	hypothetical protein FLJ10604	hypothetical protein FLJ10600
Genbank AA181060	AI766666	AA741298	Al376944	W27376	Al971695	AA708740	AA195220	AI811688
<b>Affy</b> 50280_at	74539_g_at	43439_at	53962_at	55074_at	44855_s_at	44057_at	51130_at	74343_at
SeqID 76	656	213	445	1179	825	210	62	695
## 585	293	294	295	296	297	298		300

p-values 0.0022939	4.719E-12	1.3006E-07	9.0609E-08	1.8056E-05	7.6457E-06	0.00028995	5.3484E-07
Fold Change 3.07	9.164231149	3.058813358	4.806177129	3.509937557	0.21534971	3.782457573	0.18625739
Cluster Incl. Al016073:ov26f11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1638477 /clone_end=3' (gb=Al016073 /gi=3230409 /ug=Hs. 131840 /len=561'	Cluster Incl. AI674163:wc09a11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2314652 /clone_end=3' /gb=AI674163 /gi=4874643 /ua=Hs. 14559 /len=553'	Cluster Incl. AA134589:zn90b04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-565423 /clone_end=5' /gb=AA134589 /gi=1695586 /ug=Hs. 48855 /len=608'				Cluster Incl. Al949698:wq13h04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2471191 /clone_end=3' /gb=Al949698 /gi=5742008 /ua=Hs.42309 /len=553'	Cluster Incl. AL040063:DKFZp434P0712_r1 Homo sapiens cDNA, 5 end /clone=DKFZp434P0712 /clone_end=5' /gb=AL040063 /gi=5409033 /ug=Hs.22505 /len=557'
Cluster# Hs.131840	Hs.14559	Hs.48855	Hs.122579	Hs.104650	Hs.106283	Hs.53913	Hs.22505
Gene Name hypothetical protein FLJ10578	hypothetical protein FLJ10540	hypothetical protein FLJ10468	hypothetical protein FLJ10461	hypothetical protein FLJ10292	hypothetical protein FLJ10262	hypothetical protein FLJ10252	hypothetical protein FLJ10159
Genbank Al016073	AI674163	AA134589	AI823992	A1037879	AI651535	Al949698	AL040063
<b>Affy</b> 74690_at	58235_at	52966_at	59461_at	54889_at	64666_at	52617_at	49523_at
<b>SeqID</b> 313	582	53	715	323	549	801	863
301	302	303	304	305	306	307	308

77

				7	78			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
p-values	5.8315E-11	0.00017758	0.00279468	1.5285E-06	5.019E-05	5.4416E-07	0.00026772	1.2153E-08
Fold Change	4.802394237	0.27	0.26	0.262634843	0.269743016	0.275006365	0.291337727	0.054106026
Cluster Description	Cluster Incl. AA779101:zj42h12.s1 Homo sapiens cDNA, 3 end /clone=452999 /clone_end≈3'/gb=AA779101 /gi=2838432 /ug=Hs.104859 /len=528'	Cluster Incl. Al613455:ty37b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2281229 /clone_end=3'/gb=Al613455/gi=4622622 /ug=Hs.181658 /len=418'	Cluster Incl. Al394248:tf78b06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2105363 /clone_end=3'/gb=Al394248 /gi=4223795 /ug=Hs.235588 /len=590'	Cluster Incl. Z78379:HSZ78379 Homo sapiens cDNA /clone=3.18-(CEPH) /gb=Z78379 /gi=1495152 /ug=Hs.224337 /len=1958	Cluster Incl. AL039400:DKFZp434K1210_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434K1210 /clone_end=3' /gb=AL039400 /gi=5928554 /ug=Hs.32352 /len=703'	Cluster Incl. AI632223:tt20d07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2241325 /clone_end=3' /gb=AI632223 /gi=4683553 /ug=Hs.144633 /len=721'	Cluster Incl. AA625897:zu87b02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-744939 /clone_end=3' /gb=AA625897 /gi=2538284 /ug=Hs.222095 /len=252'	Cluster Incl. AA046671:zf12d09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-376721 /clone_end=5'/gb=AA046671 /gi=1524772 /ug=Hs.17917 /len=596'
Cluster #	Hs.104859	Hs.49933	Hs.284280	Hs.279023	Hs.32352	Hs.144633	Hs.24583	Hs.278975
Gene Name	hypothetical protein DKFZp762E1312	hypothetical protein DKFZp762D1011	hypothetical protein DKFZp547H236	hypothetical protein DKFZp434N1928	hypothetical protein DKFZp434K1210	hypothetical protein DKFZp434F2322	hypothetical protein DKFZp434C0328	hyaluronic acid receptor,lymphatic vessel endothelial hyaluronan receptor 1
Genbank	AA779101	Al613455	Al394248	278379	AL039400	AI632223	AA625897	AA046671
	48045_at	77581_at	87842_at	63581_at	44682_at	53831_at	72538_at	65731_at
SeqID	225	533	460	1245	859	539	186	56
##	309	310	311	312	313	314	315	316

DEIECCOPTION - INC. ADDECOPTED 1 -

			•	19			
<b>p-values</b> 2.013E-09	0.00165492	0.00126636	0.00508853	6.2245E-06	1.93E-08	2.4107E-05	0.0031179
<b>Fold Change</b> 7.363245733	0.26	3.975570707	3.439858165	5.704063952	3.965279191	0.285742894	5.05
Cluster Description Cluster Incl. Al990409:wt74a03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2513164 /clone_end=3'/gb=Al990409 /gi=5837290 /ug=Hs.5199 /len=744'		Cluster Incl. AI670876:wa06c12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2297302 /clone_end=3 /gb=AI670876 /gi=4850607 /tua=Hs 44276 /len=798	Cluster Incl. AW024474:wu76h03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990888 /clone_end=3 /gb=AW024474 /gi=5878004 /lun=Hs_236884 /len=229'		Cluster Incl AA255502:zr85b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-682451 /clone_end=5" /gb=AA255502 /gi=1892406 /ug=Hs.46423 /len=348"	Cluster Incl. AA609509:af14d11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1031637 /clone_end=3 /gb=AA609509 /gi=2457937 /line=Hs 238503 /len=381	
Cluster# Hs.5199	Hs.278943	Hs.44276	Hs.44276	Hs.109706	Hs.46423	Hs.180877	Hs.180779
Gene Name HSPC150 protein similar to ubiquitin- conjugating enzyme	HSPC047 protein	homeo box C10	homeo box C10	HN1 protein	H4 histone family, member G	H3 histone, family 3B (H3.3B)	H2B histone family, member B
Genbank Al990409	F37133	AI670876	AW024474	AI525822	AA255502	AA609509	AI125923
<b>Affy</b> 45803_at	78942_at	52117_at	57830_s_at	56428_at	39969_at	90048_at	88155_at
SeqID 845	977	573	947	503	16	179	356
317	318	319	320	321	322	323	324

				80				
<b>p-values</b> 1.24E-04	1.5236E-07	3.9853E-10	2.305E-06	8.5076E-08	3.05E-08	2.6578E-09	1.3623E-06	1.8509E-07
Eold Change 3.590913916	0.226916444	4.119810176	0.172426013	12.40	0.259661725	0.233804467	0.17	5.46370987
Cluster Incl Al885852:wl62d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2429487 /clone_end=3" /gb=Al885852 /gi=5591016	Cluster Incl. AA115300:zl09d12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-501431 /clone_end=3' /gb=AA115300 /gi=1670497 /ug=Hs.103720 /len=588'	Cluster Incl. U82984:U82984 Homo sapiens cDNA /clone=163g24 /gb=U82984 /gi=2731436 /ug=Hs.23900 /len=1771	Cluster Incl. D60584:HUM118E12A Homo sapiens cDNA, 3 end /clone=GEN-118E12 /clone_end=3' /gb=D60584 /gi=962223 /ug=Hs.234664 /len=341'	Cluster Incl. AA613715:nq25b01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1144873 /clone_end=3' /gb=AA613715 /gi=2463685 /ug=Hs.81795 /len=607'		Cluster Incl. AA524029:ng32f02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-936507 /clone_end=3' /gb=AA524029 /gi=2264957 /ug=Hs.77889 /len=721'		
Cluster# Hs.795	Hs.23767	Hs.23900	Hs.58589	Hs.5566	Hs.160318	Hs.77889	Hs.239069	Hs.118162
Gene Name H2A histone family, member O	guanine nucleotide binding protein (G protein), gamma 2	GTPase activating protein	glycogenin 2	gap junction protein, beta 2, 26kD (connexin 26)	EXYD domain- containing ion fransport regulator 1	Friedreich ataxia	four and a half LIM domains 1	fibronectin 1
<u>Genbank</u> AI885852	AA115300	U82984	D60584	AA613715	AA524547	AA524029	AW024276	AW021977
<b>Affy</b> 32609_at	58445_at	50271_at	55630_f_at	91306_s_at	32109_at	54581_at	80572_at	45557_r_at
<b>SeqID</b> 756	40	1163	696	182	149	145	944	940
325	326	327	328	329	330	331	332	333

<b>p-values</b> 5.0303E-07	2.9946E-05	0.00020319	0.00010017	6.067E-07	0.00101117	6.263E-08	7.8076E-06
<b>Fold Change</b> 0.097550234	3.294370164	0.276576877	0.31	0.08111725	0.311274497	0.108158864	0.22460642
#	53 Cluster Incl. AI146465:qb93c06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1707658 /clone_end=3' /gb=AI146465 /gi=3674147 /ug=Hs.193053 /len=633'	•				·	
Gluster#—	Hs.193053	Hs.43697	Hs.79095	Hs.11713	Hs.21595	Hs.109439	Hs.108924
Gene Name eukaryotic translation initiation factor 4 gamma, 1	eukaryotic translation initiation factor 2C, 2	ets variant gene 5 (ets-related molecule)	epidermal growth factor receptor pathway substrate 15	E74-like factor 5 (ets domain transcription factor)	DNA segment on chromosome X and Y (unique) 155	DKFZP586P2421 protein	DKFZP586P1422 protein
<u>Genbank</u> AA156998	AI146465	AA224344	Al138998	Al912678	AA557237	AW020116	W72194
<b>Affy</b> 63893_f_at	56226_at	75258_f_at	78641_at	59390_at	60058_at	43506_at	56409_at
SeqID 70	369	87	363	768	166	937	1197
33 ta	335	336	337	338	339	340	34.1

				8	2			
p-values	7.5151E-06	6.4105E-05	0.00232454	0.00000163	6.3581E-06	0.00455471	0.000426	4.57E-06
Fold Change	0.185480277	0.308559272	0.306209896	0.296976926	3.405694621	0.222139001	0.215553985	5.17065685
Cluster Description	Cluster Incl. W78050:zd78c04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-346758 /clone_end=3' /gb=W78050 /gi=1388613 /ug=Hs.235916 /len=446'	Cluster Incl. AW026659:wv15c11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-991047 /clone_end=3' /gb=AW026659 /gi=5880112 /ug=Hs.26358 /len=551'	Cluster Incl. Al984087:wz56d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2562063 /clone_end=3' /gb=Al984087 /gi=5811306 /ug=Hs.235102 /len=479'	Cluster Incl AL050024:Homo sapiens mRNA; cDNA DKFZp564D206 (from clone DKFZp564D206) /cds=(0,404) /gb=AL050024 /gi=4884093 /ug=Hs.25956 /len=1409	Cluster Incl. AW007289:wt54f03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2511293 /clone_end=3' /gb=AW007289 /gi=5856067 /ug=Hs.16441 /len=552'	Cluster Incl. Al961431:wt22e08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2508230 /clone_end=3' /gb=Al961431 /gi=5754144 /ug=Hs.9029 /len=696'	Cluster Incl AL049798:Human DNA sequence from clone 797M17 on chromosome 1q22-24.3. Contains the DPT gene for Dermatopontin, ESTs, an STS and GSSs /cds=(9,614) /gb=AL049798 /gi=4995638 /ug=Hs.80552 /len=1705	Cluster Incl AL050118:Homo sapiens mRNA; cDNA DKFZp586C201 (from clone DKFZp586C201) /cds=(0,936) /gb=AL050118 /gi=4884143 /ug=Hs.1846^1 /len=2621
Cluster#	Hs.58419	Hs.26358	Hs.3447	Hs.25956	Hs.16441	Hs.9029	Hs.80552	Hs.184641
Gene Name	DKFZP586L2024 protein	DKFZP566K1924 protein	DKFZP564K1964 protein	DKFZP564D206 protein	DKFZP434H204 protein	DKFZP434G032 protein	dermatopontin	delta-6 fatty acid desaturase
Genbank	W78050	AW026659	Al984087	AL050024	AW007289	Al961431	AL049798	AL050118
Affy	44813_s_at	64180_at	45501_s_at	39577_at	60038_at	48684_at	38057_at	32190_at
SeqID	1208	951	839	891	922	811	886	892
##	342	343	344	345	346	347	348	349

<b>p-values</b> 1.3941E-05	0.00379696	0.00136947	1.9E-08	0.00679779	0.00061484	5.3744E-06
Fold Change 0.23	4.29	0.24	0.121682021	3.01095294 (	3.125264866 (	0.297772176
Cluster Incl. Al459140:tj65e06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2146402 /clone_end=3' /gb=Al459140 /gi=4311719 /ug=Hs.129109 /len=499'	Cluster Incl. AA909181:ol12b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1523215 /clone_end=3'/gb=AA909181 /gi=3048586 /in=Hs 234830 /len=526	Cluster Incl. X84721:HSEST222 Homo sapiens CDNA /clone=MEC-222 /gb=X84721 /di=673398 /ug=Hs.164866 /len=558	Cluster Incl AL038340:DKFZp566K192_s1 Homo sapiens cDNA, 3 end /clone=DKFZp566K192 /clone_end=3" /gb=AL038340 /gi=5407591 /ug=Hs.1940 /len=746"	Cluster Incl. AA127736:zk88c12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-489910 /clone_end=5'/gb=AA127736 /gi=1687099 /ug=Hs.237523 /len=616'		Cluster Incl. Al382415:ta72b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2049583 /clone_end=3'/gb=Al382415/gi=4195196 /ug=Hs.239510 /len=418'
Cluster # Hs.74649	Hs.1174	Hs.164866	Hs.1940	Hs.82985	Hs.179573	Hs.75106
Gene Name cytochrome c oxidase subunit VIc	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)	cyclin K	crystallin, alpha B	collagen, type V, alpha 2	collagen, type I, alpha Hs.179573 2	clusterin (complement lysis inhibitor, SP- 40,40, sulfated glycoprotein 2, testosterone- repressed prostate message 2, apolipoprotein J)
Genbank Al459140	AA909181	X84721	NM_001885	AA127736	Al610692	Al382415
<b>Affy</b> 74406_at	73132_r_at	90629_at	32242_at	65797_at	49162_f_at	<b>75384_f_at</b>
<b>SeqID</b> 481	247	1236	1100	44	531	457
320	351	352	353	354	355	356

		84			
<u>p-values</u> 2.3579E-06	2.5648E-07	0.000347	1.1789E-10	0.00000214	2.8896E-05
Fold Change 0.262336411	4.805037919	0.212939754	8.862541971	0.155185151	3.067793027
Cluster Incl. Al382415:ta72b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2049583 /clone_end=3' /gb=Al382415 /gi=4195196 /ug=Hs.239510 /len=418'	Hs.279905 'Cluster Incl. AA143745:zo31a01.s1 Homo saplens cDNA, 3 end /clone=IMAGE-588456 /clone_end=3' /gb=AA143745 /gi=1713158 /ug=Hs.62273 /len=649'	Cluster Incl AL049977:Homo sapiens mRNA; cDNA DKFZp564C122 (from clone DKFZp564C122) /cds=UNKNOWN /gb=AL049977 /gi=4884227 /ug=Hs.162209 /len=1071	Cluster Incl. AA534688:nf75c01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-925728 /clone_end=3' /gb=AA534688 /gi=2278941 /ug=Hs.238349 /len=467'	Cluster Incl AL049176:Human DNA sequence from clone 141H5 on chromosome Xq22.1-23. Contains parts of a novel Chordin LIKE protein with von Willebrand factor type C domains. Contains ESTs, STSs and GSSs /cds=(0,767) /gb=AL049176 /gi=4808226 /ug=Hs.82223 /len=3143	Cluster Incl. AA426499:zw02b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-768083 /clone_end=5' /gb=AA426499 /gi=2106744 /ug=Hs.239900 /len=553'
Cluster# Hs.75106	Hs.279905	Hs.162209	Hs.9329	Hs.82223	Hs.81800
Gene Name clusterin (complement lysis inhibitor, SP- 40,40, sulfated glycoprotein 2, testosterone- repressed prostate message 2, apolipoprotein J)	clone HQ0310 PRO0310p1	claudin 8	chromosome 20 open reading frame 1	chordin-like	chondroltin sulfate proteuglyzan 2 (versican)
<u>Genbank</u> Al382415	AA143745	AL049977	AA534688	AL049176	AA426499
<b>Affy</b> 75382_i_at	64489_at	33611_g_at AL049977	45574 <u>_g_</u> at	37630_at	45718_at
<b>SeqID</b> 457	09		158	885.	113
357	358	359	360	361	362

DESCRIPTION AND MOREOTTES IS

<b>p<u>-values.</u></b> 7.4702E-06	8.7397E-08	1.4906E-07	7.4051E-05	0.03811473	1.16E-07	0.00000833	3.194E-05
Eold Change 3.05	0.174212976	5.21	0.221161273	3.355023106	0.231001071	0.292109229	0.23945116
Cluster Description Cluster Incl. AA766775:0a35d08.s1 Homo sapiens cDNA /clone=IMAGE-1306959 /gb=AA766775 /gi=2818013 /ug=Hs.163195 /len=440	Ciuster Incl. AA545730:HBMSF2G12-REV Homo sapiens cDNA, 5 end /clone=HBMSF2G12 /clone_end=5' /gb=AA545730 /gi=2307100 /ug=Hs.31198	Cluster Incl. AF154332:AF154332 Homo sapiens cDNA /clone=CILCA3 /gb=AF154332 /gi=5055942 /ug=Hs.239736 /len=714	Cluster Incl. Al972237:wr33c02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2489474 /clone_end=3' /gb=Al972237 /gi=5769063 /lon=Hs.233663 /len=354'	Cluster Incl. Al675178:tm80g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2164474 /clone_end=3' /gb=Al675178 /gl=4875658 /ma=Hs 90207 /len=462'	Cluster Incl AB020629:Homo sapiens mRNA for KIAA0822 protein, complete cds /cds=(138,4883) /gb=AB020629 /gi=4240129 /ua=Hs,38095 /len=5677	Cluster Incl Al651024:wa96h06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2304059 /clone_end=3" /gb=Al651024 /gi=4735003 /ua=Hs, 15780 /len=657"	Cluster Incl. AA628405:af26b09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1032761 /clone_end=3' /gb=AA628405 /gl=2540792 /ug=Hs.50107 /len=548'
Cluster# Hs.240443	Hs.117582	Hs.184572	Hs.82129	Hs.90207	Hs.38095	Hs.15780	Hs.153961
Gene Name chondroitin 4- sulfotransferase,chon droitin-4- sulfotransferase (C4ST gene)	CGI-43 protein	cell division cycle 2, G1 to S and G2 to M	carbonic anhydrase III, muscle specific	calcium channel, voltage-dependent, gamma subunit 4	ATP-binding cassette, sub-family A (ABC1), member 8	ATP-binding cassette, sub-family A (ABC1), member 6	ARP1 (actin-related protein 1, yeast) homolog A (centractin alpha)
Genbank AA766775	AA545730	AF154332	AI972237	AI675178	AB020629	AI651024	AA628405
<b>Affy</b> 75722_at	50177_at	91194_at	74571_s_at Al972237	62987 r at	35717_at	35390_at	64423_s_at
SeqID 217	164	310	828	586	275	547	188
36 ₩	364	365	366	367	368	369	370

			C	O			
<i>p-values</i> 3.3556E-06	1.4825E-06	2.0018E-05	0.000333	0.000000	2.9261E-05	0.0000126	0.00059716
<b>Fold Change</b> 0.212140139	3.58350616	0.263359832	0.215928239	0.129092155	0.135508105	0.308528713	0.33
Cluster Incl. Al804914:tu43d04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2253799 /clone_end=3' /gb=Al804914 /gi=5391504 /ug=Hs.55565 /len=535'	Cluster Incl. Al341261:qx85a07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2009268 /clone_end=3 /gb=Al341261 /gi=4078188 /ug=Hs.62180 /len=538'		Cluster Incl Al381790:te41h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2089315 /clone_end=3" /gb=Al381790 /gi=4194571 /ug=Hs.74120 /len=544"	Cluster Incl H15814:yl28b07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-159541 /clone_end=3" /gb=H15814 /gi=880634 /ug=Hs.80485 /len=453"	Cluster Incl. AA393277;zt74d08.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-728079 /clone_end=5 /gb=AA393277 /gi=2046245 /ug=Hs.238152 /len=455	-	Cluster Incl. F37480:HSPD36277 Homo sapiens cDNA /clone=sH1-000003-0/G06 /gb=F37480 /gi=4823106 /ug=Hs.221714 /len=408
Cluster# Hs.55565	Hs.62180	Hs.203299	Hs.74120	Hs.80485	Hs.18268	Hs.158203	Hs.58324
Gene Name ankyrin repeat domain 3	anillin	amylase, alpha 2A; pancreatic	adipose specific 2	adipose most abundant gene transcript 1	adenylate kinase 5	actin binding LIM protein 1	a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 5
Genbank Al804914	Al341261	AI218026	Al381790	H15814	AA393277	D31883	F37480
<b>Affy</b> 46108_at	46194_at	89031_at	32527_at	40657_r_at	58927_at	40155_at	80160_at
<b>SeqID</b> 685	426	392	455	982	101	965	978
37.1	372	373	374	375	376	377	378

<u>p-values</u> 0.00028766	7.756E-06	0.00049057	1.5774E-06	2.3135E-06	3.4955E-06	2.2368E-07	3.8401E-05
<u>Fold Change</u> 3.46460752	0.14023914	0.288607766	0.310758648	4.823648195	0.241006046	0.156366951	6.80
Cluster Incl. AA135525.zl09e04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-501438 /clone_end=3 /gb=AA135525 /gi=1696573 /ug=Hs.56009 /len=609'	Cluster Incl. Al088609:qb14e04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1696254 /clone_end=3 /gb=Al088609 /gi=3427668 /ug=Hs,98558 /len=749'	Cluster Incl. AW007983:wv47f07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-991064 /clone_end=3' /gb=AW007983 /gi=5856761 /ug=Hs.236090 /len=211'	Cluster Incl. W37770:zc12g12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-322150 /clone_end=5' /gb=W37770 /gi=1319383 /ug=Hs.9851 /len=573'	Cluster Incl. AA147884:zl50b04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-505327 /clone_end=3' /gb=AA147884 /gi=1717300 /uq=Hs.9812 /len=652'	Cluster Incl. Al970823:wr20c05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2488232 /clone_end=3' /gb=Al970823 /gi=5767649 /ug=Hs.97876 /len=452'	Cluster Incl. AW016780:UI-H-BI0p-abm-f-08-0- UI.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-2712350 /clone_end=3' /gb=AW016780 /gi=5865537 /ug=Hs.238149 /len=327'	Cluster Incl. Al935915:wo07g11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2454692 /clone_end=3'/gb=Al935915/gl=5674785 /ug=Hs.188741 /len=405'
<b>Cluster#</b> Hs.56009	Hs.98558	Hs.98518	Hs.9851	Hs.9812	Hs.97876	Hs.97876	Hs.97837
Gene Name 2'-5'oligoadenylate synthetase 3							
Genbank AA135525	Al088609	AW007983	W37770	AA147884	AI970823	AW016780	A1935915
<b>Affy</b> 64450_at	58361_at	75011_at	55720_at	49052_at	63041_i_at	45353_s_at	85521_at
SeqID 54	344	927	1184	63	820	936	792
379	380	381	382	383	384	382	386

					88	3			
•	b-values	1.4682E-05	5.524E-07	8.975E-06	4.8195E-06	0.00058791	0.00034656	0.00068973	2.6139E-08
	Fold Change	0.161954139	0.281787455	0.302684307	0.12598837	0.248393008	3.039821602	3.308493975	0.282705156
	Cluster Description	Cluster Incl. Al659076:tt97d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2249487 /clone_end=3'/gb=Al659076 /gi=4762646 /ug=Hs.239118 /len=412'		Cluster Incl. D55886:HUM405B01B Homo sapiens cDNA, 5 end /clone=GEN-405B01 /clone_end=5' /gb=D55886 /gi=970293 /ug=Hs.9572 /len=553'	Cluster Incl. R54660:yj74b11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-154461 /clone_end=3' /gb=R54660 /gi=819118 /ug=Hs.95511 /len=427'			Cluster Incl. Al669212:wc13c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2315058 /clone_end=3' /gb=Al669212 /gi=4833986 /ug=Hs.92127 /len=596'	Cluster Incl. Al972873:wr44f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2490567 /clone_end=3'/gb=Al972873/gi=5769699 /ug=Hs.9167 /len=594'
:	Cluster#	Hs.97031	Hs.96996	Hs.9572	Hs.95511	Hs.94789	Hs.92679	Hs.92127	Hs.9167
	Gene Name								
	Genbank	AI659076	AI672356	D55886	R54660	AI743671	AA292431	AI669212	Al972873
	Affx	51785_s_at	63035_at	47579_at	55484_r_at	47566_at	.46737_s_at	55436_at	65976 <u>_g_</u> at
	SeqID	564	577	896	1112	635	63	572	832
	##	387	388	389	390	391	392	393	394

			•	39			
a.1056E-07	0.00185863	0.00208182	0.00000576	5.7165E-07	0.00000349	2.6349E-05	0.00010051
<b>Fold Change</b> 0.146420991	3.433762656	0.293369996	0.290791559	0.159849377	0.316621071	0.20131865	0.306142564
Cluster Description Cluster Incl. Al972873:wr44f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2490567 /clone_end=3 /gb=Al972873 /gi=5769699 /ug=Hs.9167 /len=594'	Cluster Incl. AI742239:wg39e09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367496 /clone_end=3' /gb=AI742239 /gi=5110527 /un=Hs 91109 /len=493'	Cluster Incl. AI150491:qf36b04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1752079 /clone_end=3 /gb=AI150491 /gi=3678960 /ug=Hs 126635 /len=485	Cluster Incl AF052142:Homo sapiens clone 24665 mRNA sequence /cds=UNKNOWN /gb=AF052142 /gi=3360451 /ug=Hs.90063 /len=1486	Cluster Incl. AA351076:EST58700 Homo sapiens cDNA, 3 end /clone=ATCC-104314 /clone_end=3' /gb=AA351076 /gi=2003416 /un=Hs 237155 /len=529'	Cluster Incl AL079279:Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 248114 /cds=UNKNOWN /gb=AL079279 /ci=5102585 /un=Hs 8963 /len=2428	Cluster Incl. AW006898:ws15g04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2497302 /clone_end=3' /gb=AW006898 /gi=5855676 /lin=Hs_234094 /len=228'	Cluster Incl. AA481493:aa34a10.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-815130 /clone_end=3' /gb=AA481493 /gi=2211045 /ug=Hs.88537 /len=406'
Cluster# Hs.9167	Hs.91109	Hs.90756	Hs.90063	Hs.90063	Hs.8963	Hs.88827	Hs.88537
Gene Name							
Genbank Al972873	AI742239	AI150491	AF052142	AA351076	AL079279	AW006898	AA481493
<b>Affy</b> 65975_at	55610_at	77001_at	38803_at	52294_s_at	38786_at	63994_i_at	64813_at
<b>SegID</b> 832	629	374	297	86	894	919	132
395	396	397	398	399	400	401	402

۲<u>۰</u>

			9	0			
<u>p-values</u> 1.3801E-05	6.8126E-06	1.0223E-07	2.2017E-05	4.7993E-06	2.8399E-09	5.6167E-06	1.8002E-06
<b>Fold Change</b> 0.224326303	0.319186626	4.319893329	0.300430737	0.233032608	0.16	0.113945577	0.204459738
Cluster Incl. AW007080:ws49h10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2500579 /clone_end=3 /gb=AW007080 /gl=5855858 /uq=Hs.8817 /len=523'	Cluster Incl. AA927475:om27h03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1542293 /clone_end=3' /gb=AA927475 /gi=3076372 /ine=Hs. 88162 /len=536'	Cluster Incl. Al913396:wa11g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2297816 /clone_end=3' /gb=Al913396 /gi=5633251 /ine=Hs 86619 /len=503'	Cluster Incl. A4480075:zv42b06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-756275 /clone_end=5' /gb=A4480075 /gi=2208226 /in=Hs. 85015 /len=588'	Cluster Incl. Al417267:tg76g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2114754 /clone_end=3' /gb=Al417267 /gi=4260771 /ug=Hs 84630 /len=669'	•		
Cluster# Hs.8817 Clt	Hs.88162	Hs.86619	Hs.85015	Hs.84630	Hs.83938	Hs.82669	Hs.81796
Gene Name							
Genbank AW007080	AA927475	Al913396	AA480075	AI417267	Al288745	Al346341	A1123555
Affy 47138_at	62974_at	48268_at	62952_at	55077_at	91320_at	62942_at	54593_at
SeqID 921	256	770	131	462	415	431	351
403	404	405	406	407	408	409	410

			,	<b>'1</b>			
p-values 1.8411E-07	5.4545E-06	2.739E-06	0.00000603	0.00000139	6.8391E-05	7.2051E-06	5.4948E-09
<b>Fold Change</b> 0.29962365	0.280798539	3.262260583	0.27595812	0.277326235	3.506341539	0.29408728	0.222082398
Cluster Incl. W73230:zd56c09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-344656 /clone_end=3' /gb=W73230 /gi=1383364 /ug=Hs.7913 /len=570'			Cluster Incl AL031846:dJ742C19.5 (novel Chromobox protein) /cds=(89,844) /gb=AL031846 /gi=4164368 /ug=Hs.7442 /len=3964			Cluster Incl. N95620:zb66b09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-308537 /clone_end=3' /gb=N95620 /gi=1267890 /ug=Hs 7212 /len=563'	
Cluster#	Hs.76605	Hs.76550	Hs.7442	Hs.74034	Hs.73452	Hs.7212	Hs.72089
Gene Name					·		·
Genbank W73230	Al692878	AA046853	AL031846	AF070648	AW003215	N95620	AA775711
<b>Affy</b> 54992_at	64747_at	46274_at	36894_at	36119_at	55986_at	57214_at	52844_at
<b>SeqID</b> 1203	601	27	853	304	910	1099	221
## 411	412	413	414	415	416	417	418

				9	2			
p-values	0.00059258	0.00037428	5.5293E-06	2.0222E-07	2.0661E-06	3.7787E-05	1.4531E-07	0.00033754
Fold Change	0.272334447	3.317504451	0.313288626	0.311833232	3.820099432	0.307655933	0.20785966	0.321089692
Cluster Description	Cluster Incl. AA142875:zl49b06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-505235 /clone_end=3' /gb=AA142875 /gi=1712261 /ug=Hs.71719 /len=450'	Cluster Incl. AI742057:wg38d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367383 /clone_end=3'/gb=AI742057 /gi=5110345 /ug=Hs.7155 /len=603'	Cluster Incl. R51371:yg76f03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-39107 /clone_end=3' /gb=R51371 /gi=813273 /ug=Hs.7107 /len=542'	Cluster Incl. Al694389:wd83b11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2338173 /clone_end=3 /gb=Al694389 /gi=4971729 /ug=Hs.71058 /len=514'	Cluster Incl. AA056180:zk70f09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-488201 /clone_end=5 /gb=AA056180 /gi=1548518 /ug=Hs.70704 /len=653'	Cluster Incl. AI791751:oq53g10.y5 Homo sapiens cDNA, 5 end /clone=IMAGE-1590114 /clone_end=5 /gb=AI791751 /gi=5339562 /ug=Hs.68505 /len=516'	Cluster Incl. AL039870:DKFZp434F1012_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434F1012 /clone_end=3' /gb=AL039870 /gi=5408867 /ug=Hs.6750 /len=537'	Cluster Incl. Al948551:wp91c07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2469132 /clone_end=3'/gb=Al948551 /gi=5740861 /ug=Hs.67317 /len=434'
Cluster#	Hs.71719	Hs.7155	Hs.7107	Hs.71058	Hs.70704	Hs.68505	Hs.6750	Hs.67317
Gene Name								
Genbank	AA142875	AI742057	R51371	Al694389	AA056180	AI791751	AL039870	Al948551
Affy	53762_at	46659_at	64913_at	46649_at	65999_at	53733_at	46622_at	53724_at
SeqID	56	628	1110	605	28	999	861	799
##	419	420	421	422	423	424	425	426

<b>p-values</b> 2.84E-04	6.5166E-08	0.00238804	1.7127E-07	1.3008E-05	0.00046176	0.00039039	7.743E-06
<b>Fold Change</b> 0.327537441	0.215531153	3.179888739	0.262677342	0.09523078	0.311206678	0.309546056	0.305213649
Cluster Incl AL050367:Homo sapiens mRNA; cDNA DKFZp564A026 (from clone DKFZp564A026) /cds=UNKNOWN /gb=AL050367 /gi=4914600 /ug=Hs.66762 /len=3938	Cluster Incl. AW026241:wv10d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990954 /clone_end=3'/gb=AW026241/gi=5879771 -/uq=Hs.65239 /len=520'	Cluster Incl. Al092936:qa81b05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1693137 /clone_end=3 /gb=Al092936 /gi=3431912 /ua=Hs.6459 /len=516*	Cluster Incl. Al640524:wa29b02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2299467 /clone_end=3 /gb=Al640524 /gi=4703633 /ug=Hs.6382 /len=4711	Cluster Incl. AA742697:nx30g04.s1 Homo sapiens cDNA /clone=IMAGE-1257654 /gb=AA742697 /gi=2782203 /ug=Hs.62492 /len=526	Cluster Incl. W68034:zd39e02.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-343034 /clone_end=5'/gb=W68034 /gi=1376903 /ug=Hs.6052 /len=593'	Cluster Incl. AA723692:ah85c11.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1325876 /clone_end=3'/gb=AA723692 /gl=2741399 /ua=Hs.5889 /len=491'	Cluster Incl. AI149693:qf42g05.x1 Homo saplens cDNA, 3 end /clone=IMAGE-1752728 /clone_end=3'/gb=AI149693 /gl=3678162 /ug=Hs.58606 /len=505'
Cluster# Hs.66762	Hs.65239	Hs.6459	Hs.6382	Hs.62492	Hs.6052	Hs.5889	Hs.58606
Gene Name						·	
Genbank AL050367	AW026241	A1092936	AI640524	AA742697	W68034	AA723692	AI149693
<b>Affy</b> 36821_at	53687_at	54001_at	46583_at	46200_at	62493_at	53200_at	64720_at
<b>SeqID</b> 893	949	346	. 544	214	1193	212	373
427	428	429	430	431	432	433	434

			!	94			
<u>p-values</u> 0.00051417	4.6226E-06	6.2106E-06	7.5477E-08	1.5685E-09	2.5792E-05	1.2863E-05	4.7788E-05
<b>Fold Change</b> 0.241273698	0.206509126	0.168279383	0.179788238	0.068952382	0.28516587	0.323048827	0.274783293
Cluster Description Cluster Incl. W73386:zd53e05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-344384 /clone_end=3 /gb=W73386 /gi=1383519 /ug=Hs.58303 /len=418'				-	Cluster Incl. AI743925:wg54f04.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2368927 /clone_end=3' /gb=AI743925 /gi=5112213 /ua=Hs.4944 /len=505'	Cluster Incl. AA243659:zr68c06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-668554 /clone_end=3'/gb=AA243659 /gi=1874478 /in=Hs 4863 /len=481'	
<b>Cluster#</b> Hs.58303	Hs.58043	Hs.55778	Hs.50841	Hs.49696	Hs.4944	Hs.4863	Hs.48516
Gene Name							
Genbank W73386	AA044828	AA166620	AA036952	AI799784	AI743925	AA243659	AA082546
<b>Affy</b> 46087_at	54407_at	62213_at	53011_at	64694_at	52986_at	52183_at	45786_at
<b>SeqID</b> 1204	23	47	9	678	637	88	37
43£	436	437	438	439	440	144	442

בו באוכרותיות אות מחבמיזיאים ו

			93				
<b>p-values</b> 2.6745E-08	0.00013182	5.9049E-07	1.5186E-06	4.1704E-06	7.1664E-06	6.2406E-11	6.5731E-05
<b>Fold Change</b> 0.074704469	0.237704503	0.10436228	0.279947233	0.324029566	0.276986241	0.07793742	0.298567674
Cluster Incl. Al200456:qf93d03.x1 Homo sapiens cDNA, 3 end /clone=iMAGE-1757573 /clone_end=3' /gb=Al200456 /gi=3753062 /ug=Hs.235398 /len=347'	Cluster Incl. AA541622:ni86c05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-983720 /clone_end=3' /gb=AA541622 /gi=2288056 /ua=Hs.47447 /len=604'	Cluster Incl. AL046941:DKFZp586I0717_r1 Homo saplens cDNA, 5 end /clone=DKFZp586I0717 /clone_end=5' /gb=AL046941 /gi=5435000 /ug=Hs.46531 /len=704'		Cluster Incl. N22378:yw37d04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-254407 /clone_end=3'/gb=N22378 /gi=1128512 /ug=Hs.43157 /len=450'		Cluster Incl. AI864898:wj66d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2407791 /clone_end=3' /gb=AI864898 /gi=5529005 /ug=Hs.43125 /len=523'	Cluster Incl. Al651212:wa98a10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2304186 /clone_end=3' /gb=Al651212 /gi=4735191
Cluster#** Hs.48516	Hs.47447	Hs.46531	Hs.44038	Hs.43157	Hs.43148	Hs.43125	Hs.4283
Gene Name							
Genbank Al200456	AA541622	AL046941	AI768516	N22378	AA150501	Al864898	AI651212
<b>Affy</b> 51012_at	64407_at	52140_at	62136_at	59014_at	45220_at	52080_at	52075_at
<b>SeqID</b> 383	162	876	658	1065	65	747	548
## <del>44</del> ##	444	445	446	447	848	449	450

clone\_end=3' /gb=AA921830 /gi=3069139

/ug=Hs.38178 /len=516'

85126\_at

641

454

45179\_at

896

455

46372\_at

1068

456

46365\_at

1212

457

51970 at

254

458

52019\_at

512

453

Cluster#

Gene Name

Genbank

Aff

SealD

45779\_at

451

45203 at

846

452

			9	7		10	1/0502/02170
<b>p-values</b> 2.3349E-06	5.5911E-06	2.893E-08	0.01073513	0.00164325	1.2131E-05	3.3983E-05	0.00080689
<b>Fold Change</b> 0.25714791	0.279922681	4.913802444	3.065154029	0.306446993	0.33	3.165598561	0.310421016
Cluster Incl. AI799976:wc46f03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2321693 /clone_end=3' /gb=AI799976 /gi=5365448 /ug=Hs.38163 /len=540'	Cluster Incl. Al806221:wf26e09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2356744 /clone_end=3' /gb=Al806221 /gi=5392787 /ua=Hs.38022 /len=574'	Cluster Incl. W02608:za51g08.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-296126 /clone_end=5'/gb=W02608 /gi=1274586 /ug=Hs.36830 /len=618'	Cluster Incl. H71532:ys11g09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-214528 /clone_end=3' /gb=H71532 /gi=1043348 /ug=Hs.36823 /len=422'	Cluster Incl. Al479633:tm32d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2158295 /clone_end=3' /gb=Al479633 /gi=4372801 /ug=Hs.33716 /len=488'	Cluster Incl. AA830307:oc49h02.s1 Homo sapiens cDNA /clone=IMAGE-1353075 /gb=AA830307 /gi=2903406 /ug=Hs.32615 /len=416	Cluster Incl. AI808983:wf67d02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2360643 /clone_end=3' /gb=AI808983 /gi=5395549 /ug=Hs.32458 /len=510'	Cluster Incl. W73855:zd52f10.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-344299 /clone_end=5'/gb=W73855/gi=1384028 /ug=Hs.32343/len=677'
Cluster# Hs.38163	Hs.38022	Hs.36830	Hs.36823	Hs.33716	Hs.32615	Hs.32458	Hs.32343
Gene Name							
Genbank Al799976	AI806221	W02608	H71532	AI479633	AA830307	AI808983	W73855 .
<b>Affy</b> 65094_at	49825_at	61727_at	60143_r_at	64252_at	.88308_at	45896_at	45757_at
SeqID 679	989	1170	962	485	234	689	1206
## 459	460	461	462	463	464	465	466

<b>10</b>	<i>(</i> 0	10	98	_	0		1502/021/6
<u>p-values</u> 4.1587E-06	5.9115E-06	1.4632E-05	0.00063822	0.00321371	0.00228259	0.00321198	0.00016645
<b>Fold Change</b> 0.286699064	0.171580051	0.196081354	0.287881302	0.324205584	0.227579801	0.309546276	0.283008853
Cluster Incl. Al913749:wa13d11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2297973 /clone_end=3' /gb=Al913749 /gi=5633604 /ug=Hs.32241 /len=564'	Cluster Incl. W07043:za92e08.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-300038 /clone_end=5' /gb=W07043 /gi=1281065 /ug=Hs.32135 /len=592'	Cluster Incl. AL040912:DKFZp434J0215_s1 Homo sapiens cDNA, 3 end /clone=DKFZp434J0215 /clone_end=3' /gb=AL040912 /gi=5409856 /ug=Hs.31595 /len=665'	Cluster Incl. AA921922:om40h06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1543547 /clone_end=3' /gb=AA921922 /gi=3069231 /ug=Hs.31412 /len=488'	Cluster Incl. Al557360:PT2.1_6_B08.r Homo sapiens cDNA, 3 end /clone_end=3' /gb=Al557360 /gi=4489723 /ug=Hs.193188 /len=530'	Cluster Incl. AI743715:wg53a08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2368790 /clone_end=3'/gb=AI743715/gi=5112003 /ug=Hs.37359/len=489'	Cluster Incl. AA195251:zr36d03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-665477 /clone_end=3' /gb=AA195251 /gi=1784951 /ug=Hs.30835 /len=810'	Cluster Incl. A1093702:qa31f05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1688385 /clone_end=3' /gb=A1093702 /gi=3432678 /ug=Hs.169169 /len=358'
Cluster# Hs.32241	Hs.32135	Hs.31595	Hs.31412	Hs.31297	Hs.31297	Hs.30835	Hs.30156
Gene Name							
<u>Genbank</u> Al913749	W07043	AL040912	AA921922	AI557360	AI743715	AA195251	Al093702
<b>Affy</b> 44679_at	64238_at	44575_at	61681_at	43591_r_at	50955_at	65651_s_at	50658_s_at
SeqID 771	1173	865	255	513	636	80	347
467	468	469	470	471	472	473	474

p-values	5.309E-12	7.704E-05	0.0041327	0.00030044	2.469E-12	0.00021707	1.3716E-06	4.6046E-08
Fold Change	13.96572736	0.274066497	0.321891202	0.20	4.243716901	0.259103459	0.211477764	0.131870144
Cluster Description	Cluster Incl. AA059458:zl96g05.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-512504 /clone_end=5' /gb=AA059458 /gi=1553317 /ug=Hs.28792 /len=572'							
Cluster#	Hs.28792	Hs.28625	Hs.286228	Hs.286216	Hs.286117	Hs.285995	Hs.285966	Hs.285966
Gene Name								
Genbank	AA059458	Al806324	AI439628	H54254	AA705188	AA126704	AA131648	AI680541
Affy	65626_at	44025_at	91773_at	78617_at	53490_at	52999_at	56211_at	50408_at
SealD	33	687	474	992	206	4	49	588
#	475	476	477	478	479	480	481	482

WO 02/05	92/1		. 1	100		PC	CT/US02/0217
<b>p<u>-values</u></b> 0.00017459	0.00011017	0.00024096	0.0008652	6.1606E-11	0.00027317	5.8287E-05	5.0013E-05
<b>Fold Change</b> 0.30	0.262417057	3.603536057	0.327647494	11.21387388	0.18	0.326231649	0.22
Cluster # Cluster Description  Hs.285834 Cluster Incl. Al656062:tt43b04.x1 Homo saplens cDNA, 3 end /clone=IMAGE-2243503 /clone_end=3'/gb=Al656062 /gi=4740041 /ug=Hs.239724 /len=525'	Hs.285785 Cluster Incl. W02823:za05h04.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-291703 /clone_end=5' /gb=W02823 /gi=1274868 /ug=Hs.234963 /len=461'	Hs.285590 Cluster Incl. Al458306:tk07c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2150322 /clone_end=3' /gb=Al458306 /gi=4310885 /ug=Hs.184777 /len=585'	Hs.285570 Cluster Incl. W19285:zb90g08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-310910 /clone_end=3'/gb=W19285/gi=1294973 /ug=Hs.202731 /len=460'	Hs.285473 Cluster Incl. AA669106:aa81g05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-827384 /clone_end=3' /gb=AA669106 /gi=2630605 /ug=Hs.108106 /len=537'	Hs.285414 Cluster Incl. Al983045:wz30c01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2559552 /clone_end=3' /gb=Al983045 /gi=5810264 /ug=Hs.237789 /len=566'	Hs.285247 Cluster Incl. Al963873:wt86b08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2514327 /clone_end=3' /gb=Al963873 /gi=5756586 /ug=Hs.227032 /len=704'	Hs.285233 Cluster Incl. AI557450:PT2.1_7_D12.r Homo sapiens cDNA, 3 end /clone_end=3' /gb=AI557450 /gi=4489813 /ug=Hs.235996 /len=565'
Gene Name							
<b>Genbank</b> Al656062	W02823	AI458306	W19285	AA669106	Al983045	Al963873	Al557450
<b>Affy</b> 88239_i_at	50990_at	59070_at	65988_at	48083_at	87998_at	60842_at	78103_at
<b>SeqID</b> 558	1171	478	1175	198	838	815	514
<b>#</b> 483	484	485	486	487	488	489	490

	WO 02/0592	271		10	)1		PCT/US02/02176		
p-values	1.8665E-06	0.00150517	8.0203E-05	3.4232E-05	8.7733E-05	0.00121855	2.5913E-05	0.00082565	
Fold Change	4.466366979	0.31	0.254762986	4.911742129	0.27	0.23	0.30	4.06	
Cluster Description	'20 Cluster Incl. AI869951:wl63a07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2429556 /clone_end=3' /gb=AI869951 /gi=5543919 /ug=Hs.20854 /len=752'	009 Cluster Incl. N31046;yx51h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-265307 /clone_end=5' /gb=N31046 /gi=1151445 /ug=Hs.154536 /len=422'	<ul> <li>Cluster Incl. AA824349:aj30f10.s1 Homo sapiens cDNA, 3 end /clone=1391851 /clone_end=3' /gb=AA824349 /gi=2896419 /ug=Hs.40300 /len=888'</li> </ul>	13 Cluster Incl. AA584310:nn79g01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1090128 /clone_end=3' /gb=AA584310 /gi=2368919 /ug=Hs.99769 /len=582'	960 Cluster Incl. AI435443:th94e06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2126338 /clone_end=3' /gb=AI435443 /gi=4303218 /ug=Hs.149084 /len=475'	252 Cluster Incl. AA143491:zo31a09.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-588472 /clone_end=5' /gb=AA143491 /gi=1712862 /ug=Hs.239308 /len=552'	594 Cluster Incl. Al188749:qd11c05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1723400 /clone_end=3' /gb=Al188749 /gi=3739958 /ug=Hs.181742 /len=467'	<ul> <li>Cluster Incl. AI446168:tj07h07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2140861 /clone_end=3' /gb=AI446168 /gi=4293320 /ug=Hs.176708 /len=435'</li> </ul>	
Cluster#	Hs.285220	Hs.285009	Hs.284269	Hs.283713	Hs.276860	Hs.274252	Hs.271594	Hs.271530	
Gene Name									
Genbank	AI869951	N31046	AA824349	AA584310	Al435443	AA143491	Al188749	Al446168	
Affy	63460_at	83506_at	51999_at	48774_at	83118_at	78658_at	67167_at	84893_at	
SeqID	749	1070	232	171	470	29	379	476	
##	491	492	493	494	495	496	497	498	

***********	# 1 <b>1</b>		10	02		PC	1/US02/02176
0.00710567	0.01228173	5.7601E-05	9.3673E-05	0.00017276	0.00654385	0.01366367	0.00854584
Fold Change 0.315940639	3.07	0.18	4.593843245	0.250833383	0.247069023	4.683322065	0.28
Cluster Description Cluster Incl. R17937:ye90f06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-125027 /clone_end=3 /gb=R17937 /gi=771547 /ug=Hs.61734 /len=386'	Cluster Incl. AA677864:zi13d12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-430679 /clone_end=3 /gb=AA677864 /gi=2658386 /ug=Hs.222705 /len=384'			Cluster Incl. AI418596:tg37d02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2110947 /clone_end=3' /gb=AI418596 /gi=4264527 /ug=Hs.187926 /len=431'		Cluster Incl. AA773348:ab65g04.s1 Homo sapiens cDNA, 3 end /clone=845718 /clone_end=3' /gb=AA773348 /gi=2824919 /ug=Hs.193254 /len=508'	
Cluster# Hs.271363 C of /c	Hs.271157	Hs.270549	Hs.270524	Hs.270235	Hs.270027	Hs.269628	Hs.269392
<u>Gene Name</u>					·		
<u>Genbank</u> R17937	AA677864	W72407	AI743516	Al418596	Al683911	AA773348	R69584
<b>Affy</b> .60202_i_at	72092 <u>f</u> at	76208_at	69687_at	87016_at	91206_at	88243_r_at	78883_at
<u>SeqID</u> 1103	199	1200	633	466	591	219	1115
## 466 406	200	501	502	503	504	505	506

				103				
p-values	9.1918E-06	3.1637E-07	7.5535E-05	0.00045064	6.5167E-06	0.00715494	0.00127676	0.01815078
Fold Change	0.142950221	0.27	0.092486133	0.194270285	0.27933205	3.052533662	3.03	0.310940166
ter.# Cluster Description	\$8286 Cluster Incl. R20784;yh18b08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-130071 /clone_end=3' /gb=R20784 /gi=775565 /ug=Hs.227815 /len=452'		\$0164 Cluster Incl. R53594:yj71c01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-154176 /clone_end=3' /gb=R53594 /gi=815496 /ug=Hs.221424 /len=465'					
Gene Name Cluster#	Hs.268286	Hs.265499	Hs.260164	Hs.25391	Hs.25248	Hs.250879	Hs.250594	Hs.24898
Oı								
Genbank	R20784	AW014647	R53594	Al524085	AI659533	AI742002	AI672389	R67627
Affy	49549_at	80401_at	42913_f_at	64057_at	50411_at	61333_at	78487_at	51886_at
SealD	1104	932	1111	200	566	627	929	1114
**		208	509	510	511	512	513	514

518

517

519

520

521

522

515

516

/clone\_end=3' /gb=AA909818 /gi=3050617

'ug=Hs.225822 /len=406'

			10	ບວ				
<b>p-values</b> 4.329E-05	1.5567E-06	2.5531E-05	9.8105E-06	4.0549E-05	1.9829E-05	0.00035218	0.00788877	1.7239E-06
<b>Fold Change</b> 0.313634138	0.232069434	0.31162811	4.191125642	0.325095547	0.24	3.938205017	0.20	0.290657123
Cluster Incl. C16443:C16443 Homo sapiens cDNA, 5 end /clone=GEN-321F12 /clone_end=5 /gb=C16443 /gi=1571150 /ine=Hs 24144 /len=456'	Cluster Incl. AI797276:we86f09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2348009 /clone_end=3 /gb=AI797276 /gi=5362748 /ine=Hs_23912 /len=516	Cluster Incl. AI421837:tf55c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2103186 /clone_end=3' /gb=AI421837 /gl=4267768 /ine=H\$ 23869 /len=573'		Cluster Incl. N57539:yy81c07.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-279948 /clone_end=3' /gb=N57539 /gi=1201429 /ug=Hs.23630 /len=481'				
Cluster# Hs.24144	Hs.23912	Hs.23869	Hs.237809	Hs.23630	Hs.235920	Hs.235758	Hs.235390	Hs.234898
Gene Name								
Genbank C16443	AI797276	AI421837	AA948319	N57539	AA629715	Al362288	W26589	Al970898
<b>Affy</b> 50001_at	43502_at	56624_at	52615_at	56574_at	73233_at	66131_at	78622_r_at	43427_at
<b>SeqID</b> 956	674	468	262	1086	. 190	438	1178	822
£ \$23	524	525	526	527	528	529	530	531

į

			10	06			
<b>p-values</b> 1.2854E-06	8.7469E-08	1.2339E-07	6.6059E-07	4.4094E-06	0.00181461	0.01016812	2.4083E-06
<b>Fold Change</b> 0.268475458	4.250714876	3.197888571	3.85742898	3.322756779	3.320734927	0.233986843	0.280053615
Cluster Incl. AI057637:oy31h06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1667483 /clone_end=3' /gb=AI057637 /gi=3331503 /ug=Hs.21305 /len=599'							
<b>Cluster#</b> Hs.234898	Hs.234545	Hs.234545	Hs.23448	Hs.233634	Hs.233310	Hs.232177	Hs.23202
Gene Name	:						
Genbank Al057637	Al015982	AA383718	AA133979	A!970896	Al978650	AI208691	Al419030
<b>Affy</b> 49452_at	55504_at	64282_at	44055_at	44974_at	74340_at	74162 <u>_r_</u> at	43046_at
<b>SeqID</b> 332	312	100	52	821	834	390	467
£ 232	533	534	535	536	537	538	539

/clone\_end=3' /gb=Al339240 /gl=4076154

1	n	•
	68	ж

				10	)8		PC	1/0302/021/0
1	0.012637	7.7241E-05	0.00071317	1.0609E-07	2.5827E-06	3.9564E-05	0.00147634	0.00020743
Cold Object	3.51886622	3.531852021	0.306661245	0.085100991	0.2674744	0.286772796	0.22	0:30
ï	## Cluster Incl. AA251131:zs03b12.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-684095 /clone_end=3'/gb=AA251131 /gi=1886093 /ug=Hs.220697 /len=365'		•		57 Cluster Incl. Al911149:wd24b03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2329037 /clone_end=3' /gb=Al911149 /gi=5630885 /ug=Hs.218037 /len=432'			
	Hs.220697 C	Hs.22011	Hs.21914	Hs.218707	Hs.218037	Hs.214906	Hs.21415	Hs.213923
	enen enen enen enen enen enen enen ene							
	<u>Senbank</u> AA251131	Al344312	Al949833	N63913	Al911149	AI610837	A1935522	Al917447
	<b>Any</b> 71839_at	42988_at	60813_at	44210_at	71668_at	71524_at	91345_at	87161_s_at
9	Albas 06	430	802	1090	765	532	791	477
4	<b>2</b> 48	549	550	551	552	553	554	555

/clone\_end=3' /gb=H68822 /gi=1030250

563

562

561

556

粓

557

558

559

565

## 5<sup>6</sup>

566

clone\_end=3' /gb=Al492879 /gi=4393882

570

571

569

568

567

/ug=Hs.203879 /len=521

<b>WO</b> 02/0592	71		11	1		PC	Г/US02/02176
7.7642E-05	0.0018/143	0.00030428	0.00090022	0.01216522	2.9782E-06	0.00527403	0.00084162
Fold Change 4.96		3.64	0.29	4.11	0.263799925	0.300766236	0.322154385
•	Hs.202040	Hs.201875 Cluster Incl. AI825713:wb75g02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2311538 /clone_end=3' /gb=AI825713 /gi=5446384 /ug=Hs.201875 /len=445'	Hs.199996 Cluster Incl. AI804054:tc60g03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2069044 /clone_end=3' /gb=AI804054 /gl=5369526 /ug=Hs.199996 /len=459'	Hs.199713 Cluster Incl. Al921685:wo28g10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2456706 /clone_end=3'/gb=Al921685/gi=5657649 /ug=Hs.199713 /len=427'	Hs.19827 Cluster Incl. W72511:zd64f08.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-345447 /clone_end=3'/gb=W72511/gi=1382168 /ug=Hs.19827 /len=601'	Hs.197676 Cluster Incl. Al653487:tq94h03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2216501 /clone_end=3'/gb=Al653487 /gi=4737466 /ug=Hs.197676 /len=306'	Hs.197643 Cluster Incl. Al962986:wt25g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2508538 /clone_end=3'/gb=Al962986 /gl=5755699 /ug=Hs.197643 /len=391'
Gene Name Clus	Hs.20	Hs.20	Hs.19	Hs.19	Hs. A.	Hs.19	Hs.19
Gen							
<b>Genbank</b> Al700646	A1937060	AI825713	A1804054	Al921685	W72511	AI653487	Al962986
<b>Affy</b> 75961_at	86612_at	69876_at	69600_at	79751_at	59623_at	68663_at	88622_at
<b>SeqID</b> 611	795	718	684	776	1201	554	813
# 572	573	574	575	576	577	578	579

'clone\_end=3' /gb=AI678986 /gi=4889168

/ug=Hs.192671 /len=499'

## 280

582

581

583

584

585

586

587

;

בו כפוללכספתה חשה הוויחסום

## Sapila         Aftity         Ganbanik         Gene Name         Cluster in: Cluster in: Cluster in: Cluster in: ATT/881622801 63 Honor 2001/2814         Eold Change         Pack 1001/28246           589         224         68288_gt         AAT78816         AAT78816         C000062401 63 Honor 2002/28147         C000062401 63 Honor 2002/28246         C000062401 63 Honor 2002/28246         C000062401 63 Honor 2002/28246         C000062401 63 Honor 2002/28246         C0000624022         C000064224					11	.3			
Sacilio         Affix         Gene Name         Cluster mci. Av778816.zj38a10.s1 Homo spales           224         68288_at         AA778816         Hs.192174 Cluster Incl. Av778816.zj38a10.s1 Homo spales           1102         63131_i_at         R11248         Hs.19174 Cluster Incl. Av778816.gj=283147           1102         63131_i_at         R11248         Hs.191936 Cluster Incl. Av4386474102.r1 Homo spales           260         68047_at         AA936632         Hs.19224 (Inclerincl. R1248/gj=763983           320         67962_g_at         AI031557         Hs.189284 Cluster Incl. Av438632.rundsb0.s.1 Homo spiens cDNA, 3 end (Idone-IMAGE-155104)           598         79037_at         AI031557         Hs.189040 Cluster Incl. Av438632.dj=3094560           10g=Hs.18924 Incl. Spiens cDNA, 3 end (Idone-IMAGE-155004)         Idone-Incl. R14248/gj=763983           10g=Hs.18926 Incl. Av438632.dj=2094560         Iug=Hs.18924 Incl. Spiens cDNA, 3 end (Idone-IMAGE-155004)           10g=Hs.18926 Incl. Av4038632.dj=2094560         Iug=Hs.18926 Incl. Av4038632 rg=209456           10g=Hs.18895 Incl. Incl. Av4038632 rg=209456         Iug=Hs.18895 Incl. Spiens cDNA, 3 end (Idone-IMAGE-13696)           10g=Hs.18895 Incl. Incl. Av40389324 rg=15602         Iug=Hs.18895 Incl. Spiens cDNA, 3 end (Idone-IMAGE-18696)           21         48962_at         AI0389324 rg=18892           22         48586_at         AI03	p-values	0.00126246	0.00214022	0.00044234	0.00178098	3.57E-05	0.00013261	0.0021469	1.0173E-06
SagID         Affy         Genbank         Gene Name         Cluster #           224         68288_at         AA778816         Hs.192174           1102         63131_i_at         R11248         Hs.191355           260         68047_at         AA936632         Hs.189284           260         67962_g_at         AI031557         Hs.189040           598         79037_at         AI692624         Hs.188952           21         46962_at         AA039324         Hs.188961           410         87087_at         AI283643         Hs.188120           535         67650_at         AI624103         Hs.187319	Fold Change	0.309129194	4.256875625	3.32	3.428921588	3.57	0.212242354	0.23399829	0.25
SaqID         Affy         Genbank         Gene Name           224         68288_at         AA778816         1102         63131_i_at         R11248         1102         63131_i_at         R11248         1103									
SeqID         Affy         Genbank         Gen           224         68288_at         AA778816         AA778816           1102         63131_i_at         R11248         R11248           260         68047_at         AA936632         AA936632           320         67962_g_at         AI692624         AI692624           598         79037_at         AI692624         AA039324           410         87087_at         AI283643           535         67650_at         AI624103	Cluster #	Hs.192174	Hs.191935	Hs.189284	Hs.189040	Hs.188952	Hs.188861	Hs.188120	Hs.187319
SaglD     Affy       224     68288_at     A       1102     63131_i_at     R       260     68047_at     A       320     67962_g_at     A       598     79037_at     A       410     87087_at     A       535     67650_at     A	Gene Name								
224 224 1102 320 260 260 211 21 410	Genbank	AA778816	R11248	AA936632	Al031557	AI692624	AA039324	AI283643	AI624103
	Affy	. 68288_at		68047_at	67962_g_at	79037_at	46962_at	87087_at	67650_at
## 2588 589 590 594 595 595	SeqID	224	1102	260	320	298	21	410	535
	##	588	589	290	591	592	593	594	595

				114				
p-values	1.2795E-06	0.00081831	0.00021905	0.02428683	0.00016473	0.00072735	1.4344E-05	3.5825E-06
Fold Change	3.57	3.31	0.21	3.34	3.50	3.60	0.24	0.32
Cluster # Cluster Description	Hs.186579 Cluster Incl. T79574:yd71a01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-113640 /clone_end=3' /gb=T79574 /gi=698083 /ug=Hs.186579 /len=533'	Hs.185798 Cluster Incl. AA420590:nc61b10.s1 Homo sapiens cDNA /clone=IMAGE-745723 /gb=AA420590 /gi=2094496 /ug=Hs.185798 /len=501	Hs.185708 Cluster Incl. Al381930:te72f02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2092251 /clone_end=3' /gb=Al381930 /gi=4194711 /ug=Hs.185708 /len=639'	Hs.184343 Cluster Incl. AL037594:DKFZp564J0372_s1 Homo sapiens cDNA, 3 end /clone=DKFZp564J0372 /clone_end=3' /gb=AL037594 /gi=5406959 /ug=Hs.239199 /len=795'	Hs.183918 Cluster Incl. AA846091:ak83e05.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1414496 /clone_end=3' /gb=AA846091 /gi=2932231 /ug=Hs.183918 /len=464'	Hs.183412 Cluster Incl. W05248:za83a08.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-299126 /clone_end=5'/gb=W05248 /gi=1277998 /ug=Hs.183412 /len=473'	Hs.183409 Cluster Incl. AI653441:tq94b09.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2216441 /clone_end=3' /gb=AI653441 /gi=4737420 /uq=Hs.183409 /len=448'	Hs.182809 Cluster Incl. Al985653:wt19b11.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2507901 /clone_end=3' /gb=Al985653 /gi=5812930 /ug=Hs.182809 /len=765'
Gene Name								
Genbank	<b>T79574</b>	AA420590	Al381930	AL037594	AA846091	W05248	Al653441	Al985653
Affy	85338_at	78954_at	78945_at	92031_g_at	90745_at	67311_at	85168_at	89329_at
SegID	1129	110	456	856	239	1172	553	840
##	596	597	298	599	009	601	602	603

			115				
<u>p-values</u> 8.1089E-05	6.5741E-07	1.8689E-07	0.00011263	0.0000283	5.8955E-06	3.4377E-07	0.00108233
Fold Change 0.22	0.209357681	0.143530024	3.036525383	0.268423966	0.309887046	3.92	0.214928901
- Cluster Description Cluster Incl. Al083598:ox61c09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1660816 /clone_end=3'/gb=Al083598 /gi=3422021 /ud=Hs.239551 /len=449'			Cluster Incl. AA004622:zh87b06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-428243 /clone_end=3' /gb=AA004622 /gl=1448469 /uq=Hs.18214 /len=509'	•			
Cluster.# Hs.182364	Hs.182364	Hs.182364	Hs.18214	Hs.181104	Hs.180178	Hs.179891	Hs.179673
<u>Gene Name</u>							
<u>Genbank</u> Al083598	AL044670	Al962647	AA004622	Al312646	AA284268	AI741880	AA027103
<b>Affy</b> 91173_at	58999_at	61317_f_at	59812_at	40642_at	54826_at	84983_at	63270_at
SegID 341	873	812	ო	421	92	626	<del></del>
## 604	605	909	209	808	609	610	611

AA007367

77540 at

4

619

AI522299

92091\_at

499

618

AI472331

85591\_at

483

617

Genbank AA292789

Aff

SealD

62643\_at

94

## 612 AI206063

92131\_at

389

614

N39104

78821\_at

1073

613

AI218358

85706 at

393

615

AI215667

85702 at

391

				1.	1,			
p-values	6.0474E-07	0.00090761	0.00358521	8.8677E-08	0.00028322	0.02233069	0.00013456	8.779E-05
Fold Change	0.246578758	3.484499631	0.241109168	0.289343463	0.17	3.274952213	5.310804413	0.300177072
- Cluster Description	Cluster Incl. Al672101:ty63d10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2283763 /clone_end=3' /gb=Al672101 /gi=4851832 /ug=Hs.17296 /len=554'		•	•				
Cluster#	Hs.17296	Hs.172548	Hs.171959	Hs.171939	Hs.171205	Hs.170935	Hs.170861	Hs.169943
Gene Name								
Genbank	Al672101	Al458858	Al499334	AI693178	A1039722	AI540204	Al498957	AA480009
Affv	58916_at	83000_at	85486_at	58428_at	84627_at	92007_at	85341_at	47972_r_at
SegiD	576	479	498	602	325		495	130
**	620	621	622	623	624	625	626	627

				118			
<u>p-values</u> 0.00347986	0.00289855	3.6415E-07	1.1163E-05	0.00107381	3.5001E-06	6.4421E-05	0.00236446
<b>Fold Change</b> 0.285068791	3.047322219	3.315735415	0.232010725	0.31	5.499256795	0.265071246	3.725341684
			/ug=ns.10/1/17/left=351 4 Cluster Incl. Al264299:qk20f06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1869539 /clone_end=3' /gb=Al264299 /gi=3872502 //oc=15.466784 /lon=368				
Cluster# Hs.168941	Hs.167899	Hs.167771	Hs.166784	Hs.166674	Hs.165909	Hs.165885	Hs.165805
Gene Name							
<u>Genbank</u> Al911346	Al032972	AI656807	Al264299	Al681307	AA424160	AI590385	AL044366
<b>Affy</b> 62309_at	85068_at	58354_at	84903_f_at	84314_at	62277_at	82441 <u>f</u> at	84763_at
<b>SeqID</b> 766	322	559	402	589	112	528	871
## 628	629	630	631	632	633	634	635

					19		_	
<b>p-values</b> 2.4112E-05		0.00054065	1.2564E-07	7.3767E-05	0.00288569	0.00073954	0.01192547	0.00162269
<b>Fold Change</b> 0.280524611		0.278599395	3.548116214	3.26	5.533470597	0.298063122	3.258423603	3.012339056
Cluster Incl. N21031;vx46f05.s1 Homo sapiens		Cluster Incl. A1039005:ox24g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1657304 /clone_end=3 /gb=A1039005 /gi=3278199 /ug=Hs,164680 /len=483'			_	Cluster Incl. N46855:yy73e01.s1 Homo saplens cDNA, 3 end /clone=IMAGE-279192 /clone_end=3' /gb=N46855 /gl=1188021 /ug=Hs.16262 /len=524'		
Cluster # Hs 164779		Hs.164680	Hs.164369	Hs.164226	Hs.162697	Hs.16262	Hs.162130	Hs.159983
Gene Name								
Genbank N21031		A1039005	AI436670	Al436297	AA610522	N46855	AA565654	AA993566
Affy at 82707 at	02101 <u>_</u> at	62259_at	84701_at	75740_at	84323_at	62701_at	84264_at	81810_at
SeqiD 1062	7007	324	473	472	180	1078	168	268
## 6	950	637	638	639	640	641	642	643

	WO 02/059	271		12	20		PC	T/US02/02176
p-values	2.8623E-06	0.0140631	4.5784E-06	2.7534E-07	0.00027572	0.00025369	0.00039332	0.02404954
Fold Change	0.15	3.577532367	0.275099238	0.220904269	0.198202182	3.99	0.305190872	3.01
Cluster Description	Cluster Incl. T64637:yc12h06.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-80507 /clone_end=5' /gb=T64637 /gl=673682 /ug=Hs.159367 /len=546'	Cluster Incl. Al631850:wa36h07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2300221 /clone_end=3'/gb=Al631850 /gi=4683180 /ug=Hs.158992 /len=491'	Hs.158984 ·Cluster Incl. Al380583:tf95g06.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2107066 /clone_end=3'/gb=Al380583 /gi=4190436 /ug=Hs.158984 /len=314'	Cluster Incl. Al928037:wo92h01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2462833 /clone_end=3' /gb=Al928037 /gi=5664001 /ug=Hs.158832 /len=583'	Cluster Incl. AW026553:wv14h08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-990994 /clone_end=3' /gb=AW026553 /gi=5880083 /ug=Hs.158741 /len=522'	Cluster Incl. Al916544:wa26h03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2299253 /clone_end=3' /gb=Al916544 /gi=5636399 /ug=Hs.158549 /len=475'	Cluster Incl. Al924465:wn56e01.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2449464 /clone_end=3' /gb=Al924465 /gi=5660429 /ug=Hs.158258 /len=384'	Cluster Incl. H15868:ym22a12.r1 Homo sapiens cDNA, 5 end /clone=IMAGE-48730 /clone_end=5' /gb=H15868 /gi=880688 /ug=Hs.158113 /len=660'
Cluster #	Hs.159367	Hs.158992	Hs.158984	Hs.158832	Hs.158741	Hs.158549	Hs.158258	Hs.158113
Gene Name	·							
Genbank	T64637	Al631850	Al380583	Al928037	AW026553	Al916544	Al924465	H15868
Affy	83908_at	91596_at	83727_at	81659_at	81648_at	90603_at	81591_r_at	77316_at
$\sim$								

: phy

**SeqID** 1127

/clone\_end=3' /gb=AI341602 /gi=4078529

'ug=Hs.152932 /len=461'

408

672

404

673

675

674

668

料

867

699

366

670

364

	WO 02/059	271		1:	24		PC	T/US02/02176
p-values	0.00209424	0.01380957	1.7637E-06	6.6343E-05	0.04200059	9.1255E-05	0.00044029	0.00040144
Fold Change	0.26	0.15	0.30	0.309293968	0.24	0.23	0.231031663	0.28
Cluster Description	Cluster Incl. AW0006499:wt05d12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2506583 /clone_end=3' /gb=AW006499 /gi=5855277 /ug=Hs.145989 /len=513'	Cluster Incl. AI821472::nj04c07.x5 Homo sapiens cDNA, 3 end /clone=IMAGE-985356 /clone_end=3'/gb=AI821472 /gi=5440551 /ug=Hs.145068 /len=500'	Cluster Incl. Al686114:tt92c02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2248994 /clone_end=3' /gb=Al686114 /gi=4897408 /ug=Hs.144871 /len=495'	Cluster Incl. AW052142:wx26d08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2544783 /clone_end=3' /gb=AW052142 /gi=5914501 /ug=Hs.144864 /len=549'	Cluster Incl. Al668620:yo53h06.x5 Homo sapiens cDNA, 3 end /clone=IMAGE-181691 /clone_end=3' /gb=Al668620 /gi=4827928 /ug=Hs.144151 /len=617'	Cluster Incl. AI570222:to76e03.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2184220 /clone_end=3' /gb=AI570222 /gi=4533596 /ug=Hs.143995 /len=458'	Cluster Incl. AI740621:wg23e12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2365966 /clone_end=3' /gb=AI740621 /gi=5108909 /ug=Hs.143873 /len=457'	Cluster Incl. AI694059:wd67c10.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2336658 /clone_end=3' /gb=AI694059 /gi=4971399 /ug=Hs.143789 /len=540'
Cluster#	Hs.145989	Hs.145068	Hs.144871	Hs.144864	Hs.144151	Hs.143995	Hs.143873	Hs.143789
Gene Name								
Genbank	AW006499	AI821472	Al686114	AW052142	A1668620	AI570222	AI740621	AI694059
Affy	82860_at	89087_at	77106_at	79803_at	77077_at	82595_at	79618_at	77053_at
SeqID	918	712	593	954	571	519	623	604

# 676

<b>p-values</b> 9.8109E-05	4.2869E-07	0.00038894	0.00182392	5.382E-07	0.00918651	0.0002078	0.00024859
Fold Change 6.44	0.22	3.543032267	0.326197997	0.29	0.33	0.29343002	3.063096074
Cluster Incl. AA633203:nq57b02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1147947 /clone_end=3' /gb=AA633203 /gi=2556617 /ug=Hs. 14258 /len=570'				Cluster Incl. W63684:zd30d04.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-342151 /clone_end=3' /gb=W63684 /gi=1371265 /ug=Hs.13821 /len=662'			
Cluster	Hs.142003	Hs.141024	Hs.140996	Hs.13821	Hs.137907	Hs.13766	Hs.137447
Gene Name							
Genbank AA633203	AL040178	Al963725	AA412205	W63684	AI018237	AA015613	Al539443
<b>Affy</b> 90421_at	90389_at	69928_at	75277_f_at	91422_at	75195_at	65185_g_at	61191_at
<b>SeqID</b> 193	864	814	103	1192	316	φ	507
## 684	685	686	687	688	689	069	691

VV 0 02/037	2.1		1:	26		PC	1/0502/021/0
<b>p-values</b> 1.3855E-05	0.00011435	0.00068507	0.00145442	0.00038716	0.02123852	0.03600705	8.8297E-05
<b>Fold Change</b> 0.31404932	0.25	0.24	5.00	0.127900019	3.05	4.015935457	0.260125725
Cluster Incl. N49591:yy58d01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-277729 /clone_end=3' /gb=N49591 /gi=1190757 /ug=Hs.137262 /len=459'						5 Cluster Incl. Al673818:to73f12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2183951 /clone_end=3' /gb=Al673818 /gi=4853549 /ug=Hs.134665 /len=201'	
Cluster# Hs.137262	Hs.137003	Hs.135657	Hs.13561	Hs.135405	Hs.135056	Hs.134665	Hs.134110
Gene Name							
Genbank N49591	Al242023	AA534591	AI819340	AI057450	H06350	AI673818	AI078121
<b>Affy</b> 79133_at	82436_at	82385_at	78442 <u>_</u> at	78844_at	86587_at	78668 <u>r_a</u> t	78555_at
<b>SeqID</b> 1080	396	157	708	331	626	281	337
## 692	693	694	695	969	269	869	669

/clone\_end=3' /gb=AI031771 /gi=3249983

/ug=Hs.132586 /len=454'

			12	28			
<b>p-values</b> 6.3592E-07	0.00126632	0.00124922	1.7752E-05	2.9214E-05	0.00029449	4.2586E-09	0.01303714
Fold Change 0.16	3.09	0.271854365	0.30	0.080787812	7.28	0.103783146	3.015818659
#							
Cluster# Hs.131987	Hs.131886	Hs.131170	Hs.131044	Hs.130893	Hs.130853	Hs.130699	Hs.130316
Gene Name							
<u>Genbank</u> Al890418	AW003102	A1937390	Al631301	AI124631	AI810266	AA621478	AI572156
<b>Affy</b> 76703_at	74698_at	77926_at	82120_at	59911 <u>f</u> at	82094_i_at	47481_at	90691_at
<u>SeqlD</u> 763	606	797	537	353	693	184	521
## 708	402	710	71	712	713	714	715

/clone\_end=3' /gb=AA975530 /gl=3151322

'ug=Hs.126798 /len=485'

			13	30		10	1/0502/021/0
<b>p-values</b> 1.2217E-06	2.3169E-05	0.00040139	7.0947E-06	4.2446E-06	4.7816E-06	1.6889E-06	4.0015E-05
Fold Change 0.19	3.31847909	5.050317981	3.297301166	0.26	0.169055931	0.25	0.32
Cluster #	Hs.126733 Cluster Incl. AA913703:ol38e01.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1525752 /clone_end=3'/gb=AA913703 /gi=3053095 /ug=Hs.126733 /len=507'	Hs.126672 Cluster Incl. AI792817:ol64f01.y5 Homo sapiens cDNA, 5 end /clone=IMAGE-1534393 /clone_end=5'/gb=AI792817 /gi=5340533 /ug=Hs.126672 /len=306'	Hs.126390 Cluster Incl. AA905481:ok01h09.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-1506593 /clone_end=3' /gb=AA905481 /gi=3040604 /ug=Hs.126390 /len=461'	Hs.125780 Cluster Incl. Al934342:wp04e12.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2463886 /clone_end=3 /gb=Al934342 /gi=5673212 /ug=Hs.125780 /len=521	Hs.125376 Cluster Incl. AA584403:nn81a05.s1 Homo sapiens cDNA, 3 end /clone=iMAGE-1090256 /clone_end=3 /gb=AA584403 /gi=2369012 /ug=Hs.125376 /len=512'	Hs.124436 Cluster Incl. AA844007:ai91d09.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-1388177 /clone_end=3 /gb=AA844007 /gi=2930458 /ug=Hs.124436 /len=310'	Hs.124250 Cluster Incl. AA848010:od24g07.s1 Homo sapiens cDNA /clone=IMAGE-1368924 /gb=AA848010 /gi=2934528 /ug=Hs.124250 /len=415
Gene Name							
Genbank Al589858	AA913703	AI792817	AA905481	Al934342	AA584403	AA844007	AA848010
<b>Affy</b> 90069_at	46538_at	77013_at	90479_at	73933_at	76770_at	73801_at	73794_at
SeqID 526	252	699	244	786	172	238	240
724	725	726	727	728	729	730	731

			13	91			
<b>p-values</b> 4.4423E-07	1.5522E-06	4.2459E-08	1.9577E-06	2.1736E-10	0.00094679	7.1425E-07	0.00166257
<b>Fold Change</b> 0.09	5.302996355	0.100992647	0.21246828	0.17	3.60100109	0.24	0.29523189
Cluster Incl. Al458003:tj66c07.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2146476 /clone_end=3' /gb=Al458003 /gi=4312021 /ug=Hs.124141 /len=531'							
Cluster# Hs.124141	Hs.124015	Hs.123933	Hs.12369	Hs.122593	Hs.121532	Hs.121518	Hs.120959
Gene Name							
Genbank Al458003	Al953838	AI809953	AA707308	AL037998	AA033764	H41870	Al278074
<b>Affy</b> 90009_at	59471_at	57605_at	65155_at	81670_at	90316_at	81589_at	74760_s_at
SeqID 477	807	691	209	858	16	686	409
732	733	734	735	736	737	738	739

DEICHMONIN AMO MOROZIANI

	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			13	32		FC.	170302/02170
p-values	3.0941E-06	1.5413E-05	2.9798E-06	0.00104631	4.3863E-08	0.00159704	1.3663E-05	1.5912E-05
Fold Change	0.22	0.285003866	0.239883875	0.24	0.198179833	3.768700804	0.204140593	0.240592502
Cluster#************************************	082 Cluster Incl. Al201982:qs79e02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1944314 /clone_end=3' /gb=Al201982 /gi=3754588 /ug=Hs.123318 /len=480'	7785 Cluster Incl. W73890:zd65h02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-345555 /clone_end=3' /gb=W73890 /gi=1382285 /ug=Hs.120785 /len=570'	Hs.120568 · Cluster Incl. Al302387:qn50g05.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1901720 /clone_end=3' /gb=Al302387 /gi=3961733 /ug=Hs.120568 /len=396'	)388 Cluster Incl. AI742521:wg43h08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2367903 /clone_end=3' /gb=AI742521 /gi=5110809 /ug=Hs.120388 /len=549'	<ul> <li>Cluster Incl. R42914:yg14a10.s1 Homo</li> <li>sapiens cDNA, 3 end /clone=IMAGE-32117</li> <li>/clone_end=3'/gb=R42914/gi=819821</li> <li>/ug=Hs,12024 /len=514'</li> </ul>			
	Hs.12082	Hs.120785	Hs.1206	Hs.120388	Hs.12024	Hs.118599	Hs.118513	Hs.118502
Gene Name								
Genbank	AI201982	W73890	Al302387	AI742521	R42914	Al821005	Al161367	AW052186
Affy	76326_at	57550_at	66390_at	88669_at	61879_at	90251_at	52946_at	76076_at
SegID	387	1207	419	632	1107	710	377	955
##	740	741	742	743	744	745	746	747

			13.	3			
<b>p-values</b> 3.2934E-06	3.2676E-06	0.00404612	0.00013207	0.00138841	0.00090085	0.00320729	1.5411 <b>E-</b> 07
<b>Fold Change</b> 0.223181865	3.141681584	0.314306045	0.305498776	0.325353873	0.26	0.322106515	0.090939502
Cluster Description Cluster Incl. Al824037:wj29h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2404275 /clone_end=3' /gb=Al824037 /gi=5444708 /ua=Hs.118392 /len=603'			Cluster Incl. Al124882:am57f08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1539687 /clone_end=3'/gb=Al124882/gi=3593396 /ug=Hs.118121 /len=406'	Cluster Incl. Al823572:wh55906.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-2384698 /clone_end=3'/gb=Al823572/gi=5444243 /ug=Hs.11782/len=538'		<ul> <li>Cluster Incl. R49146;yg69h06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-38818 /clone_end=3' /gb=R49146 /gi=820214 /ug=Hs.117474 /len=435'</li> </ul>	
Cluster# Hs.118392	Hs.118338	Hs.118262	Hs.118121	Hs.11782	Hs.117687	Hs.117474	Hs.116123
Gene Name							
Genbank Al824037	N24987	Al698243	Al124882 ·	AI823572	AI766029	R49146	AI016755
<b>Affy</b> 57528_at	47434_at	76029_at	76015_at	57517_at	.76163_at	66305_at	66240_s_at
<b>SeqID</b> 716	1066	609	354	713	655	1108	315.
748	749	750	751	752	753	754	755

				13	34			
p-values	7.063E-09	2.0933E-09	0.00377036	6.3947E-05	5.4104E-05	5.4138E-06	0.00036834	0.00069299
Fold Change	0.139924253	8.54	4.52	0.21	0.30	0.25	0.18	0.262512195
# Cluster Description	Cluster Incl. A sapiens cDN/ /clone_end=3 /ug=Hs.1161	)4 Cluster Incl. Al275140:ql70h02.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1877715 /clone_end=3' /gb=Al275140 /gi=3897414 /ug=Hs.116104 /len=444'						
Cluster #	Hs.116110	Hs.116104	Hs.115838	Hs.115497	Hs.115315	Hs.115173	Hs.114889	Hs.11455
Gene Name								
Genbank	Al916626	Al275140	Al344053	AI498375	Al978710	Al418405	Al797063	T64447
Affv	9016	88580_at	88567_s_at	76118_at	81061_at	89807_at	81039_at	54983_at
SedID	773	405	429	494	835	464	673	1126
#	756	757	758	759	760	761	762	763

				13	95			
sanjex-d	1.6712E-08	5.1114E-07	1.9391E-08	2.882E-07	6.2396E-05	0.00068815	2.0122E-05	0.00718188
Fold Change	0.093652816	0.200282848	0.20	0.202348411	0.084843922	3.166594901	0.116868505	0.269236792
•	50 Cluster Incl. Al091154:0018a08.x1 Homo sapiens cDNA, 3 end /clone=IMAGE-1566518 /clone_end=3' /gb=Al091154 /gi=3430213 /ug=Hs.113750 /len=437'							
Cluster #	Hs.113750	Hs.112885	Hs.112572	Hs.110406	Hs.11006	Hs.109653	Hs.109525	Hs.107253
Gene Name								
Genbank	A1091154	AI742490	AA628467	AA452295	AI732274	N91175	A1871044	AA059401
Affx	75585_at	57022_at	80917_at	56941_at	48115_at	42353_at	56910_at	63344_at
SegID	345	631	189	124	618	1098	750	32
##	764	765	992	767	768	769	770	171

			1	36			
<u>p-values</u> 0.00333978	3.0927E-05	3.2707E-05	2.4582E-06	0.04026278	6.4561E-05	4.2545E-05	7.7541E-05
<b>Fold Change</b> 0.289956429	0.212581687	0.25026049	3.113529847	0.31991901	0.194470029	0.147540619	0.29
Cluster Description  Cluster Incl. A4173572:zp04e02.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-595418 /clone_end=3 /gb=A4173572 /gi=1753704 /ug=Hs.10683 /len=595'							
Cluster# Hs.10683 Cluster	Hs.106771	Hs.103395	Hs.103305	Hs.102793	Hs.102541	Hs.102367	Hs.10198
Gene Name	,						
Genbank AA173572	AA806965	AA147751	AI885164	AI707589	AI752682	W72347	AI201965
<b>Affy</b> 48063_at	58174_at	48040_at	56190_at	58429_at	·63315_at	48032_at	87970_at
SeqID 75	229	62	753	615	642	1199	386
772	773	774	775	776	777	778	779

sapiens cDNA, 5 end /clone=GEN-501F10

'clone\_end=5' /gb=D63177 /gi=966846

5.8223E-06

0.182339389

sapiens cDNA, 5 end /clone=IMAGE-300475

Cluster Incl. W07304:za97b10.r1 Homo

53793\_at

1174

795

117

794

S

793

/clone\_end=5' /gb=W07304 /gi=1281502

/ug=Hs.12927 /len=578'

SealD

788 ##

1186

790

36

789

869

791

1190

senlex-d	6.1089E-05	0.110161171 2.7057E-06	
Fold Change	0.14	0.110161171	
Cluster Description	Cluster Incl. N50065:yz10h03.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-282677	/clone_end=3'/gb=N50065/gi=1191231 /ug=Hs.169732 /len=550' Cluster Incl. R70255:yj81f06.s1 Homo sapiens cDNA, 3 end /clone=IMAGE-155171 /clone_end=3'/gb=R70255/gi=843772	/ug=Hs.25150 /len=367'
Cluster#			
Gene Name			
Genbank	N50065	R70255	
Affx	8453	52449_at	
SealD	1081	1116	
##	962	797	

1; :

		p-value	1	5.020000=-05	3.510000E-07	2.660000E-08		2.360000E-05		7.124464E-06		1.340000E-05		6.210594E-06		4.710000E-08	1.380000E-06	4.050474E-06	7.807645E-06	4.150000E-04	1.318202E-04	•	4.120000E-07	3.247311E-05	1.610000E-04	1.518608E-06	3.900000E-07	2.613853E-08	7.205058E-06	1.770803E-06	4.329042E-05		1.000000E-04	4.436191E-07	2.373819E-06	1.093627E-04	3	1.086072E-05
		Fold Change (ratio)		0.24643/105	0.090848213	0.091111614		0.092826583		0.110855696		0.121953593		0.168279383		0.187743879	0.218509986	0.221960648	0.22460642	0.228917694	0.237704503		0.260055335	0.264360188	0.279338963	0.279947233	0.281207961	0.282705156	0.29408728	0.297990459	0.313634138	,	0.323566748	0.32670528	0.36717276	0.415471413		0.407999585
		Fold Change F	•	-4.06	-11.01	-10,98		-10.77		-9.02	-	-8.20		-5.94		-5.33	-4.58	-4.51	-4.45	-4.37	-4.21		-3.85	-3.78	-3.58	-3.57	-3.56	-3.54	-3.40	-3.36	-3.19		-3.09	-3.06	-2.72	-2.41		-2.45
! ! !		Gene Name	melanoma inhibitory activity,ras-related	GTP-binding protein 4b	actin, gamma 2, smooth muscle, enteric	calponin 1, basic, smooth muscle	myosin, heavy polypeptide 11, smooth	muscle	eukaryotic translation initiation factor 4	gamma, 1	myosin, heavy polypeptide 11, smooth	muscle	eukaryotic translation initiation factor 4	gamma, 1	laminin, alpha 3 (nicein (150kD), kalinin	(165kD), BM600 (150kD), epilegrin)	leiomodin 1 (smooth muscle)		DKFZP586P1422 protein			laminin heta 3 (nicein (125kD), kalinin	(140kD), BM600 (125kD))		myosin, light polypeptide kinase		inositol polyphosphate-1-phosphatase					RNA-binding protein gene with multiple	splicing	myosin, light polypeptide kinase		phosphatidic acid phosphatase type 2A	RN nding protein gene with multiple	splicing
	er node 2761X	<u>Genbank</u>		AA461365	D00654	D17408		AF013570		AI380979		AF001548		AA156998		L34155	X54162	AA034289	VN/72194	D10667	AA541622		017760	AI658662	U48959	AI768516	L08488	A1972873	N95620	AI 043089	C16443	•	D84110	AA526844	AB007972	AF014402		D84111
	Table 3: 35 Genes from HCA cluster node 27	Affx		39271_at	1197_at	34203_at		37407_s_at	<b>!</b>	58774_at		767_at		63893_f_at	]	37909 at	37765 at	60532 at	56409 at	772 at	64407 at	; 1	36929 at	50361_at	32847 at	62136 at	41524 at	65975 at	57214 at	65867 at	50001 at	1	38048 at	46276 at	41137 at	34797_at	l	34162_at
	35 Genes	SedID		127	959	964		288		453		283		2		1023	1223	17	1197	6 0	162	1	1141	561	1151	658	1013	832	1099	869	926	}	973	150	272	289		974
	Table 3:	##		<del></del>	8	ო		4		ß		9		7		œ	σ	10	;	- 5	4 6	2	14	15	<u> 6</u>	17	. @	<del>,</del> 6	202	7 1	22	l	23	24	25	<b>5</b> 8		27

p-value 2.789025E-04	5.432773E-06	1.694770E-05	3.251490E-06	1.715459E-03	4.653880E-06	4.038920E-05	3.551680E-04
Fold Change (ratio) 0.389097343	0.381989673	0.473538178	0.47055836	0.458611832	0.348051542	0.367062886	0.406092748
Fold Change	-2.62	-2.11	-2.13	-2.18	-2.87	-2.72	-2.46
Gene Name				CGI-43 protein	DKFZP564B0769 protein		
Genbank AA843926	AI379892	AI571525	AI744109	AI912571	W72919	W87690	W88427
Affy 66529 at	49540_at	49300_at	65734_at	46653_at	49349_at	47076_at	54668_at
SeqID 237	449	520	638	767	1202	1210	1211
#⊫ 88 1#	29	30	31	32	33	34	35

Tab	le 4: BREA	ST / INFILTRA	Table 4: BREAST / INFILTRATING DUCT CARCINOMA	VOMA			
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
	1	AA001250					340.76+/-99.54 175.47+/-67.36
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.01
		į					P-value: .00096
7	7	AA017070	218.33+/-195.52			218.33+/-195.52	218.33+/-195.52
			75.87+/-104.51			49.83+/-71.53	28.53+/-33.27
			N1=40, $N2=168$	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.8			Fold Change: 3.67	Fold Change: 5.14
			P-value: 0			P-value: 0	P-value: 0
3	11	AA027103	252.16+/-278.17		252.16+/-278.17	252.16+/-278.17	252.16+/-278.17
			53.89+/-220.22		47.94+/-61.86	14.48+/-36.79	15.58+/-46.81
			N1=39. N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.64		Fold Change: 3.3	Fold Change: 4.51	Fold Change: 4.88
			P-value: 0		P-value: .01164	P-value: 0	P-value: 0
4	12	AA029437	221.16+/-280.96			221.4+/-284.63	
			57.63+/-138.17			86.7+/-207.7	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 3.25			Fold Change: 2.95	
			P-value: 0			P-value: .00006	
20	13	AA029735					581.98+/-218.36
•	<b>}</b>						246.82+/-189
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.76
							P-value: .00174
9	15	AA031790					336.45+/-181.35
							122.36+/-61.84
		•	×	×	×	×	N1=40, N2=10
							Fold Change: 2.82
							P-value: .0009
7	17	AA034289	203.74+/-150.5		203.74+/-150.5	203.74+/-150.5	203.74+/-150.5
			30.48+/-63.02		56.05+/-43.37	41.75+/-90.59	-7.27+/-28.68
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 4.19		Fold Change: 2.69	Fold Change: 3.95	Fold Change: 6.91
			P-value: 0		P-value: .00466	P-value: 0	P-value: 0

DISCOUNT - MAIO 0005007140 1 -

20 AA037766 22 AA044828	418 418 766	370.77+/-175.09 171.84+/-132.49	MOLHIEL VS IVLEUBURIUL	Mornial Vs Stage L	367 02+/-176 43	367.92+/-176.43
	766	370.77+/-175.09			2K7 07+/-176 43	36/.92+/-1/0.43
	766	171 84+/-132 49			10.011-1:07:100	
	766				145.41+/-92.73	148.75+/-103.92
	766	N1=40 N2=168	×	×	N1=40, $N2=31$	N1=40, N2=10
	992	Fold Change: 2.41	<b>:</b>	ŀ	Fold Change: 2.76	Fold Change: 2.55
	766	P-value: 0			P-value: 0	P-value: .00125
					217.99+/-102.27	
	000				98.41+/-70	
	930	×	×	×	N1=39, N2=31	×
	000				Fold Change: 2.21	
	000				P-value: 0	
	070	228.22+/-120.36			228.25+/-121.93	228.25+/-121.93
	}	81 18+/-75.97		•	68.84+/-62.87	30.55+/-34.05
		N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.87			Fold Change: 3.18	Fold Change: 5.8
		P-value: 0			P-value: 0	P-value: 0
23 AA044830	830	384.63+/-189.59			387.92+/-190.91	387.92+/-190.91
•	}	195.74+/-112.66			142.87+/-73.75	148.94+/-75.02
		N1=40, N2=168	×	×	NI=40, N2=31	NI=40, N2=10
		Fold Change: 2.09			Fold Change: 2.81	Fold Change: 2.65
		P-value: 0			P-value: 0	P-value: .00182
24 AA045145	145	261.46+/-178.02			262.21+/-180.28	262.21+/-180.28
	<u>!</u>	83.44+/-183.41			63.71+/-149.37	8.27+/-106.8
		N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 3.35			Fold Change: 4	Fold Change: 5.08
		P-value: 0		:	P-value: 0	P-value: .00018
25 AA046457	457			254.96+/-154.86		254.96+/-154.86
				91.58+/-30.86		99.01+/-89.62
		×	×	N1=40, N2=6	×	N1=40, N2=10
				Fold Change: 2.4		Fold Change: 2.75
				P-value: .00032		P-value: .00204
27 AA046853	853	200.27+/-196.52		201.69+/-198.89	201.69+/-198.89	201.69+/-198.89
		385,33+/-229,71		406.89+/-152.52	428.46+/-216.88	370.09+/-174.14
		N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.07		Fold Change: 2.42	Fold Change: 2.44	Fold Change: 2.06
		P-value: 0		P-value: .0008	P-value: 0	P-value: .00306

RNSDOCID- (WO 02059271A2 1 >

*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
15	28	AA056180					80.83+/-48.85 254.08+/-148.48
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.07 P-value: .00013
16	29	AA056755			243+/-190.55	243+/-190.55	
					413.4+/-148.7	476.92+/-268.57	
			×	×	N1=40, N2=6	N1=40, N2=31	×
					Fold Change: 2.12	Fold Change: 2.22	
					P-value: .00235	P-value: .00002	
17	30	AA058578				282.9+/-254.52	282.9+/-254.52
						100.56+/-94.65	62.96+/-63.59
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.24	Fold Change: 3.01
		:				P-value: .00272	P-value: .00335
18	31	AA059396	383.9+/-126.38			383.25+/-127.97	383.25+/-127.97
			184.18+/-88.67			195.3+/-91.8	164.81+/-71.68
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.2			Fold Change: 2.03	Fold Change: 2.37
			P-value: 0			P-value: 0	P-value: .00006
19	32	AA059401	444.15+/-409.74		450.12+/-413.33	450.12+/-413.33	450.12+/-413.33
			108.09+/-137.58		84.82+/-108.93	78.85+/-105.76	4.41+/-98.3
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.84		Fold Change: 4.32	Fold Change: 5.13	Fold Change: 7.56
			P-value: 0		P-value: .01621	P-value: 0	P-value: 0
20	33	AA059458	73.64+/-89.7		74.76+/-90.6	74.76+/-90.6	74.76+/-90.6
			421.17+/-253.37		328.32+/-224.02	373.99+/-269.57	399.15+/-254.81
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.85		Fold Change: 4.88	Fold Change: 5.56	Fold Change: 5.85
			P-value: 0		P-value: .00774	P-value: 0	P-value: .00035
21	34	AA075632				331.71+/-236.88	331.71+/-236.88
						176.14+/-256.71	125.73+/-212.88
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.48	Fold Change: 4.1
						7100: :onim.	- varies :00007

....

DEIDDOOID: 4800 0000007480 1 4

#	Seg ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
;	35	A A 0.79839				399.21+/-217.44	399.21+/-217.44
1	3	/20/10sty				178.24+/-173.52	173.1+/-209.18
			×	×	×	N1=39, N2=31	N1=39, N2=6
			•			Fold Change: 2.2	Fold Change: 2.61
						P-value: .00001	P-value: .00239
23	37	AA082546	272.4+/-223.42			275.39+/-225.53	275.39+/-225.53
}	5		105.34+/-63.79			93.91+/-47.44	74.83+/-36.32
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.35	<b>!</b>		Fold Change: 2.55	Fold Change: 3.23
			P-value: 0			P-value: 0	P-value: .00005
24	38	AA101125				99'1-331'99	670.66+/-337.66.
;	3					325+/-154.53	292.03+/-126.99
		•	×	×	×	N1=40, N2=31	N1=40, N2=10
			•			Fold Change: 2.01	Fold Change: 2.27
						P-value: 0	P-value: .00091
35	41	AA126704	314.32+/-135.99			312.64+/-137.34	312.64+/-137.34
3	ŧ		107.92+/-81.49			77.02+/-71.72	78.95+/-75.5
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.17			Fold Change: 4.14	Fold Change: 3.75
			P-value: 0			P-value: 0	P-value: .00032
7,	64	A A 127718	238 22+/-357.2			240.21+/-361.64	
}	!		82.46+/-76.05			87.69+/-80.58	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.53			Fold Change: 2.39	
			P-value: 0			P-value: .00006	
27	43	AA127727	214.24+/-122.15		212.97+/-123.48	212.97+/-123.48	212.97+/-123.48
			81.63+/-51.81		89.92+/-52.2	66.11+/-40.88	51.85+/-29.44
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.72		Fold Change: 2.29	Fold Change: 3.29	Fold Change: 3.99
			P-value: 0		P-value: .00795	P-value: 0	P-value: .00001
28	47	AA131456	642.53+/-392.68			650.36+/-394.64	
<u> </u>			325.78+/-211.65			340.69+/-188.84	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.13			Fold Change: 2.01	
			r-value: 0			r - variac.	

RNSDOCID: <WO 02059271A2 | >

#	Seo ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
29	48	AA131632	×	×	×	376.43+/-162.83 185.82+/-88.41 N1=40, N2=31 Fold Change: 2.11 P-value: 0	×
30	<b>20</b>	AA131894	×	X	<b>×</b>	×	125.64+/46.19 310.35+/-183.98 N1=40, N2=10 Fold Change: 2.19 P-value: .00585
31	51	AA133248	401.89+/-133.14 193.81+/-109.33 N1=40, N2=168 Fold Change: 2.26 P-value: 0	X	×	×	400.91+/-134,73 182.12+/-50.15 N1=40, N2=10 Fold Change: 2.15 P-value: 0
32		AA137038	X	×	×	122.53+/-86.86 266.01+/-205.87 N1=40, N2=31 Fold Change: 2.11 P-value: .00008	×
33		AA142913	302.75+/-219.97 88.13+/-60.53 N1=40, N2=168 Fold Change: 3.49 P-value: 0	X	302.34+/-222.83 104.62+/-49.26 N1=40, N2=6 Fold Change: 2.6 P-value: .00174	302.34+/-222.83 84.31+/-62.54 N1=40, N2=31 Fold Change: 3.74 P-value: 0	302.34+/-222.83 83.75+/-83.82 N1=40, N2=10 Fold Change: 4.01 P-value: .00014
34	59	AA143491	491.76+/-382.75 278.14+/-268.9 N1=40, N2=168 Fold Change: 2.1 P-value: .00012	X .	×	×	485.72+/-385.82 206.94+/-269.35 N1=40, N2=10 Fold Change: 3.02 P-value: .02186
35	62	AA147751	480.16+/-205.12 247.19+/-214.23 N1=40, N2=168 Fold Change: 2.38 P-value: 0	×	×	478.2+/-207.42 284.09+/-237.65 N1=40, N2=31 Fold Change: 2.21 P-value: .00015	×

:

DAIGHTONIN JAIN MINEONTIAN I .

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
36	63	AA147884	46.57+/-54.48 235.82+/-200.06 N1=40, N2=168 Fold Change: 4.33 P-value: 0	×	×	×	×
37	64	AA149312		×	×	374+/-139.43 170.47+/-78.83 N1=40, N2=31 Fold Change: 2.29 P-value: 0	374+/-139.43 140.83+/-37.98 N1=40, N2=10 Fold Change: 2.57 P-value: 0
38	59	AA150501	213.29+/-103.88 89.09+/-51.7 N1=40, N2=168 Fold Change: 2.45 P-value: 0	×	215.8+/-104 97.8+/-28.03 N1=40, N2=6 Fold Change: 2.01 P-value: .00034	215.8+/-104 74.57+/-38.51 N1=40, N2=31 Fold Change: 2.85 P-value: 0	215.8+/-104 41.35+/-30.37 N1=40, N2=10 Fold Change: 4.75 P-value: 0
96 66	99	AA151346	×	×	×	180.84/-85.07 392.044/-178.92 N1=39, N2=31 Fold Change: 2.13 P-value: 0	×
94	89	AA155914	400.19+/-405.95 143.7+/-119.6 N1=40, N2=168 Fold Change: 2.56 P-value: 0	×	×	407.07+/-408.89 135.07+/-104.23 N1=40, N2=31 Fold Change: 2.69 P-value: .00009	×
41	69	AA155952	×	×	×	343.72+/-239.12 136.91+/-62.46 N1=40, N2=31 Fold Change: 2.23 P-value: 0	343.72+/-239.12 111.1+/-55.68 N1=40, N2=10 Fold Change: 2.77 P-value: .00005
42	71	AA158731	288.7+/-238.19 93.33+/-144.72 N1=40, N2=168 Fold Change: 3.48 P-value: 0	×	×	287.72+/-241.22 95.77+/-117.6 N1=40, N2=31 Fold Change: 3.08 P-value: .00001	287.72+/-241.22 183.13+/-413.53 N1=40, N2=10 Fold Change: 3.9 P-value: .01612

176.564-116.87   176.	Seq ID Genbank	Genbank	1	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
322.48+/-173.1 299.01+/-131.22  N1=40, N2=6  N1=40, N2=31  Fold Change: 2.14  Fold Change: 2.01  P-value: .0095  P-value: .0002  227.06+/-165.92  88.27+/-25.59  88.27+/-25.59  P-value: 0  P-value: .00143  X  X  X  X  X  X  X  X  X  X  X  X  X	AA165701 176.56+/		176.56+/-116.	87		176.56+/-116.87	176.56+/-116.87	176.56+/-116.87
N1=40, N2=6 N1=40, N2=31 Fold Change: 2.14 Fold Change: 2.01 P-value: .0095 P-value: .00002 227.06+/-165.92 88.27+/-25.59 88.27+/-19.41 N1=39, N2=10 N1=39, N2=31 Fold Change: 2.98 P-value: .00143 Fold Change: 2.98 P-value: .00143 X X X X X X X X X X X X X X X X X X X			335.74+/-147.31			322.48+/-173.1	299.01+/-131.22	309.98+/-142.67
Fold Change: 2.14 Fold Change: 2.01 P-value: .0095 P-value: .00002 227.06+/-165.92 227.06+/-165.92 88.27+/-25.59 85.25+/-119.41 N1=39, N2=10 N1=39, N2=31 Fold Change: 2.06 Fold Change: 2.98 P-value: .00143 P-value: 0 368.73+/-173.58 105.87+/-79.3 X X X X X X X X X X X X X X X X X X X	N1=40, N2=168	N1=40, N2=168	N1=40, N2=168		×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
P-value: .0095 P-value: .00002 227.06+/-165.92 88.27+/-25.59 88.27+/-25.59 88.27+/-19.41 N1=39, N2=10 N1=39, N2=31 Fold Change: 2.06 P-value: .00143 P-value: 0 P-value: .00143 P-value: 0 P-value: .00143 P-value: 0 001 P-value: .00001 P-value: .00002 P-value: .00002	Fold Change: 2.21	Fold Change: 2.21	Fold Change: 2.21			Fold Change: 2.14	Fold Change: 2.01	Fold Change: 2.05
227.06+/-165.92	P-value: 0	P-value: 0	P-value: 0			P-value: .0095	P-value: .00002	P-value: .00163
88.27+/-25.59 85.25+/-119.41 N1=39, N2=10 N1=39, N2=31 Fold Change: 2.06 P-value: .00143 P-value: 0  86.73+/-173.58 105.87+/-79.3 X N1=40, N2=31 Fold Change: 3.94 P-value: 0  X X X X X X X X X X X X X X X X X X	74 AA166620 227.06+/-165.92		227.06+/-165.92			227.06+/-165.92	227.06+/-165.92	227.06+/-165.92
N1=39, N2=10 N1=39, N2=31 Fold Change: 2.06 P-value: .00143 P-value: 0  868.73+/.173.58 105.87+/.79.3 X N1=40, N2=31 Fold Change: 3.94 P-value: 0  X X X X X X X X X X X X X X X X X X	100.03+/-194.31	100.03+/-194.31	100.03+/-194.31			88.27+/-25.59	85.25+/-119.41	38.81+/-22.68
Fold Change: 2.06 Fold Change: 2.98 P-value: .00143 P-value: 0 368.73+/-173.58 105.87+/-79.3 X N1=40, N2=31 Fold Change: 3.94 P-value: 0 338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001 X X X X X X X X X X X X X X X X X X X	N1=39, N2=168	N1=39, N2=168	N1=39, N2=168		×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
P-value: .00143 P-value: 0  368.73+/-173.58 105.87+/-79.3  X X X X X X X X X X X X X X X X X X	Fold Change: 2.58	Fold Change: 2.58	Fold Change: 2.58			Fold Change: 2.06	Fold Change: 2.98	Fold Change: 4.89
368.73+/-173.58 105.87+/-79.3  X N1=40, N2=31 Fold Change: 3.94 P-value: 0  338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X  X X  X X  X X  X X  X Y  N1=40, N2=31 Fold Change: 3.09 P-value: .00002 P-value: .00002	P-value: 0	P-value: 0	P-value: 0			P-value: .00143	P-value: 0	P-value: 0
105.87+/-79.3  X N1=40, N2=31 Fold Change: 3.94 P-value: 0  338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X  X X  X X  X X  X Y  N1=40, N2=31 Fold Change: 3.09 P-value: .00002 P-value: .00002	75 AA173572 368.06+/-171.39		368.06+/-171.39				368.73+/-173.58	368.73+/-173.58
X N1=40, N2=31 Fold Change: 3.94 P-value: 0  X X  X X  X X  N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X  X X  X X  X X  X X  X X  X	132.7+/-121.15	132.7+/-121.15	132.7+/-121.15				105.87+/-79.3	162.1+/-222.38
Fold Change: 3.94  P-value: 0  X  X  X  338.82+/-318.56  135.54+/-138.52  X  N1=40, N2=31  Fold Change: 2.47  P-value: .00001  X  X  X  X  X  X  X  X  X  X  X  X  X	N1=40, N2=168	N1=40, N2=168	N1=40, N2=168		×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0  X  X  338.82+/-318.56  135.54+/-138.52  X  X  X  X  X  X  X  X  X  X  X  X  X	Fold Change: 3.31	Fold Change: 3.31	Fold Change: 3.31				Fold Change: 3.94	Fold Change: 3.72
X X 338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X X X X X X X X X X X X X X P-value: .00001 P-value: .00002 P-value: .00002	P-value: 0	P-value: 0	P-value: 0				P-value: 0	P-value: .0091
X X X38.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X X X X X X X X X X X X X X X P-value: .00001 P-value: .00002 P-value: .00002	77 AA188763 109.78+/-67.46		109.78+/-67.46					109.94+/-68.33
X X 338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001 X X X X X X 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002		.,	223.51+/-105.81					210.03+/-82.61
338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X  254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002	N1=40, N2=168	N1=40, N2=168	N1=40, N2=168		×	×	×	N1=40, N2=10
338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X X X X X X X X X X X Fold Change: 3.09 P-value: .00002	Fold Change: 2.13	Fold Change: 2.13	Fold Change: 2.13					Fold Change: 2.06
338.82+/-318.56 135.54+/-138.52 X N1=40, N2=31 Fold Change: 2.47 P-value: .00001 X X X X X X X X X X X X Fold Change: 3.09 P-value: .00002	P-value: 0	P-value: 0	P-value: 0					P-value: .00159
135.54+/-138.52  X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X  X X  X 157.31+/-164.5 157.31+/-463.97  X N1=40, N2=31 Fold Change: 3.09 P-value: .00002	78 AA193340	AA193340					338.82+/-318.56	338.82+/-318.56
X N1=40, N2=31 Fold Change: 2.47 P-value: .00001  X X X  X							135.54+/-138.52	65.09+/-44.54
Fold Change: 2.47 P-value: .00001  X  X  X  254.32+/-164.5 157.31+/-463.97  X  N1=40, N2=31 Fold Change: 3.09 P-value: .00002	×	×	×		×	×	N1=40, N2=31	N1=40, N2=10
X X X X 254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002							Fold Change: 2.47	Fold Change: 4.45
X X 254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002				-			r-vame: .00001	F-value: .00006
X X 254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002	85 AA211369	AA211369						166 561/13/4.32
254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002	,	,	;			>	>	N1=40 N2=10
254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002	×	×	*		<	<b>&lt;</b>	<	01-311 (04-11) TO 13-10 (14-11)
254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002								Fold Change: 2.75
254.32+/-164.5 157.31+/-463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002								P-value: .00161
157.31+/463.97 X N1=40, N2=31 Fold Change: 3.09 P-value: .00002	88 AA227778 250.354/-164.31		250.35+/-164.31				254.32+/-164.5	254.32+/-164.5
X N1=40, N2=31 Fold Change: 3.09 P-value: .00002			103.23+/-228.68				157.31+/-463.97	92.7+/-116.55
	N1=40, N2=168	N1=40, N2=168	N1=40. N2=168		×	×	N1=40, N2=31	N1=40, N2=10
	Fold Change: 3.07	Fold Change: 3.07	Fold Change: 3.07				Fold Change: 3.09	Fold Change: 2.93
	P-value: 0	P-value: 0	P-value: 0				P-value: .00002	P-value: .00666

\_\_\_\_\_

# Seq ID Genbank Normal vs Mailgrant Normal vs Stage I Normal vs Stage II Normal vs Stage								
95 AA295451  X	#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
P-value: 0027	50	95	. AA295451	×	×	×	428.38+/-345.54 191.85+/-157.04 N1=40, N2=31 Fold Change: 2.05	×
97 AA312905  X X X X N1=40, N2=31  99 AA369887  X X X X X X X X X X X X X X X X X X X	21	96	AA310786	×	×	×	P-value: .0027 242.07+/-109.49 509.52+/-191.41 N1=40, N2=31 Fold Change: 2.19 P-value: 0	242.07+/-109.49 578.59+/-173.41 N1=40, N2=10 Fold Change: 2.55 P-value: 0
99         AA369887         X	52	97	AA312905	×	×	×	270.53+/-105.99 554.04+/-183.58 N1=40, N2=31 Fold Change: 2.06 P-value: 0	×
102         AA400080         X         X         89.66+/-112.79           246.79+/-233.75         X         N1=40, N2=31         P.value: .0043           104         AA417813         846.09+/-411.44         P.value: .0043         P.value: .0043           104         AA418636         244.96+/-23.2         R9.01+/-416.4         499.89+/-596.68           N1=40, N2=168         X         N1=40, N2=31         P.value: .00007           P-value: 0         244.96+/-112.2         P.value: .00007           106         AA418636         244.96+/-112.2         244.96+/-112.2           85.16+/-53.2         N1=39, N2=10         N1=39, N2=31           Fold Change: 2.92         X         N1=39, N2=31           Fold Change: 2.92         Fold Change: 3.75           P-value: .0032         P-value: .0	53	66	AA369887	×	×	×	×	326.24+/-259.48 88.98+/-90.46 N1=40, N2=10 Fold Change: 4.05 P-value: .00073
104       AA417813       846.09+/-411.44       849.01+/-416.4         570.86+/-624.96       X       N1=40, N2=31         N1=40, N2=168       X       N1=40, N2=31         Fold Change: 2.01       P-value: 00007         P-value: 00007       P-value: 00007         85.16+/-53.2       X       N1=39, N2=10         N1=39, N2=168       X       N1=39, N2=31         Fold Change: 2.92       Fold Change: 2.43       Fold Change: 3.75         P-value: 02032       P-value: 0	54	102	AA400080	×	×	×	89.66+/-112.79 246.79+/-233.75 N1=40, N2=31 Fold Change: 2.21 P-value: .0043	×
106     AA418636     244.96+/-112.2     244.96+/-112.2     244.96+/-112.2       85.16+/-53.2     107.39+/-80.98     62.82+/-36.83       N1=39, N2=168     X     N1=39, N2=10     N1=39, N2=31       Fold Change: 2.92     Fold Change: 3.75     P-value: 0     P-value: 0	55	104	AA417813	846.09+/-411.44 570.86+/-624.96 N1=40, N2=168 Fold Change: 2.01 P-value: 0	×	*	849.01+/-416.4 499.89+/-596.68 N1=40, N2=31 Fold Change: 2.44 P-value: .00007	×
	26	106	AA418636	244.96+/-112.2 85.16+/-53.2 N1=39, N2=168 Fold Change: 2.92 P-value: 0	×	244.96+/-112.2 107.39+/-80.98 N1=39, N2=10 Fold Change: 2.43 P-value: .02032	244.96+/-112.2 62.82+/-36.83 N1=39, N2=31 Fold Change: 3.75 P-value: 0	244.96+/-112.2 57.15+/-13.69 N1=39, N2=6 Fold Change: 3.86 P-value: 0

RNSDOCID: <WO 02059271A2 1 >

#	Sea ID	Genhank	Normal ve All	Normal vs Malignant	Normal ve Stage I	Normal ve Stage II	Normal ve Stage III
		Communic	TAGE MINE AS CALL	TOLVIA 19 TARIBURAL	Tol mai 13 Stage 1	TOTAL SOLUTION	TOT HEAT TO CLARE THE
21	107	AA418995					276.52+/-180.68
							89.94+/-34.01
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.64
							P-value: 0
58	109	AA419263					547.83+/-148.39
							268.37+/-114.78
			×	×	×	×	NI=40, N2=10
							Fold Change: 2.12
							P-value: .00021
29	112	AA424160	72.76+/-123.26			73.82+/-124.68	73.82+/-124.68
			241.99+/-260.32			344.26+/-347.34	405.04+/-245.91
			NI=40, N2=168	×	<b>×</b>	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.39			Fold Change: 5.08	Fold Change: 7.49
			P-value: 0			P-value: 0	P-value: 0
09	115	AA429308	242.38+/-144.29			237.83+/-143.23	237.83+/-143.23
			124.83+/-150.06			88.15+/-43.75	65.39+/-41.56
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.04			Fold Change: 2.47	Fold Change: 3.5
			P-value: 0			P-value: 0	P-value: .00009
19	116	AA430300					511.45+/-201.77
							242.83+/-223.58
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.55
							P-value: .00275
79	117	AA430314	265.86+/-187.91			259.57+/-186.05	259.57+/-186.05
			65.06+/-109.36			59.77+/-101.82	-4.03+/-59
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.88			Fold Change: 4.16	Fold Change: 6.66
			P-value: 0			P-value: 0	P-value: 0
63	118	AA436185				253.53+/-335.89	
						70.15+/-61.86	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.38	
						P-value: .00089	

	1			Mountain Molianont	Normal ve Stage I	Normal ve Stage II	Normal vs Stage III
#±	Sed III	Gendank	NOTHER VS ALI	IVOI IIIAI VS IVIAIIKHAIII	TOT IIIai 13 Otabo	TO THE STATE OF TH	G
64	119	AA436250				213.31+/-226.04 84.53+/-80.67	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.03 P-value: .00323	
65	120	AA447015	227.33+/-171.55			226.67+/-173.74	
3						66.02+/-51.23	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.51			Fold Change: 2.87	
			P-value: 0			P-value: 0	
99	122	AA450090	285.47+/-226.15		_	285.47+/-226.15	
3			133.85+/-131.49			125.82+/-152.5	
			N1=40. N2=168	×	×	N1=40, N2=31	×
						Fold Change: 2.88	
			P-value: 0			P-value: 0	
13	124	A A 452295	227.07+/-122.52		220.36+/-116.43	220.36+/-116.43	220.36+/-116.43
;			44 21+/-53 65		97.66+/-165.2	39.86+/-35.12	45.22+/-26.99
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.1		Fold Change: 3.73	Fold Change: 5.14	Fold Change: 4.25
			P-value: 0		P-value: .03669	P-value: 0	P-value: 0
8	125	A A 455877				295.74+/-130.76	295.74+/-130.76
3						131.5+/-76.16	102.29+/-56
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.4	Fold Change: 3.08
						P-value: 0	P-value: .0007
69	126	AA456099					375.25+/-161.56
							163.63+/-115.97
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.5
							P-value: .00094
92	128	AA464792					244.42+/-163.62
							77.5+/-57.57
			×	×	×	×	N1=40, N2=10
					•		Fold Change: 2.92
		'					P-value: .00105

#	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
11	129	. AA479033	104.1+/-260.94	0	0		
		,	N1=40, N2=168 Fold Change: 2.62 P-value: .00001	×	×	×	×
22	131	AA480075	331.51+/-157.28 155.12+/-117.94 N1=40, N2=168 Fold Change: 2.34	×	×	331,5+/-159.34 119,29+/-99.73 N1=40, N2=31 Fold Change: 3.04	331.5+/-159.34 97.24+/-36.96 N1=40, N2=10 Fold Change: 3.11
73	133	AA486366	237.554-149.6 115.84/-122.37 N1=39, N2=168 Fold Change: 2.09 P-value: 0	×	×	237.55+/-149.6 102.26+/-105.5 N1=39, N2=31 Fold Change: 2.18 P-value: .0001	237.55+/-149.6 20.97+/-35.35 N1=39, N2=6 Fold Change: 4.64 P-value: 0
47	135	AA48889	298.27+/-192.46 99.12+/-55.38 N1=40, N2=168 Fold Change: 2.64 P-value: 0	×	×	298.86+/-194.94 90.94+/-37.43 N1=40, N2=31 Fold Change: 2.8 P-value: 0	298.86+/-194.94 118.43+/-135.55 N1=40, N2=10 Fold Change: 2.62 P-value: .00133
27	136	AA496142	×	×	×	223+/-72.35 113.96+/-51.66 N1=39, N2=31 Fold Change: 2.03 P-value: 0	×
92	137	AA501987	202.15+/-87.72 123.46+/-65.5 N1=39, N2=168 Fold Change: 1.68 P-value: 0	· <b>X</b>	×	×	×
77	138	AA502943	438.99+/-109.54 262.83+/-186.3 N1=40, N2=168 Fold Change: 2.11 P-value: 0	×	×	439.24+/-110.96 250.93+/-145.84 N1=40, N2=31 Fold Change: 2.17 P-value: .00002	X

NODOOID: IND. COCCOST

							W
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage LLI
82	139	AA504253			;	;	394.39+/-105.44 151.15+/-69.52
			×	×	×	×	N1=40, N2=10 Fold Change: 2.81 P-value: .00011
			1 4 6 7 7 10 11 11 11 11			175 57+1,315 K	475 57+/-315.6
2	140	AA508196	475.57+/-315.6			4(3,3/1/23,13,0 2010-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	194 117-170 65
			223.41+/-148.84	•	;	20/1-/+10/07	CC:071-/111-481
			N1=40, N2=168	×	×	N1=40, N2=31	NI=40, NZ=10
			Fold Change: 2.02			Fold Change: 2.39	Fold Change: 2.51
		٠	P-value: 0			P-value: .00002	P-value: .00343
8	141	A A 513002	156 4+/-98 44			156.4+/-98.44	
2		TOO CTOUR	285 00+/-134 83			282.09+/-129.91	
			N1=39 N2=168	×	×	N1=39, N2=31	×
			Fold Change: 2.05	ŀ		Fold Change: 2.03	
			P-value: 0			P-value: .00001	
5	146	A A \$2.4005					1037.85+/-287.66
10	140	COLACER					517.53+/-221.07
			×	×	×	×	N1=40, N2=10
			•				Fold Change: 2.08
							P-value: .00018
8	147	A A 524250	337 9+/-133.73			340.18+/-134.68	340.18+/-134.68
70	1		180 07+/-116.79			149.6+/-62.5	98.23+/-47.07
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.02			Fold Change: 2.28	Fold Change: 3.58
			P-value: 0			P-value: 0	P-value: .00001
8	148	AA524536	304,34+/-210.76		298.68+/-210.41	298.68+/-210.41	
			116.11+/-126.7		87.05+/-113.19	113.27+/-115.65	ì
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	×
			Fold Change: 2.64		Fold Change: 3	Fold Change: 2.42	
			P-value: .00001		P-value: .03651	P-value: .00101	
84	151	AA526961	415.49+/-234.41	-		417.14+/-237.24	417.14+/-237.24
			178.69+/-118.79			163.41+/-149.82	119.79+/-62.48
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.31			Fold Change: 2.62	Fold Change: 3.37
			F-value: 0			r-value. o	r-value: .coco,

PAISDOCID: <WO 02059271A2 1 >

AA527180  X  AA527298  121.154-82.59  287.83+4-242.33  N1=39, N2=168  Fold Change: 1.92  AA533272  X  X  X  X  X  X  X  X  X  AA533218  323.08+4-135.81  155.95+4-97.92  N1=40, N2=168  X  X  X  X  X  X  X  AA543076  X  X  X  X  X  X  X  X  AA555312  X  X  X  X  X  X  X  X  X  X  X  X  X	Seg ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
121.15+/-82.59 287.83+/-242.33 N1=39, N2=168		AA527180		×	×	×	336.44+/-180.05 159.84+/-85.84 N1=40, N2=10 Fold Change: 2.03 P-value: .00507
X X X X X X X X X X X X X X X X X X X		AA527298	121.15+/-82.59 287.83+/-242.33 N1=39, N2=168 Fold Change: 1.92 P-value: 0	X	X	×	×
X X X X X X 323.08+/-135.81 155.95+/-97.92 X Y 15-40, N2=168 X X Y Pold Change: 2.27 P-value: 0 X X X X X X X X X X X X X X X X X X		AA533272	×	×	×	345.7+/-116.17 171.66+/-72 N1=40, N2=31 Fold Change: 2.1 P-value: 0	×
323.08+-135.81 155.95+/-97.92 N1=40, N2=168 Fold Change: 2.27 P-value: 0  X X X X X X X X X		AA534724	X	×	×	143.93+/-57.72 325.98+/-117.74 N1=40, N2=31 Fold Change: 2.31 P-value: 0	143.93+/-57.72 353.03+/-109.1 N1=40, N2=10 Fold Change: 2.56 P-value: 0
X X X X		AA535218	323.08+/-135.81 155.95+/-97.92 N1=40, N2=168 Fold Change: 2.27 P-value: 0	×	X	322.09+/-137.43 178.24+/-126.11 N1=40, N2=31 Fold Change: 2.06 P-value: .00002	×
x		AAS43076	X	X	X	109.8+/-95.15 365.31+/-441.38 N1=40, N2=31 Fold Change: 2.58 P-value: .00003	×
		AA555312	X	×	×	×	215.48+/-192.29 40.38+/-31.93 N1=40, N2=10 Fold Change: 3.68 P-value: .00006

i

1000010- ILIO MOENTEAN I

					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal VS Stage III
25	169	AA568397	243,4+/-227.66		243.4+/-227.66	243.4+/-227.66	243.4+/-227.66
	ì		92.45+/-68.55		86.44+/-37.31	74.95+/-70.23	52.06+/-33.54
			N1=40. N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.27		Fold Change: 2.12	Fold Change: 2.77	Fold Change: 3.85
			P-value: 0		P-value: .00208	P-value: 0	P-value: .00005
93	170	AA570519	200.18+/-172.78				200.18+/-172.78
2			77.04+/-65.26				48.77+/-33
_			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.26				Fold Change: 3.04
			P-value: 0		•		P-value: .00005
4	171	AA584310	398.21+/-320.55			402.55+/-323.55	402.55+/-323.55
:	(		1296.13+/-716.97		•	1058.09+/-583.59	1089.78+/-475.55
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.84			Fold Change: 3.12	Fold Change: 3.31
			P-value: 0			P-value: 0	P-value: .00032
ď	172	AA584403	593.26+/-1291.79			593.26+/-1291.79	593.26+/-1291.79
<u>}</u>	1		85 5+/-209 13			113.63+/-199.33	77.07+/-76.22
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.61			Fold Change: 2.7	Fold Change: 3.14
			P-value: 0			P-value: .00077	P-value: .00412
96	174	AA595800				405.39+/-344.1	
<u>'</u>	i I					167.2+/-159.75	
	•		×	×	×	N1=40, N2=31	×
						Fold Change: 2.2	
	•					P-value: .00334	
6	176	AA602521					258.64+/-109.45
:	)						92.33+/-57.89
			×	×	×	×	N1=39, N2=6
							Fold Change: 3.01
							P-value: .00015
86	178	AA609310	289.22+/-160.55			285.39+/-160.8	285.39+/-160.8
ł			106.23+/-108.02			81.33+/-54.9	139.85+/-180.52
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.16			Fold Change: 3.57	Fold Change: 2.65
			P-value: 0			P-value: 0	P-value: .00931

. !	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
	180	AA610522	803+/-768.74		803+/-768.74	803+/-768.74	
			2527.25+/-2163.34		1730.2+/-869.55	1878.88+/-1670.25	
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	×
			Fold Change: 3.75		Fold Change: 3.78	Fold Change: 2.57	
- 1			P-value: 0		P-value: .00045	P-value: .00552	
	181	AA612864				228.36+/-116.88	228.36+/-116.88
						495.29+/-290.05	440.68+/-155.22
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.03	Fold Change: 2.03
- 1						P-value: 0	P-value: .00004
	184	AA621478	394.08+/-322.25		398.69+/-325.12	398.69+/-325.12	398.69+/-325.12
			60.41+/-84.83		79.9+/-118.32	53.41+/-82.79	18+/-20.91
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.59		Fold Change: 5.51	Fold Change: 7.48	Fold Change: 11.4
			P-value: 0		P-value: .00526	P-value: 0	P-value: 0
	185	AA625387				92.36+/-35.34	92.36+/-35.34
						208.73+/-105.36	231.14+/-178.29
			×	×	×	N1=39, N2=31	N1=39, N2=6
						Fold Change: 2.15	Fold Change: 2.24
						P-value: 0	P-value: .00162
	189	AA628467	1150.97+/-497.25			1145.06+/-502.33	1145.06+/-502.33
			290.19+/-235.1			274.87+/-259.13	122.9+/-92.36
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.65			Fold Change: 4.99	Fold Change: 9.81
			P-value: 0			P-value: 0	P-value: 0
	192	AA631215		!		190.98+/-126.92	
						541.33+/-898.12	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.05	
						P-value: .00057	
	193	AA633203	127.67+/-220.56			130.61+/-222.66	130.61+/-222.66
			389.82+/-388.38			451.59+/-365.56	413.97+/-273.89
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.74			Fold Change: 5.08	Fold Change: 4.59
- 1			F-value: 0			F-value: 0	F-value: .00196

					N	Married we Other II	Normal we Stone III
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Ivolulial vs Stage Lit.
106	194	AA634799	763.44+/-619.75			739.38+/-608.62	
			367.84+/-431.55			440.74+7-020.81	;
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.41			Fold Change: 2.26	
			P-value: .00001			P-value: .00284	
107	196	A A 658561					238.89+/-114.83
2		TOO 000					110.57+/-54.76
			*	×	×	×	N1=40, N2=10
			4				Fold Change: 2.02
							P-value: .00612
100	108	A A 660106	82 72+/-129 9			84.29+/-131.22	84.29+/-131.22
901	130	DATCOOKE	202 67+/-186 26			383.96+/-227.86	381.34+/-202.47
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.65			Fold Change: 6.02	Fold Change: 6.04
			P-value: 0			P-value: 0	P-value: 0
90	000	A A 700621	467 51+/-455 09		467.51+/-455.09	467.51+/-455.09	467.51+/-455.09
707	700	17000100	66 85+/-123.51		87.68+/-141.47	36.61+/-66.8	26.41+/-35.67
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.01		Fold Change: 4.72	Fold Change: 7.35	Fold Change: 8.68
	(		P-value: 0		P-value: .02358	P-value: 0	P-value: 0
110	202	A A 703262				1213.89+/-750.28	1213.89+/-750.28
11						519.38+/-282.83	361.77+/-193.77
	)		×	×	×	N1=40, N2=31	N1=40, N2=10
				•		Fold Change: 2.09	Fold Change: 3.02
						P-value: .00044	P-value: .00125
=======================================	214	AA742697	1009.7+/-1062.61			1026.03+/-1071.41	1026.03+/-1071.41
			222.47+/-326.55			238.53+/-383.92	142.42+/-134
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.19			Fold Change: 4.18	Fold Change: 5.09
			P-value: 0			P-value: .00001	P-value: .00012
112	215	AA747315				448.86+/-190.26	448.86+/-190.26
	) !					258.21+/-198.98	135.53+/-84.89
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.02	Fold Change: 3.66
						P-value: .00001	F-value: .0001

Seq ID	la	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
216	1	AA760767	100.23+/-83.19			101.93+/-83.58	101.93+/-83.58
,			245.71+/-246.25			273.79+/-236.49	388.04+/-242.5
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.06			Fold Change: 2.59	Fold Change: 3.64
			P-value: 0			P-value: .00001	P-value: .00384
218	<b>'</b>	AA772278					137.98+/-96.56
							296.31+/-168.39
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.42
					•	•	P-value: .00585
220	ľ	AA775180					264.55+/-193.81
					•		84.64+/-55.48
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.66
							P-value: .00029
223	ľ	AA777369				104.24+/-57.98	
			,	ř	Þ	M1-40 M2-31	>
			≺	<	∢ .	Fold Change: 2.02	<
						P-value: 0	
226	1 7	AA779795					493.39+/-168.5
							227.18+/-95.72
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.25
				•			P-value: .00072
227	ι `	AA788946	568.73+/-336.98				
			1313.01+/-867.03		-		
			N1=39, N2=168	×	×	×	×
			Fold Change: 2.15				
			P-value: 0				
228	Ι'	AA789332	120.94+/-61.86			120.94+/-61.86	
			221.57+/-96.99	i	;	228.17+/-103.03	;
			N1=39, N2=168	×	×	N1=39, N2=31	×
			Fold Change: 1.91			Fold Change: 1.94	
	- 1		P-value: 0			F-value: .00007	

PNSDOCID--WO 000007140 1 5

	į,	7.7.7.	Married and All	Mount in Molianont	Normal ve Stage I	Normal ve Stage II	Normal vs Stage III
#	oed m	Gennauk	NOTHIAL VS ALL	MOI mai vs iviangmant	Mornial 13 Stage 1	Guad of thirt 1014	20 00 1 100 000
120	230	AA807154	271.93+/-107.94			273.39+/-108.95	273.39+/-108.95
			150.18+/-94.12			115.85+/-82.09	137.82+/-101.26
			N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.01			Fold Change: 2.55	Fold Change: 2.3
			P-value: 0			P-value: 0	P-value: .00953
121	235	AA830844	93.3+/-120.3			94.7+/-121.54	94.7+/-121.54
	}		272.03+/-321.32			320.78+/-455.06	361.79+/-369.37
			N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.64		€	Fold Change: 2.9	Fold Change: 3.88
			P-value: 0			P-value: .00003	P-value: .00167
122	236	AA838843					1133.4+/-889.08
	)				•		503.96+/-209.26
			×	×	×	×	N1=40, N2=10
							Fold Change: 2
						11 10 7 10 7 11	r-value: .00009
123	239	AA846091	83.83+/-80.09		84.12+/-81.11	84.12+/-81.11	
			254.24+/-227.12		271.23+/-192.47	226.57+/-179.06	
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	×
			Fold Change: 2.88		Fold Change: 3.44	Fold Change: 2.75	
			P-value: 0		P-value: .01151	P-value: 0	
124	241	AA875998					144.49+/-132.98
	! !						225.7+/-97.08
			×	×	×	×	N1=40, N2=10
			1	ļ.			Fold Change: 2.02
							P-value: .00162
125	246	A A 909042				166.1+/-92.52	166.1+/-92.52
}	2					345.62+/-200.16	375.51+/-207.38
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.07	Fold Change: 2.2
						P-value: 0	P-value: .00481
126	249	AA909958				304.09+/-148.66	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.04	
						COOOC. CONTRACT	

#	Coo H	Conbonk	Normal ve All	Normal ve Malignant	Normal vs. Stage I	Normal vs Stage II	Normal vs Stage III
ٳ	Oct Th	GCIIDAIIN	IVOI MAIN VS AM	IVOI MIAI VO MARIBIIAM	TAGING AS SIESET	TOTAL STATE OF THE	A COLUMN 19 SCHECKER
127	251	AA913079					379.55+/-192
							819.72+/-391.8
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.18
							P-value: .00102
128	254	AA921830	91.7+/-113.88			92.93+/-115.1	92,93+/-115.1
			226.43+/-153.69			257.36+/-191.81	324.58+/-186.68
			NI=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.9			Fold Change: 3.24	Fold Change: 4
			P-value: 0			P-value: 0	P-value: .0002
129	255	AA921922	312.62+/-288.86			312.44+/-292.63	312.44+/-292.63
			76.08+/-72.69			75.75+/-54.61	36.4+/-15.92
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.16			Fold Change: 3.86	Fold Change: 6.83
			P-value: 0			P-value: 0	P-value: 0
130	257	AA928698					979.86+/-357.7
							383.02+/-284.05
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.22
							P-value: .00199
131	258	AA928776	334.78+/-156.59			334.78+/-156.59	334.78+/-156.59
			126.01+/-82.79			129.6+/-115.01	91.05+/-43.12
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.72			Fold Change: 2.74	Fold Change: 3.62
			P-value: 0			P-value: 0	P-value: .00002
132	259	AA928876				279.93+/-242.15	
			Þ	>	*	N1=40 N2=31	×
			<b>*</b>	<b>:</b>	•	Fold Change: 2.37	
						P-value: .00023	
133	260	AA936632	124.77+/-125.66			125.03+/-127.3	125,03+/-127.3
			335.73+/-304.1			307.81+/-176.76	325.44+/-181.42
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.65			Fold Change: 2.68	Fold Change: 3
			P-value: 0			P-value: 0	F-value: .00001

DAIGEOCCIE: -NAC 0005007140 1 -

1	Sed ID	Genhank	Normal vs All	Normal vs Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1	255	4 4 0 4 7 4 2 2	700071000	G	C	10 00 / 11 700	202 11+7 00 01
	107	AA94/123	135.96+/-76.03			108.39+/-64.68	106.79+/-57.35
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.34			Fold Change: 2.88	Fold Change: 3.03
			P-value: 0			P-value: 0	P-value: .00116
1	263	AA968657	120.64+/-123.71				
			221.47+/-188.53				
			N1=40, N2=168	×	×	×	×
	756	4 4 0 2 0 0 2 2	F-value: .00055				15/ 00 /7 / 60 60
	<del>1</del> 07	A.A.909603					335+/-158.01
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.11
- 1							P-value: .00058
	266	AA976064	363.92+/-151.16 183.7+/-101.29				
			N1=40 N2=168	×	×	×	×
			Fold Change: 2.17 P-value: 0	;	;	<b>;</b>	!
	792	A A 977204					159.24+/-78.21
							300.74+/-74.19
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.02
							P-value: 0
	272	AB007972	317.37+/-102.68			317.37+/-102.68	317.37+/-102.68
			141.41+/-56.37			127.42+/-50.63	110.2+/-25.69
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.26			Fold Change: 2.49	Fold Change: 2.75
			P-value: 0	:		P-value: 0	P-value: 0
	280	AC004010				237.41+/-101.03	
			;	1	;	119.13+/-50.91	ļ
			×	×	×	N1=39, N2=31	×
						Fold Change: 2.01	
- 1						F-vame: 0	

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
141	281	AC004770				116.54+/-76.22	116.54+/-76.22
			231.2+/-112.79			258.92+/-95.73	353.08+/-90.31
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.41	Fold Change: 3.44
١			P-value: 0			P-value: 0	P-value: 0
142	286	AF007150					560.67+/-252.85
							244.22+/-118.81
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.3
							P-value: .00021
143	287	AF009314	280.81+/-113.17				280.81+/-113.17
			138.34+/-66.55				90.09+/-43.95
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.04				Fold Change: 3.18
			P-value: 0	i			P-value: .00003
144	297	AF052142	307.17+/-169.55			307.17+/-169.55	307.17+/-169.55
			136.07+/-86.42			134.05+/-84.74	131.75+/-87.96
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.28			Fold Change: 2.25	Fold Change: 2.44
			P-value: 0			P-value: 0	P-value: .00309
145	300	AF058075					-15.62+/-107.9
							355.75+/-489.88
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.73
							P-value: .0394
146	304	AF070648	1031.52+/-429.52			1031.52+/-429.52	1031.52+/-429.52
			432.03+/-213.34			357.01+/-152.1	292.72+/-163.49
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.41			Fold Change: 2.82	Fold Change: 3.62
			P-value: 0			P-value: 0	P-value: .00002
147	309	AF150174	211.02+/-104.05			211.02+/-104.05	211.02+/-104.05
			86.63+/-46.76			86.92+/-51.98	78.32+/-31.52
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.26			Fold Change: 2.26	Fold Change: 2.38
			P-value: 0			P-value: 0	P-value: 0

BNSDOCID: «WO 0205927142 I >

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
148	311	AI002238					254.67+/-91.81 105.29+/-71.62
			×	×	×	×	N1=40, N2=10
•							Fold Change: 2.72
							P-value: .00083
149	314	AI016604			•	502.7+/-255.95	502.7+/-255.95
						262.05+/-145.41	226.05+/-112.74
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.02	Fold Change: 2.18
						P-value: .00002	P-value: .00111
150	317	AI018523	422.08+/-187.64		•	422.08+/-187.64	422.08+/-187.64
			94.36+/-123.53			77.78+/-105.86	44.08+/-59.8
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.56			Fold Change: 6.54	Fold Change: 9.77
			P-value: 0			P-value: 0	P-value: 0
151	321	AI031771	85.9+/-105.07			85.9+/-105.07	
			257.24+/-405.17			298.84+/-697.75	
			N1=40, N2=168	×	×	NI=40, N2=31	×
			Fold Change: 2.53			Fold Change: 2.33	
			P-value: 0			P-value: .00142	
152	324	AI039005	201.84+/-130.44			203.54+/-131.69	203.54+/-131.69
			77.34+/-61.5			61.56+/-42.38	44.43+/-54.48
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.58			Fold Change: 3.03	Fold Change: 3.97
			P-value: 0			P-value: 0	P-value: .0001
153	325	AI039722	990.63+/-1152.38			1007.24+/-1162.59	1007.24+/-1162.59
			438.37+/-1004.04			232.49+/-466.94	207.73+/-245.94
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.87			Fold Change: 6.17	Fold Change: 5.76
			P-value: 0			P-value: 0	P-value: .00392
154	326	AI049549	653.84+/-535.62			653.84+/-535.62	653.84+/-535.62
			267.97+/-227.53			226.29+/-141.74	155.78+/-116.9
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.36			Fold Change: 2.5	Fold Change: 3.66
			P-value: 0			P-value: .00001	P-value: .00006

#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
E	130	Company	THE THE PARTY OF THE	9	8		201 0511100 70
155	327	. AI049973					391.85+/-108.68
							199.36+/-27.62
			×	×	×	×	N1=39, N2=6
							Fold Change: 1.95
							P-value: .00002
156	330	A1056241	241 39+/-152 04		241.39+/-152.04	241.39+/-152.04	241.39+/-152.04
3			36 35 /T89 L9		03 33+/-104 89	49,94+/-43,13	45.49+/-48.07
			07.06-7-168 07.06-7-168	*	N1=39 N2=10	N1=39, N2=31	N1=39. N2=6
			E-14 Chance 2 00	€	Fold Change: 2 9	Fold Change: 3.33	Fold Change: 4.03
			Fold Change: 2.00  Database: 0		P-value: .03101	P-value: 0	P-value: .00003
157	221	AT057450	381 32+/-1572 07			381.32+/-1572.07	381.32+/-1572.07
)CT	100	OCT / COTY	20.72+/-180.68			27.5+/-176.72	10.16+/-47.15
<del></del>			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.92			Fold Change: 2.87	Fold Change: 2.99
			P-value: .0006			P-value: .00026	P-value: .00095
158	332	AT057637	568 22+/-502 47		573.52+/-507.9	573.52+/-507.9	573.52+/-507.9
3			153 6+/-81 89		163.69+/-59.04	129.31+/-59.91	124.36+/-39.47
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.29		Fold Change: 2.9	Fold Change: 3.79	Fold Change: 3.81
			P-value: 0		P-value: .0001	P-value: 0	P-value: 0
150	336	AT078033	454 77+/-280.5			454.77+/-280.5	454.77+/-280.5
3	3		203 08+/-158 36			183.47+/-128.31	129.56+/-78.11
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.27			Fold Change: 2.42	Fold Change: 3.22
			P-value: 0			P-value: 0	P-value: .00008
160	337	AT078121	267 92+/-121 01				267.92+/-121.01
3	3		129 6+/-75 04				124.52+/-39.11
			N1=39 N2=168	×	×	×	N1=39, N2=6
			Fold Change: 2 01	<b>;</b>			Fold Change: 2.05
			P-value: 0				P-value: .00004
171	228	AT070545	- Lange		248.94+/-138.38		
	2	CLC / COTE			463.39+/-104.61		
			×	×	N1=40, N2=6	×	×
					Fold Change: 2.14		
					I -value00004		

	5	1		Normal ve Malianant	Normal ve Stage I	Normal vs Stage II	Normal vs Stage III
#	Sed ID	Сеповик	NOTHER VS ALL	MOI IIIai vs iviaiiguaiii	TAGENER AS STERRA	D	
162	339	AI079558				115./6+/-141./1 214.96+/-122.84	
			×	×	×	N1=40, N2=31	×
			1			Fold Change: 2.3	
						P-value: .00001	
163	341	A1083598	344.81+/-287.52			339.56+/-289.33	339.56+/-289.33
3	5		151 49+/-429 97	•		210.77+/-736.98	31.3+/-28.36
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.75	ł		Fold Change: 4.41	Fold Change: 6.76
			P-value: 0			P-value: 0	P-value: 0
164	240	AT086614	300.02+/-151.08			301.2+/-152.86	301.2+/-152.86
507	4	100001	127 26+/-88 54			96.79+/-68.03	68.08+/-44.9
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.5			Fold Change: 3.25	Fold Change: 3.7
			P-value: 0			P-value: 0	P-value: 0
165	343	AI087975	137.52+/-92.28				
	1		277.44+/-204.79				;
			N1=39, N2=168	×	×	×	×
			Fold Change: 1.96				
			P-value: 0				
1,66	344	AT088609	711 92+/-592.71		=	709.25+/-600.21	709.25+/-600.21
3	,		327.21+/-706.4		•	163.7+/-218.98	78.97+/-52.81
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.75			Fold Change: 4.73	Fold Change: 6.93
			P-value: 0			P-value: 0	P-value: 0
19	345	AI091154	351.29+/-406.17		351.29+/-406.17	351.29+/-406.17	351.29+/-406.17
	) )		73.95+/-133.05		87.21+/-103.53	86.99+/-153.12	62.86+/-69.84
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.29		Fold Change: 3.04	Fold Change: 3.61	Fold Change: 3.91
			P-value: 0		P-value: .0365	P-value: 0	P-value: .00107
168	346	AI092936	185.51+/-150.9			186.98+/-152.58	
			417.08+/-227.5		1	425.95+/-204.95	ļ
			N1=40, N2=168	×	×	N1=40, N2=31	*
			Fold Change: 2.2			Fold Change: 2.35	
			F-value: 0			1 - value: :00001	

			1				<del></del>
Normal vs Stage III	×	354.78+/-131.25 184.82+/-126.35 N1=40, N2=10 Fold Change: 2.08 P-value: .00216	300+/-164.6 55.08+/-36.39 N1=40, N2=10 Fold Change: 4.97 P-value: .00001	297.76+/-110.04 120.8+/-50.92 N1=39, N2=6 Fold Change: 2.46 P-value: .00002	×	220.92+/-142.18 366.48+/-123.56 N1=40, N2=10 Fold Change: 2.01 P-value: .00008	×
Normal vs Stage II	X	×	300+/-164.6 67.15+/-70.68 N1=40, N2=31 Fold Change: 4.66 P-value: 0	297.76+/-110.04 152.58+/-82.32 N1=39, N2=31 Fold Change: 2.04 P-value: 0	69.28+/-126.42 215.91+/-164.16 N1=39, N2=31 Fold Change: 2.27 P-value: .00023	X	230.52+/-149.31 872.58+/-881.67 N1=40, N2=31 Fold Change: 2.85 P-value: .00002
Normal vs Stage I	X	×	300+/-164.6 91.12+/-67 N1=40, N2=6 Fold Change: 3.22 P-value: .00482	×	×	×	×
Normal vs Malignant	X	×	X	×	X	X	×
Normal vs All	204.98+/-121.07 348.38+/-182.49 N1=39, N2=168 Fold Change: 1.75 P-value: .00003	×	300.32+/-162.49 75.22+/-66.82 N1=40, N2=168 Fold Change: 4.19 P-value: 0	297.76+/-110.04 156.35+/-127.73 N1=39, N2=168 Fold Change: 2.06 P-value: 0	69.28+/-126.42 217.42+/-192.92 N1=39, N2=168 Fold Change: 2.31 P-value: 0	X ·	×
Genbank	AI094535	AI096389	AI123555	AI123738	AI125252	AI126237	AI127289
Seq ID	348	349	351	352	355	357	358
<b>#</b> ±	691	170	171	172	173	174	175

BNSDOCID: -WO COSCOZIAO I

	Contains 19 fall	Normai vs iylangnant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage LL
AT128820				224.42+/-90.96	224.42+/-90.96
	101.84+/-66.82			96.42+/-39.89	82.27+/-38.37
	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
	Fold Change: 2.29			Fold Change: 2.29	Fold Change: 2.85
	P-value: 0			P-value: 0	P-value: .0008
AI129320	462.88+/-248.98			462.06+/-252.18	462.06+/-252.18
	223.69+/-111.28			218.45+/-156.49	242.37+/-237.11
	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
	Fold Change: 2.08			Fold Change: 2.3	Fold Change: 2.23
	P-value: 0		•	P-value: 0	P-value: .00458
AI131078	299.48+/-223.81			299.48+/-223.81	299.48+/-223.81
	105.31+/-56.6		•	102.41+/-57.3	99.18+/-37.7
	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
	Fold Change: 2.51			Fold Change: 2.6	Fold Change: 2.48
	P-value: 0			P-value: 0	P-value: .00001
AI140764	241.9+/-66.27				241.9+/-66.27
	127.44+/-57.54				119.16+/-48.86
	N1=39, N2=168	×	×	×	NI=39, N2=6
	Fold Change: 2.03		-		Fold Change: 2.11
	P-value: 0				P-value: .00026
AI141556					297.58+/-90.49
					101.69+/-39.39
	×	×	×	×	N1=40, N2=10
					Fold Change: 2.97
					P-value: 0
AI144477	560.95+/-250.34			564.89+/-252.35	
	250.3+/-192.18			332.2+/-275.56	
	N1=40, N2=168	×	×	N1=40, N2=31	×
	Fold Change: 2.61		-	Fold Change: 2.04	
	P-value: 0			P-value: .00003	
AI148006	241.32+/-191.01			241.17+/-193.5	241.17+/-193.5
	84.05+/-116.71			51.87+/-67.91	25.24+/-42.83
	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
	Fold Change: 2.99			Fold Change: 4.03	Fold Change: 5.56
	P-value: 0			P-value: 0	P-value: 0

<u>.</u>	:																			_,				_											
Normal vs Stage III	. 223.18+/-91.72	113.09+/-116.05	N1=39, N2=6	Fold Change: 2.37	P-value: .00396	243+/-112.73	111.62+/-39.76	N1=40, N2=10	Fold Change: 2.04	P-value: .00009	301.58+/-452.1	76.68+/-82.57	N1=40, N2=10	Fold Change: 2.77	P-value: .00751			×		201 7±/ 101 6	. 264./+/-101.6	12/.96+/-60.39	N1=40, N2=10	Fold Change: 2.41	P-value: .00278	205.71+/-81.06	101.78+/-59.91	N1=40, N2=10	Fold Change: 2.2	P-value: .00676	290.63+/-103.17	100.98+/-38.82	N1=40, N2=10	Fold Change: 2.9	P-value: .00001
Normal vs Stage II	223.18+/-91.72	107.58+/-66.58	NI=39, N2=31	Fold Change: 2.25	P-value: 0			×			301.58+/-452.1	76.69+/-52.21	N1=40, N2=31	Fold Change: 2.46	P-value: .00013			×					×					×			290.63+/-103.17	141.14+/-64.83	N1=40, N2=31	Fold Change: 2.13	P-value: 0
Normal vs Stage I			×					×			-		×					×					×			-		×					×		
Normal vs Malignant			×				•	×					×					×					×					×	ł				×		
Normal vs All	223.18+/-91.72	95.74+/-62.93	N1=39, N2=168	Fold Change: 2.5	P-value: 0			×			301.58+/-452.1	77.97+/-71.53	N1=40, N2=168	Fold Change: 2.61	P-value: .00001	356.99+/-119.9	188.39+/-84.68	N1=39, N2=168	Fold Change: 1.94	r-vaine: 0			×					*	•				×		
Genbank	AI149693					AI160811					AI161049					A1168057					AI189011					AI189255					AI190755				
Sea ID	373					375					376					378					380					381	1				382	1			
#	183 183					184					185					186					187				•	188	}				180	}			

					1000	No Stock II	Normal ve Stage III
*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	MOLIURI VS Stage AL	Avol Ilian vs Stage Att
100	384	A1200954	529.23+/-316.46			524.84+/-319.36	524.84+/-319.36
120	100		256 1+/-158 56			219.57+/-119.93	165.98+/-93.19
			N1=40 N7=168	*	×	N1=40, N2=31	N1=40, N2=10
			Told Change: 2 07	1	!	Fold Change: 2.28	Fold Change: 3.18
			P-value: 0			P-value: .00001	P-value: .00195
101	385	AT201273	535.25+/-296.2			533.25+/-299.79	533.25+/-299.79
171	265		238 85+/-188 24			203.14+/-125.12	125.11+/-95.45
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.5			Fold Change: 2.61	Fold Change: 4.56
			P-value: 0			P-value: 0	P-value: .0001
3	386	AT201065	237 22+/-148.65			234.24+/-149.37	234.24+/-149.37
727	360	ALEUL/05	107 53+/-70 7			100.47+/-56.35	65.63+/-51.87
			N1=40 N7=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.18	Ţ		Fold Change: 2.19	Fold Change: 3.63
			P-value: 0			P-value: .00001	P-value: .00031
5	207	AT201082	77 97-1-146 77			279.97+/-146.77	279.97+/-146.77
5	307	70670714	114 06+/-74.45			121.58+/-55.99	121.2+/-81.62
			N1=39 N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.45	!		Fold Change: 2.14	Fold Change: 2.51
			D-value: ()			P-value: 0	P-value: .00327
3	300	ATOROTA	213 72+/-107 69			211.4+/-108.08	211.4+/-108.08
174	200	F1000714	81 38+/-54 34			80.55+/-42.41	60.05+/-31.32
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.63			Fold Change: 2.54	Fold Change: 3.36
			P-value: 0			P-value: 0	P-value: .00001
195	389	AI206063	133.1+/-160.7		-	133.1+/-160.7	
			339.26+/-339.95			353.59+/-366.06	;
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.57			Fold Change: 2.7	
			P-value: .00002			P-value: .00061	
196	393	AI218358	210.74+/-117.83		210.74+/-117.83	210.74+/-117.83	210.74+/-117.83
) ) 			87.3+/-105.07		82.51+/-91.18	76.3+/-97.56	74.44+/-133.85
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.43		Fold Change: 2.74	Fold Change: 2.64	Fold Change: 3.62
			P-value: 0		P-value: .0333	P-value: 0	F-value: .00101

	Coo III	Conbont	Normal ne All	Normal ve Malignant	Normal ve Stage I	Normal vs Stage II	Normal vs Stage III
ŧ	254 20	GCIIDAIIR	TANK THE LAND	TOT WHAT TO LANGUAGE	TOTALINE TO DEED A	The state of the s	Sund of the sund o
197	394	AI222594	431.73+/-162.38			431.73+/-162.38	
			CF: (11-(120:CO1	>	>	15-CM OV-114	>
			NI=40, NZ=108	<	<	IC-ZVI, OH-IVI	<
			Fold Change: 2.81			Fold Change: 3.23	
			F-vaine: 0			r-value: 0	
198	397	AI242160	320.5+/-159.05				
			170.68+/-74.58				
			N1=39, N2=168	×	×	×	×
			Fold Change: 1 73				
			road Calange, 1.75 P-value: 0		•		
190	308	A1244908					425.47+/-356.02
`	)				•		148.1+/-83.25
			<b>×</b>	×	×	×	N1=40. N2=10
			<b>4</b>	•	1	{	Fold Change: 2.51
							P-value: .00165
200	399	AI247837	250.33+/-314.52			250.33+/-314.52	250.33+/-314.52
,			40.01+/-55.99			34.79+/-48.59	20.13+/-36.3
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.88			Fold Change: 4.13	Fold Change: 4.49
			P-value: 0			P-value: 0	P-value: 0
201	401	AI264135					246.38+/-130.33
							97.95+/-69.13
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.68
	•						P-value: .00126
202	403	AI266650					657.85+/-222.05
					•		309.8+/-83.6
			×	×	×	×	N1=40, N2=10
					-		Fold Change: 2.09
							P-value: .00001
203	405	AI275140				26.4+/-47.96	
			×	×	×	N1=40, N2=31	×
						Fold Change: 6.41	
						T-VILLOS	

BNSDOCID: <WO 02059271A2 1 >

.

. )

#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
504	407	A1276259	10	×	×	121.51+/-224.22 245.37+/-268.39 N1=40, N2=31 Fold Change: 2.09 P-value: .00466	×
205	408	AI277612	1009.49+/-899.38 93.86+/-163.03 N1=40, N2=168 Fold Change: 9.23 P-value: 0	X	1022.91+/-907.07 163.73+/-156.36 N1=40, N2=6 Fold Change: 5.12 P-value: .00592	1022.91+/-907.07 82.75+/-117.04 N1=40, N2=31 Fold Change: 10.43 P-value: 0	1022.91+/-907.07 40.07+/-27.26 N1=40, N2=10 Fold Change: 16.08 P-value: 0
506	413	AI285970	X	×	×	269.01+/-274.71 88.12+/-54.51 N1=40, N2=31 Fold Change: 2 P-value: .00393	×
207	414	AI288586	×	×	×	313.32+/-139.2 113.39+/-56.77 N1=39, N2=31 Fold Change: 2.6 P-value: 0	313.32+/-139.2 107.36+/-49.96 N1=39, N2=6 Fold Change: 2.94 P-value: .00028
208	415	AI288745	276.49+/-146.02 108.9+/-73.82 N1=39, N2=168 Fold Change: 2.51 P-value: 0	×	×	276.49+/-146.02 104.75+/-63.19 N1=39, N2=31 Fold Change: 2.5 P-value: 0	276.49+/-146.02 67.42+/-24.06 N1=39, N2=6 Fold Change: 3.69 P-value: 0
209	417	AI300876	601.83+/-985.51 74.02+/-258.41 N1=40, N2=168 Fold Change: 6.47 P-value: 0	×	×	601.83+/-985.51 54.33+/-149.24 N1=40, N2=31 Fold Change: 6.66 P-value: 0	601.83+/-985.51 13.6+/-22.13 N1=40, N2=10 Fold Change: 8.67 P-value: 0
210	422	A1333767	×	×	×	×	201.68+/-104.32 104.93+/-75.04 N1=40, N2=10 Fold Change: 2 P-value: .00805

7	E se	O'subant.	Menney Land A 11	Manual and Malianous	Monney I am Ottom I	Merune I am Charact	Monte of the Charles Title
# E E	423	Al333987	LIOLINAL VS AM	Morning vs Manghane	TOT MAIL 13 DEABOY	208.53+/-320.79	To man 49 code of the
			×	×	×	57.0077-100.50 N1=40, N2=31 Fold Change: 2.4 P-value: .00125	×
212	424	AI338536	×	×	×	×	548.6+/-192.05 227.52+/-68.12 N1=40, N2=10 Fold Change: 2.31 P-value: 0
213	427	Al341602	135.16+/-276.86 593.58+/-944.91 N1=40, N2=168 Fold Change: 4.46 P-value: 0	×	137.44+/-280.1 438.85+/-447.12 N1=40, N2=6 Fold Change: 3.86 P-value: .03152	137.44+/-280.1 723.06+/-652.3 N1=40, N2=31 Fold Change: 6.28 P-value: 0	137.44+/-280.1 580.91+/-380.87 N1=40, N2=10 Fold Change: 6.09 P-value: .00062
214	428	AI342169	X	X	×	×	496.19+/-393.99 1347.53+/-986.09 N1=40, N2=10 Fold Change: 2.64 P-value: .0043
215	430	AI344312	84.72+/-57.63 209.71+/-134.29 N1=40, N2=168 Fold Change: 2.33 P-value: 0	×	×	×	×
216	431	AI346341	640.59+/-422.41 155.96+/-203.21 N1=40, N2=168 Fold Change: 4.26 P-value: 0	×	×	635.18+/-426.52 120.31+/-143.98 N1=40, N2=31 Fold Change: 4.92 P-value: 0	635.18+/-426.52 104.05+/-133.87 N1=40, N2=10 Fold Change: 5.89 P-value: .00006
217	432	AI351043	236.73+/-93.44 109.27+/-56.02 N1=40, N2=168 Fold Change: 2.23 P-value: 0	×	×	236.3+/-94.62 98.05+/-50.78 N1=40, N2=31 Fold Change: 2.47 P-value: 0	236.3+/-94.62 73.16+/-38.18 N1=40, N2=10 Fold Change: 3.35 P-value: .00009

3	Clar III	Conhonk	Normal ve All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
٤	1	A 1252171		Ø		222 69 +/-144 28	222.69+/-144.28
917	404	1/17CCTW				77.49+/-85.14	51.96+/-71.13
			×	×	×	N1=39, N2=31	N1=39, N2=6
			•			Fold Change: 2.28	Fold Change: 2.86
						P-value: 0	P-value: .00032
210	436	A1357639					103.44+/-82.21
}	2	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\					229.26+/-76.25
			×	×	×	×	N1=40, N2=10
			<b>{</b>				Fold Change: 2.51
							P-value: 0
1000	437	AT361002				226.33+/-66.64	209.31+/-66.11
3	ì					131.77+/-56.91	116.1+/-36.28
			×	×	×	N1=39, N2=31	NI=39, N2=6
			•			Fold Change: 1.8	Fold Change: 1.82
						P-value: 0	P-value: .00118
221	441	A1369275	412 08+/-182 64			404.52+/-178.58	404.52+/-178.58
4	į		160.8+/-88.56			156.69+/-71.33	124.99+/-48.08
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.56			Fold Change: 2.52	Fold Change: 3.09
			P-value: 0			P-value: 0	P-value: 0
222	443	AI375115	215.71+/-84.93			211.26+/-81.18	211.26+/-81.18
ļ	2		107.21+/-43.49			101.07+/-42.95	95.25+/-21.17
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.02			Fold Change: 2.07	Fold Change: 2.08
			P-value: 0			P-value: 0	P-value: 0
223	446	AI377937				360.06+/-360.99	360.06+/-360.99
						150.11+/-76.77	160.98+/-94.5
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.07	Fold Change: 2
						P-value: .00001	P-value: .0091
224	447	AI378584	837.48+/-393.22			815.22+/-371.96	815.22+/-371.96
!			288.6+/-150.82			263.18+/-114.79	231+/-80.99
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.77			Fold Change: 2.89	Fold Change: 3.19
			P-value: 0			r-value: 0	r-value: 0

BNG00010 - WO 02050271A2 1 >

A1379723   386.864+176.47   380.224+173.64   380.224+173.64     1.05(184-1143.63   X   X   X   X   X   X   X   X   X	#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
#450 AL17123 308.05071-17.304  #50 AL17125 308.05071-17.304  #51 Fold Change: 3.46	ų	740	A 1940439	70 704 1170 700		2000001110000	77 657 7 60 60 6	17 000 1.00 000
Alignost	Ç	8448	ALS/9/23	380.86+/-1/6.4/		380.22+/-1/3.64	380.22+/-1/3.64	380.22+/-173.64
Fold Change: 3.46   X   Nil-40, Ni2-31				120.18+/-143.03		136.6+/-134.47	8/.51+/-00.3	68.16+/-48.01
Fold Change: 3.46   Fold Change: 4.24				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
450 AI380204 P-value: 0 P-value: 03454 P-value: 0 861.547-46.86				Fold Change: 3.46		Fold Change: 3.5	Fold Change: 4.24	Fold Change: 5.51
450 AI380204  X	-			P-value: 0		P-value: .03454	P-value: 0	P-value: 0
Accordance   Acc	9	450	AI380204				194.43+/-169.86	
452 AI380932							361.5+/-246.51	
452 AI380932 X X X X X X X X X X X X X X X X X X X				×	×	×	N1=40, N2=31	×
452         A1380932         X-44-4-46.82         A 3-24-46.82         A 3-44-46.40							Fold Change: 2.15	
452         A1380932         X         N 1=40, N2=31         P-value: 0         P-value:							P-value: .00078	
456         A1381930         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         34.22+/-46.82         3	7	452	AI380932					191.48+/-96.27
456         AI381930         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         44.47+/-46.55.46         A1381930         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         34.22+/-46.82         A12.245.06         A12.245.44								387.31+/-138.62
456         AI381930         269.91+/-245.06         269.91+/-246.06         269.91+/-246.06         269.91+/-245.06         269.91+/-246.09				×	×	×	×	N1=40, N2=10
456         A1381930         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         269.91+/-245.06         244.47+6.55.4         A13.27+/46.82         A13.27+/48.74         A23.17+/48.74         A23.1								Fold Change: 2.16
456         AI381930         269.91+/.245.06         269.91+/.246.03         269.42+/.46.82         269.42+/.46.82         269.42+/.46.82         269.42+/.46.82         269.42+/.46.82         269.42+/.46.82         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.46.32         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74         269.42+/.48.74 <t< td=""><th>1</th><th></th><td></td><td></td><td></td><td></td><td></td><td>P-value: .00071</td></t<>	1							P-value: .00071
44.47+-65.54  N1=39, N2=168  N1=39, N2=10  Fold Change: 3.7  Fold Change: 3.7  Fold Change: 3.7  A1393356  A1393356  A1393356  A1401832  X  X  X  X  X  X  X  X  X  X  X  X  X	<b>20</b>	456	AI381930	269.91+/-245.06		269.91+/-245.06	269.91+/-245.06	269.91+/-245.06
N1=39, N2=168				44.47+/-65.54		63.86+/-29.55	34.22+/-46.82	62.78+/-171.44
Fold Change: 3.7 Fold Change: 3.85  P-value: 0.0133 Fold Change: 3.85  P-value: 0.0133 P-value: 0  458 A1393356				N1=39, N2=168	×	NI=39, N2=10	N1=39, N2=31	N1=39, N2=6
458 AI393356 P-value: 0 P-value: 0 P-value: 00133 P-value: 0  X X X444+/-64.03 339.43+/-658.29 X X N1=40, N2=31 Fold Change: 2.18 P-value: 0				Fold Change: 3.7		Fold Change: 3.2	Fold Change: 3.85	Fold Change: 3.91
458         AI393356         X         74.44+/-64.03           450         AI401832         X         N1=40, N2=31           461         AI401832         X         N1=40, N2=31           A62         AI417267         927.34/-482.64         X         N1=40, N2=31           462         AI417267         927.34/-482.64         N1=40, N2=6         N1=40, N2=31           Fold Change: 3.36         AN1=40, N2=6         N1=40, N2=31         P-value: .0003         P-value: 0				P-value: 0		P-value: .00133	P-value: 0	P-value: .0021
Alabeaconstraints   X   X   X   X   X   X   X   X   X	6	458	AI393356				74.44+/-64.03	
461 AI401832 X X X N1=40, N2=31 Fold Change: 2.18 P-value: .00164 72.16+/-151.56 408.66+/-668.16 X X X N1=40, N2=31 Fold Change: 2.63 P-value: .00745 462 AI417267 927.3+/-482.64 S259.61+/-119.48 N1=40, N2=168 X N1=40, N2=6 P-value: 0							339.43+/-658.29	
461         AI401832         Fold Change: 2.18           461         AI401832         X         X         X1.16+/-151.56           462         AI417267         927.3+/-482.64         X         X         N1=40, N2=31           462         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41         933.35+/-487.41           AI417267         927.3+/-119.48         X         N1=40, N2=6         N1=40, N2=31           Fold Change: 3.36         X         N1=40, N2=6         N1=40, N2=31           Fold Change: 3.36         Fold Change: 2.11         Fold Change: 3.54           P-value: 0         P-value: 0         P-value: 0		٠		×	×	×	N1=40, N2=31	×
461         AI401832         P-value: .00164           72.16+/-151.56         72.16+/-151.56           462         AI417267         927.3+/-482.64         X         X         N1=40, N2=31           A62         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41         933.35+/-487.41           A1417267         927.3+/-119.48         X         N1=40, N2=31         P-value: .00745           A1417267         927.3+/-482.64         387.97+/-131.13         238.15+/-85.44           A1417267         927.3+/-482.64         N1=40, N2=6         N1=40, N2=31           Fold Change: 3.36         Fold Change: 2.11         Fold Change: 3.54           P-value: 0         P-value: 0         P-value: 0							Fold Change: 2.18	
461         AI401832         X         X         72.16+/-151.56           408.66+/-668.16         X         X         N1=40, N2=31           Fold Change: 2.63         P-value: .00745           462         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41           462         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41           462         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41           AI417267         927.3+/-482.64         387.97+/-131.13         228.15+/-85.44           N1=40, N2=168         X         N1=40, N2=31           Fold Change: 3.36         Fold Change: 2.11         Fold Change: 3.54           P-value: 0         P-value: 0         P-value: 0							P-value: .00164	
462 AI417267 927.3+/482.64 P-value: 0  A63 AI417267 927.3+/482.64  A64 AI417267 927.3+/482.64  A65 AI417267 927.3+/482.64  A65 AI417267 927.3+/482.64  A66 AI417267 927.3+/482.64  B-value: .00745	0	461	AI401832				72.16+/-151.56	
AM 17267         927.3+/482.64         P-value: .00745           462         AI417267         927.3+/482.64         933.35+/487.41         933.35+/487.							408.66+/-668.16	
462         AI417267         927.3+/-482.64         P-value: .00745           462         AI417267         927.3+/-482.64         P-value: .00745           AI217267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41           AI317267         933.35+/-487.41         933.35+/-487.41         933.35+/-487.41           AI317267         933.35+/-487.41         933.35+/-487.41         933.35+/-487.41           AI317267         AI317.13         238.15+/-85.44         AI317.13         238.15+/-85.44           AI317267         AI317.13         AI317.13         AI317.13         AI317.13         AI317.14         AI317.13         AI317.14         AI317.14 <th< td=""><th></th><th></th><td></td><td>×</td><td>×</td><td>×</td><td>N1=40, N2=31</td><td>×</td></th<>				×	×	×	N1=40, N2=31	×
462         AI417267         927.3+/-482.64         933.35+/-487.41         P-value: .00745           462         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41           259.61+/-119.48         X         387.97+/-131.13         238.15+/-85.44           N1=40, N2=168         X         N1=40, N2=31           Fold Change: 3.36         Fold Change: 2.11         Fold Change: 3.54           P-value: 0         P-value: 0         P-value: 0							Fold Change: 2.63	
462         AI417267         927.3+/-482.64         933.35+/-487.41         933.35+/-487.41           259.61+/-119.48         X         387.97+/-131.13         238.15+/-85.44           N1=40, N2=168         X         N1=40, N2=6         N1=40, N2=31           Fold Change: 3.36         Fold Change: 2.11         Fold Change: 3.54           P-value: 0         P-value: 0         P-value: 0				i			P-value: .00745	
387.97+/-131.13 238.15+/-85.44  X N1=40, N2=6 N1=40, N2=31 Fold Change: 2.11 Fold Change: 3.54 P-value: .0003 P-value: 0		462	AI417267	927.3+/-482.64		933.35+/-487.41	933.35+/-487.41	933.35+/-487.41
X N1=40, N2=6 N1=40, N2=31 Fold Change: 2.11 Fold Change: 3.54 P-value: .0003 P-value: 0				259.61+/-119.48		387.97+/-131.13	238.15+/-85.44	240.55+/-123.45
Fold Change: 2.11 Fold Change: 3.54 P-value: .0003 P-value: 0				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
P-value: .0003 P-value: 0				Fold Change: 3.36		Fold Change: 2.11	Fold Change: 3.54	Fold Change: 3.74
				P-value: 0		P-value: .0003	P-value: 0	P-value: .00001

Phichocal - Way account to t

# Seg ID Genbank Normal vs Malignini Normal vs Stage 1 Normal vs Stage 2 Normal vs Stage 1 Normal vs Stage 2 Normal vs S								70
463   A141917   264.394-315.14   267.474-218.65     10	*	Sed ID	Genbank		Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal Vs Stage III
According to the first content of the first conte	5	463	AT417917	564 39+/-315 14			567.47+/-318.65	567.47+/-318.65
Mil-40, N2-168	7	e e e e e e e e e e e e e e e e e e e	17/174	271 174/167 23			218 33+/-110.93	115.26+/-82.27
According to the control of the co				07:-CIV 07-IIV	>	>	N1=40 N2=31	N1=40 N2=10
Fold Change: 2.25   Fold Change: 2.01				INI-40, INZ-108	<	<	16 211 04-111	To 14 Change 6 16
According to P-value: 0   P-value: 0				Fold Change: 2.25			Fold Change: 2.01	Fold Change: 5.10
A1418481				P-value: 0			P-value: 0	P-value: .00005
466 AI418596  X  X  X  X  X  X  X  X  X  X  X  X  X	33	465	AI418481				77.52+/-60.1	
466 AI418596  X  X  X  X  X  X  X  X  X  X  X  X  X	}	}					257.35+/-253.01	
Fold Change: 2.83				×	×	×	N1=40, N2=31	×
466 A1418596  X  X  X  X  X  X  X  X  X  X  X  A1419030 446.124/-255.78  467 A1419030 446.124/-255.78  A18.414-132.36  A18.414-132.36  A18.414-132.36  A18.414-132.36  A18.414-145.9  A18.418.7  A18.418.7  A18.418.7  A18.418.7  A18.418.7  A18.418.7  A18.418.6  A143.17.9  A143.17.9  A143.18.8  A143.18.9  A143.18.9  A144.43.33.14  A171 A143.58.28  A A143.18.9  A A143.18.				<b>!</b>			Fold Change: 2.83	
466         AI418596         X							P-value: 0	
A   A   A   A   A   A   A   A   A   A	34	466	AI418596					229.67+/-120.12
Alignost	ţ		O CONTANT					43.69+/-43.08
467         AI419030         446.12+/-255.78         445.97+/-259.12           467         AI419030         446.12+/-255.78         X         NI=40, N2=31           NI=40, N2=168         X         X         NI=40, N2=31           Fold Change: 3.03         P-value: 0         P-value: 0           468         AI421837         294.74-145.9         P-value: 0           11.04+/-64.19         X         NI=40, N2=31           NI=40, N2=168         X         NI=40, N2=31           Rold Change: 2.62         X         NI=40, N2=31           P-value: 0         463.05+/-382.43         P-value: 0           AI31799         X         X         NI=40, N2=51           P-value: .00993         S87.69+/414.14           A71         AI435828         X         X         X         X         NI=40, N2=31           A71         AI435828         X         X         X         X         X         X         NI=40, N2=31           A71         AI435828         X         X         X         X         X         X         X         X         X         X         X         X         X         X         X         X         X         X         X				×	×	×	×	N1=39, N2=6
467         A1419030         446.12+/-255.78         445.97+/-259.12           467         A1419030         446.12+/-255.78         X         N1=40, N2=31           8         A1421837         294.7+/-145.9         P-value: 0         P-value: 0           468         A1421837         294.7+/-145.9         102.42+/-57.12           111.04+/-64.19         X         X         N1=40, N2=31           Fold Change: 2.62         P-value: 0         P-value: 0           P-value: 0         463.05+/-382.43         Fold Change: 2.8           P-value: 0         463.05+/-382.43         Fold Change: 2.8           P-value: 0         463.05+/-382.43         S87.69+/-414.14           A1435828         X         Fold Change: 2           P-value: .00993         587.69+/-414.14           A1435828         X         Fold Change: 2           P-value: .00993         587.69+/-414.14           P-value: .00993         587.69+/-414.14           P-value: .00061         P-value: .00061								Fold Change: 3.79
467         A1419030         446.12+/-255.78         445.97+/-259.12           158.41+/-132.36         138.41+/-123.4         133.67+/-123.4           NI=40, N2=168         X         NI=40, N2=31           Fold Change: 3.03         P-value: 0         P-value: 0           P-value: 0         P-value: 0         P-value: 0           NI=40, N2=168         X         NI=40, N2=31           NI=40, N2=168         X         NI=40, N2=31           P-value: 0         P-value: 0         P-value: 0           P-value: 0         463.054/-382.43         Fold Change: 2.8           P-value: 0         463.054/-382.43         Fold Change: 2.8           P-value: 0         463.054/-382.43         Fold Change: 2.8           P-value: 0         A43.054/-382.43         Fold Change: 2.8           P-value: 0         P-value: 0.00993         587.694/-414.14           A71         A435828         X         X           Rold Change: 2.52         P-value: 0.00993         587.694/-414.14           P-value: 0.00993         P-value: 0.00993         P-value: 0.00693           P-value: 0.00993         P-value: 0.00693         P-value: 0.00693								P-value: 0
158.41+-132.36 N1=40, N2=168 N1=40, N2=168 N1=40, N2=31 Fold Change: 3.65 P-value: 0 P-value: 0 A1421837 111.04+-64.19 N1=40, N2=31 P-value: 0 A22.7+-145.9 N1=40, N2=31 P-value: 0 P-value: 0 A63.05+1-382.43 A1431799 X X X X X X X X X X X X X X X X X X	35	194	AT419030	446 12+/-255 78			445,97+/-259.12	445.97+/-259.12
Ni	3	è	20071	158 41+/-132 36			133.67+/-123.4	81,99+/-31.49
Fold Change: 3.03  Fold Change: 3.65  P-value: 0  P-value: 0  P-value: 0  P-value: 0  111.04+/-64.19  N1=40, N2=168  N1=40, N2=168  P-value: 0  A63.05+/-382.43  Fold Change: 2.8  P-value: 0  A63.05+/-382.43  A1431799  A1431799  A1435828  X  X  X  X  X  X  X  X  X  X  X  X  X				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
468 AI421837 294.74-145.9  AI421837 294.74-145.9  N1=40, N2=168  N1=40, N2=168  P-value: 0  P-value: 0  P-value: 0  AI431799  AI431799  AI431799  AI431799  AI435828  AI431794  AI435828  AI441.44  AI435828  AI441.44  AI435828  AI441.44  AI435828  AI441.44  AI435828  AI441.433.14  AI435828  AI441.44  AI435828  AI441.44  AI45828  AI441.433.14  AI435828  AI441.433.14  AI435828  AI441.433.14  AI435828  AI441.433.14  AI435828  AI441.433.14  AI435828  AI441.433.14  AI435828  AI441.433.14  AI456.16  AI460.16				Fold Change: 3.03			Fold Change: 3.56	Fold Change: 4.69
468         AI421837         294.7+.145.9         293.96+.147.73           111.04+/-64.19         X         N1=40, N2=31           N1=40, N2=168         X         N1=40, N2=31           Fold Change: 2.62         P-value: 0           P-value: 0         463.05+/-382.43           AI431799         K         X           X         X         X           Fold Change: 2.8         X           Fold Change: 2.8         X           Fold Change: 2.8         X           Fold Change: 2.8         X           Fold Change: 2.9         P-value: 00993           471         AI435828         S87.69+/-414.14           X         X         N1=40, N2=31           P-value: 00993         S87.69+/-414.14           X         X         N1=40, N2=31           P-value: 00993         Fold Change: 2.52           P-value: 00093         P-value: 00093				P-value: 0			P-value: 0	P-value: 0
111.04+/-64.19  N1=40, N2=168  N1=40, N2=31  Fold Change: 2.62  P-value: 0  469  A1431799  X  X  X  X  X  X  X  X  X  X  X  X	36	468	AI421837	294.7+/-145.9			293.96+/-147.73	293.96+/-147.73
N1=40, N2=168	<b>)</b>	}		111.04+/-64.19			102.42+/-57.12	109.78+/-55.53
Fold Change: 2.62  P-value: 0  A463.05+/-382.43  A1431799  X  X  X  X  X  X  X  X  X  X  X  X				N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
469 AI431799 F-value: 0  A463.05+/-382.43 658.8+/-240.03  X  X  X  X  X  X  X  X  X  X  X  X  X				Fold Change: 2.62			Fold Change: 2.8	Fold Change: 2.62
469         AI431799         463.05+/-382.43           588.8+/-240.03         588.8+/-240.03           588.8+/-240.03         X         X           Fold Change: 2         P-value: .00993         587.69+/-414.14           471         AI435828         587.69+/-414.14           X         X         XII=40, N2=31           P-value: .00061         P-value: .00061				P-value: 0			P-value: 0	P-value: .00100
A 71 AI435828 X	37	469	AI431799			463.05+/-382.43		
A 71 AI435828 X				i	;	658.8+/-240.03	à P	÷
Fold Change: 2 P-value: .00993 587.69+/-414.14 X X X X N1=40, N2=31 X X Pold Change: 2 P-value: .00993 587.69+/-414.14 Z99.14+/-333.14 X Pold Change: 2.52 P-value: .00061				×	×	N1=40, N2=6	×	*
H-value: .00993  S87.69+/-414.14  A1435828  S87.69+/-414.14  299.14+/-333.14  X  X  X  X  X  Fold Change: 2.52  P-value: .00061						Fold Change: 2		
471 AI435828 587.69+/-414.14 299.14+/-333.14 X X N1=40, N2=31 Fold Change: 2.52 P-value: .00061		•				P-value: .00993		
X X N1=40, N2=31 Y Fold Change: 2.52 P-value: .00061	88	471	AJ435828				587.69+/-414.14	587.69+/-414.14
. Fold Change: 2.52 P-value: .00061				ž	÷	Þ	299.14+/-335.14 N11-40 ND-21	119.3/4/-42.01 N11-40 N2-10
				<	≺	∢ .	Fold Change: 2 52	Fold Change: 3.0
							D_volue: 00061	P-value: 00001

BNSDOCID: <WO 02059271A2 1 >

Seq ID Genbank Normal vs All	Normal	Normal vs.	Ali	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
475 AI446030 383.04+/-264.2	383.04+/	383.04+/-264.2				383.04+/-264.2	
935.53+/-916.21	935.53+/-916.21	935.53+/-916.21				987.66+/-795.06	
N1=40, N2=168 X			×		×	N1=40, N2=31	×
Fold Change: 2.29 P-value: 0	Fold Change: 2.29 P-value: 0	Fold Change: 2.29 P-value: 0				Fold Change: 2.53 P-value: 0	
476 AI446168 216.67+/-584.58		216.67+/-584.58				220.39+/-591.75	220.39+/-591.75
561.08+/-695.63	561.08+/-695.63	561.08+/-695.63				606.41+/-908.81	603.11+/-527.41
N1=40, N2=168 X			×		×	N1=40, N2=31	N1=40, N2=10
Fold Change: 3.28	Fold Change: 3.28	Fold Change: 3.28				Fold Change: 3.51	Fold Change: 3.91
		P-value: 0				P-value: 0	P-value: .00476
477 AI458003 276.51+/-201.47		276.51+/-201.47			280.16+/-202.76	280.16+/-202.76	280.16+/-202.76
38.41+/-97.2	38.41+/-97.2	38.41+/-97.2			81.96+/-89.4	43.42+/-152.26	4.43+/-42.79
N1=40, N2=168 X			×		N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
Fold Change: 5.07	Fold Change: 5.07	Fold Change: 5.07			Fold Change: 3.22	Fold Change: 4.35	Fold Change: 7.36
P-value: 0	P-value: 0	P-value: 0			P-value: .03405	P-value: 0	P-value: 0
482 AI468491	AI468491						256.57+/-264.41
			;		;	;	84.09+/-113.95
×			×		×	×	N1=40, N2=10
							Fold Change: 2.68 P-value: .00796
487 AI480215 122.23+/-104.86		122.23+/-104.86				125.66+/-103.93	
295.22+/-297.68	295.22+/-297.68	295.22+/-297.68			-	321.02+/-262.5	
N1=40, N2=168 X			×		×	N1=40, N2=31	×
Fold Change: 2.15	Fold Change: 2.15	Fold Change: 2.15				Fold Change: 2.49	
P-value: .00005	P-value: .00005	P-value: .00005		. !		P-value: .0002	
489 AI492051 384.45+/-175.99		384.45+/-175.99				382,34+/-177.78	382.34+/-177.78
157.89+/-176.84	157.89+/-176.84	157.89+/-176.84				91.96+/-44.92	154.08+/-202.28
N1=40, N2=168 X			×		×	N1=40, N2=31	N1=40, N2=10
Fold Change: 3.12	Fold Change: 3.12	Fold Change: 3.12				Fold Change: 4.08	Fold Change: 3.91
P-value: 0	P-value: 0	P-value: 0				P-value: 0	P-value: .0032
490 AI492091	AI492091						146.39+/-59.05
							321.61+/-116.38
X			×		×	×	N1=40, N2=10
							Fold Change: 2.22
							T-value00000

בו במוכרותיות אות המתבססדומס ו

#	Sea ID	Genhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
				E	0.000	01017/1010	010 40 / 750 10
246	493	AI492879	214.23+/-650.46		219.42+/-658.12	219.42+/-658.12	219.42+/-058.12
			465.24+/-396.65		277.88+/-265.92	663.74+/-488.43	771.71+/-307.65
			N1=40. N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.22		Fold Change: 3.72	Fold Change: 9.89	Fold Change: 14.12
			P-value: 0		P-value: .01903	P-value: 0	P-value: 0
247	494	AI498375	244.41+/-203.11		244.41+/-203.11	244.41+/-203.11	244.41+/-203.11
;   			46+/-55.84		47.6+/-45.95	43.16+/-57.68	48.55+/-41.9
			N1=39. N2=168	×	N1=39, N2=10	N1=39, N2=31	NI=39, N2=6
			Fold Change: 3.62		Fold Change: 3.32	Fold Change: 3.62	Fold Change: 3.45
			P-value: 0		P-value: .00134	P-value: 0	P-value: .00002
248	498	AI499334	236.34+/-181.29		236.34+/-181.29		236.34+/-181.29
}	· •		117.03+/-221.42		83.26+/-88.81		16.68+/-51.22
			N1=39, N2=168	×	N1=39, N2=10	×	N1=39, N2=6
			Fold Change: 2.28		Fold Change: 2.68		Fold Change: 4.22
			P-value: 0		P-value: .0244		P-value: 0
249	200	A1524085	380.84+/-525.16		388.89+/-529.52	388.89+/-529.52	388.89+/-529.52
			54.03+/-109.2		35.06+/-63.65	36.84+/-79.16	8.33+/-48.11
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.48		Fold Change: 4.76	Fold Change: 5.39	Fold Change: 7
			P-value: 0		P-value: .00065	P-value: 0	P-value: 0
250	501	AI525044	319.4+/-142.13			316.89+/-143.08	316.89+/-143.08
			131.06+/-178.35			121.55+/-76.85	65.73+/-20.84
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.93			Fold Change: 2.83	Fold Change: 4.61
			P-value: 0			P-value: 0	P-value: 0
251	502	AI525601			-		223.25+/-101.98
							605.18+/-406.21
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.43
							P-value: .00221
252	504	AI535997	526.38+/-278.8			527.18+/-282.39	527.18+/-282.39
			203.43+/-127.91			182.64+/-99.43	177.05+/-109.73
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.55			Fold Change: 2.76	Fold Change: 2.81
			F-value: 0			r-vaiue: 0	F-value: .00005

Č	Genhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
AI539386	9	1911.09+/-2400.57			1924.9+/-2430.34 4667.18+/-4736.01	
		N1=40, N2=168	×	×	N1=40, N2=31	×
		Fold Change: 2.2 P-value: 00002			Fold Change: 2.62 P-value: .00005	
AI539443	3	105.57+/-75.36			105.57+/-75.36	
		244.51+/-212.14			235.02+/-188.35	
		N1=39, N2=168	×	×	N1=39, N2=31	×
		Fold Change: 2.05			Fold Change: 2.11 P-value: .00011	
A1546943	43	o contract				310.79+/-204.98
	<u>:</u>					120.98+/-130.81
		×	×	×	×	N1=40, N2=10
						Fold Change: 3.17 P-value: .01143
AI553918	18	831.82+/-279.85			821.96+/-276.38	821.96+/-276.38
		384.25+/-176.84			364.75+/-169.81	378.99+/-216.53
		N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 2.22			Fold Change: 2.31	Fold Change: 2.43
		P-value: 0			P-value: 0	P-value: .00313
AI554514	14			90.74+/-52.8		
				232.59+/-162.79		
		×	×	N1=40, N2=6	×	×
				Fold Change: 2.54		
				P-value: .00/34		
AI557210	210	126.32+/-140.31			129.15+/-140.98	129.15+/-140.98
		534.58+/-397.4			364.46+/-223.6	306.19+/-192.07
		N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
		Fold Change: 4.98			Fold Change: 3.55	Fold Change: 2.84
		P-value: 0			P-value: 0	P-value: .00915
A1560064	164				885.2+/-306.13	885.2+/-306.13
					473.3+/-341.89	284.56+/-117.13
		×	×	×	N1=40, N2=31	N1=40, N2=10
				•	Fold Change: 2.17	Fold Change: 3.2
					P-value: 0	P-value: .00002

#	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III.
.   5	213	A TECO 1 E0				249.15+/-159.54	249.15+/-159.54
207	010	CTOOCTY				475.18+/-183.53	849.92+/-667.24
			*	×	×	N1=40, N2=31	N1=40, N2=10
			<b>{</b>	£	ŀ	Fold Change: 2.08	Fold Change: 3.13
						P-value: 0	P-value: .00061
261	517	A1566038	257.62+/-109.32			436.1+/-150.59	
1			154 67+/-104 12			302.74+/-153.34	
			N1=39 N2=168	×	×	N1=39, N2=31	×
			Fold Change: 1.94			Fold Change: 1.57	
			P-value: 0			P-value: .00104	
263	523	A1583942	231.62+/-1223.34			237.55+/-1238.75	
3	2		574.26+/-2305.76		•	1788.59+/-4779.29	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.18			Fold Change: 4.69	
			P-value: 00076			P-value: .00099	
262	204	A1587178					222.78+/-143.35
3							88.43+/-75.43
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.64
							P-value: .00579
264	576	A1589858	296 87+/-162 49			296.87+/-162.49	296.87+/-162.49
5			138.95+/-123			143.85+/-108.99	121.61+/-47.86
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.17			Fold Change: 2.1	Fold Change: 2.31
			P-value: 0			P-value: .00002	P-value: .00132
265	527	AI590093	316.95+/-171.55			314.33+/-172.98	314.33+/-172.98
			167.02+/-141.99			149.67+/-84.85	121.07+/-88.54
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.1			Fold Change: 2.08	Fold Change: 2.91
			P-value: 0		-	P-value: .00003	P-value: .00504
266	529	AI598252				417.54+/-196.25	
						833.81+/-317.16	1
			×	×	×	N1=39, N2=31	×
						Fold Change: 2.06	
						F-value: 0	

Genbank	L	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
	``	270.5+/-122.37			267.15+/-122.1	267.15+/-122.1
	Ι.	115.84+/-107.17			101.95+/-53.86	55.7+/-20.35
Z	Z	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
Fo	Fo	Fold Change: 2.62			Fold Change: 2.69	Fold Change: 4.57
		P-value: 0			P-value: 0	P-value: 0
AI610837 207	207	2072.69+/-1692.17			2072.69+/-1692.17	2072.69+/-1692.17
72	72	724.59+/-659.17	٠		544+/-358.27	319.79+/-159.71
Z	Z	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
Fold	Folc	Fold Change: 2.65	•		Fold Change: 3.17	Fold Change: 4.66
		P-value: 0			P-value: 0	P-value: 0
AI620381						610.77+/-316.3
		>	>	>	*	1217.36+/-274.04 N1=40 N2=10
		<b>¢</b>	4	<u>.</u>	!	Fold Change: 2.16
						P-value: 0
AI624103 289.	289	289.59+/-159.89		289.59+/-159.89	289.59+/-159.89	289.59+/-159.89
	123.	123.14+/-143.73		116.4+/-81.91	82.42+/-59.19	71.19+/-34.34
II.	Z	N1=39, N2=168	×	N1=39, N2=10	NI=39, N2=31	N1=39, N2=6
Fold (	Fold (	Fold Change: 2.74		Fold Change: 2.65	Fold Change: 3.4	Fold Change: 3.74
Å	<u>α</u>	P-value: 0		P-value: .03426	P-value: 0	P-value: 0
AI631301 328.	328.	328.42+/-165.41			328,42+/-165.41	328.42+/-165.41
	126	126.68+/-74.53		-	111+/-70.99	58.7+/-32.01
"K	=EX	N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
Fold	Fold	Fold Change: 2.52			Fold Change: 2.8	Fold Change: 5.02
	д	P-value: 0			P-value: 0	P-value: 0
AI631850				=	26.13+/-35.18	
					224.44+/-595.61	
		×	×	×	N1=40, N2=31	×
					Fold Change: 2.14	
					P-value: .00784	
AI634852					278.07+/-162.92	
			ļ	;	171.54+/-216.03	,
		×	×	×	NI=40, NZ=31	×
					Fold Change: 2.18	

7	Con Th	Conhonk	Normal ve All	Normal ve Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
*	or bac	Gendaun	TOTAL STATE	TOT THE 13 TARKED		210 27 1 00 64	712 221/ 02 64
274	541	AI635774	212.33+/-93.64			212.33+/-93.64	212.33+/-93.04
			92.03+/-51.47			93.14+/-61.28	89.05+/-56.69
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.39			Fold Change: 2.5	Fold Change: 2.62
			P-value: 0			P-value: 0	P-value: .00169
275	546	AI650514	108.33+/-162.01		110.57+/-163.5	110.57+/-163.5	110.57+/-163.5
1	)		321.96+/-278.48		306.38+/-174.2	495.16+/-349.41	380.44+/-266.81
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.14		Fold Change: 3.3	Fold Change: 5.31	Fold Change: 3.44
			P-value: 0		P-value: .02515	P-value: 0	P-value: .01035
276	550	AI651732					200.01+/-105.06
2	3					•	67.38+/-39.88
			×	×	×	×	N1=40, N2=10
			•	1			Fold Change: 3.01
							P-value: .00028
77.2	551	A1652058					182.73+/-51.39
:	100						384.98+/-89.44
			×	×	×	×	N1=40, N2=10
			1				Fold Change: 2.14
							P-value: 0
27.8	552	A1652459					724.8+/-344.86
2							274.16+/-175.44
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.8
							P-value: .00159
279	554	AI653487	251.37+/-223.37		251.37+/-223.37	251.37+/-223.37	251.37+/-223.37
:			44.78+/-81.85		41.71+/-73.61	30.69+/-76.04	4.44+/-69.04
			N1=39, $N2=168$	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.04		Fold Change: 3.36	Fold Change: 3.36	Fold Change: 4.16
			P-value: 0		P-value: .00441	P-value: 0	P-value: .00002
280	555	AI654035	227.06+/-388.81			227.06+/-388.81	
			65.4+/-275.63	;	;	56.3+/-242.23	;
			N1=40, N2=168	×	×	N1=40, N2=31	*
			Fold Change: 2.9			Fold Change: 3.21	
			F-vaine: .00003			r-value: .0001	

		Control	Mountain All	Mountain Markens	Mountail sto Chara I	Moumol we Change II	Mountain Charlette
I	354 40	Gennalik	IVOI IIIIAI VS PAII	IVOLUTAL VS IVLAHIGHAILI	Moi mai va Stage I	It of itial to Diage II	Normal vs Stage III
281	556	AI655499	46.97+/-125.7			47.75+/-127.24	
			313.1+/-881.21			453.25+/-957.09	
			N1=40. N2=168	×	×	N1=40. N2=31	×
			Fold Change: 2.28	!		Fold Change: 2.89	1
			P-value: 0			P-value: .00225	
282	560	AI656836					496.58+/-144.86
							242.93+/-91.56
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.07
							P-value: .00005
283	295	AI658925	545.69+/-343.76			542.56+/-347.67	542.56+/-347.67
			259.08+/-213.04			233.63+/-187.46	164.54+/-115.15
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.3			Fold Change: 2.42	Fold Change: 3.62
			P-value: 0			P-value: .00001	P-value: .00181
284	563	AI658928	230.91+/-89.43			230.91+/-89.43	230.91+/-89.43
			89.62+/-64.08			75.71+/-63.86	130.21+/-102.4
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.76			Fold Change: 3.17	Fold Change: 2.16
			P-value: 0			P-value: 0	P-value: .02073
285	565	AI659418					261.02+/-116.11
							125.48+/-61.12
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.05
							P-value: .00057
286	999	AI659533	566.04+/-199.44			563.4+/-201.34	563.4+/-201.34
			260.59+/-219.32			289.88+/-264.96	161.05+/-65.87
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.68			Fold Change: 2.58	Fold Change: 3.49
			P-value: 0			P-value: 0	P-value: 0
287	268	AI659927				-	427.88+/-182.76
							161.17+/-86.36
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.71
							F-value: .00004

BNSDOCID- ZWO MONEGOTTAD I S

119064-130.86		m son	Conhank	Mormol ve All	Normal ve Malianant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
Second	±	or bac		IVOI III AI AII	TOT III AT INTAILE HAIL	Toffillal 13 Stage T	Tolling South	20000
ST7.49+246.97	×	695		119.06+/-130.86				119.06+/-130.86
Fold Change: 2.1	2			277.49+/-246.97				357.85+/-302.39
Fold Change: 2.1  Fold Change: 2.82  Fold Change: 2.17  Fold Change: 2.17  Fold Change: 2.17  Fold Change: 2.17  Fold Change: 2.34  F				N1=39 N2=168	×	×	×	N1=39, N2=6
F-yalue: 0				11 20 11 20 11 12 12 12 12 12 12 12 12 12 12 12 12	•	1		Fold Change: 2 63
571   Al668620				Fold Change: 2.1 Payalue: 0				P-value: .01212
574 AI671836  574 AI671836  575 AI671894  576 AI673539  580 AI673735  583 AI674603  581 Red Change: 2.82  578 AI674603  579 AI674603  570 AI674603  570 AI6769.79  570 AI673735  570 AI673735  570 AI674603  570 AI6746003  570 AI674603  570 AI6746003  570 AI6746	6	571	AT668620				1443.34+/-1731.78	
ST4   Al671836	7	7/6	PAUDOUAL				1028 64+/-1660 70	
574 Al671836  574 Al671836  575 Al671984  579 Al673539  580 Al673735  583 Al674603  570 X X X X X X X X X X X X X X X X X X X				ļ	;	;	7.5001-/1-t0:501	*
Fold Change: 282				×	×	×	N1=40, N2=31	×
S74   Al671836   P-value: .01542							Fold Change: 2.82	
574         Al671836         X							P-value: .01542	
575 AI671984  X X X X X X X X X X X X X X X X X X X	18	574	AI671836					112+/-77.42
575 Al671984  X X X X X X X X X X X X X X X X X X X	>	;						229.83+/-111.91
575         AI671984         X				<b>&gt;</b>	>	×	*	N1=40, N2=10
575         Al671984         X				<b>ŧ</b>	4	1	i	Fold Change: 2.3
Name								P-value: 00034
Name	=	242	AT67100A					172 75+/-104.93
X	7	6/6	WI0/1704					376 064/-163 08
X X X X X X X X X X X X X X X X X X X						;	,	320.001-/-02.02
579         Al673539         X         X         XI-468.95 (443.27+/-468.95 (443.27+/-468.95 (443.27+/-468.95 (443.27+/-468.95 (443.27+/-468.95 (443.27+/-468.95 (443.27+/-468.95 (443.27+/-139.31 (444.139.36 (443.27+/-139.36 (443.27+/139.36 (443.27+/				×	×	×	×	NI=40, NZ=10
579         A1673539         X         X         X185.25         643.27+/-185.25         643.27+/-468.95         X         N1=40, N2=31         Fold Change: 2.17         P-value: .00012         P-value: .00012         P-value: .00012         P-value: .0001         281.86+/-139.36         128.43+/-98.38         X         NI=40, N2=31         Fold Change: 2.34         P-value: .00001         P-value: .00001         P-value: .00001         P-value: .00001         P-value: .0								Fold Change: 2.1
579 AI673539  X  X  S80 AI673735  X  X  X  X  X  X  X  X  X  X  X  X  X								P-value: .00523
580 AI673735  X  X  X  X  X  X  X  X  X  X  X  X  X	2	579	AI673539				285.7+/-185.25	=
580 AI673735 X X X X X X X X X X X X X X X X X X X	1	: :					643.27+/-468.95	
580 AI673735 X X X X X X X X X X X X X X X X X X X				>	*	<b>&gt;</b>	N1=40 N2=31	×
580 AI673735  X  X  X  X  X  S83 AI674603  X  X  X  X  X  X				<	<b>:</b>	<b>;</b>	Fold Change: 2.17	1
580 AI673735  X  X  X  X  583 AI674603  X  X  X					•		P-value: .00012	
583 AI674603 X X X X X X	18	580	AI673735				281.86+/-139.36	
583 AI674603 X X X	)	· ·					128,43+/-98.38	
583 AI674603 X X				×	×	×	N1=40, N2=31	×
583 AI674603 X X							Fold Change: 2.34	
583 AI674603 X X							P-value: .00001	
x x x	2	583	AI674603				278.54+/-168.6	
×							119.84+/-49.46	
Fold Change: 2.13 P-value: 0				×	×	×	N1=40, N2=31	×
P-value: 0							Fold Change: 2.13	
							P-value: 0	

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
295	584	AI675106	353.92+/-130.58 188.82+/-101.49 N1=39, N2=168 Fold Change: 2.02 P-value: 0	×	×	×	×
296	288	AI680541	516.15+/-202.37 138.66+/-107.52 N1=40, N2=168 Fold Change: 4.19 P-value: 0	×	×	510.08+/-201.29 149.24+/-129.55 N1=40, N2=31 Fold Change: 3.77 P-value: 0	510.08+/-201.29 101.96+/-86.37 N1=40, N2=10 Fold Change: 5.63 P-value: .00001
297	590	AI683036	106.33+/-110.74 328.16+/-267.3 N1=39, N2=168 Fold Change: 2.81 P-value: 0	×	×	106.33+/-110.74 296.92+/-224.37 N1=39, N2=31 Fold Change: 2.63 P-value: 0	×
298	591	AI683911	241.46+/-200.89 35.47+/-57.1 N1=40, N2=168 Fold Change: 4.64 P-value: 0	×	x	241.46+/-200.89 28.41+/-33.49 N1=40, N2=31 Fold Change: 5.05 P-value: 0	241.46+/-200.89 29.45+/-35.37 N1=40, N2=10 Fold Change: 5.29 P-value: 0
299		AI684457	96.99+/-74.31 233.36+/-405.3 N1=40, N2=168 Fold Change: 2 P-value: .00001	X	X	×	×
300	593	AI686114	375.54+/-271.13 158.93+/-158.15 N1=40, N2=168 Fold Change: 2.67 P-value: 0	×	×	374.48+/-274.59 155.96+/-124.29 N1=40, N2=31 Fold Change: 2.4 P-value: .00006	×
301	594	AI686316	255.25+/-97.58 102.19+/-93.67 N1=39, N2=168 Fold Change: 2.55 P-value: 0	×	255.25+/-97.58 120.04+/-93.28 N1=39, N2=10 Fold Change: 2.52 P-value: .0397	255.25+/-97.58 79.78+/-67.6 N1=39, N2=31 Fold Change: 2.99 P-value: 0	255.25+/-97.58 51.42+/-78.59 N1=39, N2=6 Fold Change: 3.34 P-value: .00001

#	Sea TD	Genhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
-		The same of the sa	Tion min to	The state of the s		Guerra de mara de la companya de la	0
302	595	AI689747	229.57+/-81.34			229.57+/-81.34	229.57+/-81.34
			113,53+/-98.71			120.42+/-76.86	74.4+/-34.38
			N1=39 N2=168	>	<b>&gt;</b>	N1=39 N2=31	N1=39 N2=6
			7110	4	4	1000	
			Fold Change: 2.2			Fold Change: 2.0/	Fold Change: 2.9
			F-value: 0			r-value: 0	r-vaiue: 0
303	597	AI691077	201.9+/-110.51				
			84.62+/-106.12				
			N1=40, N2=168	×	×	×	×
			Fold Change: 2 35				
			P-value: 0				
304	599	AI692687					215.65+/-82.22
							106.33+/-67.45
			×	×	×	×	N1=39, N2=6
							Fold Change: 2.27
							P-value: .00376
305	603	AI693690					187.55+/-153.71
							419.84+/-166.89
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.84
			•	=			P-value: .00002
306	604	AI694059	256.63+/-189.71			256.63+/-189.71	256.63+/-189.71
			63.49+/-68.69			45.9+/-74.24	24.83+/-23.88
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.4			Fold Change: 3.8	Fold Change: 5.35
			P-value: 0			P-value: 0	P-value: 0
307	909	AI695684					284.08+/-85.43
							138.19+/-31.83
			×	×	×	×	N1=40, N2=10
					-		Fold Change: 2.01
							P-value: 0
308	809	AI698134	801.15+/-394.52		803.86+/-399.3	803.86+/-399.3	803.86+/-399.3
			295.3+/-157.04		305.4+/-156.08	238.5+/-98.66	290.26+/-225.95
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.66		Fold Change: 2.52	Fold Change: 3.16	Fold Change: 3.23
			P-value: 0		P-value: .00483	P-value: 0	P-value: .00182

#	Sec 10	Conbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1000		AT700484	404 40+/-304 86		404,49+/-304.86	404,49+/-304.86	404.49+/-304.86
coc	010	AL./00464	140.08±7.02.82		151 52+/-60 91	139.3+/-55.78	132.26+/-50.46
			149.96-1-93.62	>	N1=40 N2=6	N1=40, N2=31	N1=40, N2=10
			NI=40, N2=100	<	E-14 Change: 2 40	Fold Change: 2 66	Fold Change: 275
			Fold Change: 2.59		Fold Change, 2.45 D-yahie: 00796	P-value: 0	P-value: 0
			F-value: 0		I -value. :00/20	1 - Variac: O	20000000
310	612	AI701034					215./8+/-96.65
							101.91+/-38.36
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.03
							P-value: .00018
311	613	AT702441				166.32+/-110.39	166.32+/-110.39
1170	25	71.00/107				348.27+/-255.22	332.43+/-137.78
			*	*	×	N1=40, N2=31	N1=40, N2=10
			\$	1		Fold Change: 2	Fold Change: 2.31
						P-value: .00052	P-value: .00003
317	614	A1703451				58.72+/-154.11	
316	1	10100110				479.31+/-977.92	
			×	×	×	N1=40, N2=31	×
			1			Fold Change: 3.05	
						P-value: .00313	
212	615	A1707589	446 78+/-668.95			414.9+/-646.18	414.9+/-646.18
CTC	CY O	1001011	359 77+/-1435 2			236.79+/-693.96	-8.82+/-71.63
			N1=6N 02=1N	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.73	1		Fold Change: 2.49	Fold Change: 4.36
			P-value: .00099			P-value: .01893	P-value: .00006
217	617	A1720763					216.2+/-123.53
15							94.49+/-39.1
			*	×	×	×	N1=40, N2=10
			•				Fold Change: 2.05
							P-value: .00026
215	610	AT72277A	026 554/-085 51		947.08+/-989.69	947.08+/-989.69	947.08+/-989.69
210	070	1 1 1 1 1 1 1	133 4+/-273 85		92.83+/-139.88	17.45+/-85.58	25.59+/-138.38
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 7.17	1	Fold Change: 8.37	Fold Change: 13.2	Fold Change: 14.18
			P-value: 0		F-value: .00401	I - value. V	)

BNGDOOD - WO 0205027182 1 5

1	E STO	Control 1	Normal ve All	Normal we Malianant	Normal ve Stoge I	Normal ve Stage II	Normal vs Stage III
*	oed III	Gennalik	IVOI III VS PAII	I O I I I I I I I I I I I I I I I I I I	Contract of the contract of th		202/10/202
316	619	AI733679	319.55+/-589.9		325.9+/-596.22	325.9+/-596.22	77.040-/+6.075
			41.3+/-61.11		26.3+/-20.79	23.3+/-13.87	22.92+/-14.21
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.96		Fold Change: 4.56	Fold Change: 5.05	Fold Change: 5.39
			P-value: 0		P-value: .00001	P-value: 0	P-value: 0
317	621	A1740483					519.7+/-165.79
:	i i						245.74+/-94.64
			×	×	×	×	NI=39, N2=6
			•				Fold Change: 2.11
							P-value: .00011
318	622	AI740516	23.68+/-49.95			24.14+/-50.52	
) (	}		230.26+/-254.07			211.05+/-266.38	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 5.25			Fold Change: 4.63	
			P-value: 0		,	P-value: 0	
319	623	AI740621	231.84+/-247.13			231.84+/-247.13	. 231.84+/-247.13
ì	Ì		51.4+/-63.67			55.89+/-78.15	58.59+/-71.76
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.99			Fold Change: 2.92	Fold Change: 2.89
			P-value: 0			P-value: .00006	P-value: .00645
320	624	AJ741026	324.97+/-140.14			321.67+/-140.4	<del></del>
			152.41+/-75.46			156.42+/-93.26	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.1			Fold Change: 2.06	
			P-value: 0			P-value: 0	
321	627	AI742002	109.12+/-131.8		111.78+/-132.43	111.78+/-132.43	111.78+/-132.43
			356.63+/-240.05		392.25+/-219.22	395.11+/-278.86	430.05+/-236.92
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.82	•	Fold Change: 4.18	Fold Change: 3.97	Fold Change: 4.87
			P-value: 0		P-value: .00524	P-value: 0	P-value: 0
322	628	AI742057	200.43+/-229.58			203.47+/-231.77	203.47+/-231.77
			445.89+/-295.68			460.52+/-275.2	448.38+/-232.46
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.37		-	Fold Change: 2.6	Fold Change: 2.46
			P-value: 0			P-value: 0	P-value: .00303

7	E 25	Conhonly	Normal we All	Normal ve Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
#22	000	A1742230	160 34+/-196 79			159.76+/-199.32	
343	670	CC771 184	321 12+/-260 74			420.92+/-297.86	
			N1=40 N2=168	×	×	N1=40, N2=31	×
			E-14 Change: 2.24	( ;		Fold Change: 3.17	
			Fold Change: 2.24 P-value: 00004			P-value: .00002	
27.4	631	A1742490	608 25+/-253 14			601.57+/-252.84	601.57+/-252.84
1	3		244 8+/-205 92			202.34+/-107.23	135.78+/-110.24
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.99			Fold Change: 3.01	Fold Change: 5.03
			P-value: 0			P-value: 0	P-value: .00005
325	623	10367114	213 11+/-232 57		215.93+/-234.91	215.93+/-234.91	215.93+/-234.91
245	450	PAL ( 46.261	35.67+1-56.27		60.9+/-90.73	35.9+/-49	21.54+/-22.52
-			N1=40 N2=168	*	NI=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3 92	•	Fold Change: 3.31	Fold Change: 3.94	Fold Change: 4.49
			P-value: 0		P-value: .02617	P-value: 0	P-value: 0
326	628	1742671	578 21+1-315 16			582.82+/-317.91	582.82+/-317.91
260	633	1/064/14	275 87+/-183 42			172.55+/-151.01	150.6+/-109.83
			M1=40 N2=168	*	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2 70	<i>i</i>	ļ	Fold Change: 3.82	Fold Change: 3.98
			P-value: 0		i	P-value: 0	P-value: .0009
227	707	A1742715	320 58+/-241 61			312.02+/-238.55	312.02+/-238.55
746	20	CT / CL / TO	00 04+/-151 07			78.92+/-130.98	17.92+/-64.11
			N1=40 N7=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.54	}		Fold Change: 4.04	Fold Change: 6.18
			P-value: 0			P-value: 0	P-value: .00001
328	637	AI743925	665.72+/-305.69				
			344.09+/-309.12			•	) Y
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.33				
			P-value: 0				
329	639	AI745624	×	×	×	210.12+/-81.11 116.93+/-65.22 N1=39, N2=31	×
			ł		•	Fold Change: 1.89 P-value: 0	

697.86+/-254.44 377.83+/-298.25 N1=40, N2=31 Fold Change: 2.36 P-value: .00005 144.67+/-188.73 466.36+/-471.12 N1=40, N2=31 Fold Change: 2.85 P-value: 0 369.82+/-189.17 148.94+/-124.57 N1=40, N2=31 Fold Change: 2.85 P-value: .00001 833.52+/-665.83 164.76+/-581.67 N1=40, N2=31 Fold Change: 2.07 P-value: 0 P-value: 0 691.21+/-512.28 259.02+/-226.94 N1=40, N2=31 Fold Change: 2.37 P-value: 0 691.21+/-512.28 259.02+/-226.94 N1=40, N2=31 Fold Change: 2.3						Moumol we Stone I	Normal ve Stage II	Normal vs Stage III
March   Marc	#	Seq ID	Genbank	Normal vs All	Normal vs Manguant	Ivol iliai vs Stage A	A N N SC 1 1 20 702	607 86+/-254 44
March   Marc	330	640	AI750575	702.71+/-253.03			09/.00+/+C2+/+00/ 09//	71.00.170
Mi=40, N2=168	}			412.71+/-328.09			311.83+1-298.23	77:007-1-17:017
Fold Change: 2.14  Fold Change: 2.15  Fold Change: 3.11  Fold Change: 3.11  Fold Change: 3.11  Fold Change: 3.12  Fold Change: 3.21  Fold Change: 3.21  Fold Change: 3.21  Fold Change: 3.21  Fold Change: 3.22  Fold Change: 3.21  Fold Change: 3.21  Fold Change: 3.22  Fold Change: 3.22  Fold Change: 3.23  Fold Change: 3.24  Fold Change: 3.25  Fold Change: 3.24  Fold Change: 3.25  Fold Change:				N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
Alt				Eold Change: 2 14			Fold Change: 2.36	Fold Change: 3.89
641   Al751438   141.85+187.15   144.67+188.73   144.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+188.73   146.67+189.				P-value. 0			P-value: .00005	P-value: .00699
Mi=40, N2=168	1	150	AT751430	141 85±/_187 15			144.67+/-188.73	144.67+/-188.73
Ni	331	140	AL/31430	65 NCT / + CO 952			466.36+/-471.12	306.05+/-201.86
Fold Change: 4.71   P-value: 0   P-value:				0.50.027/-1720.050 N140 N2=168	*	×	N1=40, N2=31	N1=40, N2=10
642 A752682 375.264-189.87				Fold Change: 4.71	<b>;</b>		Fold Change: 3.51	Fold Change: 2.79
642         AI752682         375.264-189.17         369.824-189.17           643         AI75823         160.224-155.84         X         X         148.94+124.57           643         AI75823         836.074-657.44         833.524-665.83         P-value: 0.0001           644         AI758408         X         X         X         X           645         AI760319         208.694-653.34         102.624-65.34         208.694-65.34         102.624-65.34           646         AI760319         208.694-65.34         X         X         X         X           646         AI760319         208.694-65.34         208.694-65.34         208.694-65.34         208.694-65.34         208.694-65.34           646         AI760319         208.694-65.34         208.694-65.34         208.694-65.34         208.694-65.34           646         AI760370         P-value: 0         P-value: 0         P-value: 0           646         AI760370         X         X         X           7         X         X         X           801-64-1-10-10-10-10-10-10-10-10-10-10-10-10-1			•	Fold Change: 4.7.1			P-value: 0	P-value: .00492
642         A172024         512077-123-87         148.94+/124.57           643         A1758223         Fold Change: 3.01         Fold Change: 3.01         Fold Change: 2.85           643         A1758223         83.674-65.83         833.524-665.83         833.524-665.83           644         A1758408         X         X         X         X         X           5 44         A1758408         X         X         X         X         X         X           645         A1760319         208.694-65.34         208.694-65.34         208.694-65.34         208.694-65.34         208.694-65.34         208.694-65.34           5 646         A1760370         A1760372         A1760370         A1760372         A1760372         A1760372         A1760372 <th></th> <th></th> <th>100000</th> <th>275 26±/ 190 97</th> <th></th> <th></th> <th>369.82+/-189.17</th> <th>369.82+/-189.17</th>			100000	275 26±/ 190 97			369.82+/-189.17	369.82+/-189.17
NII=40, N2=31	332	642	7807C/TW	160 224/-162.67			148.94+/-124.57	76.67+/-82.11
Fold Change: 2.85   Fold Change: 2.85   Fold Change: 2.85     Fold Change: 3.01   P-value: 0.0001     P-value: 0.0001   P-value: 0.0001     Fold Change: 9.32   Fold Change: 6.2   Fold Change: 0.99     Fold Change: 9.32   Fold Change: 0.99     Fold Change: 9.32   Fold Change: 0.99     Fold Change: 0.2859   Fold Change: 0.99     Fold Change: 0.2859   P-value: 0.99     Fold Change: 0.2959   P-value: 0.99     Fold Change: 0.208   Fold Change: 0.208     Fold Change: 0.208   Fold Change: 0				100.221-/+22.001 100.221-/+22.001	<b>&gt;</b>	×	N1=40, N2=31	N1=40, N2=10
P-value: 00001				D1-40, N2-100	€	ļ	Fold Change: 2.85	Fold Change: 5.81
643         AI758223         83.52+/-665.83         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/-65.34         833.52+/				Fold Cuange: 5.01			P-value: .00001	P-value: .00014
643 A1758123 83.0/7/-03/.44  153.81+/-456.44  X	-			ooc od 17 CET 44		833 57+/-665 83	833.52+/-665.83	833.52+/-665.83
March   Marc	333	643	AL/58223	830.0/7/-03/.44		215 9+/-314.77	164.76+/-581.67	52.12+/-64.89
Fold Change: 9.32  P-value: 0.2859  P-value: 0.2859  P-value: 0.2859  P-value: 0.2859  P-value: 0.2859  P-value: 0.99  P-value: 0.90				133.61-4-30.44	>	N1=40 N2=6	N1=40, N2=31	N1=40, N2=10
F-value: 0.2859  P-value: 0.28594-65.34  P-value: 0.28594-7-226.94  Rold Change: 2.3  P-value: 0.00272				T-14 Change 0 22	4	Fold Change: 6.2	Fold Change: 10.99	Fold Change: 14.24
644         AI758408         X				rold Change: 5.32		P-value: .02859	P-value: 0	P-value: 0
644 A1/36408  X  X  X  X  X  X  X  X  X  X  X  X  X			0010000	1 - value: 0				383.82+/-126.82
645         AI760319         208.69+/-65.34         208.69+/-65.34         208.69+/-65.34         X <th< th=""><th>334</th><th>644</th><th>AI/58408</th><th></th><th></th><th></th><th></th><th>188.25+/-213.28</th></th<>	334	644	AI/58408					188.25+/-213.28
645 AI760319 208.69+/-65.34 208.69+/				Þ	>	×	×	N1=40, N2=10
645         AI760319         208.69+/-65.34				<	<b>(</b>	•	-	Fold Change: 3.58
645         AI760319         208.69+/-65.34         209.72         208.69+/-65.34         209.72         208.69+/-65.34         209.72         208.69+/-65.34         209.72         208.69+/-65.34         209.72         208.69+/-65.34         208.69+/-65.34         209.72 </th <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>P-value: .01039</th>								P-value: .01039
645         AI/00317         102.62+/-62.32         102.62+/-62.32         102.48+/-38.82           105.79+/-40.89         X         N1=39, N2=10         N1=39, N2=31           N1=39, N2=16         N1=39, N2=31         Fold Change: 2.07         P-value: 0           Fold Change: 2         P-value: 0         P-value: 0         691.21+/-512.28           AI760370         X         X         N1=40, N2=31           Fold Change: 2.3         P-value: .00272	3	4,7	A 17/20210	76 59-1409 80C		208.69+/-65.34	208.69+/-65.34	208.69+/-65.34
N1=39, N2=168	333	0 <del>4</del> 0	AL/00317	105 79+/-40.89		102.62+/-62.32	102.48+/-38.82	104.41+/-52.84
Fold Change: 2.02 Fold Change: 2.07 Fold Change: 2.07 Fold Change: 2.07 P-value: 0 P-value: 0.1579 P-value: 0 P-value: 0.1579 P-value: 0 691.21+/-512.28 259.02+/-226.94 X X N1=40, N2=31 Fold Change: 2.3 P-value: .00272				M1=20 M2=168	*	N1=39, $N2=10$	N1=39, N2=31	N1=39, N2=6
646 AI760370 P-value: 0  P-value: .01579 P-value: 0  691.21+/-512.28  259.02+/-226.94  X X N1=40, N2=31  Fold Change: 2.3  P-value: .00272				Eold Change: 7	<b>!</b>	Fold Change: 2.02	Fold Change: 2.07	Fold Change: 2.13
646 AI760370 5-yatuc. 9 646 AI760370 559.02+/-512.28 259.02+/-226.94 X N1=40, N2=31 Fold Change: 2.3 P-value: .00272				Told Change. 2		P-value: .01579	P-value: 0	P-value: .00136
040 A1/003/0 259.02+/-226.94  X X N1=40, N2=31  Fold Change: 2.3  P-value: .00272		,,,,	02000	r-value. V			691.21+/-512.28	691.21+/-512.28
X N1=40, N2=31 Fold Change: 2.3 P-value: .00272	330	940	AL/005/0				259.02+/-226.94	142.47+/-133.11
Fold Change: 2.3 P-value: .00272				<b>&gt;</b>	×	×	N1=40, N2=31	N1=40, N2=10
				<b>4</b>	ļ		Fold Change: 2.3	Fold Change: 4.03
					٠		P-value: .00272	P-value: .00082

#	Sea 10	Genbank	Normal vs All	Normal vs Malionant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
337	648	AI760589	X	×	×	81.29+/-140.48 214.53+/-216.44 N1=40, N2=31 Fold Change: 3.26 P-value: 0	×
338	649	AI761241	891.41+/-331.82 417.19+/-273.72 N1=40, N2=168 Fold Change: 2.32 P-value: 0	×	×	883.3+/-332.12 352.83+/-245.83 N1=40, N2=31 Fold Change: 2.7 P-value: 0	883.3+/-332.12 238.36+/-101.2 N1=40, N2=10 Fold Change: 3.83 P-value: .00005
339	650	AI761274	346.01+/-181.77 114.5+/-91.9 N1=40, N2=168 Fold Change: 3.44 P-value: 0	X	×	342.36+/-182.65 121.75+/-92.05 N1=40, N2=31 Fold Change: 3.23 P-value: 0	342.36+/-182.65 77.48+/-76.11 N1=40, N2=10 Fold Change: 4.73 P-value: .00028
340	651	AI761782	X	×	×	×	41.02+/-103.08 282.44+/-98.22 N1=39, N2=6 Fold Change: 6.26 P-value: 0
341	652	AI761844	284.64+/-141.48 117.61+/-150.43 N1=40, N2=168 Fold Change: 2.8 P-value: 0	X	×	278.83+/-138.41 132.4+/-302.8 N1=40, N2=31 Fold Change: 3.35 P-value: 0	278.83+/-138.41 94.71+/-60.55 N1=40, N2=10 Fold Change: 3.05 P-value: .0007
342	654	AI763298	247.25+/-99.93 113.86+/-100.53 N1=40, N2=168 Fold Change: 2.6 P-value: 0	×	×	242.06+/-95.62 148.77+/-173.93 N1=40, N2=31 Fold Change: 2.29 P-value: .00002	242.06+/-95.62 84.64+/-67.22 N1=40, N2=10 Fold Change: 3.32 P-value: .00045
343	655	A1766029	265.74+/-522.75 15.92+/-35.83 N1=40, N2=168 Fold Change: 3.94 P-value: 0	×	271.74+/-528.19 11.19+/-13.38 N1=40, N2=6 Fold Change: 4.33 P-value: 0	271.74+/-528.19 4.73+/-8.61 N1=40, N2=31 Fold Change: 4.64 P-value: 0	271.74+/-528.19 8.83+/-25.01 N1=40, N2=10 Fold Change: 4.09 P-value: 0

DEIDUNCIU MACATERA E

#£	Seq ID	Genbank	Normal va All	M			
344	629	*	INO INGI NA ANI	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
			*	×	×	×	263.99+/-143.63 686.1+/-326.01 N1=40, N2=10
345	199	A1769550					Fold Change: 2.67
			×	×	×	213.16+/-92.6 101.34+/-76.51 N1=39, N2=31 Fold Change: 2.13	X
346	799	AI770080	450.33+/-335.5			P-value: 0	
			166.16+/-190.29			453.96+/-339.09	453.96+/-339.09
			N1=40, N2=168	*		129.2+/-107.13	94.56+/-93.08
			Fold Change: 2.79	<b>!</b>	<	N1=40, N2=31 Fold Change: 3.2	N1=40, N2=10
472	633	4 7700 400	r-value: 0			D moline.	rold Change: 4.55
Ì	500	A1783490	767.15+/-947.17			r-value: 0	P-value: .00046
			1513.38+/-2167.1				
			N1=40, N2=168	×	>	A #	
			Fold Change: 2.14		<	*	×
			P-value: .00537				
348	999	AI791632	255.06+/-150.68				
			122.84+/-86.83				255.06+/-150.68
			N1=40 N2=168	>			96.82+/-63.86
			Fold Change: 2.22	<	×	×	N1=40, N2=10
			P-value: 0				Fold Change: 2.58
349	. 199	AI792405					P-value: .00084
			*	>	:	93.82+/-112.78 202.01+/-224.89	
			ţ	<	×	N1=40, N2=31	×
- 1						Fold Change: 2.02	
320	699	AI792817	112.38+/-143.52			P-value: .00448	
			558.02+/-937.45			112.38+/-143.52	112.38+/-143.52
			N1=40, N2=168	×	>	510.79+/-557.67	849.79+/-711.76
			Fold Change: 3.33	į	<	NI=40, N2=31	N1=40, N2=10
			P-value: 0			Fold Change: 3.97	Fold Change: 7.3
						0	r-vaine: .00101

					10 1	Manual and Others II	Mountain Ctone III
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal Vs Stage I	Normal vs Stage 11	INOLINAL VS Stage III
351	029	AI795953	407.3+/-278.56		407.3+/-278.56	407.3+/-278.56	407.3+/-278.56
1	) }		146 44+/-111.32		173.14+/-117.81	122.61+/-57.78	137.64+/-123.78
			N1=39 N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2 62		Fold Change: 2.32	Fold Change: 2.89	Fold Change: 3.16
			P-value: 0		P-value: .03224	P-value: 0	P-value: .00069
352	671	AI796083			114.7+/-66.6		
}					207.1+/-77.72		
			×	×	N1=40, N2=6	×	×
					Fold Change: 2.06		
2,63	043	A 17052310	300 25±/ 171 10		I - Value: :00100	300.25+/-171.19	300.25+/-171.19
CCC	7/0	A1/20410	136.42+/-1160.54			142,27+/-164.88	68,23+/-32,91
			N1=39 N2=168	*	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.45	1		Fold Change: 2.36	Fold Change: 3.93
			P-value: 0			P-value: 0	P-value: 0
354	673	A1707063	217 39+/-201 68			220.19+/-203.53	220.19+/-203.53
5	2		181 18+/-462 43			161.62+/-454.65	58.77+/-92.21
				×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.2	l T		Fold Change: 3.09	Fold Change: 3.3
			P-value: .00014			P-value: .00028	P-value: .00535
355	674	AI797276	270.66+/-135.07		271.48+/-136.73	271.48+/-136.73	271.48+/-136.73
3			91 42+/-65 13		110.91+/-50.09	84.22+/-53.14	51.53+/-37.65
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.1		Fold Change: 2.28	Fold Change: 3.2	Fold Change: 5.08
			P-value: 0		P-value: .00368	P-value: 0	P-value: 0
356	57.9	A1797788					268.73+/-161.42
}	)						121.99+/-102
			×	×	×	×	N1=40, N2=10
			4	ł			Fold Change: 2.27
							P-value: .00827
357	929	AI798144	74.39+/-112.61				
			243.81+/-208.55	Þ	*	*	×
			Fold Change: 2.13	<b>{</b>	}		
			P-value: 0				

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
358	849	AI799784	599.82+/-379.39		603.99+/-383.42	603.99+/-383.42	603.99+/-383.42
			67.15+/-81.53		148.43+/-186.96	63.08+/-91.29	38.2+/-47.49
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 9.18		Fold Change: 5.77	Fold Change: 10.41	Fold Change: 14.19
			P-value: 0		P-value: .01759	P-value: 0	P-value: 0
359	681	A1801545					107.72+/-63.11
							240.16+/-135.66
			×	×	×	×	NI=40, N2=10
							Fold Change: 2.33
							P-value: .00036
360	682	AI803208					358.64+/-152.22
							196.65+/-140.61
			×	×	×	×	N1=39, N2=6
							Fold Change: 2.05
							P-value: .01446
361	683	AI803648	107.03+/-109.9				
			295.41+/-304.62				
			N1=39, N2=168	×	×	×	×
			Fold Change: 2.31				
			P-value: 0				
362	684	A1804054	307.23+/-232.94			302.97+/-234.41	302,97+/-234.41
			92.54+/-103.69			73.14+/-50.57	43.17+/-28.15
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.71			Fold Change: 3.81	Fold Change: 5.95
			P-value: 0			P-value: 0	P-value: 0
363	989	AI806221	206.98+/-125.27		206.98+/-125.27	206.98+/-125.27	206.98+/-125.27
			57.8+/-39.92		64.87+/-57.18	49.38+/-39.25	31.17+/-27.12
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.4		Fold Change: 2.98	Fold Change: 3.82	Fold Change: 5.54
			P-value: 0		P-value: .00675	P-value: 0	P-value: 0
364	<b>289</b>	AI806324	214.04+/-130.5			211.46+/-131.17	211.46+/-131.17
			64.16+/-76.08			48.58+/-64.25	21.48+/-26.9
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.61			Fold Change: 4.36	Fold Change: 6.44
			P-value: 0			P-value: 0	P-value: 0

*#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
		The state of the s		G	C	B 20 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	H 1/4
365	069	AI809925				283./9+/-467.54	283./9+/-467.54
_						95.99+/-60.68	72.84+/-38.61
_			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.37	Fold Change: 3.03
						P-value: .00001	P-value: .00019
366	169	AI809953	383,3+/-186.88			383.43+/-189.32	383.43+/-189.32
			78.06+/-108.22			59.3+/-98.99	19.05+/-40.62
_			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
_			Fold Change: 5.91			Fold Change: 7.01	Fold Change: 10.5
			P-value: 0		•	P-value: 0	P-value: 0
367	692	AI810042					494.45+/-173.8
							211.09+/-46.06
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.24
							P-value: 0
368	693	AI810266	68.69+/-105.28		68.88+/-106.64	68.88+/-106.64	68.88+/-106.64
			955.73+/-1984.55		1044.03+/-865.49	1634.45+/-2196.2	521.04+/-362.47
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
	•		Fold Change: 6.41		Fold Change: 16.18	Fold Change: 13.8	Fold Change: 9.22
			P-value: 0		P-value: .00033	P-value: 0	P-value: 0
369	694	AI810764				202.16+/-159.83	
}						408.84+/-303.87	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.01	
_	,					P-value: .00293	
370	200	AI816806	551.09+/-313.71			560.99+/-311.41	560.99+/-311.41
			267.19+/-176.02			242.91+/-135.88	221.89+/-110.66
_			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.1			Fold Change: 2.3	Fold Change: 2.4
			P-value: 0	•		P-value: 0	P-value: .00018
371	701	AI816835	360.85+/-289.77			360.85+/-289.77	360.85+/-289.77
			146.43+/-155.9			158.38+/-181.37	80.71+/-87.22
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.82			Fold Change: 2.55	Fold Change: 4.99
			P-value. 0			P-value: .00002	P-value: .00046

DESCRIPTION AND MARCHARIA

#	Sea III	Genhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
372	702	⋖	X	X	×	×	241.5+/-87.57 116.59+/-51.83 N1=40, N2=10 Fold Change: 2.2 P-value: .003
373	703	A1817698	X	X	×	879.11+/-582.6 519.31+/-493.58 N1=40, N2=31 Fold Change: 2.38 P-value: .0048	×
374	706	AI818579	396.29+/-225.56 181.53+/-192.42 N1=40, N2=168 Fold Change: 2.49 P-value: 0	·×	X	394.08+/-228.07 173.3+/-120.25 N1=40, N2=31 Fold Change: 2.39 P-value: .00004	×
375	707	AI819198	×	×	X	24.28+/-46.39 341.95+/-719 N1=40, N2=31 Fold Change: 2.75 P-value: .00243	×
376	708	AI819340	60.25+/-126.35 301.57+/-342.95 N1=40, N2=168 Fold Change: 3.51 P-value: 0	×	63.25+/-126.56 247.5+/-201.27 N1=40, N2=6 Fold Change: 3.53 P-value: .04505	63.25+/-126.56 468.97+/-447.94 N1=40, N2=31 Fold Change: 5.82 P-value: 0	63.25+/-126.56 450.47+/-509.91 N1=40, N2=10 Fold Change: 4.85 P-value: .00541
377	709	AI820661	-117.72+/-96.27 255.76+/-788.64 N1=40, N2=168 Fold Change: 2.95 P-value: 0	×	X	×	×
378	711	AI821432	×	×	×	349.15+/-245.88 114.84+/-86.63 N1=40, N2=31 Fold Change: 2.66 P-value: .00004	349.15+/-245.88 55.83+/-64.32 N1=40, N2=10 Fold Change: 5.96 P-value: .00004

#	Coo I	Contoni	AT.				
100	73.5	Anguana.	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
3/3	717	A1821472	524.32+/-685.96		519.11+/-694.13	519 11+/-694 13	G
			227.66+/-1932.77		10.64+/-179.34	83 31+7.670 25	
			N1=40 N7=168	>	N11-40 N12-0	7.620-1110-00	
			E-14 (4. 14. 106	<	0=7N' 05=IN	N1=40, N2=31	×
			roid Change: 5.78		Fold Change: 4.41	Fold Change: 5.76	
380	713	ATOTOETA	231 24 : / 100 10		P-value: .02894	P-value: 0	
200	CT/	7/CC70TW	231.34+/-193.19			232.21+/-195.63	
			124.55+/-179.13			80.48+/-58.66	
			N1=40, N2=168	×	×	N1=40 N2=31	>
			Fold Change: 2.37		ţ	Eold Change: 202	<
			P-value: 0			rold Change: 2.82	
381	714	AI823649	88.12+/-78.99			88 17±/ 70 00	00 00 1 00
			225 47+/-213 00			00.127/-/6.99	88.12+/-/8.99
			N1-20 N2-169	,	;	223.88+/-174.27	239.23+/-237.92
			To 13 Cl. 102	<	×	N1=39, N2=31	N1=39, N2=6
			rold Change: 2.16			Fold Change: 2.31	Fold Change: 2.2
202	130	ATOSCOTA	r-vaine: 0			P-value: 0	P-value: .01309
700	07/	A1823877				418.53+/-162.52	418.53+/-162.52
			;			174.35+/-58.42	183.59+/-84.31
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.28	Fold Change: 2.23
1	200					P-value: 0	P-value: .00011
303	77,	AI826437	44.87+/-117.62			45.86+/-118.99	
			241.17+/-525.8			347.56+/-551.29	
			N1=40, N2=168	×	×	N1=40, N2=31	>
			Fold Change: 2.29			Fold Change: 3.07	<del>-</del>
			P-value: 0			P-value: .00134	
384	57/	AL827230	711.88+/-268			708.38+/-270.57	708.38+/-270.57
			M11-40 M2-10/.33	;	1	266.08+/-114.65	273.56+/-97.64
			F-11 Cl. 0 00	×	×	N1=40, N2=31	N1=40, N2=10
			roid Change: 2.22			Fold Change: 2.67	Fold Change: 2.5
		3, 31, 32, 31, 31, 31, 31, 31, 31, 31, 31, 31, 31	P-value: 0			P-value: 0	P-value: 0
203	t <sub>3</sub> /	AI87/248					1009.54+/-892.35
			>	ř	;	!	424.88+/-561.45
			<	≺	×	×	N1=40, N2=10
							Fold Change: 3.8
							P-value: .0309

BNSDOCID: WO 02050271421

1	Cog ID	Conhonly	Normal ve Ali	Normal ve Malianant	Normal ve Stone I	Normal ve Stage II	Normal ve Stage III
	Oct III	Gennalik		IVOLUITAL VS IVIALIBUALIC	MOI mai vs Stage I	Morniar vs Stage At	Ivor mar vs Stage and
	725	A1828075					55.74+/-25.88 208.73+/-146.52
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.44 P-value: .0001
	730	AI829520	78.95+/-63.55				
			N1=39, N2=168	×	×	×	×
			Fold Change: 2.05 P-value: 0				
	733	AI833102					152.23+/-73.43
							301.22+/-134.13
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.05
							F-value: .00005
	734	AI857788					201.77+/-88.15
							79.71+/-43.65
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.61
							P-value: .00082
	735	AI857856				157.81+/-89.37	157.81+/-89.37
						341.48+/-151.28	329.17+/-128.25
			×	×	×	N1=39, N2=31	N1=39, N2=6
						Fold Change: 2.22	Fold Change: 2.15
						P-value: 0	P-value: .00013
	739	AI859620	47.7+/-100.9			47.7+/-100.9	47.7+/-100.9
			335.29+/-308.39			292.66+/-218.11	289.43+/-181.71
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 4.1			Fold Change: 4.09	Fold Change: 3.84
			P-value: 0			P-value: 0	P-value: .00203
	740	AI860012				91.22+/-72.75	91.22+/-72.75
						226.82+/-105.84	232.58+/-120.25
			×	×	×	N1=39, N2=31	N1=39, N2=6
					•	Fold Change: 2.64	Fold Change: 2.58
						P-value: 0	P-value: .00185

BNSDOCID: <WO 02059271A2 1 >

#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
393	742	AI860651	×	×	×	183.59+/-123.14 449.58+/-384.81 N1=40, N2=31 Fold Change: 2.2 P-value: 0	×
394	743	AI863166	×	×	225.98+/-111.31 101.21+/-69.32 N1=39, N2=10 Fold Change: 2.4 P-value: .0473	×	X
395	747	AI864898	406.1+/-256.59 54.76+/-81.97 N1=40, N2=168 Fold Change: 8.17 P-value: 0	X	X	401.86+/-258.51 39.21+/-56.87 N1=40, N2=31 Fold Change: 9.5 P-value: 0	401.86+/-258.51 31.77+/-56.32 N1=40, N2=10 Fold Change: 10.87 P-value: 0
396	748	A1868289	×	×	×	386.08+/-242.58 184.36+/-111.4 N1=40, N2=31 Fold Change: 2.22 P-value: .00003	386.08+/-242.58 156.1+/-103.22 N1=40, N2=10 Fold Change: 2.54 P-value: .00207
397	750	AI871044	777.08+/-499.12 185.08+/-242.68 N1=40, N2=168 Fold Change: 4.86 P-value: 0	X	X	766.39+/-500.99 180.1+/-276.48 N1=40, N2=31 Fold Change: 5.2 P-value: 0	766.39+/-500.99 112.03+/-106.51 N1=40, N2=10 Fold Change: 6.31 P-value: 0
398	751	AI872267	267.23+/-203.1 574.94+/-319.02 N1=40, N2=168 Fold Change: 2.41 P-value: 0	· ×	×	267.23+/-203.1 557.03+/-278.09 N1=40, N2=31 Fold Change: 2.36 P-value: .00001	267.23+/-203.1 504.87+/-295.04 N1=40, N2=10 Fold Change: 2.17 P-value: .00277
399	753	AI885164	×	×	×	×	99.32+/-89.64 276.5+/-111.42 N1=40, N2=10 Fold Change: 2.94 P-value: .00002

*	Seq ID	Genbank	Normal vs Ali	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
400	754	AI885498	220.94+/-153.32 574.07+/-702.09 N1=40, N2=168 Fold Chance: 2.00	×	×	×	×
			P-value: .00005				
401	755	AI885781				219.35+/-109.49	219.35+/-109.49
						556.06+/-397.8	582.43+/-483.5
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.14	Fold Change: 2.47
						P-value: .00015	P-value: .00109
402	757	AI887362			•	817.12+/-289.64	817.12+/-289.64
					-	355.42+/-140.94	243.89+/-105.11
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.26	Fold Change: 3.29
						P-value: 0	P-value: 0
403	758	AI888322				319.22+/-320.74	319.22+/-320.74
						161.88+/-221.65	108.01+/-133
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.73	Fold Change: 3.9
						P-value: .00024	P-value: .00657
404	761	AI889178			372.23+/-146.77	372.23+/-146.77	372.23+/-146.77
					183.45+/-70.01	196.21+/-126.54	194.59+/-97.59
			×	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
					Fold Change: 2.03	Fold Change: 2.04	Fold Change: 2.03
					P-value: .00518	P-value: 0	P-value: .00236
405	762	AI889959				140.79+/-151.42	140.79+/-151.42
			;			298.84+/-296.55	319.25+/-177.44
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.11	Fold Change: 2.62
						P-value: .00028	P-value: .00302
406	763	AI890418	218.25+/-140.58		218.25+/-140.58	218.25+/-140.58	218.25+/-140.58
			37.18+/-39.2		76.35+/-66.16	35.49+/-32.04	26.22+/-48
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.82		Fold Change: 3.02	Fold Change: 3.92	Fold Change: 4.12
			P-value: 0		P-value: .02078	P-value: 0	P-value: 0

#	Co.	Canhonk	Normal ve All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
ŧ	250	OCHDAHR	TANTHHI 19 CAL	TANK TRUMP TO STREET PROPERTY			20 10:1177 75
407	764	AI890488					498.18+/-1/3.20
: !							235.59+/-100.47
			>	*	×	×	N1=40, N2=10
			•	1	•		Fold Change: 2.19
							P-value: .00095
400	760	AT012772					124.98+/-38.73
0 1	è	4114114					344.88+/-151.12
			<b>&gt;</b>	*	×	×	N1=40, N2=10
			<b>:</b>	!			Fold Change: 2.65
							P-value: .00005
400	777	A1016544	150 68+/-161 18			151.27+/-163.24	151.27+/-163.24
62	1	TT-COT CTE				548.66+/-436.19	636.35+/-560.17
			N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2 97	ľ		Fold Change: 3.81	Fold Change: 3.69
			D-value ()			P-value: 0	P-value: .01086
410	775	A 101 7901	501 38+/-804 54		601.53+/-812.45	601.53+/-812.45	601.53+/-812.45
27	C.	10011000	76 3007/48 92		57.95+/-67.95	32.64+/-44.74	15.05+/-18.69
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Hold Change: 5.07		Fold Change: 4.77	Fold Change: 6.97	Fold Change: 9.62
			P-value: 0		P-value: .00228	P-value: 0	P-value: 0
411	77.6	AT021685	102 15+/-191 42			104.01+/-193.56	
111	2	000111/10	27477777			633.55+/-1087.03	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.03			Fold Change: 3.3	
			P-value: .0025			P-value: .00274	
412	777	A1922892				203.33+/-90.32	203.33+/-90.32
	•					481.16+/-300.69	498.39+/-402.89
			×	×	×	N1=39, N2=31	N1=39, N2=6
			•			Fold Change: 2.13	Fold Change: 2.02
						P-value: 0	P-value: .02385
413	778	AI923108				245.08+/-135.84	
					:	576.66+/-441.15	,
			×	×	×	NI=40, NZ=31	<
					•	Fold Change: 2.10 P-value: 0	

*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
414	6//	AI924028					426.33+/-126.02 190+/-63.01
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.25
415	780	AI924465	448.27+/-478.27		448.27+/-478.27	448.27+/-478.27	448.27+/-478.27
			123.26+/-122.11	•	110.32+/-53.45	104.34+/-104.06	46.51+/-27.28
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.18		Fold Change: 2.73	Fold Change: 3.88	Fold Change: 6.5
			P-value: 0		P-value: .00317	P-value: 0	P-value: 0
416	781	AI924794				132.27+/-116.84	132.27+/-116.84
						324.59+/-170.2	321.46+/-186.7
			×	×	×	N1=39, N2=31	N1=39, N2=6
	-					Fold Change: 2.6	Fold Change: 2.5
						P-value: 0	P-value: .0029
417	782	AI927695					624.33+/-219.53
							287.2+/-131.6
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.22
							P-value: .00029
418	784	AI928296			-		146.02+/-113.56
							281.82+/-97.95
			×	×	×	×	NI=40, N2=10
							Fold Change: 2.05
							P-value: .00016
419	785	AI928393	302.49+/-122.77			297.26+/-119.77	297.26+/-119.77
			166.83+/-119.33			142.57+/-77.64	130.31+/-96.66
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.17	Fold Change: 2.67
			P-value: 0			P-value: 0	P-value: .0034
420	787	AI934361	215.99+/-241.37		220.01+/-243.16	220.01+/-243.16	220.01+/-243.16
			49.3+/-62.57		47.28+/-26.36	33.19+/-18.11	32.04+/-24.58
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.48		Fold Change: 3.18	Fold Change: 4.31	Fold Change: 4.29
			P-value: 0		P-value: .00079	P-value: 0	P-value: 0

-	W - 13	Carbon.	Normal ve All	Normal ve Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
*	Sed III	Сепрапк	NOTHIAI VS ALI	IVOI IIIAI VO IVIAIIBLAIIL	Coduna a initial	Q	160 61±/ 100 02
421	788	AI934407					377.54+/-147.2
			<b>&gt;</b>	×	×	×	N1=40, N2=10
			4	4 1			Fold Change: 2.61
							P-value: .00001
422	707	A1035915	26 52+/-106 71			28.01+/-107.68	28.01+/-107.68
771	461	C1/22/17	26.32.7-1334.72			364.49+/-370.15	510.1+/-498.57
			37:FC-7:11:/02 N1=40 N2=168	<b>×</b>	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.41	1		Fold Change: 6.74	Fold Change: 8.29
			P-value: 0			P-value: 0	P-value: .00153
422	703	A 1026600	2			769.05+/-392.56	769.05+/-392.56
C7#	661	AL 20007				344.85+/-187.03	208.46+/-65.42
			<b>&gt;</b>	*	×	N1=40, N2=31	N1=40, N2=10
			<b>4</b>	<b>:</b>		Fold Change: 2.04	Fold Change: 3.07
						P-value: .00007	P-value: 0
5	707	A1026973					109.06+/-86.01
171	•	MA730063					210.69+/-119.04
			×	×	×	×	N1=40, N2=10
			1				Fold Change: 2.33
							P-value: .00059
425	705	A1937060	73 53+/-63.87			73.53+/-63.87	73.53+/-63.87
77	2	2001000	221 63+/-200 57			275.58+/-253.28	293.86+/-212.3
			75:007-(CC:177	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2 37	1		Fold Change: 2.86	Fold Change: 3.17
			P-value: 0			P-value: 0	P-value: .00776
426	962	AI937365	458.68+/-248.47		461.09+/-251.24	461.09+/-251.24	
			1357.16+/-1303.29	>	N1=40, N2=6	N1=40, N2=31	×
			101-40, INZ-108		Fold Change: 3 81	Fold Change: 2 32	
			Fold Change: 2.31		P-value: 03322	P-value: .00007	
100	100	A1020£07	r-value. U				67.26+/-38.98
174	06/	AL535301					211.34+/-144.81
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.91
							70100: :Carret

203

7	T. C.	Carterit	N	74			
#	or bac	Упрапа	LAOTHARI VS ALI	Normal vs Mangnant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage LII
428	803	AI950023				335.59+/-291.5	335,59+/-291.5
						129.73+/-80.19	94.45+/-69.77
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.04	Fold Change: 2.9
						P-value: .00084	P-value: .00112
429	802	AI952965				161.89+/-108.6	161.89+/-108.6
						347.01+/-159.99	461.65+/-262.27
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.38	Fold Change: 2.78
					•	P-value: 0	P-value: .00455
430	908	AI953053					96.66+/-61.58
							403.41+/-323.73
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.33
							P-value: .00265
431	808	AI954874			209.46+/-107.86		
					96.19+/-23.42		
			×	×	N1=40, N2=6	×	×
					Fold Change: 2.01		
					P-value: .00017		
432	810	AI961206				46.06+/-77.63	46.06+/-77.63
						204.28+/-102.33	225.27+/-103.4
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 3.96	Fold Change: 4.13
						P-value: 0	P-value: .00043
433	817.	AI968379	296.71+/-383.1			295.46+/-388.02	295.46+/-388.02
			45.24+/-243.3			104.96+/-424.91	-12.25+/-22.65
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.99			Fold Change: 4.47	Fold Change: 6.3
			P-value: 0			P-value: .00001	P-value: 0
434	818	AI968904	744.48+/-291.11			738.79+/-292.65	
			370.58+/-143.78	1		373.44+/-151.46	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2			Fold Change: 2.01	
			P-value: 0			P-value: 0	

# Seq ID Genbank Normal vs Malignant Normal vs Stage II Normal vs Normal vs Stage II Norm								
5 822         AI970898         505.694/422.11         509.534-4456.92         No. 334-4456.92         No. 346.45.93         No. 346.46.46.93         No. 346.46.46.93         No. 346.46.93         No. 346.46.46.93	#	Seq ID	Genbank		Normal vs Malignant	Normal we Chang	Normal St. Charlet	
6 823 A1971441	435	822	A TO 70808	· 505 60±/ 422 11	Toring of Mangham	Tage to a series to	Normal vs Stage II	Normal vs Stage III
Ni=40, Ni=60   116,994-60.55     Ni=40, Ni=60   Ni=40, Ni=60   116,994-60.55     Fold Change: 3.33	3		AL7 / 0070	303.09+/-422.11 143.24 / 84.50		509.53+/-426.92	509.53+/-426.92	509.53+/-426.92
Fold Change: 3.33				142.34=/-54.39	;	155.46+/-70.61	116.99+/-60.55	117.04+/-63.48
Fold Change: 3.53   Fold Change: 2.81   Fold Change: 3.87     Fold Change: 3.45   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 3.87     Fold Change: 3.87     Fold Change: 3.87   Fold Change: 2.24     Fold Change: 3.7   Fold Change: 3.17     Fold Change: 4.55   Fold Change: 3.17     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.55   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.15   Fold Change: 4.15   Fold Change: 4.15     Fold Change: 4.15   Fold Change: 4.15   Fold Change: 4.15				NI=40, NZ=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
6 823 AB971441 F-Value: 0 P-value: 0 (0097 P-value: 0 (0997 P-value: 0 (09				Fold Change: 3.33		Fold Change: 2.81	Fold Change: 3.87	Fold Change: 3.88
No. of the control	136	973	A TOW1 4.41	r-value: 0		P-value: .00097	P-value: 0	P-value: 0
State	5	C70	A19/1441			224.36+/-258.15	224.36+/-258.15	224.36+/-258.15
Ni = 40, N2 = 6   Ni = 40, N2 = 5				;	ļ	25.49+/-91	44.4+/-132.79	-63.46+/-142.66
Name				×	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
National State						Fold Change: 3.79	Fold Change: 2.75	Fold Change: 4.45
S30   AI972498   285.82+/111.27   286.51+/112.64     134.28+/71.62   X   X   X   X   X     134.28+/71.62   X   X   X   X   X   X   X   X   X	2.0	200	, 1024011			P-value: .01447	P-value: .0003	P-value: .0004
S30   AI972498   285.82+-111.27   286.51+/-112.64     134.28+/-111.27   134.28+/-111.62     N1=40, N2=168	2	/70	AL9/1914					121.63+/-64.27
830   A1972498   285.82+/-111.27   286.51+/-112.64     134.28+/-71.62   134.28+/-71.62     134.28+/-71.62   134.28+/-11.264     134.28+/-71.62   134.28+/-112.64     134.28+/-71.62   134.28+/-71.63     134.28+/-71.62   134.28+/-71.63     134.28+/-71.62   134.28+/-71.63     134.28+/-71.62   124.7+/-61.16     134.28+/-71.62   124.7+/-61.16     134.28+/-71.62   124.7+/-61.16     134.28+/-71.62   124.7+/-61.16     134.28+/-71.62   134.28+/-71.63     134.28+/-71.63   134.28     134.28+/-71.63				Þ	;			329.2+/-298.85
8 830         A1972498         285.82+/-111.27         286.51+/-112.64           134.28+/-71.62         X         X         NI=40, N2=31           Pold Change: 2.22         X         NI=40, N2=31           P-value: 0         P-value: 0         P-value: 0           831         A1972661         X         X         NI=40, N2=31           Rold Change: 2.22         X         NI=40, N2=31         P-value: 0         482.12+/-600.67           832         A1972873         437.97+/-212.54         X         NI=40, N2=31         P-value: 01047           832         A1972873         437.97+/-212.54         436.16+/-215         P-value: 01047         P-value: 01047           834         A1972873         437.97+/-212.54         436.16+/-215         P-value: 01047           835         A1972873         X         X         NI=40, N2=31           P-value: 0         P-value: 0.21         P-value: 0         P-value: 0           836         A197261         Rold Change: 3.37         Fold Change: 2.14         Fold Change: 2.14           P-value: 0         P-value: 0.021         P-value: 0.021         P-value: 0.021         P-value: 0.0002           R         X         X         X         X         NI=40, A223 </td <td></td> <td></td> <td></td> <td>≺</td> <td>×</td> <td>×</td> <td>×</td> <td>N1=40, N2=10</td>				≺	×	×	×	N1=40, N2=10
8 30         AI972498         285.82+i-111.27         286.51+i-112.64           134.28+i-71.62         NI=40, N2=168         X         NI=40, N2=31           Fold Change: 2.22         P-value: 0         P-value: 0           831         AI972661         X         X         X         NI=40, N2=31           A 1775661         X         X         NI=40, N2=31         P-value: 0         P-value: 0           832         AI972873         437.97+i-212.54         X         X         NI=40, N2=31           NI=40, N2=168         X         X         NI=40, N2=31           NI=40, N2=168         X         NI=40, N2=31         P-value: 0         P-value: 0           R36         AI97261         Rold Change: -1.25         164.58+i-1.25.74         126.68+i-109.81           NI=40, N2=168         X         NI=40, N2=6         NI=40, N2=31           P-value: 0         P-value: 0.021         P-value: 0         P-value: 0           AI97261         X         X         NI=40, N2=31           R36         AI97261         R46, N2=6         NI=40, N2=31           R37.97+i-103.23         R46, N2=6         R46, N2=6         NI=40, N2=31           R37         R46, N2=4         R46, N2=4         R46, N2=4<								Fold Change: 2.25
286.514-711.64 134.284-771.62 N1=40, N2=168 X X X X X X X X X X X X X X X X X X X	38	830	A 1077400	205 901 / 111 02				P-value: .00832
124.74-61.16	3		9Ch7/CTW	12.111-/+20.007			286.51+/-112.64	286.51+/-112.64
N1=40, N2=31				134.28+/-/1.62	i		124.7+/-61.16	109.37+/-47.71
P-value: 0   P-value: 0   P-value: 0   P-value: 0				NI=40, NZ=168	; <b>×</b>	×	N1=40, N2=31	N1=40, N2=10
Mathematical Paralue; 0   Paralue; 0				Fold Change: 2.22			Fold Change: 2.3	Fold Change: 2.7
832 AI972601 X X X N1=40, N2=31 Fold Change: 2.24  832 AI972873 437.97+/-212.54 7616/5774 126.68+/-105.81 N1=40, N2=31 Fold Change: 4.14 P-value: 0 P-value: 0.21 Fold Change: 2.17 Fold Chan	١	934	777	P-value: 0			P-value: 0	P-value: .00057
832         AI972873         437.97+/-212.54         Fold Change: 2.24           832         AI972873         437.97+/-212.54         P-value: .01047           834         AI972873         437.97+/-212.54         P-value: .01047           835         AI972873         437.97+/-212.54         P-value: .01047           836         AI979261         X         N1=40, N2=31           P-value: 0         P-value: .021         P-value: 0           R36         AI979261         X         X           836         AI979261         X         X           837         Fold Change: 3.7         P-value: 0           P-value: .021         P-value: 0           R501 Ghange: 2.17         R501 Ghange: 2.17	Š	931	ALY/2661				482.12+/-600.67	
832 AI972873 437.97+/-212.54 Fold Change: 2.24  832 AI972873 437.97+/-212.54 Fold Change: 2.24  834 AI97261 X 437.97+/-215.54 126.68+/-109.81  835 AI979261 X 845.16+/-215 436.16+/-215  836 AI979261 X 845.16+/-215 436.16+/-109.81  836 AI979261 X 845.16+/-109.81  837 AI979261 Fold Change: 3.37 Fold Change: 4.14  838 P-value: 0 P-value: 0  839 AI979261 Fold Change: 2.17  840 Change: 2.17  850 Fold Change: 2.17							177.9+/-209.56	
Fold Change: 2.24  P-value: 01047  832 AI972873 437.97+/-212.54  P-value: 01047  816 AI972873 437.97+/-212.54  P-value: 01047  816 AI97281  Rold Change: 4.55  P-value: 0.1047  816 AI97281  Rold Change: 3.37  P-value: 0  P-value: 0  P-value: 0  P-value: 0  Rold Change: 4.14  P-value: 0  Rold Change: 4.14  P-value: 0  Rold Change: 2.17  P-value: 0  P-value: 0.21  P-value: 0  P-value: 00002				×	×	×	N1=40, N2=31	×
832         AI972873         437.97+/-212.54         P-value: .01047           832         AI972873         437.97+/-212.54         436.16+/-215         436.16+/-215           117.56+/-101.2         X         164.58+/-155.74         126.68+/-109.81           N1=40, N2=168         X         N1=40, N2=31           Fold Change: 4.55         Fold Change: 4.14           P-value: 0         P-value: 0           P-value: 0         P-value: 0           N1=40, N2=31         145.88+/-125.11           301.16+/-194.23         X           Rold Change: 2.17         P-value: .00002           P-value: .00002         P-value: .00002							Fold Change: 2.24	
834 AL972873 437.97+/-212.54 436.16+/-215 436.16+/-215 117.56+/-101.2 164.58+/-155.74 126.68+/-109.81 N1=40, N2=168 X N1=40, N2=31 Fold Change: 4.55 Fold Change: 3.37 Fold Change: 4.14 P-value: 0 P-value: 0 145.88+/-125.11 301.16+/-194.23 X X X N1=40, N2=31 Fold Change: 2.17 Fold Change: 2.17 P-value: 0 145.88+/-125.11 Fold Change: 2.17 P-value: 0 00002	١	8					P-value: .01047	
117.56+/-101.2  117.56+/-101.2  117.56+/-101.2  117.56+/-101.2  117.56+/-101.2  118-40, N2=31	⊋	759	AL9/2873	437.97+/-212.54		436.16+/-215	436.16+/-215	436.16+/-215
N1=40, N2=168				117.56+/-101.2		164.58+/-155.74	126.68+/-109.81	75.01+/-128.01
Fold Change: 4.55 Fold Change: 4.14  P-value: 0 P-value: 0  836 AI979261  X X X X Fold Change: 4.14  P-value: 0  145.88+/-125.11  301.16+/-194.23  X X X N1=40, N2=31  Fold Change: 2.17  P-value: 00002				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40 N2=10
836         AI979261         P-value: 0         P-value: 0           X         X         145.88+/-125.11           301.16+/-194.23         X         N1=40, N2=31           Fold Change: 2.17         P-value: 00002				Fold Change: 4.55		Fold Change: 3.37	Fold Change: 4.14	Fold Change, 8 78
836 AI979261 145.88+/-125.11 301.16+/-194.23 X X N1=40, N2=31 Fold Change: 2.17 P-value: .00002						P-value: .021	P-value: 0	P-value: 00006
X X N1=40, N2=31 Fold Change: 2.17 P-value: .00002	=	836	AI979261				145.88+/-125.11	
Fold Change: 2.17 P-value: .00002				×	×	×	N1=40, N2=31	×
							Fold Change: 2.17 P-value: 00002	

				: 4	W. 1	Manage In Change	Normal ve Stage III
*	Sed ID	Genbank	Normal vs All	Normal vs Mailgnant	Normal vs Stage I	NOUTHAN VS STARE II	Tol mar vs Suggara
442	837	AI982669				352.73+/-154.77 769.65+/-400.6	352.73+/-154.77 839.63+/-451.94
			×	×	×	N1=39, N2=31	N1=39, N2=6
						Fold Change: 2.11	Fold Change: 2.2
						P-value: 0	P-value: .00452
443	838	A1983045	282.14+/-333.79		281.02+/-338.08	281.02+/-338.08	281.02+/-338.08
}	3		-2.89+/-61.5		6.46+/-26.18	-12.28+/-33.2	-25.74+/-23.32
			N1=40 N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 6.23		Fold Change: 6.38	Fold Change: 6.91	Fold Change: 7.49
			P-value: 0		P-value: 0	P-value: 0	P-value: 0
444	840	AT985653				243.4+/-112.77	243.4+/-112.77
	3					111.29+/-55.01	81.33+/-38.99
			<b>×</b>	×	×	N1=39, N2=31	N1=39, N2=6
			•	!		Fold Change: 2.12	Fold Change: 2.93
						P-value: 0	P-value: 0
445	841	AI989588			160.57+/-119.71		
<b>:</b>	! }				240.25+/-78.81		
			×	×	N1=40, N2=6	×	×
					Fold Change: 2.01		
					P-value: .00445		
446	846	AI990483				35.21+/-34.58	
:	:					207.82+/-290.06	
			×	×	×	N1=40, N2=31	×
			ł			Fold Change: 2.5	
						P-value: .00091	
447	853	AL031846	446.58+/-157.69			446.58+/-157.69	446.58+/-157.69
:	}		203.55+/-90.87			182.45+/-74.24	148.67+/-68.99
			N1=40. N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.21			Fold Change: 2.41	Fold Change: 3.01
			P-value: 0			P-value: 0	P-value: .00002
448	855	AL037368					576.75+/-132.07
						į	296.15+/-132.55
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.12 P-value: .0014

#	Sea ID	Conbonk	Mountain All	N. S.			
	200	GCMUAIIR	MOFINAL VS AM	Normal vs Mangnant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
449	857	AL037805	624.14+/-319.31			614.2+/-317.15	614.2+/-317.15
			281.94+/-168.3			258.58+/-142.99	168 50+/-62 00
			N1=40, N2=168	×	×	N1=40 N2=31	N1=40 N2-10
			Fold Change: 2 20	I n	( )	10 201 (01 111	01-7v; '1v;
			P-value: 0			Fold Change: 2.38 Pergine: 0	Fold Change: 3.3
450	860	AL039445				7 - Agraco: 0	102 CE+/ 20 07
		•					103.03+/-39.9/
			À	;	1		204.36+/-54.58
			≺	*	×	×	N1=40, N2=10
							Fold Change: 2.03
							P-value: 0
451	861	AL039870	229.33+/-119.68			226.4+/-119.79	226.4+/-119.79
			104.08+/-62.24			95.07+/-69.54	85.61+/-45.98
			N1=40, N2=168	×	×.	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.19			Fold Change: 2.41	Fold Change: 2.58
			P-value: 0			P-value: 0	P-value: .0005
452	862	AL039917					190.41+/-139.22
•			:				427.64+/-204.38
			×	×	×	×	N1=40, N2=10
					•		Fold Change: 2.48
	.,,						P-value: .00467
453	864	AL040178	277.18+/-128.12		277.18+/-128.12	277.18+/-128.12	277.18+/-128.12
			73.94+/-56.64		106.38+/-90.67	59.11+/-47.84	44.44+/-29.67
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
			Fold Change: 3.48		Fold Change: 2.79	Fold Change: 3.76	Fold Change: 4.57
			P-value: 0		P-value: .01209	P-value: 0	P-value: 0
45 45	865	AL040912	311.14+/-137.52			304.56+/-132.78	304.56+/-132.78
			86.94+/-86.46			69.8+/-53.68	52.07+/-61.09
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.08			Fold Change: 4.66	Fold Change: 6.69
			P-value: 0			P-value: 0	P-value: .00001
455	998	AL041815	257.28+/-104.74			257.35+/-106.11	
			129.57+/-68.69			124.69+/-56.27	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.04			Fold Change: 2	
			r-value. 0			r-vame: 0	

.

ב ב מצרכת החובת החובת ולווים

Seq ID G		Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
	⋖	AL042492	801.96+/-843.5		809.69+/-853.09	809.69+/-853.09	809.69+/-853.09
			56.95+/-101.91		101.65+/-170.57	40.59+/-106.87	11.79+/-18.8
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 12.71		Fold Change: 8.78	Fold Change: 15	Fold Change: 20.99
			P-value: 0		P-value: .00362	P-value: 0	P-value: 0
868 AI	4	AL042923					3125.4+/-1239.9
							1575.01+/-724.4
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.07
•	•						P-value: .00207
870 AI	ΑI	AL043980				498.96+/-198.25	498.96+/-198.25
						248.27+/-101.89	206.45+/-96.76
			×	×	×	N1=40, N2=31	N1=40, N2=10
			!	1		Fold Change: 2.06	Fold Change: 2.43
						P-value: 0	P-value: .00002
871 AI	A	AL044366	137.98+/-186.9				
			313.36+/-363.79				
			N1=40 N2=168	*	×	×	*
			Fold Change: 2.23	•	4	<b>!</b>	•
			P-value: .00018				
872 AJ	Y	AL044613					304+/-112.89
							102.49+/-79.71
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.15
							P-value: .00076
876 AI	¥	AL046941	425.75+/-236.48			428.58+/-238.89	428.58+/-238.89
			53.79+/-102.7			34.11+/-80.54	-23.64+/-33.24
			N1=40, N2=168	×	×	N1=40, N2=31	NI=40, N2=10
			Fold Change: 8.01			Fold Change: 9.66	Fold Change: 16.81
			P-value: 0			P-value: 0	P-value: 0
877 AJ	[₹	AL046946					713.56+/-217.52
			i	;	!	;	287.87+/-116
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.57
	- 1						P-value: .00006

ENCLOCID: AND DODGOTAN I

18,40

#	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage Π	Normal vs Stage III
463	878	AL.048304			8		308 70+/-74 67
}	)						97 9+/-114 69
			×	*	×	*	N1=40 N2=10
			ł	Į.	ļ	!!	Fold Change: 3 99
:					-		P-value: .00402
464	67.8	AL048386	233.2+/-107.71		5	232.52+/-109.03	232.52+/-109.03
			118.45+/-83.53			94.13+/-59.17	73.94+/-51.55
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.19			Fold Change: 2.63	Fold Change: 3.32
			P-value: 0			P-value: 0	P-value: .00019
465	880	AL048399				768.94+/-280.35	768.94+/-280.35
						336.8+/-159.66	378.81+/-201.68
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.37	Fold Change: 2.22
						P-value: 0	P-value: .00292
466	881	AL048962	951.97+/-353.33			944+/-354.29	944+/-354.29
			498.61+/-346.17			469.14+/-334.1	400.6+/-283.17
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.17	Fold Change: 2.45
			P-value: 0			P-value: 0	P-value: .00012
467	883	AL049257				258.77+/-104.32	258.77+/-104.32
						110.97+/-53.29	104.27+/-37.82
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.35	Fold Change: 2.34
						P-value: 0	P-value: 0
468	884	AL049423				385,45+/-146.45	385.45+/-146.45
						176.43+/-82.21	131.88+/-33.79
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.19	Fold Change: 2.73
						P-value: 0	P-value: 0
469	885	AL049471				585.55+/-164.83	585.55+/-164.83
						312.66+/-134.95	304.04+/-127.09
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.01	Fold Change: 2.01
						r-value, 0	r-value: .00004

#	Sen II	Conhonly	M		1	:	
£ 2	887	AT 040040	Normal vs All	Normal vs Maliguant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
?	ŝ	ALU47747				525.51+/-234.08	525.51+/-234.08
			>	>	;	218.01+/-118.84	184.51+/-151.36
			4	<	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.27	Fold Change: 3.21
471	888	AL049957				P-value: 0	P-value: .00178
						664.06+/-250.51	
			>	*	j	339.26+/-164.3	
			ς.	≺	×	N1=39, N2=31	×
						Fold Change: 1.98	
472	890	AL050002				P-value: 0	
							320.95+/-114.96
			>	ì			152,33+/-60.11
			<	<b>×</b>	×	×	N1=40, N2=10
							Fold Change: 2.08
473	893	AL050367	257 50+1,-77 75				P-value: .00017
			155+/-120.63			257.59+/-77.75	
			N1=40 N7=168	>	;	117.16+/-76.86	
			Fold Change: 2	<	×	N1=40, N2=31	×
			P-value: 0			Fold Change: 2.49	
474	894	AL079279	313.49+/-189.76		212 401/ 400 00	F-value: 0	
			108 20+/-83 88		313.49+/-189.76	313.49+/-189.76	313.49+/-189.76
			N1=40 N2-168	ì	114+/-76.08	86.73+/-51.4	49.04+/-28.4
			Fold Change: 2 97	<b>~</b>	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			P-value: 0		Fold Change: 2.51	Fold Change: 3.29	Fold Change: 5.69
475	968	AL079707	258.01+/-224.37		r-value: .00823	P-value: 0	P-value: 0
			67.86+/-48.3		201.69+/-226.08	261.69+/-226.08	261.69+/-226.08
			N1=40 N7=168	<b>&gt;</b>	82.89+/-41.99	48.17+/-30.27	78.83+/-21.26
			Fold Change: 3.55	<	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			D-volue: 0		Fold Change: 2.73	Fold Change: 4.63	Fold Change: 2.7
476	768	AL079769	108 26+1.265 48		P-value: .0013	P-value: 0	P-value: 0
			337 38+/-218 01			201.74+/-268.02	201.74+/-268.02
			N1=40, N2=168	>	;	451.36+/-269.91	415.85+/-142.87
			Fold Change: 2.06	<	≺	N1=40, N2=31	NI=40, N2=10
			P-value: 0			Fold Change: 2.73	Fold Change: 2.88
						P-value: 0	D_value. 0

#	Sea 1D	Genhank	Normal vs All	Nomen of the Maliane	M		
1	988	A STANS	TOURS AS WILL	Morinal vs Malignant	Normal Vs Stage I	Normal vs Stage II	Normal vs Stage III
1/4	898	AL079949				382.36+/-135.98	382.36+/-135.98
			;	,		172.14+/-65.04	160.74+/-65.7
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.21	Fold Change: 2.34
478	800	AT 090102				P-value: 0	P-value: .00001
9	660	ALU60192				103.54+/-69.27	
			;	;	į	242.17+/-111.66	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.54	
						P-value: 0	
479	903	AL120446	304.54+/-95.79			302.81+/-96.4	302.81+/-96.4
			151.01+/-51.13	·		143.68+/-46.25	137.13+/-46.57
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2			Fold Change: 2.07	Fold Change: 2.16
			P-value: 0			P-value: 0	P-value: .00001
480	904	AW000899	255.52+/-122.34			255.52+/-122.34	
			125.26+/-107.3			136.12+/-122.63	
			N1=39, N2=168	×	×	N1=39, N2=31	*
			Fold Change: 2.23			Fold Change: 2.06	41
			P-value: 0			P-value: .00003	
481	907	AW002846	282.39+/-199.06				283.14+/-201.6
			139.23+/-115.04				97.8+/-63.96
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.15				Fold Change: 2.7
18	010		F-value: 0				P-value: .00045
797	716	AW003362			211.57+/-81.24 89.06+/-83.95		
			×	×	N1=39, N2=10	×	<b>×</b>
					Fold Change: 2.32	!	4
					P-value: .02046		
483	914	AW005418				205.57+/-234.3	205.57+/-234.3
			;	i		67.1+/-110.71	10.33+/-83.48
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.41	Fold Change: 3.7
						r-value: .00065	F-value: .00052

#	Seg ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
484	915	AW005814		×	146.08+/-90.43 310.43+/-106.68 N1=40, N2=6 Fold Change: 2.4 P-value: .00072	×	×
485	916	AW006235	344.79+/-207.97 103.81+/-60.65 N1=40, N2=168 Fold Change: 3.17 P-value: 0	×	346.9+/-210.26 126.57+/-35.39 N1=40, N2=6 Fold Change: 2.35 P-value: .00014	346.9+/-210.26 95.72+/-56.93 N1=40, N2=31 Fold Change: 3.43 P-value: 0	346.9+/-210.26 99.92+/-23.08 N1=40, N2=10 Fold Change: 2.94 P-value: 0
486	919	AW006898	841.88+/-394.55 331.12+/-203.65 N1=40, N2=168 Fold Change: 2.68 P-value: 0	×	×	835.42+/-397.56 305.25+/-163.97 N1=40, N2=31 Fold Change: 2.7 P-value: 0	835.42+/-397.56 305.65+/-212.32 N1=40, N2=10 Fold Change: 2.91 P-value: .00883
487	920	AW006998	×	×	×	79.75+/-104.09 221.43+/-283.12 N1=40, N2=31 Fold Change: 2.76 P-value: .00002	×
488	921	AW007080	226.13+/-116.85 62.58+/-55.91 N1=40, N2=168 Fold Change: 3.65 P-value: 0	X	×	223.2+/-116.87 55.48+/-39.27 N1=40, N2=31 Fold Change: 3.79 P-value: 0	223.2+/-116.87 48.27+/-49.28 N1=40, N2=10 Fold Change: 4.6 P-value: .00008
489	925	AW007586	552.57+/-493.88 992.94+/-672.01 N1=40, N2=168 Fold Change: 2.04 P-value: .00003	X	×	552.57+/-493.88 1388.39+/-797.65 N1=40, N2=31 Fold Change: 2.99 P-value: 0	×
490	927	AW007983	308.57+/-180.09 124.89+/-104.9 N1=39, N2=168 Fold Change: 2.45 P-value: 0	×	308.57+/-180.09 120.02+/-133.67 N1=39, N2=10 Fold Change: 3.11 P-value: .02642	308.57+/-180.09 98.43+/-60.3 N1=39, N2=31 Fold Change: 2.82 P-value: 0	308.57+/-180.09 57.05+/-49.19 N1=39, N2=6 Fold Change: 4.11 P-value: 0

							THE COLUMN
#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal VS Stage I	Normal vs Stage 11	NOTHIAL VS STARE ALL
491	929	AW009505					210.48+/-63.01 452.13+/-225.92
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.06 P-value: .00023
492	930	AW013949			228.98+/-140.11		
			>	>	N1=40 N2=6	×	×
			<	€	Fold Change: 2.49	į	
					P-value: .00743		
463	032	AW014647	222 93+/-95 23			222.93+/-95.23	222.93+/-95.23
?	100		93 53+/-66.06			87.53+/-67.66	103.61+/-77.88
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.35			Fold Change: 2.48	Fold Change: 2.1
			P-value: 0			P-value: 0	P-value: .00171
494	933	AW014764	299.88+/-160.3			299.88+/-160.3	
: }	}		148.29+/-123.67			143.2+/-104.38	
			N1=39 N2=168	×	×	N1=39, N2=31	×
			Fold Change: 2.02	i		Fold Change: 2.02	•
			P-value: 0			P-value: 0	
405	939	AW015571					648.86+/-400.58
}	5						174.43+/-228.74
			×	×	×	×	NI=40, N2=10
			ł				Fold Change: 6.15
							P-value: .00262
496	938	AW021108	220.45+/-143.17			220.45+/-143.17	220.45+/-143.17
<u>}</u>			97.68+/-75.55			87.82+/-65.1	76.42+/-41.74
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2.37			Fold Change: 2.67	Fold Change: 2.68
			P-value: 0			P-value: 0	P-value: .00045
407	030	AW021169	256 18+/-141 26				254.1+/-142.48
}	ì		128 88+/-175 65				131+/-172.12
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.2			•	Fold Change: 2.58
			P-value: 0				P-value: .00997

i

Normal vs All   Normal vs Malignant   Normal vs Stage 1     X							H	NI 1
941 AW022607  X  X  X  X  Y  943 AW024285  X  Y  Y  944 AW024285  X  X  X  X  X  X  X  X  X  X  X  X  X	*	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal Vs Stage III
943 AW023188 X X X X 945 AW024285 X X X X X 946 AW024434 790.91+/.331.85 946 AW024434 790.91+/.331.85 948 AW024795 X X X 952 AW044663 X X X X 8	8	941	AW022607				820.58+/-231.5	820.58+/-231.5
943 AW023188 X X X X 945 AW024285 X X X X X 946 AW024434 790.91+/-331.85 946 AW024434 790.91+/-331.85 948 AW024795 X X X 952 AW044663 X X X X 8				×	×	×	N1=40, N2=31	N1=40, N2=10
943 AW023188				<b>;</b>	•		Fold Change: 2.16	Fold Change: 2.39
943 AW023188  X  X  Y  Y  945 AW024285  Y  X  X  X  X  X  X  X  X  X  X  Y  12.05+1-30.27  X12.05+1-30.27  X12.05+1-30.27  X12.05+1-30.27  X12.05+1-30.27  X X  X  X  X  X  X  X  X  X  X  X  X							P-value: 0	P-value: .00116
945 AW024285  X  X  X  X  X  X  X  X  X  X  Y  946 AW024434 790.91+/-331.85  948 AW024795  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y	g	943	AW023188				290.36+/-132.68	
945 AW024285  X  X  X  X  X  X  X  X  X  X  X  X  X	•	<u>:</u>					130.36+/-49.53	
945 AW024285  X  X  X  X  X  X  X  X  X  Y  946 AW024434 790.91+/-331.85  P-value: 0  948 AW024795  X  X  X  X  X  X  X  X  X  X  X  X  X				×	×	×	N1=39, N2=31	×
945 AW024285  X  X  X  X  X  X  X  946 AW024434 790.91+/-331.85  948 AW024434 790.91+/-331.85  P-value: 0  948 AW024795  X  X  X  X  X  X  X  X  X  X  X  X  X	•						Fold Change: 2.07	
945 AW024285  X  X  X  X  X  X  X  Y0.91+/-331.85  946 AW024434 790.91+/-331.85  Pola Change: 2.03  P-value: 0  948 AW024795  X  X  X  X  X  X  X  X  X  X  X  X  X	- [						r-value: 0	750 00 /TOC 03C
946 AW024434 790.91+/-331.85 946 AW024434 790.91+/-331.85 N1=40, N2=168 X X P-value: 0 948 AW024795 X X X X  952 AW044663 X X X X X X X X X X X X X X X X X X X	9	945	AW024285					730.734/-96.67
946 AW024434 790.91+/-331.85  946 AW024434 790.91+/-331.85  N1=40, N2=168				>	*	*		N1=40, N2=10
946 AW024434 790.91+/-331.85				<	<	<b>&lt;</b>	<b>:</b>	Fold Change: 2.27
946 AW024434 790.91+/-331.85  N1=40, N2=168								P-value: .00009
948 AW024795  AW044663  AW061492 440.5+/-328.97  P-value: 0  952 AW051492 440.5+/-328.97  N1=40, N2=168  X  X  X  X  X  X  X  X  X  X  X  X  X	=	946	AW024434	790.91+/-331.85			789.9+/-336.13	
Pold Change: 2.03 P-value: 0  948 AW024795  X  X  X  X  X  X  X  X  X  X  X  X  X				432.05+/-300.27		į		ì
Fold Change: 2.03  P-value: 0  X  X  X  X  X  X  Y  952  AW044663  X  X  X  X  X  X  X  X  X  X  X  X  X				N1=40, N2=168	×	×	N1=40, N2=31	*
948 AW024795  X  X  X  X  X  X  X  X  X  X  X  X  X				Fold Change: 2.03			Fold Change: 2.21	
948 AW024795  X  X  X  X  X  X  X  X  X  X  X  X  X	-			F-value: 0			r -value: 0	2007 (1100 00
952 AW044663  X  X  X  X  X  X  X  X  X  X  X  X  X	2	948	AW024795					194.61+/-162./6
952 AW044663  X X X  X X  X X  X X  X X  X X  X X								374.26+/-130.52
952 AW044663  X  X  X  X  X  X  X  X  X  X  X  X  X				×	×	×	×	N1=40, N2=10
952 AW044663  X X X X X X X X X X X X X Y=0.34+/-109.37 X   X X X Y=40.34+/-109.37 X   X X X X X X X X X X X X X X X X X X								Fold Change: 2.22
952 AW044663  X  X  X  X  X  X  X  X  X  X  X  X  X								P-value: .00004
953 AW051492 440.5+/-328.97 200.34+/-109.37 N1=40, N2=168 Fold Change: 2.03 P-value: 0	2	952	AW044663					216.92+/-78.22
953 AW051492 440.5+/-328.97 200.34+/-109.37 N1=40, N2=168 Fold Change: 2.03 P-value: 0	)							104.46+/-39.86
953 AW051492 440.5+/-328.97 200.34+/-109.37 N1=40, N2=168 Fold Change: 2.03 P-value: 0				×	×	×	×	N1=40, N2=10
953 AW051492 440.5+/-328.97 200.34+/-109.37 N1=40, N2=168 X X Fold Change: 2.03 P-value: 0				<b>!</b>				Fold Change: 2.01
953 AW051492 440.5+/-328.97 200.34+/-109.37 N1=40, N2=168 X Fold Change: 2.03 P-value: 0								P-value: .00001
200.34+/-109.37 N1=40, N2=168 X Fold Change: 2.03 P-value: 0	4	953	AW051492	440.5+/-328.97			442.65+/-332.99	442.65+/-332.99
×		1		200.34+/-109.37	,		174.66+/-95.13	133.38+/-80.06
				N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
				Fold Change: 2.03			Fold Change: 2.4	Fold Change: 3.04
				P-value: 0		;	P-value: 0	P-value: .00008

DUELTOCITY - WITH 1005007142 1 >

202	Seg ID Genbank	Normal vs All	MY - warmen I am M. M			
		17 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
		200.32+/-119.43		200 32+/-119 43	200 22+/ 119 43	200 22 / 110 42
		68.25+/-52.36		83.05+/-58.17	67 34+/-119,45	200.32+/-119.43
		N1=30 N2=168	>	N1-20 N2-10	02.34-7-42.3	45.0/+/-44.89
		TI-13 CI-1100	<	NI=39, NZ=10	NI=39, N2=31	N1=39, N2=6
		rold Change: 2.4/		Fold Change: 2.54	Fold Change: 2.68	Fold Change: 3.64
- [		P-value: 0		P-value: .0089	P-value: 0	P-value: .00001
506	956 C16443	470.61+/-305.63		470.75+/-309.62	470.75+/-309.62	470,75+/-309.62
		179.69+/-105		197.91+/-113.36	144.75+/-66.63	143.41+/-109.79
		N1=40, N2=168	×	N1=40, N2=6	N1=40 N2=31	N1=40 N2=10
		Fold Change: 2.63		Fold Change: 2.24	Fold Change: 2-12	01-20, 104-101 E-14 Off-1-2
		P-value: 0		P-value: .00778	P-value: 5.15	Fold Change: 3.49 D-yolye: 00021
507 95	957 C17781	233.51+/-142.32			o comme	1 -value, .00031
		116.34+/-81.47				
		N1=40, N2=168	×	×	>	>
		Fold Change: 2.05		ļ	<b>{</b>	<b>&lt;</b>
		P-value: 0				
208	967 D55884				231.13+/-145.06	
					105.18+/-64.42	
		×	×	×	N1=40. N2=31	*
					Fold Change: 2.13	<b></b>
-1					P-value: .00004	
509 970	70 D63177	72.4+/-72.56				
		225.06+/-178.61				
		N1=40, N2=168	×	×	×	×
		Fold Change: 3.08				}
510 971	71 D79487					
						215.9+/-67.18
		ř	;	;		84.24+/-31.19
		<b>×</b>	×	×	×	N1=39, N2=6
			٠			Fold Change: 2.6
-						P-value: .00001
511 981	H11724				321.52+/-187.56	321.52+/-187.56
		1			158.38+/-76	124.97+/-54.73
		×	×	×	N1=40, N2=31	N1=40, N2=10
				-	Fold Change: 2	Fold Change: 2.5
					P-value: 0	P-value: .00011

				M	Mountain Stone I	Normal ve Stage II	Normal vs Stage III
#	Seq ID	Genbank	Normal vs All	Normal vs Mangham	Mornial vs Stage I	Ivorinai 13 Stage	G
512	.983	H15868	347.4+/-390.17		344.41+/-394.81 967 69+/-1057.17		
			N1=40 N2=168	×	N1=40, N2=6	×	×
			Fold Change: 2.13	1	Fold Change: 3.28		
			P-value: .00049		P-value: .02477		
513	786	H16294					812.95+/-387.97
CTC		. /					295.8+/-82.15
			*	×	×	×	N1=40, N2=10
			\$	1			Fold Change: 2.51
					•		P-value: 0
15	700	116568	203 47+/-211 85			288.53+/-212.27	288.53+/-212.27
110	767	0000111	CC:117-1-17:CC7		•	46.38+/-45.45	38.38+/-26.86
			N1=00 N2=168	*	<b>×</b>	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.74	1		Fold Change: 4.69	Fold Change: 5.41
			P-value: 0			P-value: 0	P-value: 0
100	100	E177048	221 34+/-117 87			221.34+/-117.87	221.34+/-117.87
crc	707	0461710	86 40+/-44 22			80.01+/-37.66	76.82+/-36.99
			N1=30 N2=168	*	×	N1=39, N2=31	N1=39, N2=6
	•		Fold Change: 2 46			Fold Change: 2.42	Fold Change: 2.75
			P-value: 0	•		P-value: 0	P-value: .00004
215	000	H42085					405.54+/-244.99
OTC	220						174.03+/-102.69
			*	×	×	×	N1=40, N2=10
			<b>!</b>				Fold Change: 2.17
							P-value: .00064
517	100	H43374					588.83+/-221.87
;	1						314.31+/-230.39
			×	×	×	×	NI=40, N2=10
			ł				Fold Change: 2.1
			-				P-value: .00493
619	000	H54254	370.85+/-679.27		377.04+/-687.01	377.04+/-687.01	377.04+/-687.01
310	7		33.63+/-58.23		31.69+/-34.95	21.83+/-62.85	12.93+/-28.05
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 5.23		Fold Change: 4.88	Fold Change: 6.53	Fold Change: 6.25
			P-value: 0		P-value: .00045	P-value: 0	r-value: 0

ENGLICATION - MUNICIPAL -

D Genbank	Genbank	Normal vs A	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
H58608 2	H58608	202.11+/-137.98			201.08+/-139.62	201.08+/-139.62
		82.39+/-48.64			64.47+/-33.26	53.32+/-25
N1=40, N2=168	N1=40, N2=168	N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
Fold Change: 2.25	Fold Change: 2.25	Fold Change: 2.25			Fold Change: 2.77	Fold Change: 3.21
P-value: 0	P-value: 0	P-value: 0			P-value: 0	P-value: 0
1061 N21030	N21030				822.97+/-445.6 356.31+/-294.65	
×	×	×	×	×	N1=40, N2=31	×
					Fold Change: 2.5	
					P-value: .00002	
1064 N21424 ·	N21424					344.38+/-141.72
						134.11+/-57.31
×	×	×	×	×	×	NI=40, NZ=10
						Fold Change: 2.56
						F-value: .00005
1066 N24987	N24987				92.04+/-95.24	92.04+/-95.24
					206.91+/-82.99	210.74+/-113.1
×	×	×	×	×	N1=40, N2=31	N1=40, N2=10
					Fold Change: 2.71	Fold Change: 2.65
					P-value: 0	P-value: .00009
1067 N25096	N25096					308.47+/-138.2
						118.5+/-63.44
×	×	×	×	×	×	N1=40, N2=10
						Fold Change: 2.77 P-value: .00098
1068 N25267 26.22+/-51.01		26.22+/-51.01				
217.96+/-178.06	217.96+/-178.06	217.96+/-178.06	;	;	;	,
N1=40, N2=168	N1=40, N2=168	N1=40, N2=168	×	×	×	×
Fold Change: 5.07	Fold Change: 5.07	Fold Change: 5.07				
P-value: 0		P-value: 0				
1071 N31946						156.39+/-61.76
					;	332.92+/-151.29
×	×	×	×	×	×	NI=40, NZ=10
						Fold Change: 2.11
						F-Value: .00022

PHISPOOLD, MICO. DODGOOTAAO L.

,	5			Mountain Malianest	Normal in Chara I	Normal we Change II	Normal ve Stage III
*	Seq 1D	Genbank	Normal Vs All	Normai vs Mangnant	Normal vs Stage I	MOI III AS STARE TI	Mornal 13 Stage In
526	1072	N32254					116.51+/-51.56 249.15+/-168.21
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.03 P-value: .0051
527	1074	N42752	63.26+/-47.52			63.77+/-48.02	
			203.51+/-259.92			251.31+/-284.54	į
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.23 P-value: 0			Fold Change: 2.74 P-value: .00008	
528	1075	N45224					574.83+/-196.53
2	2						208.47+/-108.26
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.79
9	7007	M145220	265 771/ 173 02			350 46+/-117 88	359 46+/-117.88
670	0/01	14554N	505.7/7/-125.03			20 00 1177	150 12 1 20 04
			164.05+/-84.04	}	ţ	103.40+/-/8.8/	150.154/-52.64
			N1=40, N2=168	×	×	N1=40, N2=31	OI=7N'0'#=IN
			Fold Change: 2.35			Fold Change: 2.36	Fold Change: 2.34
			P-value: 0			P-value: 0	P-value: .00001
530	1079	N48809			130.33+/-82.96		130.33+/-82.96
					233.51+/-111.27		249.11+/-95.4
			×	×	N1=40, N2=6	×	N1=40, N2=10
				•	Fold Change: 2.03		Fold Change: 2.14
					P-value: .00829		P-value: .00153
531	1082	N51335				108.78+/-93.56 222.06+/-201.45	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2	
						P-value: .00003	
532	1083	N52086	289.83+/-310.5			289.83+/-310.5	289.83+/-310.5
			106.77+/-102.27			95.72+/-73.59	77.86+/-63.6
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.07			Fold Change: 2.16	Fold Change: 2.55
			r-value: .00114			1 -value. :002-1/	1-value: :0000

RNSDOCID <WO 02059271A2 ( >

1084 N52352	#	E sea	Conhank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
1085   N56877   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+80.79   109.54+20.70   109.54+80.79   109.54+20.79   109.54+80.79   109.54+20.79   109.54+60.79   109.54+60.79   109.54+60.79   109.54+101.42	± 5	1001	NEDSES					268.01+/-82.24
1085   N56877   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-101.42   109.54-1	S C C	1001	756757					136.43+/-64.33
1085   N56877   10954-80.79   10954-80.79   10954-80.79   10954-80.79   10954-80.79   10954-80.79   10954-80.79   10954-80.79   10954-80.79   1096   N12-40, N2-16   N12-40, N2-21   Pold Change: 2.45   Pold Change: 2.37   Pold Change: 2.39   Pold Change: 2.39   Pold Change: 2.45   Pol				· <b>×</b>	×	×	×	N1=40, N2=10
1085   N56877   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   109.54-80.79   108.54-270.27   108.54-270.27   108.54-270.27   108.54-270.27   108.54-270.27   108.54-270.27   108.54-270.27   108.54-270.27   108.54-270.28   108.54-270.27   108.54-270.28   108.54-270.27   108.54-270.28   108.				<b>£</b>				Fold Change: 2.09
1085   N56877   109.54-80.79   109								P-value: .00/4
1086   N57539   225.43+7.1027   N1=6, N2=168   X   N1=6, N2=31   Paralne; 0.281   Paralne; 0.0281   Paralne; 0.086   N1=39, N2=16   Paralne; 0.0159   Paralne; 0.0096   Pa	534	1085	N56877	109 5+/-80.79			109.5+/-80.79	109.5+/-80.79
Ni	70	1003	//0001	300 03+/-270 27			327.79+/-348.66	306.18+/-259.39
Fold Change: 2.15   Fold Change: 2.15   Fold Change: 2.15   P-value: 0.0281				N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
1086   NS7539   225.43+1.101.42   NI				Enld Change: 7 45			Fold Change: 2.15	Fold Change: 2.68
1086   N57539   225,43+/-1001.42   NI = 39, N2=10     NI = 39, N2=16				D-volue: 0		•	P-value: .00281	P-value: .00382
106.354/-190.86   106.354/-190.86   106.354/-190.86   106.354/-190.86   106.354/-190.86   106.354/-190.86   106.354/-190.86   106.354/-190.86   108.334/-100.13   1087   NS9432	525	1004	NE7E30	225 43+/-101 42			225.43+/-101.42	225.43+/-101.42
Ni = 59, N2 = 31	66	1000	VOC ICAI	103 31+/-100 1		•	106.35+/-190.86	96.95+/-76.68
Fold Change: 2.37   P-value: 0   P-value:				N1=20 N2=168	*	×	N1=39, N2=31	N1=39, N2=6
P-value: 0   P-value: 0				Eold Change: 2 37	1		Fold Change: 2.94	Fold Change: 2.43
1087   N59432   1.74m.c.   237.954/-107.53   71.264/-38.6   105.024/-65.3   71.264/-38.6   105.024/-65.3   71.264/-38.6   105.024/-65.3   71.264/-38.6   105.024/-65.3   71.264/-38.6   105.024/-65.3   71.264/-38.6   71.264/-38.6   71.264/-38.6   71.264/-38.6   71.264/-38.6   71.264/-38.6   71.264/-38.6   72.7514/-156.97   72.7514/-156.97   72.7514/-156.97   72.7514/-156.97   72.7514/-156.97   72.7514/-156.97   72.7514/-156.97   72.7514/-156.97   72.7514/-13				rold Change, 2.37			P-value: 0	P-value: .00273
108 N62126  N62126  X  X  X  X  N1=39, N2=31  Fold Change: 2.39  P-value: .00159  P-value: 0  P-value: .00096  P-value: .	1	1007	NE0422	1 - value:		237.95+/-107.53	237.95+/-107.53	237.95+/-107.53
No.	920	7001	7546CNI			71.26+/-38.6	105.02+/-65.3	110.93+/-111.49
Fold Change: 3.32 Fold Change: 2.39 I P-value: 00159 P-value: 0  R X X X X X X X X X X X X X X X X X X				>	*	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
1088   N62126   N63126   N63126   N63126   N63237   217.51+'-156.97   S2.65+'-34.21   S2.57+'-33.35   S2.65+'-34.21   S2.57+'-33.35   S2.65+'-34.21   S2.57+'-33.35   S2.65+'-34.21   S2.57+'-33.35   S2.65+'-34.21   S2.57+'-33.35   S2.65+'-34.21   S2.57+'-33.35   S2.65+'-34.21   S2.67+'-33.35   S2.65+'-34.21   S2.67+'-33.35   S2.65+'-34.21   S2.67+'-34.21   S2.67+				4		Fold Change: 3.32	Fold Change: 2.39	Fold Change: 2.61
1088         N62126         X						P-value: .00159	P-value: 0	P-value: .00543
N63237   217.51+/-156.97   2	202	1000	Mentak					280.04+/-181.07
New Year   X	\. ?	1088	07170N					109.11+/-74.94
1089 N63237 217.51+/-156.97 52.65+/-34.21 52.57+/-156.97 52.65+/-34.21 52.57+/-33.35 N1=39, N2=168 X N1=39, N2=10 N1=39, N2=31 Fold Change: 2.55 P-value: 0 Fold Change: 2.84 Fold Change: 5.84 Fold Change: 5.84 P-value: 0 P-value: 0 P-value: 0 Fold Change: 5.84 P-value: 0 P-v				>	×	×	×	N1=40, N2=10
1089 N63237 217.51+/-156.97 217.51+/-156.97 217.51+/-156.97 52.65+/-34.21 52.57+/-33.35 52.65+/-34.21 52.57+/-33.35 52.65+/-34.21 52.57+/-33.35 N1=39, N2=168 X N1=39, N2=10 N1=39, N2=31 Fold Change: 2.55 P-value: 0 Fold Change: 5.84 Fold Change: 5.84 Fold Change: 5.84 P-value: 0 P-valu				<b>&lt;</b>	ł			Fold Change: 2.59
1089         N63237         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         217.51+/-156.97         22.65+/-34.21         52.67+/-33.35         52.67+/-33.35         52.67+/-33.35         52.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-33.35         72.67+/-34.91         72.67+/-316.71         72.67+/-316.71         72.67+/-105.81         72.67+/-						!		P-value: .00734
1090 N63913 X N1=39, N2=16 N1=39, N2=31 S2.65+/-34.21 S2.57+/-33.35 N1=39, N2=10 N1=39, N2=31 Pold Change: 2.5 P-value: 0	620	1000	N62727	217 51+/-156 97		217.51+/-156.97	217.51+/-156.97	217.51+/-156.97
N1=39, N2=16	000	1007	167601	63 12+/-54 35		52.65+/-34.21	52.57+/-33.35	24.34+/-38.62
Fold Change: 2.55 Fold Change: 2.55 Fold Change: 2.9 Fold Change: 2.55 Fold Change: 2.9				N1=30 N7=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
1090 N63913 463.66+7.314.65  88.17+7.134.91  N1=40, N2=168  Fold Change: 5.84  P-value: 0  458.01+7.316.71  87.05+7.105.81  N = 40, N2=31  N = 40, N2=31  Fold Change: 5.84  P-value: 0				Eold Change: 2 55	ŀ	Fold Change: 3.16	Fold Change: 2.9	Fold Change: 3.83
1090 N63913 463.664/-314.65 87.054/-105.81 87.054/-105.81 87.054/-105.81 N1=40, N2=168 X N1=40, N2=31 Fold Change: 5.84 P-value: 0				D-value: 0		P-value: .00096	P-value: 0	P-value: .00001
88.17+/-134.91 X N1=40, N2=158 N1=40, N2=168 X Fold Change: 5.25 P-value: 0	623	1000	N62013	463 66+/-314 65			458.01+/-316.71	458.01+/-316.71
X N1=40, N2=31 Fold Change: 5.25 P-value: 0	, , ,	nan	CICCON	88 17+/-134 91			87.05+/-105.81	65.18+/-127.89
Fold Change: 5.25 P-value: 0				N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0				Fold Change: 5.84	•		Fold Change: 5.25	Fold Change: 7.57
				P-value: 0			P-value: 0	P-value: .00008

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
3	1001	NZAZAO				17 78-/-18 696	167 87+/-87 71
340	1691	1404049				129.76+/-54.11	114.48+/-29.26
			*	*	*	N1=40, N2=31	N1=40, N2=10
			€	•	1	Fold Change: 2 00	Fold Change: 2.21
						P-value: 0	P-value: 0
541	1092	N76867				210.78+/-96.34	
						106.18+/-57.67	
			×	×	×	N1=39, N2=31	×
						Fold Change: 1.97	
						P-value: 0	
542	1094	N79004					93.29+/-75.16
						;	273.05+/-182.9
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.79
							P-value: .00222
543	1095	N80935	266.86+/-83.21				266.66+/-84.29
			143.94+/-87.39				130.9+/-68.88
			N1=40, N2=168	×	×	×	N1=40, N2=10
			Fold Change: 2.01				Fold Change: 2.17
			P-value: 0				P-value: .00097
544	1096	N90525	117.6+/-226.89			118.22+/-229.82	
			226.51+/-203.72			255.32+/-119.15	
	•		N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 2.23			Fold Change: 2.98	
			P-value: .00001			P-value: 0	
545	1101	R08000	501.45+/-685.59		502.76+/-694.51	502.76+/-694.51	502.76+/-694.51
			78.58+/-101		79.82+/-77.61	57.68+/-127.95	65.51+/-107.84
			N1=40, N2=168	×	N1=40, N2=6	NI=40, N2=31	N1=40, N2=10
			Fold Change: 4.96		Fold Change: 4.45	Fold Change: 7.21	Fold Change: 6.92
			P-value: 0		P-value: .0049	P-value: 0	P-value: .00004
546	1102	R11248				114.31+/-112.68	114.31+/-112.68
						295.22+/-374.37	538.23+/-597.4
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.09	Fold Change: 3.42
						P-value: .00187	P-value: .01362

					1 . M. 1.	Normal ve Ctore I	Normal ve Stage II	Normal ve Stage III
1104   R20784   110.23+4.833.81   111.278+9.4943.05   111.278+9.4943.05   111.278+9.4943.05   111.278+9.4943.05   111.278+9.4943.05   111.278+9.296.05   111.278+9.276.05   111.278+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05   111.2788+9.296.05	*	Sed ID	Genbank	Normal vs All	NOTITIAL VS INTALLIGUALIT	Noi mai vs Diage I	Traffing to minimum	20 C/O / 100 O111
Ni	547	1104	R20784	1107.23+/-833.81		1112.78+/-843.96	1112./8+/-843.96	1112./8+/-843.90
Ni=40, N2=168	:			264.46+/-256,11		257.86+/-243.05	168.78+/-236.94	123.27+/-153.07
Fold Change: 4.88   Fold Change: 4.78   Fold Change: 7.78   Fold Change: 4.78   Fold Change: 7.78   Fold Change: 7.26   Fold Change: 7.26   Fold Change: 2.14   Fold Change: 2.15   Fold				N1=40. N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
110   R49392   P-value: 0   P-value: 0   P-value: 0   P-value: 0   P-value: 0   156.98+-110.51				Fold Change: 4.88		Fold Change: 4.54	Fold Change: 7.78	Fold Change: 10.71
1109   R49392   R49392   R49392   R49392   R49392   R49392   R49392   R49392   R49392   R4940410.51   R40, N2=91   R40,				P-value: 0		P-value: .00794	P-value: 0	P-value: .00001
1112   R54660   X	548	1100	R49392				267.35+/-98.92	267.35+/-98.92
NI = 40, N2=31	2	611	- COCLAN				156.98+/-110.51	143.02+/-95.35
1112 R54660   P-value: 0.0002				*	×	×	N1=40, N2=31	N1=40, N2=10
1112   R54660   R54660   R54660   R54660   R54660   R54660   R54660   R54660   R54660   R5466133.86   R54660   R5466133.86   R5667-133.86   R5614-153.86				<b>&lt;</b>	!		Fold Change: 2.05	Fold Change: 2.14
1112   R54660   X							P-value: .00002	P-value: .0067
1113   R62346   92.55+/48.64   Fold Change: 5.96   Ni=40, N2=31     1113   R62346   92.55+/48.64   Fold Change: 5.96   Ni=40, N2=31     1114   R67627   R69584   211.19+/227.25   Fold Change: 2.17   R73-47-425.8     1115   R69584   211.19+/227.25   S3.06+/91.11     1116   R70255   241.03+/-179.01   P-value: 0.0002   P-value: 0.0001   P-value: 0.0002   P-value: 0.0001   P-value: 0.0001   P-value: 0.0001   P-value: 0.0001   P-value: 0.0002   P-value: 0.0001   P-value: 0.0001   P-value: 0.0001   P-value: 0.0001   P-value: 0.0002   P-value: 0.0001   P-value: 0.0001   P-value: 0.0002   P-value: 0.0001   P-value: 0.0002   P-value: 0.0002   P-value: 0.0002   P-value: 0.0001   P-value: 0.0002   P-value: 0.0002   P-value: 0.0002   P-value: 0.0002   P-value: 0.0002   P-value: 0.0003	540	1112	D54660			200.26+/-133.86	200.26+/-133.86	200.26+/-133.86
Ni	747	7117	2001			49.74+/-62.98	16.03+/-23.1	6.98+/-15.78
Fold Change: 4.34   Fold Change: 5.96   P-value: .00827   P-value: 0				<b>×</b>	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
1113   R62346   92.55+/-48.64   P-value: .00827   P-value: 0	_			\$	!	Fold Change: 4.34	Fold Change: 5.96	Fold Change: 6.74
1113   R62346   92.55+/48.64   20.55+/48.64   218.35+/108.48   218.35+/108.48   218.35+/108.48   218.35+/108.48   218.35+/108.48   NI=39, N2=16   NI=39, N2=11						P-value: .00827	P-value: 0	P-value: 0
218.34+/108.48	550	1113	R62346	92 55+/-48 64			92.55+/-48.64	
Ni = 39, N2 = 168	966	CIT		218.35+/-108.48			218.34+/-122.05	
Fold Change: 2.17  P-value: 0  P-value: 0  P-value: 0  P-value: 0  T03.42+/425.8  319.29+/199.18  X  X  X  X  X  X  X  X  X  X  X  X  X				N1=39, N2=168	×	×	N1=39, N2=31	×
1114   R67627   P-value: 0   P-value: 0				Fold Change: 2.17			Fold Change: 2.14	
1114   R67627   X				P-value: 0		•	P-value: 0	
X   X   X   X   X   X   X   X   X   X	551	1114	R67627				703.42+/-425.8	
The color of the	100						319.29+/-199.18	
Fold Change: 2.32 P-value: 0 P-value: 0 Fold Change: 2.32 P-value: 0 Fold Change: 2.32 P-value: 0 Fold Change: 2.91 Fold Change: 2.91 P-value: 0.002 P-value: 0 P-value: 0 P-value: 0 P-value: 0 Fold Change: 3.62 33.3+/-86.44 X Fold Change: 5.34				×	×	×	N1=40, N2=31	×
P-value: 0				<b>:</b>			Fold Change: 2.32	
1115         R69584         211.19+/-227.25         214.32+/-229.35         214.32+/-229.35           1116         R70255         23.06+/-91.11         X         N1=40, N2=16         N1=40, N2=31           Fold Change: 2.91         Fold Change: 3.38         Fold Change: 3.62           P-value: .00001         P-value: .0002         P-value: .0           1116         R70255         241.03+/-179.01         241.29+/-181.34           13.3+/-86.44         X         N1=40, N2=31           Fold Change: 5.3         Fold Change: 5.24           P-value: 0         P-value: 0							P-value: 0	
53.06+/-91.11	552	1115	R69584	211.19+/-227.25		214.32+/-229.35	214.32+/-229.35	214.32+/-229.35
N1=40, N2=168	}	1		53.06+/-91.11		30.89+/-23.04	37.79+/-84.48	6.84+/-26.67
Fold Change: 2.91 Fold Change: 3.38 Fold Change: 3.62  P-value: .00001 P-value: 00002 P-value: 0  3.3.4-179.01 241.29+/-181.34  241.29+/-181.34  241.29+/-181.34  241.29+/-181.34  241.29+/-181.34  241.29+/-181.34  X N1=40, N2=31  Fold Change: 5.24  P-value: 0  P-value: 0  P-value: 0  P-value: 0				N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
1116 R70255 241.03+/-179.01 P-value: .0002 P-value: 0 P-value: .00001 P-value: 0 241.29+/-181.34 241.29+/-181.34 25.72+/-39.39 33.3+/-86.44 X N1=40, N2=31 Fold Change: 5.3 P-value: 0 P-value: 0 P-value: 0				Fold Change: 2 91		Fold Change: 3.38	Fold Change: 3.62	Fold Change: 4.76
1116 R70255 241.03+/-179.01 241.29+/-181.34 25.72+/-39.39 33.3+/-86.44 X N1=40, N2=31 N1=40, N2=168 X Pold Change: 5.3 P-value: 0				D-volue: 00001		P-value: .0002	P-value: 0	P-value: 0
25.72+/-39.39 33.3+-86.44 X N1=40, N2=31 N1=40, N2=168 X Pold Change: 5.24 Fold Change: 5.3 Fold Change: 5.24 P-value: 0	553	1116	D70755	241 03+/-179 01			241.29+/-181.34	241.29+/-181.34
X N1=40, N2=31 Fold Change: 5.24 P-value: 0	55	0111	2000	33 3+/-86 44			25.72+/-39.39	17.97+/-75.13
Fold Change: 5.24 P-value: 0				N1=40 N2=168	×	×	N1=40, N2=31	N1=40, N2=10
P-value: 0				Fold Change: 5.3			Fold Change: 5.24	Fold Change: 5.55
				P-value: 0			P-value: 0	P-value: .00003

BNG00000 - WO 000007140 1 5

#	Sea ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
اء	130	The state of the s			9	202 (6.1.024.40	36 450 1 137 405
554	1117	R73518	397.68+/-234.48			397.68+7-234.48	397.08+/-234.48
			142.17+/-86.32			129.9/+/-/5.3	130.92+/-91.03
			N1=39, N2=168	×	×	NI=39, N2=31	N1=39, N2=6
			Fold Change: 2.61			Fold Change: 2.92	Fold Change: 2.93
			P-value: 0			P-value: 0	P-value: .00003
555	1118	R74561				425.23+/-350.96	
						871.35+/-705.04	
			×	×	×	N1=40, N2=31	×
						Fold Change: 2.06	
						P-value: .00036	
556	1119	R83604	294.9+/-858.81		304.76+/-867.74	304.76+/-867.74	304.76+/-867.74
 			-49.34+/-85.75		-70.76+/-37.34	-62.65+/-38.9	-42.74+/-57.17
			N1=40, N2=168	×	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.18		Fold Change: 3.74	Fold Change: 3.74	Fold Change: 3.25
			P-value: .00005		P-value: .00001	P-value: .00001	P-value: .0002
557	1121	T16144				67.72+/-60.08	67.72+/-60.08
						246.32+/-239.25	213.1+/-108.52
			×	×	×	N1=40, N2=31	N1=40, N2=10
			-			Fold Change: 3.16	Fold Change: 3.43
						P-value: 0	P-value: .00004
558	1122	T57042				286.11+/-193.74	286.11+/-193.74
						114.39+/-69.74	125.4+/-63.01
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.34	Fold Change: 2.01
						P-value: 0	P-value: .00122
559	1123	T57670				404.19+/-128.46	404.19+/-128.46
						212.97+/-107.98	186+/-108.03
			×	×	×	N1=40, N2=31	N1=40, N2=10
						Fold Change: 2.03	Fold Change: 2.39
						P-value: 0	P-value: .00117
260	1124	T57773				•	214.22+/-119.35
							76.17+/-87.27
			×	×	×	×	N1=40, N2=10
							Fold Change: 3.27
							F-value: .002

7	E	A b l	MT 4 11	MT	Mr Che T	Manage 1 and 10.	Manney I am Oke - Tree
<u></u>	oed TD	Genoank	Normal Vs All	Normal VS Mailgnant	Normal vs Stage 1	Normal vs Stage II	Normal vs Stage III
561	1125	T61106	164.66+/-104.9			164.66+/-104.9	164.66+/-104.9
			345.33+/-209.56			339.88+/-198.04	341.68+/-227.02
			N1=39, N2=168	×	×	N1=39, N2=31	N1=39, N2=6
			Fold Change: 2,21			Fold Change: 2.11	Fold Change: 2.17
			P-value: .00001			P-value: .00077	P-value: .01513
562	1126	T64447	216.31+/-152.39		216.31+/-152.39	216.31+/-152.39	216.31+/-152.39
			41.01+/-92.12		39.2+/-138.62	17.71+/-47.39	-19.08+/-58.11
			N1=39, N2=168	×	N1=39, N2=10	N1=39, N2=31	N1=39, N2=6
_			Fold Change: 3.99		Fold Change: 3.8	Fold Change: 5.18	Fold Change: 7.39
			P-value: 0		P-value: .01694	P-value: 0	P-value: 0
563	1130	T79945	266.46+/-143.28				
			196.1+/-275.3				
			N1=40, N2=168	×	×	×	×
			Fold Change: 2.04				
			P-value: 0				
564	1133	T92947	370.07+/-299.38			359.82+/-296.09	359.82+/-296.09
			173.72+/-164.88			134.2+/-88.77	113.03+/-41.6
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.08			Fold Change: 2.39	Fold Change: 2.36
			P-value: .00004			P-value: .00007	P-value: .00008
595	1134	T93570				344.83+/-197.39	344.83+/-197.39
						156.26+/-76.45	137.27+/-55.02
			×	×	×	N1=40, N2=31	N1=40, N2=10
	•					Fold Change: 2.12	Fold Change: 2.27
			:	;		P-value: 0	P-value: .0001
995	1170	W02608	83.49+/-56.33			82.66+/-56.82	82.66+/-56.82
			238.33+/-117.55			216.35+/-112.51	206.9+/-95.19
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.06			Fold Change: 2.77	Fold Change: 2.61
			P-value: 0			P-value: 0	P-value: .00124
267	1171	W02823	220.34+/-88.04			217.4+/-87.18	217.4+/-87.18
			83.44+/-86.86			71.46+/-47.57	107.28+/-72.66
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.96			Fold Change: 3.16	Fold Change: 2.32
			P-value: 0			P-value: 0	P-value: .00987

•

\*

_	_		_		_	_															_											_			<del></del>
Normal vs Stage III	200 21 +/- 164 12	71:401-/17:667	00000 11 1000	NI=40, NZ=10	Fold Change: 5.11	P-value: 0	1139.71+/-444.58	291.49+/-262.25	N1=40, N2=10	Fold Change: 5.29	P-value: .00046	172.41+/-85.84	443.37+/-353.68	N1=40, N2=10	Fold Change: 2.22	P-value: .00917			×					×			720.17+/-951.89	39.22+/-65.55	N1=40, N2=10	Fold Change: 7.71	P-value: 0	100.04+/-68.17	213+/-119.61	N1=40, N2=10	Fold Change: 2.14 P-value: .00375
Normal vs Stage II	200 214/ 164 12	29.21-/-104.12 56.7+/-41.66	00:14-7:200	NI=40, NZ=31	Fold Change: 4.81	P-value: 0	1139.71+/-444.58	244.74+/-245.86	N1=40, N2=31	Fold Change: 5.59	P-value: 0			×			314.68+/-111.87	147.05+/-53.04	N1=39, N2=31	Fold Change: 2.14	P-value: 0	67.04+/-84.41	322.95+/-770.03	N1=40, N2=31	Fold Change: 2.05	P-value: .00441	720.17+/-951.89	169.52+/-503.24	N1=40, N2=31	Fold Change: 4.62	P-value: 0			×	
Normal vs Stage I	000 011/16/10	109 65±/ 140 45	C+:O+T-/+CO:9OT	N1=40, N2=6	Fold Change: 3.51	P-value: .03256			×					×			-		×					×					×					×	•
Normal vs Malignant			;	×		!			×					×					×		•			×					×					×	
Normal vs All	201 (11.1.100	301.61+/-162.72	01.7447-32.09	N1=40, N2=168	Fold Change: 4.19	P-value: 0	1144.81+/-440.02	379.83+/-343.79	N1=40, N2=168	Fold Change: 3.79	P-value: 0			×					×					×			707.63+/-942.95	144.29+/-433.7	N1=40, N2=168	Fold Change: 5.42	P-value: 0			×	
Genbank	07.000.12	· W07043					W07304					W22264					W28281					W31919					W32480					W55924			
Sea ID		1173					1174					1177					1181					1182	<u> </u>				1183					1189			
*		208					995					570					571					572	!				573				_	574			

,

CONTINUE AND MARCOTTAN

	Dey Are	Gendank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
263	1105	CX0.CF/XV	201 06±/ 163 16			200 6047 165 13	200001110000
0/0	CKIT	7007/ 14	381.807/-103.10 192 12±/ £2 01			380.08+/-163.12	380.68+/-165.12
			182.134/-02.01		!	1/3.84+/-50.18	1/0.3+/-00.81
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.03			Fold Change: 2.04	Fold Change: 2.07
			· P-value: 0			P-value: 0	P-value: .00001
216	1196	W72182					83.09+/-49
							231.34+/-134.05
			×	×	×	×	N1=40, N2=10
							Fold Change: 2.71
							P-value: .00094
577	1199	W72347	367.98+/-155.29			368.08+/-157.32	368.08+/-157.32
			146.12+/-193.47			94.65+/-155.82	261.92+/-468.76
			NI=40, NZ=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 3.46			Fold Change: 5.14	Fold Change: 3.22
			P-value: 0			P-value: 0	P-value: .03608
578	1200	W72407	235.27+/-157.67			234.77+/-159.7	
			63.55+/-76.04			85.52+/-101.27	
			N1=40, N2=168	×	×	N1=40, N2=31	×
			Fold Change: 3.77			Fold Change: 3.02	
			P-value: 0			P-value: .00001	
579	1201	W72511	995.7+/-434.28			988.5+/-437.53	988.5+/-437.53
			430.04+/-283.24		•	418.47+/-331.96	250.59+/-208.45
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.53			Fold Change: 2.63	Fold Change: 4.54
			P-value: 0			P-value: 0	P-value: .00008
280	1203	W73230	526.33+/-307.22			524.48+/-311.01	524.48+/-311.01
			205.2+/-108.64			185.59+/-79.06	164.36+/-67.2
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.58			Fold Change: 2.72	Fold Change: 3
			P-value: 0			P-value: 0	P-value: 0
581	1204	W73386	242.96+/-399.57	469.37+/-905.14	248.29+/-403.35	248.29+/-403.35	248.29+/-403.35
			16.99+/-76.53	95.29+/-88.61	3.09+/-55.26	-16.75+/-32.9	-2.29+/-42.09
			N1=40, N2=168	N1=17, N2=49	N1=40, N2=6	N1=40, N2=31	N1=40, N2=10
			Fold Change: 4.25	Fold Change: 3.43	Fold Change: 4.79	Fold Change: 5.86	Fold Change: 4.92
			P-value: 0	P-value: .00019	P-value: .00079	P-value: 0	P-value: 0

						F	Manual we Other III
*	Sed ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs Stage I	Normal vs Stage II	Normal vs Stage III
583	1205	W73819			i	993.58+/-625.18	993.58+/-625.18
3						399.14+/-205.47	277.46+/-140.58
			×	×	×	N1=40, N2=31	N1=40, N2=10
			1			Fold Change: 2.23	Fold Change: 3.36
						P-value: 0	P-value: .00039
583	1206	W73855				201.45+/-105.43	
}						87.02+/-86.49	
			×	×	×	N1=40, N2=31	×
			1			Fold Change: 2.72	
		-			•	P-value: 0	
584	1207	W73890	223.3+/-129.09			223.01+/-130.77	223.01+/-130.77
3			73.33+/-44.79			65.62+/-33.81	62.68+/-63.75
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.96			Fold Change: 3.14	Fold Change: 3.85
			P-value: 0			P-value: 0	P-value: .00019
585	1209	W80496	221.23+/-140.42			214.3+/-135.15	214.3+/-135.15
}	) 1		105.98+/-75.28			95.94+/-55.75	53.76+/-58.28
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.11			Fold Change: 2.13	Fold Change: 3.87
			P-value: 0			P-value: .00004	P-value: .00029
586	1211	W88427	669.14+/-243.38			661.21+/-241.27	661.21+/-241.27
-			316.73+/-233.88			304.22+/-202.92	187.14+/-59.43
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
			Fold Change: 2.35			Fold Change: 2.35	Fold Change: 3.45
			P-value: 0			P-value: 0	P-value: 0
587	1246	Z99386	615.03+/-208.26			611.71+/-209.91	611.71+/-209.91
			262.6+/-122.89			245.54+/-120.4	231.83+/-120.93
			N1=40, N2=168	×	×	N1=40, N2=31	N1=40, N2=10
_			Fold Change: 2.48	•		Fold Change: 2.66	Fold Change: 3.04
			P-value: 0			P-value: 0	P-value: .00124

226
Table 5: BREAST / INFILTRATING LOBULAR CARCINOMA

PHOPOGIO, 4810 - MOEMZ440 C.

#_	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
1	7	AA017070	218.33+/-195.52		·
			77.15+/-79.13	•	
			N1=40, N2=17	X	X
			Fold Change: 2.53		
			P-value: .00187		
2	15	AA031790	336.45+/-181.35		
			156.08+/-81.33		
			N1=40, N2=17	X	x
			Fold Change: 2.16		
			P-value: .00003		
3	23	AA044830	387.92+/-190.91	•	
			188.55+/-88.55		
			N1=40, N2=17	X	· X
			Fold Change: 2.14		
			P-value: .00023		
4	24	AA045145	262.21+/-180.28		
•			76.07+/-123.14		
			N1=40, N2=17	X	x
			Fold Change: 3.26		
		·	P-value: .00038		
5	25	AA046457	254.96+/-154.86		
			128.89+/-118.57		
			N1=40, N2=17	X	X
			Fold Change: 2.3		
			P-value: .00176		
6	31	AA059396	383.25+/-127.97		383.25+/-127.97
			170.7+/-70.05		120.28+/-48.53
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.32		Fold Change: 3.22
	·-·		P-value: 0		P-value: .01218
7	33	AA059458	74.76+/-90.6		74.76+/-90.6
			314.12+/-111.83		344.29+/-46.75
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 5.79		Fold Change: 6.82
	<del></del>		P-value: 0		P-value: 0
8	41	AA126704	312.64+/-137.34		
			130.96+/-82.96	**	, J
			N1=40, N2=17	X	X
			Fold Change: 2.5		
		4.4405510	P-value: .00009		
9	42	AA127718	240.21+/-361.64		
			75.73+/-121.03	v	x
			N1=40, N2=17	X	Λ.
			Fold Change: 3.09		
10	43	A A 107707	P-value: .00005 212.97+/-123.48		
ΙŪ	43	AA127727	100.07+/-53.82		
			N1=40, N2=17	x	X
			Fold Change: 2.1	^	A
			P-value: .00014		
11	51	A A 122249			
11	21	AA133248	400.91+/-134.73 201.52+/-119.8		
	•		201.52+7-119.8 N1=40, N2=17	x	X
			Fold Change: 2.24	Λ	Α.
			P-value: .00009		
			1 - value. 100003		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
12	57	AA142913	302.34+/-222.83		302.34+/-222.83
			104.53+/-62.4		68.29+/-31.77
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.84		Fold Change: 4.03
			P-value: 0		P-value: .00871
13	62	AA147751	478.2+/-207.42		
			245.52+/-144.78		
			N1=40, N2=17	X	X
			Fold Change: 2.03		
l			P-value: .00015		
14	63	AA147884	46.86+/-55.16		
			212.3+/-151.24		
			N1=40, N2=17	$\mathbf{x}$	X
1			Fold Change: 3.93		
			P-value: .00001		
15	64	AA149312	374+/-139.43		
	••		179.7+/-77.1		
			N1=40, N2=17	X	X
l			Fold Change: 2.18		
			P-value: .00003		
16	65	AA150501	215.8+/-104		
•	00	12110000	97.75+/-48.53		
l			N1=40, N2=17	X	X
			Fold Change: 2.27		
			P-value: .00006		
17	71	AA158731	287.72+/-241.22		
1		IMILIDOTOI	94.76+/-99		
			N1=40, N2=17	· X	X
1			Fold Change: 3.29		
		•	P-value: .00036		·
18	72	AA160156	630.23+/-274.77		
1.0	,,,	111100100	297.85+/-166.73		
			N1=40, N2=17	X	x
1			Fold Change: 2.39		
1			P-value: .00076		
19	75	AA173572	368.73+/-173.58		368.73+/-173.58
~	,,,		140.6+/-66.1		101.84+/-30.25
1			N1=40, N2=17	x	N1=40, N2=17
Į.			Fold Change: 2.52		Fold Change: 3.17
			P-value: .00001		P-value: .00053
20	84	AA203663	288.39+/-92.75		
1	••		151.54+/-90.12		
1			N1=40, N2=17	X	X
1			Fold Change: 2.19	•	
1			P-value: .00062		
21	88	AA227778	254.32+/-164.5		
			129.32+/-121.52		
1			N1=40, N2=17	X	X
			Fold Change: 2.21		_
			P-value: .00551		
22	99	AA369887	326.24+/-259.48		
	77	1 0000 1	1569.71+/-1564.61		
			N1=40, N2=17	X	X
			Fold Change: 3.13	••	
			P-value: .00723		
<u></u>			1 - value00/23		

PHIPPOPID: 1410 - 000F007440 F -

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
23	117	AA430314	259.57+/-186.05		259.57+/-186.05
			94.12+/-84.62		51.43+/-32.49
			N1=40, N2=17	$\mathbf{x}$	N1=40, N2=17
			Fold Change: 2.81		Fold Change: 4.33
			P-value: .00057		P-value: .0109
24	120	AA447015	226.67+/-173.74		226.67+/-173.74
			86.47+/-87.06		49.75+/-49
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.44		Fold Change: 3.69
			P-value: .00239		P-value: .04932
25	121	AA448195	82.22+/-92.11		
			252.38+/-226.28		
			N1=40, N2=17	$\mathbf{x}$	x
ĺ			Fold Change: 2.56		
			P-value: .00561		
26	122	AA450090	285.47+/-226.15		285.47+/-226.15
)			121.51+/-105.64		80.74+/-67.6
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.56		Fold Change: 3.67
			P-value: .00017		P-value: .04277
27	124	AA452295	220.36+/-116.43		220.36+/-116.43
- '			43.55+/-34.23		27.93+/-7.95
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.8		Fold Change: 6.64
l			P-value: 0		P-value: 0
28	129	AA479033	105.96+/-264.08		
			699.96+/-1244.37		
l			N1=40, N2=17	X	x
l			Fold Change: 3.25		
1			P-value: .01862	•	
29	131	AA480075	331.5+/-159.34		
			170.51+/-174.22		
1			N1=40, N2=17	X	X
			Fold Change: 2.36		
ł			P-value: .00065		
30	134	AA486731	417.18+/-216.76		
	•		258.38+/-279.38		The state of the s
l			N1=40, N2=17	X	<b>X</b> "'
			Fold Change: 2.26		
{			P-value: .0077		
31	135	AA488889	298.86+/-194.94		
1			114.61+/-41.42		
1			N1=40, N2=17	X	X
}			Fold Change: 2.16		
			P-value: .00001		
32	138	AA502943	439.24+/-110.96		
	· ·		200.97+/-110.89		
			N1=40, N2=17	X	X
1			Fold Change: 2.41		
			P-value: 0		
33	140	AA508196	475.57+/-315.6		
1	~ ••		208.59+/-128.6		
			N1=40, N2=17	X	X
			Fold Change: 2.29	**	<del></del>
İ			P-value: .0014		
L			1-144400017		<del> </del>

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
34	142	AA516420	208.7+/-209.98		
			762.28+/-919.5		
			N1=40, N2=17	X	X
			Fold Change: 2.83		
			P-value: .00199		
35	151	AA526961	417.14+/-237.24		
			139.33+/-66.58		
			N1=40, N2=17	X	x
1			Fold Change: 2.89		
			P-value: 0		
36	156	AA534456	1130.9+/-759.82		
			504.53+/-276.17		
			N1=40, N2=17	X	X
l			Fold Change: 2.23		
			P-value: .00282		•
37	160	AA535218	322.09+/-137.43		
3"	100	AASSSAIO	130.51+/-83.58		
			N1=40, N2=17	X	X
			Fold Change: 2.69		
1			P-value: .00001		
38	171	AA584310	402.55+/-323.55		
30	1/1	AA304310	1185.08+/-725.81		
Ì			N1=40, N2=17	X	X
			Fold Change: 3.27		
			P-value: .00003		
39	172	AA584403	593.26+/-1291.79		593.26+/-1291.79
39	1/2	AAJOTTUJ	73.69+/-113.44		46.94+/-41.5
1			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 3.63		Fold Change: 4.08
1			P-value: .0001		P-value: .01967
40	175	AA601511	2941.11+/-4823.41		
1	175	AAUUISII	8196.8+/-10494.86		
			N1=40, N2=17	X	X
1			Fold Change: 3.59		<del></del>
			P-value: .04627		
41	178	AA609310	285.39+/-160.8		
71	1/0	ALAUV/JIU	103.37+/-63.8		
			N1=40, N2=17	X	X
			Fold Change: 2.73		- <b>-</b>
			P-value: .00003		
42	180	AA610522	803+/-768.74		803+/-768.74
72	100	AMUIUJ##	2236.91+/-2047.57		1948.9+/-1536.5
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 3.15		Fold Change: 3.65
			P-value: .00504		P-value: .04632
43	184	AA621478	398.69+/-325.12		
173	104	P1/20/214/0	105.85+/-99.55		
			N1=40, N2=17	X	x
			Fold Change: 3.76	21	
			P-value: .00002		
144	100	A A /20/4/7	1145.06+/-502.33	·····	1145.06+/-502.33
44	189	AA628467			263.82+/-233.17
			483.55+/-276.22	X	N1=40, N2=17
1			N1=40, N2=17	^	Fold Change: 5.48
			Fold Change: 2.59		P-value: .04561
1			P-value: .00016		r-value: .04301

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
45	191	AA631047	615.9+/-364.24		
			335.52+/-248.64		
			N1=40, N2=17	X	X
			Fold Change: 2.12		1
			P-value: .00214		
46	194	AA634799	739.38+/-608.62		
1			265.99+/-273.02		
			N1=40, N2=17	X	X
			Fold Change: 3.37		
			P-value: .00153		
47	198	AA669106	84.29+/-131.22		
			224.41+/-230.31		
			N1=40, N2=17	X	x
			Fold Change: 3.18		
			P-value: .00001		
48	200	AA700621	467.51+/-455.09		467.51+/-455.09
			127.5+/-198.7	<b></b>	65.41+/-73.63
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.36		Fold Change: 4.6
46		1 1 7 40 507	P-value: .00047		P-value: .03306
49	214	AA742697	1026.03+/-1071.41		1026.03+/-1071.41
			497.89+/-1362.07	37	72.76+/-23.65
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.28	•	Fold Change: 7.24
50	253	AA921809	P-value: .00238 459.15+/-1266.29		P-value: 0
3U	253	AA921009	1144.77+/-1121.05		
			N1=40, N2=17	X	. X
1			Fold Change: 2.76	A	
			P-value: .00483		
51	254	AA921830	92.93+/-115.1		92.93+/-115.1
	254	111321000	214.98+/-154.53		328.17+/-235.36
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.53		Fold Change: 4.07
1			P-value: .00048		P-value: .03148
52	255	AA921922	312.44+/-292.63		312.44+/-292.63
			101.23+/-57.27		79.08+/-33.3
1			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.73		Fold Change: 3.21
		·	P-value: .00001		P-value: .00566
53	260	AA936632			125.03+/-127.3
]					341.96+/-182.6
			X	X	N1=40, N2=17
1					Fold Change: 3.13
					P-value: .02208
54	266	AA976064	363.9+/-153.14		
			150.7+/-67.67		
			N1=40, N2=17	X	X
			Fold Change: 2.48		
<del></del>	404		P-value: 0		000 041/ 450 04
55	281	AC004770			222.34+/-159.84
1			47	47	51.7+/-14.58 N140, N217
			X	X	N1=40, N2=17
1				•	Fold Change: 3.51
					P-value: .00008

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
56	297	AF052142	307.17+/-169.55		
			101.7 <del>6+</del> /-54.87		
			N1=40, N2=17	X	X
			Fold Change: 2.92		
			P-value: 0		
57	317	AI018523	422.08+/-187.64		
			137.17+/-133.59		
			N1=40, N2=17	X	X
			Fold Change: 3.55		
			P-value: .00002		
58	321	AI031771	85.9+/-105.07		
			273.11+/-256.97		
			N1=40, N2=17	X	X
			Fold Change: 2.82		
			P-value: .00563		
59	324	AI039005	203.54+/-131.69		
			79.78+/-68.07		
ļ			N1=40, N2=17	X	X
			Fold Change: 2.7		
<u></u>			P-value: .00048		
60	325	AI039722			1007.24+/-1162.59
					71.46+/-83.95
			X	X	N1=40, N2=17
					Fold Change: 11.94
	<u>.                                    </u>				P-value: .00965
61	331	AI057450	381.32+/-1572.07		381.32+/-1572.07
			-3.82+/-29.02	77	-11.17+/-8.38
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.3		Fold Change: 3.63
<u> </u>			P-value: .00001		P-value: 0
62	333	AI073394	124.23+/-101.36		
			255.64+/-158.11	X	X
ĺ			N1=40, N2=17	<b>A</b>	^
			Fold Change: 2.2		
<del></del>		4 T0 50000	P-value: .00025		
63	335	AI073992	110.23+/-145.3		
l			533.62+/-785.24 N1=40, N2=17	x	X
ļ			Fold Change: 3.22	Λ.	A
			P-value: .00574		
64	220	A T070545			
64	338	AI079545	248.94+/-138.38 465.02+/-171.05		
1			465.02+/-171.05 N1=40, N2=17	X	X
1			Fold Change: 2.01	Λ	
			P-value: .00007		
65	241	A T002500	339.56+/-289.33		339.56+/-289.33
05	341	AI083598	339.50+/-289.33 75.11+/-72.52		38.38+/-30.41
			/5.11+/-/2.52 N1=40, N2=17	x	N1=40, N2=17
			Fold Change: 3.79	Λ	Fold Change: 5.72
			P-value: .00003		P-value: .00274
66	242	AT00//14	301.2+/-152.86		1-14140002/7
66	342	AI086614	301.2+/-152.86 128.33+/-84.7		
			128.33+7-84.7 N1=40, N2=17	· X	X
				А	22
			Fold Change: 2.51 P-value: .00041		

#	Seq ID	Genbank	Normal vs Ali	Normal vs Malignant	Normal vs SII and SIII
67	343	AI087975	68.87+/-58.02		
			211.46+/-250.57		
			N1=40, N2=17	X	X
			Fold Change: 2.28		
			P-value: .00976		
68	344	AI088609	709.25+/-600.21		
			265.96+/-356.75		
			N1=40, N2=17	X	X
			Fold Change: 3.21		
			P-value: .00094		
69	345	AI091154	351.29+/-406.17		351.29+/-406.17
			74.97+/-110.43		12.49+/-5.56
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.1		Fold Change: 8.99
			P-value: .00011		P-value: 0
70	351	AI123555	300+/-164.6		300+/-164.6
			65.25+/-46.06		48.57+/-47.56
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.55		Fold Change: 6
			P-value: 0		P-value: .01993
71	359	AI128820	224.42+/-90.96		
			108.28+/-86.45		
			N1=40, N2=17	X	x
			Fold Change: 2.34		
			P-value: .00033		
72	361	AI129626	278.92+/-134.16		
			134.17+/-77.75		
			N1=40, N2=17	$\mathbf{X}$	X
			Fold Change: 2.13		
			P-value: .00023		
73	362	AI131078	299.48+/-223.81		299.48+/-223.81
			111.16+/-71.9		67.7+/-89.93
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.6		Fold Change: 5.06
			P-value: .0002		P-value: .04594
74	370	AI148006	241.17+/-193.5		, mag
			77.61+/-92.82		)
			N1=40, N2=17	X	<b>X</b>
			Fold Change: 2.93		
			P-value: .00043		
75	372	AI149637	212.6+/-241.64		212.6+/-241.64
			39.92+/-27.3		39.29+/-41.66
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.37		Fold Change: 3.31
	200	ATTOROGE	P-value: 0		P-value: .04204
76	380	AI189011	284.7+/-101.6		
			126.14+/-81.81	N.	77
			N1=40, N2=17	X	X
			Fold Change: 2.75		
77	204	A T200024	P-value: .00017		
77	384	AI200954	524.84+/-319.36		
			253.81+/-173.45	*7	77
			N1=40, N2=17	X	X
			Fold Change: 2.17		
<del></del>			P-value: .00291		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
78	386	AI201965			234.24+/-149.37
					59.16+/ <del>-44</del> .89
			X	$\mathbf{x}$	N1=40, N2=17
					Fold Change: 3.61
	_				P-value: .03602
79	394	AI222594	431.73+/-162.38	<del></del>	
			196.71+/-138.58		
			N1=40, N2=17	X	X
			Fold Change: 2.48		
			P-value: .00005		
80	395	AI223817	221.5+/-204.3		
			686.72+/-465.96		
			N1=40, N2=17	X	X
			Fold Change: 3.28		
			P-value: .00041		
81	399	AI247837	250.33+/-314.52		250.33+/-314.52
			53.27+/-43.26		28.03+/-28.56
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.95		Fold Change: 4.49
			P-value: .00014		P-value: .00427
82	408	AI277612	1022.91+/-907.07		387.19+/-203.85
			101.24+/-106.96		584.56+/-51.28
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 8.06		Fold Change: 2.01
			P-value: 0		P-value: .00012
83	417	AI300876	601.83+/-985.51		601.83+/-985.51
0.5		1115000.0	26.36+/-32.43		28.36+/-46.5
	•		N1=40, N2=17	. <b>X</b>	N1=40, N2=17
			Fold Change: 7.1		Fold Change: 6.7
			P-value: 0	·	P-value: .00688
84	418	AI301060	1095.7+/-461.79		
•		12201100	3285.81+/-2230.69		
			N1=40, N2=17	X	X
			Fold Change: 2.58		
			P-value: .00018		
85	422	AI333767	201.68+/-104.32		
00	722	111555707	94.33+/-75		
			N1=40, N2=17	X	X
			Fold Change: 2.32		
			P-value: .00023		
86	423	AI333987			208.53+/-320.79
_ •					-12.06+/-45.78
			X	X	N1=40, N2=17
			-		Fold Change: 4.29
					P-value: .00037
87	427	AI341602	137.44+/-280.1		137.44+/-280.1
	•		473.63+/-503.04		1084.1+/-558.85
			N1=40, N2=17	x	N1=40, N2=17
			Fold Change: 3.72		Fold Change: 14.07
			P-value: .00123		P-value: .00013
88	430	AI344312	85.72+/-58.03		
00	750	PISTTS14	241.24+/-132.01		
i			N1=40, N2=17	x	x
l			Fold Change: 2.77	22	<del></del>
i			P-value: .00003		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
89	431	AI346341	635.18+/-426.52		
			192.7+/-146.21		
			N1=40, N2=17	X	X
			Fold Change: 2.74		
			P-value: .00095		
90	442	AI369840	239.87+/-167.43		
			91.16+/-73.21		
			N1=40, N2=17	X	X
			Fold Change: 2.54		
			P-value: .00091		
91	447	AI378584	815.22+/-371.96		815.22+/-371.96
			289.2+/-132.28		225.35+/-105.83
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.65		Fold Change: 3.53
			P-value: 0		P-value: .02945
92	448	AI379723	380.22+/-173.64		
			171.75+/-85.82		
			N1=40, N2=17	X	$\mathbf{x}$
			Fold Change: 2.11		
			P-value: .00049		
93	459	AI394013			81.65+/-57.28
					206.8+/-28.72
			X	X	N1=40, N2=17
					Fold Change: 3.01
					P-value: 0
94	462	AI417267	933.35+/-487.41		933.35+/-487.41
			367.83+/-178.5		232.02+/-44.3
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.35		Fold Change: 3.44
			P-value: 0		P-value: 0
95	467	AI419030	445.97+/-259.12		445.97+/-259.12
			141.54+/-110.04		100.89+/-50.85
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.4		Fold Change: 3.94
			P-value: .00002		P-value: .00968
96	468	AI421837	293.96+/-147.73		
			122.58+/-60.8		
			N1=40, N2=17	X	X
			Fold Change: 2.25		
			P-value: .00003		
97	477	AI458003	280.16+/-202.76		280.16+/-202.76
			58.35+/-64.44		29.02+/-54.63
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.09		Fold Change: 6.1
			P-value: 0		P-value: .01261
98	484	AI479262	56.35+/-67.19		
			253.01+/-258.86		
			N1=40, N2=17	X	X
			Fold Change: 3.34		-
			P-value: .00113		
99	489	AI492051	382.34+/-177.78		382.34+/-177.78
			99.97+/-58.1		84.79+/-58.36
			N1=40, N2=17	· <b>X</b>	N1=40, N2=17
			Fold Change: 3.83	44	Fold Change: 4.59
			P-value: 0		P-value: .01274
			P-value: 0		P-value: .01274

#_	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
100	493	AI492879	219.42+/-658.12		
j			360.39+/-664.73		
			N1=40, N2=17	X	X
			Fold Change: 3.18		
		•	P-value: .00218		
101	500	AI524085	388.89+/-529.52		
1			77.76+/-117.23		
1			N1=40, N2=17	· X	X
			Fold Change: 3.83		
			P-value: .00013		
102	501	AI525044	316.89+/-143.08		
		•	163.75+/-85.16		
1			N1=40, N2=17	X	X
			Fold Change: 2.13		
Ĺ			P-value: .00114		
103	505	AI537407	278.8+/-204.74		
			783.29+/-533.91		
			N1=40, N2=17	X	X
1			Fold Change: 2.81		
			P-value: .00083		
104	506	AI539386	1924.9+/-2430.34		
			6121.55+/-7013.05		
			N1=40, N2=17	X	X
			Fold Change: 3.2		
	····		P-value: .00044		
105	511	AI554514	90.74+/-52.8		
			201.02+/-166.43		·
			N1=40, N2=17	<b>X</b>	X
1			Fold Change: 2.08		
<u></u>			P-value: .00026		100 15 1/110 00
106	512	AI557210	129.15+/-140.98		129.15+/-140.98
			491.52+/-264.84	37	573+/-162.6
İ			N1=40, N2=17	$\mathbf{X}$	N1=40, N2=17
			Fold Change: 5.08		Fold Change: 6.68
105		175C(000	P-value: 0		P-value: .00001
107	517	A1566038	257.62+/-109.32 124.43+/-63.25		
				X	x
			N1=40, N2=17	<b>A</b>	^
1			Fold Change: 2.16 P-value: .00015		
108	520	ATETIETE			
108	520	AI571525	265.11+/-78.71 141.93+/-62.73		
			N1=40, N2=17	X	X
			Fold Change: 2.04	A	A
			P-value: .00015		
109	536	AI624853	373.05+/-166.36		
103	330	A1024033	180.19+/-106.47		
			N1=40, N2=17	X	X
1			•	71	
1					
110	540	A1634957			
1	J 10	PEOPLOSE			
1	•			x	X
					_
1					
110	540	AI634852	Fold Change: 2.21 P-value: .00004 278.07+/-162.92 122.35+/-122.97 N1=40, N2=17 Fold Change: 2.6 P-value: .00095	x	х

CHOCOLO 100 00000074401.

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
111	542	AI638295			220.74+/-876.87
					3.1+/-10.99
1			X	X	N1=40, N2=17
					Fold Change: 3.16
				•	P-value: 0
112	545	AI650341	123.6+/-154.23		ł
			209.61+/-97.49		
			N1=40, N2=17	$\mathbf{X}$	x
			Fold Change: 2.41		
	=46	17/70711	P-value: .00028		
113	546	AI650514	110.57+/-163.5		
			295.11+/-242	v	x
			N1=40, N2=17 Fold Change: 2.56	X	^
			P-value: .00744		
114	562	AI658925	542.56+/-347.67		
***	JU2	A1030723	259.65+/-161.58		
			N1=40, N2=17	X	$\mathbf{x}$
		•	Fold Change: 2.07		***
			P-value: .00351		
115	565	AI659418	261.02+/-116.11		
!			133.75+/-108.49		i
			N1=40, N2=17	X	x
			Fold Change: 2.41		
			P-value: .00088		
116	566	AI659533	563.4+/-201.34		
			291.04+/-136.51		
			N1=40, N2=17	. <b>X</b>	x
•			Fold Change: 2.1		·
		17600714	P-value: .00023		·
117	588	AI680541	510.08+/-201.29		510.08+/-201.29
			186.08+/-102.82	x	106.49+/-44.75
			N1=40, N2=17 Fold Change: 2.84	<b>A</b>	N1=40, N2=17 Fold Change: 4.54
			P-value: 0		P-value: .00246
118	591	AI683911	241.46+/-200.89		241.46+/-200.89
110		12000711	27.24+/-52.93		32.69+/-57.65
			N1=40, N2=17	X	N1=40, N2=17
]			Fold Change: 4.58		Fold Change: 3.74
			P-value: 0		P-value: .01617
119	592	AI684457	96.99+/-74.31		
			253.71+/-245.09		
1			N1=40, N2=17	X	X
			Fold Change: 2.25		
100		17000111	P-value: .00425		074.40.11074.70
120	593	AI686114	374.48+/-274.59		374.48+/-274.59
1			120.83+/-92.86	v	76.06+/-83.42
			N1=40, N2=17	X	N1=40, N2=17 Fold Change: 4.43
			Fold Change: 3.03 P-value: .0001		P-value: .04695
121	612	AI701034	215.78+/-96.65		r-vatue04093
141	ULL	AL/U1U34	213.78+7-90.03 111.85+/-71.77		
			N1=40, N2=17	x	X
			Fold Change: 2.11	Λ	43
			P-value: .00036		
		····	1 - 7414000050		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
122	618	AI732274	947.08+/-989.69		
			285.99+/-458.46		
			N1=40, N2=17	. <b>X</b>	$\mathbf{X}$
			Fold Change: 3.94		
			P-value: .00251		
123	619	AI733679	325.9+/-596.22		
123	019	A1/33077	48.5+/-33.81		
			N1=40, N2=17	X	X
			Fold Change: 3.21		
i			P-value: .00002		
12/	(22	A TEL 40/01	231.84+/-247.13	····	
124	623	AI740621			
			77.35+/-124.9	X	X
İ			N1=40, N2=17	<b>A</b>	A
			Fold Change: 2.62		
			P-value: .00315		111 501 / 120 42
125	627	AI742002	111.78+/-132.43		111.78+/-132.43
1			379.6+/-168.26		388+/-292.79
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 4.61		Fold Change: 4.32
1			P-value: 0		P-value: .0111
126	629	AI742239	159.76+/-199.32		
			419.47+/-377.4		
			. N1=40, N2=17	X	X
			Fold Change: 3.29		
1			P-value: .00013		
127	631	A1742490	601.57+/-252.84		
12/	031	A1142430	285.13+/-140.07		
			N1=40, N2=17	X	· <b>X</b>
1			Fold Change: 2.05	A	
1			P-value: .00003		
1	(22	A TO 42521			215.93+/-234.91
128	632	AI742521	215.93+/-234.91		23.3+/-12.66
1			23.91+/-22.33	v	N1=40, N2=17
1			N1=40, N2=17	X	Fold Change: 4.76
			Fold Change: 4.4		P-value: .00002
<u></u>			P-value: 0		F-value: .00002
129	635	AI743671	582.82+/-317.91		
1			281.49+/-185.49		
1			N1=40, N2=17	X	X
			Fold Change: 2.26		
1			P-value: .00964		
130	636	AI743715	312.02+/-238.55		
			99.48+/-141.4		
			N1=40, N2=17	$\mathbf{x}$	X
1			Fold Change: 3.47		
1			P-value: .0005		
131	637	AI743925	663.58+/-309.38		
131	<b>UJ</b> (	FEETTUJEU	221.31+/-142.28		
1			N1=40, N2=17	X	X
l				A	1.
			Fold Change: 3.13		
-			P-value: 0		144.67+/-188.73
132	641	AI751438	144.67+/-188.73		
			551.05+/-364.64		612.92+/-347.94
1			N1=40, N2=17	· X	N1=40, N2=17
			Fold Change: 4.85		Fold Change: 5.61
1			P-value: 0		P-value: .02877

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
133	643	AI758223	833.52+/-665.83		833.52+/-665.83
ŀ			89.52+/-74.43		98.81+/-90.66
			N1=40, N2=17	X	N1=40, N2=17
i			Fold Change: 8.3		Fold Change: 8
1			P-value: 0		P-value: .02464
134	649	AI761241	883.3+/-332.12		
			415.64+/-208.2		
			N1=40, N2=17	X	x
			Fold Change: 2.21		
1			P-value: .00005	-	
135	650	AI761274	342.36+/-182.65		342.36+/-182.65
1			121.18+/-64.61		75.25+/-39.87
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.86		Fold Change: 4.5
			P-value: .00001		P-value: .01949
136	652	AI761844	278.83+/-138.41		278.83+/-138.41
		-	99.54+/-56.16		87.16+/-56.51
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.79		Fold Change: 3.1
1			P-value: .00001		P-value: .02791
137	653	AI763136	282.1+/-149.81		
			118.7+/-131.83		
			N1=40, N2=17	X	х
			Fold Change: 2.53		
l			P-value: .00163		
138	655	AI766029	271.74+/-528.19		271.74+/-528.19
		•	22.11+/-18.39		30.31+/-29.22
ļ		•	N1=40, N2=17	$\mathbf{X}$	N1=40, N2=17
			Fold Change: 3.71		Fold Change: 3.07
L			P-value: 0		P-value: .01978
139	657	AI768325	114.7+/-66.43		
			257.51+/-172.22		
			N1=40, N2=17	X	X
			Fold Change: 2.12	·	
			P-value: .00044		
140	664	AI791182	286.48+/-162.61		
ł			621.07+/-388.18		i de la companya de la companya de la companya de la companya de la companya de la companya de la companya de
			N1=40, N2=17	X	X
			Fold Change: 2.07		
<u></u>			P-value: .00052		
141	668	AI792635			800.24+/-717.81
1					1968.88+/-866
ļ			X	X	N1=40, N2=17
1					Fold Change: 4.27
				· · · · · · · · · · · · · · · · · · ·	P-value: .0038
142	674	AI797276	271.48+/-136.73		271.48+/-136.73
1			106.25+/-58.1		76.49+/-46.61
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.56		Fold Change: 3.58
<u> </u>			P-value: .00001		P-value: .02759
143	678	AI799784	603.99+/-383.42		603.99+/-383.42
	•		93.05+/-88.68		82.71+/-78.29
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 6.66		Fold Change: 7.34
L			P-value: 0		P-value: .01379

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
144	684	A1804054	302.97+/-234.41		302.97+/-234.41
			108.18+/-91.04		77.58+/-36.68
}			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.83		Fold Change: 3.3
i			P-value: .00011		P-value: .01862
145	687	AI806324	211.46+/-131.17	<del></del>	
1			108.84+/-79.43		
ł			N1=40, N2=17	X	X
1			Fold Change: 2.03		~
l			P-value: .00874		
146	691	AI809953	383.43+/-189.32		
1 1 1	0,7	12007700	120.52+/-100.18		
			N1=40, N2=17	X	X
1			Fold Change: 3.27		A
j			P-value: .00013		
147	693	AI810266	68.88+/-106.64	<del></del>	
~ ' '	0,0	.11010200	761.49+/-1126.65		
l			N1=40, N2=17	X	x
1			Fold Change: 6.3		
ł			P-value: .00013		
148	694	AI810764	202.16+/-159.83		
	• • •	12010701	1084.09+/-1401.59		
ļ			N1=40, N2=17	X	X
İ			Fold Change: 4.41		
			P-value: .00007		
149	701	AI816835	360.85+/-289.77		
1			171.05+/-158.66		
1			N1=40, N2=17	· X	x
}			Fold Change: 2.13		
		•	P-value: .00229		-
150	704	AI817967			112.71+/-118.41
					308.86+/-160.78
1		•	X	X	N1=40, N2=17
1					Fold Change: 3.45
L					P-value: .00951
151	706	AI818579	394.08+/-228.07		
1			204.91+/-197.94		
1		•	N1=40, N2=17	X	X
1			Fold Change: 2.13		
<u></u>		···	P-value: .00391		
152	712	AI821472	519.11+/-694.13		519.11+/-694.13
}			-5.59+/-218.89		-49.74+/-70.96
1			N1=40, N2=17	X	N1=40, N2=17
}			Fold Change: 5.69		Fold Change: 9.33
			P-value: .00005		P-value: 0
153	713	AI823572	232.21+/-195.63		
1			91.57+/-60.62	<u>.</u>	
1			N1=40, N2=17	X	X
}			Fold Change: 2.43		
			P-value: .00008		
154	721	AI825936	229.86+/-148.12		
1			98.58+/-81.47		
}			N1=40, N2=17	X	X
1			Fold Change: 2.58		ł
			P-value: .00016		

DAISTOPHIN - WA HORSONTIAN I S

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
155	722	AI826437	45.86+/-118.99		
i			281.35+/-448.25		
			N1=40, N2=17	X	x
			Fold Change: 3.03		
			P-value: .0122		
156	744	AI863167	183.76+/-73.48		
			406.96+/-190.24		
			N1=40, N2=17	X	X
			Fold Change: 2.16		
			P-value: 0		
157	747	AI864898	401.86+/-258.51		
1			75.46+/-68.5		
			N1=40, N2=17	X	x
ł			Fold Change: 5.61		
1			P-value: 0		
158	750	AI871044	766.39+/-500.99		766.39+/-500.99
ļ			189.5+/-179.55		84.85+/-70.19
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 4.03		Fold Change: 8.12
			P-value: .00001		P-value: .00884
159	751	AI872267	267.23+/-203.1		
ł			627.26+/-368.25		
1			N1=40, N2=17	X	x
		·	Fold Change: 2.55	•	
			P-value: .00015		
160	752	AI879337	431.51+/-184.18		
			215.5+/-115.86		
			N1=40, N2=17	X	· <b>X</b>
			Fold Change: 2.18		
			P-value: .00062	<u> </u>	
161	758	AI888322			319.22+/-320.74
					71.54+/-51.15
1			X	X	N1=40, N2=17
1					Fold Change: 3.78
				· · · · · · · · · · · · · · · · · · ·	P-value: .03277
162	772	AI916544	151.27+/-163.24		-
1			373.43+/-334.2		<b>)</b>
1			N1=40, N2=17	X	X
			Fold Change: 2.45		
<b> </b>			P-value: .00524		
163	775	AI917901	601.53+/-812.45		601.53+/-812.45
			76.98+/-131.25		26.66+/-20.01
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.95		Fold Change: 7.3
			P-value: .00005		P-value: .00001
164	780	AI924465	448.27+/-478.27		
			149.48+/-115.97		_
			N1=40, N2=17	X	X
1			Fold Change: 2.43		
			P-value: .00214	······································	
165	<b>787</b>	AI934361	220.01+/-243.16		220.01+/-243.16
1			54.43+/-44.52		52.02+/-37.1
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.1		Fold Change: 3.01
L			P-value: .00001		P-value: .03711

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
166	789	AI934881	316.72+/-226.37		
			659.59+/-486.96		j
			N1=40, N2=17	X	X
			Fold Change: 2.01		
			P-value: .00378		
167	816	AI968151	127.39+/-61.78		
			376.92+/-292.97		
			N1=40, N2=17	X	x
			Fold Change: 2.53		
			P-value: .00031		
168	817	AI968379	295.46+/-388.02		295.46+/-388.02
			-8.49+/-25.52		.59+/-34.6
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 6.27		Fold Change: 5.43
l			P-value: 0		P-value: .00032
169	818	A1968904	738.79+/-292.65		
			307.62+/-119.37		
]			N1=40, N2=17	X	X
			Fold Change: 2.35		
			P-value: 0		
170	830	AI972498	286.51+/-112.64		
1			135.46+/-66.44		
			N1=40, N2=17	X	Х
l			Fold Change: 2.18		
	_		P-value: .00003	•	
171	832	AI972873	436.16+/-215		
1			132.01+/-99.1		
ļ		•	N1=40, N2=17	X	. <b>X</b>
1			Fold Change: 3.85		
			P-value: 0		
172	838	AI983045	281.02+/-338.08		281.02+/-338.08
			40.45+/-125.75		-9.19+/-15.96
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.78		Fold Change: 7.52
			P-value: 0		P-value: 0
173	857	AL037805			614.2+/-317.15
1			~~	77	183.89+/-87.99
			X	X	N1=40, N2=17
					Fold Change: 3.13
<u></u>	065	AT 040040	204 56 1 122 50		P-value: .01435
174	865	AL040912	304.56+/-132.78		
			112.19+/-70.33	v	x
			N1=40, N2=17	X	^
			Fold Change: 2.8		
1==	065	AT 040 400	P-value: .00006		1022.91+/-907.07
175	867	AL042492	809.69+/-853.09		85.76+/-67.41
1			72.75+/-93.44 N1=40, N2=17	· <b>x</b>	N1=40, N2=17
			N1=40, N2=17 Fold Change: 9.48	• •	Fold Change: 8.09
			•		P-value: .00176
150	05/	AY 046044	P-value: 0		428.58+/-238.89
176	876	AL046941	428.58+/-238.89		55.32+/-48.1
			146.79+/-176.57 N1=40, N2=17	X	N1=40, N2=17
1			N1=40, N2=17 Fold Change: 4.06	Λ	Fold Change: 7.58
			P-value: .00007	•	P-value: .01267
			r-value: .0000/		1 - valueV120/

ה ב משנים ביותר בי

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
177	881	AL048962	944+/-354.29		944+/-354.29
l			399.3+/-211.63		289.62+/-184.81
[			N1=40, N2=17	X	N1=40, N2=17
i			Fold Change: 2.5		Fold Change: 3.52
			P-value: .00001		P-value: .03411
178	893	AL050367	257.59+/-77.75		257.59+/-77.75
			111.77+/-59.21		76.12+/-36.74
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.47		Fold Change: 3.45
			P-value: 0		P-value: .01201
179	894	AL079279	313.49+/-189.76		
			127.56+/-77.14		
			N1=40, N2=17	X	x
}			Fold Change: 2.4		
			P-value: .00036		
180	896	AL079707	261.69+/-226.08		
100	070	ALBOTOTOT	73.98+/-35.27		
			N1=40, N2=17	X	$\mathbf{x}$
			Fold Change: 3.16	A	<b>A.</b>
			P-value: 0		
181	902	AL118746	234.63+/-113.05		234.63+/-113.05
101	90 <i>u</i>	ALLIO/40	84.77+/-47.29		46.19+/-34.43
			N1=40, N2=17	X	N1=40, N2=17
İ			Fold Change: 2.86	A	Fold Change: 5.14
l			P-value: .00001		P-value: .0179
182	905	AW000952	98.9+/-72.25		1-varue. :0175
102	703	A 11 000732	204.67+/-105.21		
Ì			N1=40, N2=17	X	X
1			Fold Change: 2.16	A	Α.
		•	P-value: .00011		
183	907	AW002846	283.14+/-201.6		
103	<i>701</i>	A 11 002040	119.62+/-87.38		
i			N1=40, N2=17	X	X
l			Fold Change: 2.43	A	21
1			P-value: .00065		
184	908	AW002941	959.64+/-342.08		
137	700	23.11 UU <i>47</i> 71	493.25+/-243.21		· ·
1			N1=40, N2=17	X	$\mathbf{x}$
1			Fold Change: 2.13	Λ	42
			P-value: .0001		j
185	916	AW006235	346.9+/-210.26		
103	710	A 11 000433	121.01+/-58.03		
]			N1=40, N2=17	X	X
			Fold Change: 2.69	A	A
			P-value: 0		
186	917	AW006352	235.29+/-179.11		
100	71.1	A 11 000334	534.97+/-420.56		
			N1=40, N2=17	X	X
1			Fold Change: 2.17	A	A
			P-value: .00953		
107	021	A \$\$7007000			223.2+/-116.87
187	921	AW007080	223.2+/-116.87		
			69.24+/-50.48	37	36.39+/-14.01
			N1=40, N2=17	X	N1=40, N2=17
•			Fold Change: 3.27		Fold Change: 5.16
			P-value: .00001		P-value: .0001

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
188	926	AW007803	153.39+/-142.06		•
			442.5+/-397.54		
ļ			N1=40, N2=17	$\mathbf{x}$	X
1			Fold Change: 2.55		
		•	P-value: .00867		<u> </u>
189	931	AW014155	214.48+/-209.56		
]			624.36+/-372.34		
1			N1=40, N2=17	X	X
			Fold Change: 3.15		
			P-value: .00005		
190	953	AW051492	442.65+/-332.99		
			203.39+/-140.38		
			N1=40, N2=17	X	X
			Fold Change: 2.22		
			P-value: .00151		
191	957	C17781	229.36+/-141.71		•
			84.23+/-69.19		
			N1=40, N2=17	X	X
			Fold Change: 2.59		
			P-value: .00012		
192	975	F22640	416.82+/-153.5		
		÷	204.94+/-169.19		
1			N1=40, N2=17	X	X
			Fold Change: 2.37		
			P-value: .00007		
193	985	H16568	288.53+/-212.27		288.53+/-212.27
			74.99+/-76.74		32.47+/-46.57
l			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 3.32		Fold Change: 5.01
			P-value: .00019		P-value: .01332
194	988	H30384	194.93+/-133.51		
ŀ			479.18+/-480.95		
1			N1=40, N2=17	X	X
			Fold Change: 2.18		
			P-value: .00329		255 04 / 605 01
195	992	H54254	377.04+/-687.01		377.04+/-687.01
			38.27+/-23.01	**	36.82+/-32.95
1			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 4.25		Fold Change: 4.51
104	005	TTOOOCO	P-value: 0		P-value: .00966
196	997	H92988	390.91+/-149.13		
			205.04+/-140.06	v	v
			N1=40, N2=17	X	X
			Fold Change: 2.33		
105	1051	N/40550	P-value: .00168		
197	1074	N42752	63.77+/-48.02		
			291.54+/-224.99	x	X
			N1=40, N2=17	^	^
			Fold Change: 3.86 P-value: .00006		
100	1005	NECOTT			
198	1085	N56877	109.5+/-80.79 402.12+/-388.61		
			N1=40, N2=17	x	X
			Fold Change: 3	^	A
			P-value: .00087		
L			F-Value0000/		

BUCTOCIO--WO 0205027182 1 5

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
199	1090	N63913	458.01+/-316.71		458.01+/-316.71
			67.39+/-79.5		8.79+/-40.55
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 6.57	•	Fold Change: 11.59
			P-value: 0		P-value: .00004
200	1101	R08000	502.76+/-694.51		502.76+/-694.51
			82.03+/-53.39		90.53+/-93.25
			N1=40, N2=17	X	N1=40, N2=17
ļ			Fold Change: 3.78		Fold Change: 4.05
			P-value: 0		P-value: .04964
201	1104	R20784	1112.78+/-843.96		
			359.34+/-233.36		
			N1=40, N2=17	. X	x
			Fold Change: 2.91		
			P-value: .00005		
202	1105	R39938	111.89+/-67.41	· · · · · · · · · · · · · · · · · · ·	
202	1105	10//50	222.22+/-111.16		
			N1=40, N2=17	X	$\mathbf{x}$
			Fold Change: 2.12	A	<b>12</b>
			P-value: .00002		
203	1106	R42575	90.17+/-38.15		
203	1100	1042575	215.36+/-156.29		
			N1=40, N2=17	X	x
			Fold Change: 2.01	A	A
			P-value: .00211		
204	1112	R54660	200.26+/-133.86		200.26+/-133.86
204	1112	K34000	48.69+/-33.36		29.39+/-27.33
			N1=40, N2=17	X .	N1=40, N2=17
			Fold Change: 3.43	Α .	Fold Change: 4.69
			P-value: 0		P-value: .0025
205	1116	R70255	241.29+/-181.34		241.29+/-181.34
203	1110	1870255	14.29+/-38.71		-8.34+/-15.47
l			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 5.79	A	Fold Change: 7.98
			P-value: 0		P-value: 0
206	1118	R74561	425.23+/-350.96		1 - value. U
200	1110	IX/4501	879.43+/-654.71		· ·
			N1=40, N2=17	X	$\mathbf{x}$
			Fold Change: 2.16	A	A
			P-value: .0019		
207	1119	R83604	304.76+/-867.74		
20,		100007	-32.63+/-64.18		
			N1=40, N2=17	X	X
			Fold Change: 3.15	A	A
			P-value: .00017		
208	1125	T61106	180.38+/-114.3		
400	1147	¥01100	180.38+/-114.3 349.03+/-164.74		
				X	X
			N1=40, N2=17	<b>A</b>	<b>A</b>
			Fold Change: 2.35		
200	1122	TF0504 4	P-value: .00001		16601/11600
209	1132	T85314			166.2+/-116.99
			₹7	37	644.58+/-401.95
			X	X	N1=40, N2=17
1			,	•	Fold Change: 4.09
L			•	•	P-value: .03546

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
210	1171	W02823	217.4+/-87.18		217.4+/-87.18
			81.39+/-47.18		53.69+/-25.71
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.83		Fold Change: 3.92
			P-value: .00001		P-value: .00806
211	1173	W07043	299.21+/-164.12		299.21+/-164.12
			105.66+/-83.76		59.94+/-40.54
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 2.82		Fold Change: 4.46
ŀ			P-value: .00008		P-value: .01951
212	1174	W07304	1139.71+/-444.58		1139.71+/-444.58
			502.93+/-458.99		349.93+/-213.71
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 2.64		Fold Change: 3.49
			P-value: .00012		P-value: .04978
213	1180	W27541			486.94+/-189.31
	1100	***************************************			113.57+/-41.71
			Х .	X	N1=40, N2=17
			44		Fold Change: 4.17
					P-value: .0025
214	1183	W32480	720.17+/-951.89	······································	720.17+/-951.89
214	1105	1132400	76.05+/-158.18		18.91+/-12.14
			N1=40, N2=17	X	N1=40, N2=17
			Fold Change: 7.94	A	Fold Change: 12.97
1			P-value: 0		P-value: 0
215	1184	W37770	208.87+/-62	<del></del>	1-value. 0
213	1104	W37770	108.93+/-55.29		
			N1=40, N2=17	X	Х
l			Fold Change: 2.1		X
-			P-value: .00006	•	
216	1185	W37896	499.73+/-192.2		
210	1105	1137070	1636.96+/-1336.48		
			N1=40, N2=17	X	, X
			Fold Change: 2.49	A	A
			P-value: .00074		
217	1198	W72338	464.08+/-121.49		
211	1170	W 72330	964.48+/-427.69		
			N1=40, N2=17	X	x
			Fold Change: 2	A	Α
			- · · ·		
210	1199	W/72247	P-value: 0		
218	1177	W72347	368.08+/-157.32 134.9+/-113.13		
1			N1=40, N2=17	X	х
1				^	^
1			Fold Change: 3.01		
1210	1200	W/70 407	P-value: .00008		234.77+/-159.7
219	1200	W72407	234.77+/-159.7		44.31+/-63.03
			50.76+/-52.77	v	
			N1=40, N2=17	X	N1=40, N2=17
1			Fold Change: 4.25		Fold Change: 5.12
100		TTT	P-value: 0		P-value: .03464
220	1201	W72511	988.5+/-437.53		
			477.34+/-271.59		***
			N1=40, N2=17	X	X
			Fold Change: 2.11		
L			P-value: .00006		

#	Seq ID	Genbank	Normal vs All	Normal vs Malignant	Normal vs SII and SIII
221	1204	W73386	248.29+/-403.35	469.37+/-905.14	
			35.26+/-68.97	101.34+/-51.41	
1			N1=40, N2=17	N1=17, N2=7	X
			Fold Change: 3.18	Fold Change: 2.82	
1			P-value: .0001	P-value: .01061	•
222	1207	W73890	223.01+/-130.77		
1			84.82+/-49.32		
			N1=40, N2=17	X	X
ŀ			Fold Change: 2.49		
•			P-value: 0		
223	1246	Z99386	611.71+/-209.91		
			288.23+/-106.96		
			N1=40, N2=17	X	X
			Fold Change: 2.19		
			P-value: .00001		

PCT/US02/02176

What is claimed is:

- 1. A method of diagnosing breast cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer.

247

- 2. A method of detecting the progression of breast cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from

  Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of breast cancer progression.
  - 3. A method of monitoring the treatment of a patient with breast cancer, comprising:
    - (a) administering a pharmaceutical composition to the patient;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
  - (c) comparing the patient gene expression profile to a gene expression from a cell population selected from the group consisting of normal breast cells and cancerous breast cells.

20

25

15

- 4. A method of treating a patient with breast cancer, comprising:
- (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5;
- (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising tumor cells; and
  - (c) comparing the patient expression profile to a gene expression profile selected from the group consisting of normal breast cells and cancerous breast cells.
  - 5. A method of typing breast cancer in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of a type of breast cancer selected from a group consisting of infiltrating ductal carcinoma, microinvasive carcinoma, cribiform carcinoma, stage I carcinoma, stage II carcinoma or lobular carcinoma.

5

10

15

20

- 6. A method of detecting the presence or progression of infiltrating ductal carcinoma in a patient, comprising:
- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of infiltrating ductal carcinoma progression.
  - 7. A method of monitoring the treatment of a patient with infiltrating ductal carcinoma, comprising:
    - (a) administering a pharmaceutical composition to the patient;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
  - (c) comparing the patient gene expression profile to a gene expression from a cell population comprising normal breast cells or to a gene expression profile from a cell population comprising infiltrating ductal carcinoma cells or to both.
  - 8. A method of treating a patient with infiltrating ductal carcinoma, comprising:
  - (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5;
- (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising infiltrating ductal carcinoma cells; and
  - (c) comparing the patient expression profile to a gene expression profile from a untreated cell population comprising infiltrating ductal carcinoma cells.
- 9. A method of diagnosing a microinvasive form of breast tumor in a patient, comprising:
  - (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of a microinvasive form of breast cancer.
  - 10. A method of detecting the progression of a microinvasive for of breast cancer in a patient, comprising:

10

15

20

2)

- (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of the progression of a microinvasive form of breast cancer.
- 5 11. A method of monitoring the treatment of a patient with a microinvasive form of breast cancer, comprising:
  - (a) administering a pharmaceutical composition to the patient;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient; and
  - (c) comparing the patient gene expression profile to a gene expression from a cell population comprising normal breast cells or to a gene expression profile from a cell population comprising microinvasive breast cancer cells or to both.
  - 12. A method of treating a patient with a microinvasive form of breast cancer, comprising:
  - (a) administering to the patient a pharmaceutical composition, wherein the composition alters the expression of at least one gene in Tables 1-5;
  - (b) preparing a gene expression profile from a cell or tissue sample from the patient comprising microinvasive breast cancer cells; and
  - (c) comparing the patient expression profile to a gene expression profile from an untreated cell population comprising microinvasive breast cancer cells.
    - 13. A method of differentiating microinvasive breast cancer from a benign growth in a patient, comprising:
- 25 (a) detecting the level of expression in a tissue sample of two or more genes from Tables 1-5; wherein differential expression of the genes in Tables 1-5 is indicative of microinvasive breast cancer rather than benign growth.
- 14. A method of screening for an agent capable of modulating the onset or progression30 of breast cancer, comprising:
  - (a) preparing a first gene expression profile of a cell population comprising breast cancer cells, wherein the expression profile determines the expression level of one or more genes from Tables 1-5;
    - (b) exposing the cell population to the agent;

WO 02/059271 PCT/US02/02176

250

- (c) preparing second gene expression profile of the agent-exposed cell population; and
  - (d) comparing the first and second gene expression profiles.
- 5 15. The method of claim 14, wherein the breast cancer is a infiltrating ductal carcinoma.
  - 16. The method of claim 14, wherein the breast cancer is a microinvasive breast cancer.
- 17. A composition comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 1-5.
  - 18. A composition according to claim 17, wherein the composition comprises at least 3 oligonucleotides.
- 15 19. A composition according to claim 17, wherein the composition comprises at least 5 oligonucleotides.
  - 20. A composition according to claim 17, wherein the composition comprises at least 7 oligonucleotides.
  - 21. A composition according to claim 17, wherein the composition comprises at least 10 oligonucleotides.

20

- 22. A composition according to any one of claims 17-21, wherein the oligonucleotides are attached to a solid support.
  - 23. A composition according to claim 22, wherein the solid support is selected from a group consisting of a membrane, a glass support, a filter, a tissue culture dish, a polymeric material, a bead and a silica support.
  - 24. A solid support comprising at least two oligonucleotides, wherein each of the oligonucleotides comprises a sequence that specifically hybridizes to a gene in Tables 1-5.

5

15

- 25. A solid support according to claim 24, wherein the oligonucleotides are covalently attached to the solid support.
- 26. A solid support according to claim 24, wherein the oligonucleotides are non-covalently attached to the solid support.
  - 27. A solid support according to claim 24, wherein the support comprises at least about 10 different oligonucleotides in discrete locations per square centimeter.
- 10 28. A solid support according to claim 24, wherein the support comprises at least about 100 different oligonucleotides in discrete locations per square centimeter.
  - 29. A solid support according to claim 24, wherein the support comprises at least about 1000 different oligonucleotides in discrete locations per square centimeter.
  - 30. A solid support according to claim 24, wherein the support comprises at least about 10,000 different oligonucleotides in discrete locations per square centimeter.
  - 31. A computer system comprising:
- 20 (a) a database containing information identifying the expression level in breast tissue of a set of genes comprising at least two genes in Tables 1-5; and
  - (b) a user interface to view the information.
- 32. A computer system of claim 31, wherein the database further comprises sequence information for the genes.
  - 33. A computer system of claim 31, wherein the database further comprises information identifying the expression level for the genes in normal breast tissue.
- 30 34. A computer system of claim 31, wherein the database further comprises information identifying the expression level for the genes in breast cancer tissue.
  - 35. A computer system of claim 34, wherein the breast cancer tissue comprises infiltrating ductal carcinoma cells.

- 36. A computer system of claim 34, wherein the breast cancer tissue comprises microinvasive breast cancer cells.
- 5 37. A computer system of any of claims 31-36, further comprising records including descriptive information from an external database, which information correlates said genes to records in the external database.
  - 38. A computer system of claim 37, wherein the external database is GenBank.

10

- 39. A method of using a computer system of any one of claims 31-36 to present information identifying the expression level in a tissue or cell of at least one gene in Tables 1-5, comprising:
- (a) comparing the expression level of at least one gene in Tables 1-5 in the tissue or cell to the level of expression of the gene in the database.
  - 40. A method of claim 39, wherein the expression level of at least two genes are compared.
- 20 41. A method of claim 39, wherein the expression level of at least five genes are compared.
  - 42. A method of claim 39, wherein the expression level of at least ten genes are compared.

25


30

- 43. A method of claim 39, further comprising displaying the level of expression of at least one gene in the tissue or cell sample compared to the expression level in breast cancer.
- 44. A kit comprising at least one solid support of any one of claims 24-30 packaged with gene expression information for said genes.
  - 45. A kit of claim 44, wherein the gene expression information comprises gene expression levels in a breast cancer tissue or cell sample.


WO 02/059271 PCT/US02/02176

253


46. A kit of claim 45, wherein the gene expression information is in an electronic format.




()tty Ref 44921-5070-WO/1737678



3/5



4/5



## (19) World Intellectual Property Organization International Bureau





#### (43) International Publication Date 1 August 2002 (01.08.2002)

#### **PCT**

## (10) International Publication Number WO 02/059271 A3

(51) International Patent Classification<sup>7</sup>: G01N 33/48

(21) International Application Number: PCT/US02/02176

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/263.757 25 January 2001 (25.01.2001) US 60/286.090 25 April 2001 (25.04.2001) US 60/292.517 23 May 2001 (23.05.2001) US

(71) Applicant (for all designated States except US): GENE LOGIC, INC. [US/US]; 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ORR, Michael, S. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). NATION, Michele [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). DIGGANS, James, C. [US/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US). ZENG, Wen [CN/US]; c/o GENE LOGIC, INC., 708 Quince Orchard Road, Gaithersburg, MD 20878 (US).

(74) Agent: MORGAN, LEWIS & BOCKIUS LLP; TUS-CAN, Michael S., WEIMAR, Elizabeth C. et al., 1111 Pennsylvania Avenue, N.W., Washington, DC 20004 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau
- (88) Date of publication of the international search report: 7 November 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION PROFILES IN BREAST TISSUE

(57) Abstract: The present invention results from the examination of tissue from breast carcinomas to identify genes differentially expressed between tumor biopsies and normal tissue. The invention includes diagnostic and screening methods using these genes as well as solid supports comprising oligonucleotide arrays that are complementary to or hybridize to the differentially expressed genes.

#### **INTERNATIONAL SEARCH REPORT**

International application No.

		PCT/US02/02176	' I
A. CLASSIFICATION OF SUBJECT MATTER			
IPC(7) : G01N 33/48			
US CL : 702/19			
	International Patent Classification (IPC) or to both n	ational classification and IPC	
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols)			
U.S.: 702/19			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
bocumentation searched other man imminum documentation to the extent that such documents are included in the neigh searched			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)			
			1
	UMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where ap		Relevant to claim No.
Y,P	US 6,312,909 B1 (SHYJAN et al) 06 November 200	01 (06.11.2001), the entire document.	1-46
	****		
Y US 5,759,776 A (SMITH et al) 02 June 1998 (02.06.1998), the entire document.		1-46	
V IIC 5 776 692 A (CASTITI - A -1) 07 I1. 1000 (07 06 1000) 4			
Y US 5,776,683 A (SMITH et al) 07 July 1998 (07.06.1998), the entire document.		1-46	
A US 6.040.138 A (LOCKHART et al) 21 March 2000 (21.03.2000), the entire document.		1-46	
A US 6,040,138 A (LOCKHART et al) 21 March 2000 (21.03.2000), the entire document.		1-40	
		•	
	·		
	·		
Further	documents are listed in the continuation of Box C.	Sce patent family annex.	
	documents are listed in the continuation of Box C.	"T" later document published after the int	
• s	pecial categories of cited documents:	"T" later document published after the int date and not in conflict with the appli	cation but cited to understand the
* S		"T" later document published after the ini date and not in conflict with the appli principle or theory underlying the inv	cation but cited to understand the cention
* S  "A" document of particu	pecial categories of cited documents: defining the general state of the art which is not considered to be dar relevance	"T" later document published after the ini date and not in conflict with the appli principle or theory underlying the int "X" document of particular relevance; the	ication but cited to understand the cention  claimed invention cannot be
"A" document of partict	pecial categories of cited documents:  defining the general state of the art which is not considered to be dar relevance  plication or patent published on or after the international filing date	"T" later document published after the ini date and not in conflict with the appli principle or theory underlying the inv	ication but cited to understand the cention  claimed invention cannot be
*A" document of particut  "E" carlier ap  "L" document	pecial categories of cited documents:  defining the general state of the art which is not considered to be alar relevance  plication or patent published on or after the international filing date twhich may throw doubts on priority claim(s) or which is cited to	"T" later document published after the int date and not in conflict with the appli principle or theory underlying the inv "X" document of particular relevance; the considered novel or cannot be considered when the document is taken alone	ication but cited to understand the rention cannot be claimed invention cannot be ered to involve an inventive step
*A" document of particut  "E" carlier ap  "L" document	pecial categories of cited documents:  defining the general state of the art which is not considered to be alar relevance  plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"T" later document published after the interest date and not in conflict with the apply principle or theory underlying the interest document of particular relevance; the considered novel or cannot be considered.	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step  claimed invention cannot be
*A" document of partict  "E" cartier ap  "L" document establish specified	pecial categories of cited documents:  defining the general state of the art which is not considered to be dar relevance  plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"T" later document published after the interest date and not in conflict with the appliprinciple or theory underlying the interest document of particular relevance; the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive steep combined with one or more other sur	ection but cited to understand the rention  claimed invention cannot be ered to involve an inventive step  claimed invention cannot be ep when the document is in documents, such combination
*A" document of partict  "E" cartier ap  "L" document establish specified	pecial categories of cited documents:  defining the general state of the art which is not considered to be alar relevance  plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"T" later document published after the interest date and not in conflict with the apply principle or theory underlying the interest document of particular relevance; the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step.	ection but cited to understand the rention  claimed invention cannot be ered to involve an inventive step  claimed invention cannot be ep when the document is in documents, such combination
* S  "A" document of partict "E" earlier ap  "L" document establish specified  "O" document "P" document	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance  plication or patent published on or after the international filing date  which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as  referring to an oral disclosure, use, exhibition or other means  published prior to the international filing date but later than the	"T" later document published after the interest date and not in conflict with the appliprinciple or theory underlying the interest document of particular relevance; the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive steep combined with one or more other sur	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step  claimed invention cannot be powhen the document is the documents, such combination he art
* S  "A" document of partict "E" earlier ap  "L" document establish specified  "O" document "P" document	pecial categories of cited documents:  defining the general state of the art which is not considered to be alar relevance  plication or patent published on or after the international filing date to the twhich may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"T" later document published after the indate and not in conflict with the apply principle or theory underlying the invalidation of particular relevance; the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive steembined with one or more other aux being obvious to a person skilled in the	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step  claimed invention cannot be powhen the document is the documents, such combination he art
"A" document of partict "E" earlier ag "L" document establish specified, "O" document priority d	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance  plication or patent published on or after the international filing date  which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as  referring to an oral disclosure, use, exhibition or other means  published prior to the international filing date but later than the	"T" later document published after the indate and not in conflict with the apply principle or theory underlying the invalidation of particular relevance; the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive steembined with one or more other aux being obvious to a person skilled in the	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step claimed invention cannot be powhen the document is in documents, such combination he art
"A" document of partict "E" earlier ag "L" document establish specified "O" document priority d	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance  plication or patent published on or after the international filing date  which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as  referring to an oral disclosure, use, exhibition or other means t published prior to the international filing date but later than the late claimed  actual completion of the international search	"T" later document published after the indate and not in conflict with the appliprinciple or theory underlying the invalidation of particular relevance; the considered novel or cannot be considered novel or cannot be considered to involve an inventive state combined with one or more other subsing obvious to a person skilled in the document member of the same paten.  Date of mailing of the international se	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step claimed invention cannot be powhen the document is in documents, such combination he art
"A" document of partict "E" earlier ag "L" document establish specified "O" document priority of  Date of the a	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance  plication or patent published on or after the international filing date  which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as  referring to an oral disclosure, use, exhibition or other means  published prior to the international filing date but later than the late claimed  actual completion of the international search  202 (26.08.2002)	"T" later document published after the indate and not in conflict with the appliprinciple or theory underlying the interest of the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive steembined with one or more other surbeing obvious to a person skilled in the document member of the same patern to the sam	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step claimed invention cannot be powhen the document is in documents, such combination he art
"A" document of partict "E" cartier ag "L" document stablish specified "O" document priority of Date of the a 26 August 20 Name and m	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance  plication or patent published on or after the international filing date  t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as  t referring to an oral disclosure, use, exhibition or other means  t published prior to the international filing date but later than the tate claimed  actual completion of the international search  2002 (26.08.2002)  ailing address of the ISA/US	"T" later document published after the indate and not in conflict with the appliprinciple or theory underlying the invalidation of particular relevance; the considered novel or cannot be considered novel or cannot be considered to involve an inventive state combined with one or more other subsing obvious to a person skilled in the document member of the same paten.  Date of mailing of the international se	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step claimed invention cannot be powhen the document is in documents, such combination he art
"A" document of partict "E" earlier ag "L" document establish specified "O" document priority of Date of the a  26 August 24 Name and m  Con Box	pecial categories of cited documents:  defining the general state of the art which is not considered to be dar relevance  plication or patent published on or after the international filing date to which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as a referring to an oral disclosure, use, exhibition or other means a published prior to the international filing date but later than the late claimed actual completion of the international search  2002 (26.08.2002)  ailling address of the ISA/US amissioner of Patents and Trademarks	"T" later document published after the indate and not in conflict with the appliprinciple or theory underlying the interest of the considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive steembined with one or more other surbeing obvious to a person skilled in the document member of the same patern to the sam	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step claimed invention cannot be powhen the document is in documents, such combination he art
"A" document of partict "E" earlier ag "L" document establish specified, "O" document priority d  Date of the a  26 August 20  Name and m  Com  Box  Wat	pecial categories of cited documents:  defining the general state of the art which is not considered to be lar relevance  plication or patent published on or after the international filing date  which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as  referring to an oral disclosure, use, exhibition or other means  published prior to the international filing date but later than the late claimed  actual completion of the international search  202 (26.08.2002)  ailing address of the ISA/US  mussioner of Patents and Trademarks	"T" later document published after the indate and not in conflict with the appliprinciple or theory underlying the invalidation of particular relevance; the considered novel or cannot be considered novel or cannot be considered to involve an inventive state combined with one or more other state of particular relevance; the considered to involve an inventive state combined with one or more other state of the same patent document member of the same patent to the considered to involve an inventive state of the same patent document member of the same patent to the considered to involve an inventive state of the same patent document member of the same patent to the considered to involve an inventive state of the same patent document member of the same patent to the considered to involve an inventive state of the same patent document member of the same patent document international security and the considered to involve an inventive state of the same patent document international security and the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to involve an inventive state of the considered to inventive state of the considered to inventive state of the considered to inventive state of the considered to inventive state of the considered to inventive state of the considered to inventive state of the co	ication but cited to understand the rention  claimed invention cannot be ered to involve an inventive step claimed invention cannot be powhen the document is in documents, such combination he art

Form PCT/ISA/210 (second sheet) (July 1998)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

#### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

### IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

## THIS PAGE BLANK (USPTO)